

© The Kirby Institute
for infection and immunity in society

ISSN 1448-5915

This publication is available at: <http://www.kirby.unsw.edu.au>

The Kirby Institute
for infection and immunity in society
UNSW Sydney
Sydney NSW 2052
Australia

Telephone: **02 9385 0900** Facsimile: **02 9385 0920** International prefix: **612** Email: recpt@kirby.unsw.edu.au

Suggested citation: Heard S, Iversen J, Geddes L, and Maher L. Australian Needle Syringe Program Survey National Data Report 2014-2018: Prevalence of HIV, HCV and injecting and sexual behaviour among NSP attendees. Sydney: Kirby Institute, UNSW Sydney; 2019. ISSN: 1448-5915.

AUSTRALIAN NSP SURVEY
Prevalence of HIV, HCV and injecting and
sexual behaviour among NSP attendees

NATIONAL DATA REPORT
2014 - 2018

Report prepared by

Sue Heard, Jenny Iversen, Louise Geddes and Lisa Maher

The Kirby Institute

for infection and immunity in society
UNSW Sydney
Sydney NSW 2052
Australia

July 2019

The Australian Needle and Syringe Program Survey is funded by the Australian Government Department of Health. The Kirby Institute is affiliated with the Faculty of Medicine, UNSW Sydney.

ACKNOWLEDGEMENTS

We would like to acknowledge the many people who assist each year in the development and conduct of the Australian NSP Survey (ANSPS), particularly the clients, staff and managers at participating NSP services. We also appreciate the dedication and vision of the founding members of the project and the late Dr Margaret MacDonald who was responsible for the development and conduct of the ANSPS from 1995 until 2003.

Special thanks go to Mr Philip Cunningham, Senior Scientist and Operations Manager, Ms Beth Catlett, DBS Coordinator and Mr Mitchell Starr, Senior Hospital Scientist at the NSW State Reference Laboratory for HIV at St Vincent's Hospital and St Vincent's Centre for Applied Medical Research. We also appreciate the assistance provided by Ms Rachel McCleave from the Kirby Institute and Mr Greg Smith and Mr Ashwin Prekesh from Educational Assessment Australia, UNSW Global Pty Limited.

In 2018, the project received support and input from the following members of the ANSPS National Advisory Group: Ms Jennifer Taleski (ACT); Ms Annabelle Stevens (NSW); Mr David Decolongon (NT); Mr Stephen Lymb and Mr Rob Gerrie (SA); Ms Francine Smith and Ms Myf Briggs (TAS); Mr Brian McDowell and Ms Terrie Spall (VIC); Ms Jude Bevan (WA); Ms Melanie Walker (Australian Injecting and Illicit Drug Users League); and Ms Sue Heard, Dr Jenny Iversen and Professor Lisa Maher (Kirby Institute). We would particularly like to thank Mr Robert Kemp (QLD) for chairing the National Advisory Group.

Ethical approvals were obtained from institutional ethics committees associated with the investigators and participating NSP sites. The Australian Needle Syringe Program Survey is funded by the Australian Government Department of Health and Ageing. The Kirby Institute is affiliated with the Faculty of Medicine, UNSW Sydney.

ABBREVIATIONS

ANSPS	Australian Needle and Syringe Program Survey
DAA	Direct acting antiviral
DBS	Dried blood spot
HCV	Hepatitis C virus
HIV	Human immunodeficiency virus
NSP	Needle syringe program
OST	Opioid substitution therapy
PIEDs	Performance and image-enhancing drugs
PBS	Pharmaceutical Benefits Scheme
RNA	Ribonucleic acid
RSS	Receptive syringe sharing

TABLE OF CONTENTS

Summary

Key Points	i
Introduction.....	1
Demographic characteristics	1
Injecting behaviour	2
Sexual behaviour.....	4
Drug treatment	5
HIV antibody prevalence	5
HCV antibody prevalence.....	6
HIV and HCV testing	8
HCV treatment uptake.....	8
HCV RNA prevalence.....	10
References	12

Tables

1. National	14
2. Australian Capital Territory.....	40
3. New South Wales.....	58
4. Northern Territory	84
5. Queensland	102
6. South Australia	128
7. Tasmania.....	154
8. Victoria	172
9. Western Australia	198

Appendix

A. Participating NSP services	224
B. Methodological notes	226
C. List of tables	228

KEY POINTS

- The Australian NSP Survey (ANSPS) functions as a strategic early-warning system designed to monitor blood borne viral infections and injecting and sexual behaviour among people who inject drugs.
- In 2018, 53 Needle and Syringe Programs (NSPs) throughout Australia participated in the ANSPS and 2,742 NSP attendees completed the survey. The response rate was 45%.

Demographic characteristics:

- Over the five-year period 2014 to 2018, the median age of survey respondents increased from 39 to 42 years, with a concurrent decline in the proportion of young injectors (aged <25 years) from 6% in 2014 to 4% in 2018 (χ^2 trend $p=0.013$).
- The median time since first injection increased from 19 years in 2014 to 22 years in 2018, and the proportion of new initiates (those injecting for less than three years) declined from 7% in 2014 to 5% in 2018 (χ^2 trend $p=0.004$).
- The proportion of respondents from an Indigenous Australian background increased significantly, from 14% to 19% over the period 2014 to 2018 (χ^2 trend $p<0.001$).
- The proportion of respondents reporting incarceration in the 12 months prior to survey completion increased from 11% to 13% over the five-year period 2014 to 2018 (χ^2 trend $p=0.009$).

Injecting behaviour:

- Daily or more frequent injecting in the month prior to the survey was reported by approximately half of respondents in all survey years 2014 to 2018.
- The proportion of respondents reporting methamphetamine as the last drug injected increased from 33% in 2014 to 48% in 2018 (χ^2 trend $p<0.001$). In all years since 2014 methamphetamine was the most commonly reported drug last injected nationally.
- The proportion of respondents reporting heroin as the last drug injected declined from 31% in 2014 to 26% in 2018 (χ^2 trend $p=0.005$).
- Pharmaceutical opioids were the third most commonly reported class of drugs last injected in all years 2014 to 2018, however prevalence declined from 11% to 7% over this period (χ^2 trend $p<0.001$).
- The proportion of respondents who reported last injecting performance and image enhancing drugs (PIEDs) declined from 7% in 2014 to 4% in 2018 (χ^2 trend $p<0.001$).
- In 2014, two in five (42%) new initiates to injection reported last injecting PIEDs and one in three (29%) reported last injecting methamphetamine. Conversely in 2018, two thirds (63%) of new initiates reported last injecting methamphetamine and one in five (18%) reported last injecting PIEDs.
- The proportion of respondents reporting recent reuse of needles and syringes (including reuse of one's own syringes) increased, from 21% in 2014 to 26% in 2018 (χ^2 trend $p=0.023$).
- There was also a significant increase in the proportion of respondents reporting receptive sharing of needles and syringes in the last month, from 16% in 2014 to 18% in 2018 (χ^2 trend $p=0.034$).
- The prevalence of recent receptive sharing of drug preparation equipment remained stable, ranging from 27% to 29% over the five-year period (χ^2 trend $p=0.157$).

- The proportion of respondents who reported injecting in public in the last month increased from 36% in 2014 to 46% in 2018 (χ^2 trend $p < 0.001$).
- The prevalence of self-reported drug overdose in the past 12 months increased significantly, from 15% in 2014 to 19% in 2018 (χ^2 trend $p < 0.001$).

HIV antibody prevalence:

- HIV antibody prevalence remained low and stable nationally, ranging from 1.4% to 2.1% over the period 2014 to 2018 (χ^2 trend $p = 0.641$).
- In all years 2014 to 2018, HIV antibody prevalence was higher among homosexual men compared to bisexual or heterosexual men, and compared to women.
- In 2018, HIV antibody prevalence was higher among Aboriginal and Torres Strait Islander respondents compared to non-Indigenous respondents (3.6% vs 1.1%, $p < 0.001$). However, prevalence of HIV infection among Aboriginal and Torres Strait Islander respondents was stable between 2014 to 2018 (range 2.0% in 2014 to 3.6% in 2018, χ^2 trend $p = 0.093$).

HCV antibody prevalence:

- Hepatitis C virus (HCV) antibody prevalence declined nationally from 54% in 2014 to 45% in 2018 (χ^2 trend $p < 0.001$). This is the second consecutive year that less than half of respondents had been exposed to HCV, following two decades of HCV antibody prevalence $\geq 50\%$ (all years 1999-2016).
- Across all survey years 2014 to 2018, prevalence of HCV antibody was higher among older than among younger respondents and among those with longer injection histories.

HCV treatment uptake:

- Among respondents assessed as eligible for HCV treatment, the proportion who reported a lifetime history of HCV treatment increased significantly, from 13% in 2014 to 55% in 2018 (χ^2 trend $p < 0.001$).
- Similarly, among respondents assessed as eligible, the proportion who reported recent (last 12 months) HCV treatment increased significantly, from 1% in 2014 to 39% in 2018 (χ^2 trend $p < 0.001$).

HCV RNA prevalence:

- In 2015, the ANSPS commenced HCV ribonucleic acid (RNA) testing in addition to HCV antibody testing. National data from 2017 and 2018 are presented for the first time in this report, along with previously reported data from 2015 and 2016. Jurisdictional data from 2015 to 2018 are also presented for the first time in this report.
- Among respondents tested for HCV RNA, the proportion with detectable HCV RNA declined from 51% in 2015 to 20% in 2018 (χ^2 trend $p < 0.001$).
- The proportion of HCV antibody positive respondents with detectable HCV RNA also declined from 76% in 2015 to 42% in 2018 (χ^2 trend $p < 0.001$).

INTRODUCTION

The Australian Needle and Syringe Program Survey (ANSPS) provides serial point prevalence estimates of human immunodeficiency virus (HIV) and hepatitis C virus (HCV) antibody prevalence and sexual and injecting risk behaviour among people who inject drugs (PWID) in Australia. Conducted annually over a one-two week period in October, all clients attending participating Needle and Syringe Program (NSP) services are invited to complete a brief, anonymous questionnaire and to provide a capillary blood sample for HIV and HCV antibody testing (see methodological notes [Appendix B] for further details on the ANSPS design and implementation). Commencing in 2015, HCV ribonucleic acid (RNA) testing has been conducted among HCV antibody positive respondents with sufficient dried blood spot (DBS) samples. This report presents national and state/territory findings for the period 2014 to 2018 and HCV RNA data for the period 2015 to 2018.

In 2018, 53 NSP services participated in the ANSPS. Over the period 2014 to 2018, the number of ANSPS respondents ranged from 2,210 to 2,742 and the annual response rate ranged from 41% to 48% (Table 1.1.1). Of the 2,742 ANSPS respondents in 2018, the majority (83%) were recruited from the 43 NSP services that participated in the ANSPS in all years 2014 to 2018. A list of participating NSP services in 2018 is provided at Appendix A.

Demographic Characteristics

Approximately two thirds of survey respondents were male and less than one percent identified as transgender across all survey years 2014 to 2018. In 2018, the majority (78%) of respondents identified as heterosexual, while 9% identified as bisexual and 4% as homosexual (Table 1.1.1).

The proportion of respondents from an Indigenous Australian background increased significantly, from 14% to 19% over the period 2014 to 2018 (χ^2 trend $p < 0.001$)^{1,2}. In all survey years, the majority of respondents were born in Australia (ranging from 85% to 87%), with the United Kingdom, Ireland (4%) and New Zealand (3%) the predominant countries of birth outside Australia in 2018. Most respondents also reported that their parents spoke English at home (range 92% to 94% over the period 2014 to 2018).

The median age at survey completion increased from 39 years in 2014 to 42 years in 2018 and there was a concurrent significant decline in the proportion of young injectors (aged <25 years) from 6% in 2014 to 4% in 2018 (χ^2 trend $p = 0.013$). The median time since first injection increased from 19 years in 2014 to 22 years in 2018, and the proportion of new initiates (those injecting for less than 3 years) declined from 7% in 2014 to 5% in 2018 (χ^2 trend $p = 0.004$). The median age at first drug injection was stable across the period 2014 to 2018, ranging from 18 to 19 years of age (Table 1.1.1).


The proportion of respondents reporting incarceration in the 12 months prior to survey completion increased from 11% to 13% over the five-year period 2014 to 2018 (χ^2 trend $p = 0.009$). Approximately one in three respondents (34%) with a history of recent incarceration reported injecting while in prison (Table 1.1.1).

Injecting behaviour

Methamphetamine was the most commonly reported drug last injected nationally in all years 2014 to 2018 (Table 1.1.2). Reports of methamphetamine injection increased significantly over the five-year period, from 33% in 2014 to 48% in 2018 (χ^2 trend $p < 0.001$, Figure 1). In 2018, methamphetamine was the most commonly injected drug in all but one jurisdiction, including the Australian Capital Territory (47%), New South Wales (35%), Northern Territory (40%), Queensland (48%), South Australia (57%), Tasmania (35%) and Western Australia (69%).

Heroin was the second most commonly reported drug last injected nationally in 2018, with a significant decline in prevalence between 2014 (31%) and 2018 (26%, χ^2 trend $p = 0.005$). As in all previous years since 2014, heroin remained the most commonly reported drug last injected in Victoria (51%) in 2018. Heroin was the second most commonly reported drug last injected in the Australian Capital Territory (40%), NSW (30%), South Australia (31%) and Western Australia (15%) in 2018.

Figure 1. Proportion of respondents (%) reporting last injecting heroin, methamphetamine, and all other drugs, 2014–2018



The third most commonly reported class of drugs last injected nationally was pharmaceutical opioids (including morphine, oxycodone and fentanyl), although prevalence declined from 11% to 7% over the period 2014 to 2018 (χ^2 trend $p < 0.001$, Figure 2). In 2018, pharmaceutical opioids were the second most commonly reported class of drugs last injected in the Northern Territory (36%), Queensland (16%) and Tasmania (31%)^{3,4}.


Methadone was reported as the last drug injected by less than ten percent of ANSPS respondents in all years 2014 to 2018 (range 6% to 4%) with a significant decline in prevalence over this period (χ^2 trend $p = 0.002$). In 2018, methadone was the third most commonly reported class of drugs last injected in South Australia (5%) and Tasmania (19%). Buprenorphine and buprenorphine-naloxone

injection were reported by a minority of survey respondents. The prevalence of both buprenorphine-naloxone injection (2% to 1%, χ^2 trend $p=0.551$), and the prevalence of buprenorphine injection (3% to 2%, χ^2 trend $p=0.385$) was stable over the period 2014 to 2018.

A minority of survey respondents (1% across all survey years) reported cocaine as the last drug injected. The prevalence of performance and image enhancing drugs (PIEDs) as the last drug injected declined significantly over the period 2014 to 2018 (χ^2 trend $p<0.001$, Figure 2). PIEDs injection declined from 14% in 2014 to 4% in 2018 in Queensland ($p<0.001$), while prevalence remained stable at between 10% and 12% in NSW (χ^2 trend $p=0.961$). The proportion of respondents who reported last injecting PIEDs was <3% in all other jurisdictions in 2018.

In 2014, PIEDs were the most commonly reported last drug injected among new initiates (less than 3 years since first injection) nationally. However, in each year from 2015-2018, methamphetamine was the most commonly reported last drug injected among this group, with a significant increase observed between 2014 (29%) and 2018 (63%, χ^2 trend $p<0.001$).


Figure 2. Proportion of respondents (%) reporting last injecting pharmaceutical opioids, methadone, and performance and image enhancing drugs, 2014–2018



Daily or more frequent injection was reported by approximately half of respondents in all of the past five years (Table 1.1.2). Prevalence of at least one public injection (injection in a car, beach, park, street or squat) in the month prior to survey completion increased significantly from 36% in 2014 to 46% in 2018 (χ^2 trend $p<0.001$, Table 1.1.3). In 2018, almost one in five respondents reported they had experienced a drug overdose in the previous 12 months ($n=520$, 19%, Table 1.1.2), also reflecting a significant increase over the period 2014 (15%) to 2018 (19%) (χ^2 trend $p<0.001$).

As shown in Figure 3, there was a significant increase in two of the three key injecting risk behaviours over the five-year period 2014 to 2018. The proportion of respondents who reported reuse of needles and syringes (including one’s own) in the month preceding the survey increased, from 21% in 2014 to 26% in 2018 (χ^2 trend $p=0.023$). There was also a significant increase in the prevalence of receptive sharing of needles and syringes in the month prior to survey completion, from 16% in 2014 to 18% in 2018 (χ^2 trend $p=0.034$). Receptive sharing of ancillary equipment was stable over the period 2014 to 2018 (range 27% to 29%, χ^2 trend $p=0.157$). As in previous years, spoons and water were the most commonly identified receptively shared ancillary items in 2018 (Table 1.1.3).

Figure 3. Proportion of respondents (%) reporting reuse and receptive sharing of needles and syringes and receptive sharing of ancillary equipment in the last month, 2014–2018



Sexual behaviour

In all years 2014 to 2018 approximately half of respondents reported sex with a regular partner in the month prior to survey completion (range 43% to 47%, Table 1.1.6). Of these, the majority (72% to 77%) reported that they did not use condoms with their regular sex partner. A smaller proportion of respondents (13% to 15%) reported sex with other partners in the month preceding survey participation. Condom use was higher among this group, with approximately two fifths reporting some condom use and one quarter reporting always using condoms with non-regular partners in the 2018 survey. The proportion of respondents reporting sex work in the month prior to the survey remained low and stable at 4% to 6% over the last five years (χ^2 trend $p=0.491$) and the use of condoms at last paid sex was relatively high at between 62% and 71% in all years between 2014 and 2018 (Table 1.1.6). Of the respondents who reported sex work in the previous month in 2018 ($n=154$), 53% were women, 44% were men, and 3% identified as transgender.

Drug treatment


Engagement with drug treatment services was high (Table 1.1.4), with two thirds (69%) of respondents reporting a lifetime history of drug treatment in 2018. Nonetheless, there was a significant decline in the overall proportion of respondents reporting current opioid substitution therapy (OST; methadone, buprenorphine or buprenorphine-naloxone treatment) from 38% in 2014 to 31% in 2018 (χ^2 trend $p < 0.001$). This may reflect a significant increase in the proportion of respondents reporting methamphetamine as the last drug injected (from 33% to 48% 2014-2018) with OST not indicated for methamphetamine dependence. However, current OST among respondents who reported last injecting opioids was stable over the period 2014 to 2018 (range 48% to 49%, χ^2 trend $p = 0.984$). In 2018, current methadone maintenance treatment was reported by 21% of respondents, with current buprenorphine treatment reported by 7% of respondents and buprenorphine-naloxone treatment by 8% of respondents.

HIV antibody prevalence

HIV antibody prevalence remained low and stable nationally over the period 2014 to 2018 (range 1.4% to 2.1%, χ^2 trend $p = 0.641$, Table 1.2.1). At the jurisdictional level (Figure 4), HIV antibody prevalence was also low and stable.

No respondents in the Northern Territory, Tasmania or the Australian Capital Territory, and no women in South Australia tested positive to HIV antibodies in any of the previous five years, 2014 to 2018.

Figure 4. HIV antibody prevalence (%) by jurisdiction, 2014–2018




Nationally, across all survey years, HIV antibody prevalence was consistently higher among homosexual male respondents than among bisexual and heterosexual male respondents or female respondents (Table 1.2.2 and Figure 5). In the last five years (2014 to 2018), HIV prevalence was also higher among men who reported methamphetamine as the last drug injected (3.0% in 2018)

compared to men who reported last injecting other drugs (2.4% in 2018, Table 1.2.4). In the four years from 2014 to 2017 HIV prevalence was higher among men who reported sex work in the month preceding the survey compared to men who did not report recent sex work. However, in 2018 there was no significant difference in HIV prevalence between men who reported recent sex work and men who did not (Table 1.2.10)⁵.

In 2018, respondents from an Aboriginal and/or Torres Strait Islander background were significantly more likely to test HIV antibody positive than non-Indigenous respondents (3.6% vs 1.1% respectively, $p < 0.001$). However, prevalence of HIV infection among Aboriginal and Torres Strait Islander respondents was stable between 2014 and 2018 (2.0% in 2014 to 3.6% in 2018, χ^2 trend $p = 0.093$). Of the $n = 19$ Indigenous respondents who tested HIV antibody positive in 2018, 53% ($n = 10$) identified as heterosexual.

Figure 5. HIV antibody prevalence (%) by gender and sexual identity, 2014–2018



In 2018, the median age of HIV antibody positive respondents was 46.5 years (range 24-63 years) and respondents first injected a median of 16 years prior to survey participation (range 1-41 years). In 2018, there was no difference in the median age ($p = 0.316$) or the median time since first injection ($p = 0.166$) among HIV positive and HIV negative respondents.

HCV antibody prevalence

HCV antibody prevalence declined nationally from 54% in 2014 to 45% in 2018 (χ^2 trend $p < 0.001$, Table 1.3.1). Over the five-year period 2014 to 2018, HCV antibody prevalence declined among men (from 53% in 2014 to 46% in 2018, χ^2 trend $p = 0.002$) and among women (from 56% in 2014 to 43% in 2018, χ^2 trend $p < 0.001$). At the jurisdictional level (Figure 6), HCV antibody prevalence remained stable over the period 2014 to 2018, including among men and women in five of the eight jurisdictions. However, decreases in HCV antibody prevalence were observed in NSW (total $p = 0.011$, women $p = 0.018$), SA (women $p = 0.049$) and WA (total $p = 0.006$, men $p = 0.029$). Across all

five years of the survey, HCV antibody prevalence was significantly higher among older respondents and those with longer injection histories (Table 1.3.3 and 1.3.4). Figure 7 illustrates the relationship between exposure to HCV and time since first injection among respondents in 2018.

Figure 6. HCV antibody prevalence (%) by jurisdiction, 2014–2018






Figure 7. HCV antibody prevalence (%) by time since first injection, 2018



In all survey years, prevalence of HCV was also higher among respondents reporting heroin or other opioids as the last drug injected compared to respondents who last injected methamphetamine (Figure 8). HCV antibody prevalence was also consistently higher among respondents who reported imprisonment in the year preceding survey completion compared to those who did not ($p < 0.001$ in

all years 2014 to 2018) and among respondents who reported receptive syringe sharing in the last month compared to respondents who did not ($p < 0.05$ in 2014, 2015, 2017 and 2018).

Figure 8. HCV antibody prevalence (%) by drug last injected and gender, 2014–2018



HIV and HCV testing

Prevalence of HIV diagnostic screening among ANSPS respondents over the period 2014 to 2018 was high, with 81% to 85% reporting a lifetime history of HIV diagnostic testing (Table 1.1.5). In 2018, 50% of respondents reported an HIV diagnostic test in the previous 12 months. Among the $n=46$ respondents who tested HIV antibody positive, almost two thirds (63%, $n=29$) were aware of their HIV positive status. A minority (13%, $n=6$) of respondents who tested HIV positive reported that they were HIV negative, 7% ($n=3$) reported they did not know their HIV status and 17% ($n=8$) did not report their HIV status.

Respondents also reported high prevalence of lifetime HCV diagnostic screening over the period 2014-2018 (range 80% to 88%). In 2018, just over half (53%) of respondents reported an HCV diagnostic test in the previous 12 months.

HCV treatment uptake

Among respondents who tested HCV antibody positive and after excluding those who reported spontaneous HCV clearance, the proportion who reported a lifetime history of HCV treatment increased significantly, from 13% in 2014 to 55% in 2018 (χ^2 trend $p < 0.001$, Figure 9). Similarly, among respondents who tested HCV antibody positive and after excluding those who reported spontaneous or treatment-induced clearance more than 12 months previously, the proportion who reported recent (last 12 months) HCV treatment increased significantly from 1% in 2014 to 39% in 2018 (χ^2 trend $p < 0.001$). As shown in Figure 10, there was an increase in the proportion of respondents reporting a lifetime history of HCV treatment over the period 2014 to 2018 in all jurisdictions except the Northern Territory.

Figure 9. Proportion of respondents (%) reporting lifetime and recent HCV treatment among HCV antibody positive respondents, 2014–2018





Figure 10. Lifetime history of HCV treatment (%) nationally and by jurisdiction, 2014–2018




HCV RNA prevalence

Given universal access to HCV Direct Acting Antiviral (DAA) therapy through the Australian Government’s Pharmaceutical Benefits Scheme (PBS) from March 2016 and a projected increase in treatment uptake⁶, the ANSPS commenced HCV RNA testing, in addition to antibody testing in 2015 (Tables 1.4.1 to 1.4.11). Laboratory procedures are detailed in the Methodological Notes (Appendix B). It should be noted that only a sub-sample of respondents had sufficient DBS samples for HCV RNA testing. Weightings were therefore applied to account for potential sample bias among the subset eligible for RNA testing with respect to gender (given higher rates of spontaneous clearance among women) and HCV antibody status. Further, results with small sample sizes, particularly at the jurisdictional level, should be interpreted with caution.

As previously stated, HCV antibody prevalence declined significantly (from 54% in 2014 to 45% in 2018, χ^2 trend $p < 0.001$) and lifetime HCV treatment increased significantly (from 13% in 2014 to 55% in 2018, χ^2 trend $p < 0.001$). Among respondents who were tested for HCV RNA (range 35%-62% of overall sample), the proportion with detectable HCV RNA (active infection) also declined significantly, from 51% in 2015 to 20% in 2018 (χ^2 trend $p < 0.001$). As shown in Figure 11, HCV RNA prevalence declined significantly among both males (53% in 2015 to 21% in 2018, χ^2 trend $p < 0.001$) and females (45% in 2015 to 19% in 2018, χ^2 trend $p < 0.001$).


Figure 11. Proportion of respondents (%) with detectable HCV RNA by gender, 2015–2018*



* Weighted for gender and HCV antibody status


Results of HCV antibody and RNA testing can be combined to provide an estimate of the viraemic status among respondents⁶. As shown in Figure 12, the proportion of respondents with evidence of exposure to HCV was 45% nationally in 2018 and varied from 37% (Western Australia) to 56% (Victoria) at the jurisdictional level. After accounting for both spontaneous and treatment-related viral clearance, the proportion of respondents with active HCV infection was 20% nationally and <30% in all jurisdictions in 2018.

Figure 12. HCV viraemic status (%) nationally and by jurisdiction in 2018



Among respondents who tested HCV antibody positive, the proportion who spontaneously cleared the virus was stable at between 21%-26% over the period 2015 to 2018 (χ^2 trend $p=0.090$, Figure 13). The proportion of HCV antibody positive respondents who had cleared the virus with treatment increased from 3% in 2015 to 32% in 2018 (χ^2 trend $p<0.001$), while the proportion of respondents with active HCV infection declined from 76% in 2015 to 42% in 2018 (χ^2 trend $p<0.001$).

Figure 13. HCV viraemic status (%) among HCV antibody positive respondents nationally, 2015 to 2018



References

1. Doyle M, Maher L, Graham S, Wand H, Iversen J. Hepatitis C virus prevalence and associated risk factors among Indigenous Australians who inject drugs. *Aust N Z J Public Health* 2018;42(1):52-6.
2. Graham S, Maher L, Wand H, Doyle M, Iversen J. Trends in hepatitis C antibody prevalence among Aboriginal and Torres Strait Islander people attending Australian Needle and Syringe Programs, 1996-2015. *Int J Drug Policy* 2017;47:69-76.
3. Iversen J, Dertadian G, Geddes L, Maher L. High risk injecting behaviour among people who inject pharmaceutical opioids in Australia. *Int J Drug Policy* 2017;42:1-6.
4. Geddes L, Iversen J, Memedovic S, Maher L. Intravenous fentanyl use among people who inject drugs in Australia. *Drug Alcohol Rev* 2018;37 Suppl 1:S314-S22.
5. Iversen J, Wand H, Topp L, Kaldor J, Maher L. Extremely low and sustained HIV incidence among people who inject drugs in a setting of harm reduction. *AIDS* 2014;28(2):275-8.
6. Iversen J, Dore G, Catlett B, Cunningham P, Grebely J, Maher L. Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia. *Journal of Hepatology* 2019;70(1):33-39.

National

Table 1.1.1 Number (percentage) of respondents by demographic characteristics and survey year

National	2014	2015	2016	2017	2018
Number of sites	50	47	50	52	53
N° surveyed	N=2378	N=2304	N=2210	N=2600	N=2742
Response rate (%)	48%	41%	41%	41%	45%
Gender (%)					
Male	1635 (69)	1568 (68)	1449 (66)	1721 (66)	1828 (67)
Female	725 (30)	716 (31)	740 (33)	848 (33)	899 (33)
Transgender	16 (<1)	18 (1)	15 (1)	24 (1)	13 (<1)
Not reported	2 (<1)	2 (<1)	6 (<1)	7 (<1)	2 (<1)
Sexual identity (%)					
Heterosexual	1914 (80)	1900 (82)	1727 (78)	2019 (78)	2133 (78)
Bisexual	209 (9)	192 (8)	220 (10)	233 (9)	259 (9)
Homosexual	92 (4)	95 (4)	93 (4)	132 (5)	122 (4)
Not reported	163 (7)	117 (5)	170 (8)	216 (8)	228 (8)
Aboriginal and Torres Strait Islander origin (%)					
No	2010 (85)	1930 (84)	1738 (79)	2081 (80)	2135 (78)
Yes	321 (14)	334 (15)	395 (18)	460 (18)	533 (19)
Not reported	47 (2)	40 (2)	77 (3)	59 (2)	74 (3)
Region/country of birth (%)					
Australia	2021 (85)	1961 (85)	1904 (86)	2257 (87)	2347 (86)
Other Oceania	89 (4)	83 (4)	74 (3)	81 (3)	83 (3)
Asia	40 (2)	42 (2)	25 (1)	31 (1)	31 (1)
UK & Ireland	100 (4)	107 (5)	81 (4)	111 (4)	122 (4)
Other	107 (5)	73 (3)	76 (3)	86 (3)	120 (4)
Not reported	21 (<1)	38 (2)	50 (2)	34 (1)	39 (1)
Main language spoken at home by parents (%)					
English	2195 (92)	2158 (94)	2036 (92)	2455 (94)	2538 (93)
Non-English	165 (7)	117 (5)	133 (6)	130 (5)	168 (6)
Not reported	18 (<1)	29 (1)	41 (2)	15 (1)	36 (1)
Age and time since first injection (years)					
<i>Median age</i>	39	40	42	42	42
<i>Age range</i>	14-68	15-70	17-76	16-76	14-78
Age group (%)					
<25 years	143 (6)	108 (5)	86 (4)	122 (5)	116 (4)
25+ years	2226 (94)	2191 (95)	2119 (96)	2466 (95)	2617 (95)
Not reported	9 (<1)	5 (<1)	5 (<1)	12 (<1)	9 (<1)
Median age first injection					
<i>Median age first injection</i>	18	19	18	19	19
<i>Age range</i>	14-68	10-63	10-76	10-76	11-48
<i>N° not reported</i>	67	62	83	127	128
Median yrs since first injection					
<i>Median yrs since first injection</i>	19	20	21	21	22
Range					
<i>Range</i>	<1-49	<1-52	<1-53	<1-59	<1-53
Years since first injection					
<3 years	165 (7)	147 (6)	110 (5)	149 (6)	137 (5)
3+ years	2140 (90)	2093 (91)	2016 (91)	2324 (89)	2475 (90)
Not reported	73 (3)	64 (3)	84 (4)	127 (5)	130 (5)
Imprisonment last year (%)					
No	1947 (82)	1958 (85)	1821 (82)	2105 (81)	2208 (81)
Yes	254 (11)	231 (10)	269 (12)	316 (12)	346 (13)
Not reported	177 (7)	115 (5)	120 (5)	179 (7)	188 (7)
N° in prison					
<i>N° in prison</i>	N=254	N=231	N=269	N=316	N=346
Injected in prison	91 (36)	80 (35)	89 (33)	100 (32)	116 (34)

Table 1.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year

National N° surveyed	2014 N=2378	2015 N=2304	2016 N=2210	2017 N=2600	2018 N=2742
Drug last injected (%)					
Cocaine	29 (1)	20 (1)	17 (1)	27 (1)	28 (1)
Methamphetamine	779 (33)	838 (36)	953 (43)	1070 (41)	1314 (48)
Heroin	727 (31)	725 (31)	608 (28)	778 (30)	714 (26)
Pharm. opioids	252 (11)	226 (10)	176 (8)	227 (9)	204 (7)
Methadone	139 (6)	139 (6)	121 (5)	130 (5)	112 (4)
Buprenorphine	53 (2)	62 (3)	52 (2)	51 (2)	63 (2)
Buprenorphine/naloxone	42 (2)	26 (1)	38 (2)	30 (1)	39 (1)
PIEDs	156 (7)	148 (6)	86 (4)	117 (5)	100 (4)
More than one	128 (5)	92 (4)	129 (6)	120 (5)	137 (5)
Other	62 (3)	28 (1)	30 (1)	25 (1)	18 (1)
Not reported	11 (<1)	0 (0)	0 (0)	25 (1)	13 (<1)
Ever injected opioids					
No	-	-	445 (20)	573 (22)	627 (23)
Yes	-	-	1757 (80)	2013 (77)	2078 (76)
Not reported	-	-	8 (<1)	14 (1)	37 (1)
Frequency of injection last month (%)					
Not last month	206 (9)	200 (9)	170 (8)	249 (10)	228 (8)
Less than weekly	364 (15)	377 (16)	338 (15)	387 (15)	387 (14)
Weekly not daily	617 (26)	605 (26)	545 (25)	593 (23)	669 (24)
Daily or more	1160 (49)	1089 (47)	1110 (50)	1334 (51)	1396 (51)
Not reported	31 (1)	33 (1)	47 (2)	37 (1)	62 (2)
Present when someone injected for the first time in the last 12 months (%)					
No	1902 (80)	1881 (82)	1771 (80)	2048 (79)	2157 (79)
Yes	403 (17)	367 (16)	382 (17)	452 (17)	475 (17)
Not reported	73 (3)	56 (2)	57 (3)	100 (4)	110 (4)
Overdosed in last 12 months					
No	1935 (81)	1922 (83)	1739 (79)	2029 (78)	2106 (77)
Yes	367 (15)	328 (14)	403 (18)	463 (18)	520 (19)
Not reported	76 (3)	54 (2)	68 (3)	108 (4)	116 (4)

Table 1.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year

National	2014	2015	2016	2017	2018
N° injected last month	N=2141	N=2071	N=1993	N=2314	N=2452
Places injected last month (%)					
All private	1346 (63)	1287 (62)	1067 (54)	1275 (55)	1307 (53)
Any public	781 (36)	774 (37)	915 (46)	1022 (44)	1129 (46)
Not reported	14 (<1)	10 (<1)	11 (1)	17 (1)	16 (1)
Use of new and sterile needles and syringes last month (%)					
All injections	1657 (77)	1537 (74)	1424 (71)	1734 (75)	1795 (73)
Most of the time	381 (18)	426 (21)	442 (22)	457 (20)	502 (20)
Half of the time	33 (2)	55 (3)	49 (2)	46 (2)	60 (2)
Some of the time	20 (1)	23 (1)	33 (2)	30 (1)	44 (2)
Not last month	8 (<1)	11 (1)	19 (1)	12 (1)	20 (1)
Not reported	42 (2)	19 (1)	26 (1)	35 (2)	31 (1)
Re-used someone else's used needle & syringe last month (%)					
None	1772 (83)	1728 (83)	1597 (80)	1890 (82)	1977 (81)
Once	129 (6)	104 (5)	114 (6)	126 (5)	164 (7)
Twice	84 (4)	85 (4)	111 (6)	115 (5)	92 (4)
3-5 times	71 (3)	85 (4)	78 (4)	87 (4)	104 (4)
>5 times	48 (2)	58 (3)	73 (4)	61 (3)	89 (4)
Not reported	37 (2)	11 (1)	20 (1)	35 (2)	26 (1)
Number of people needle & syringe was re-used after last month (%)					
None	1772 (83)	1728 (83)	1597 (80)	1890 (82)	1977 (81)
One	136 (6)	142 (7)	152 (8)	158 (7)	194 (8)
Two	27 (1)	36 (2)	37 (2)	39 (2)	36 (1)
Three to five	12 (<1)	19 (1)	31 (2)	24 (1)	34 (1)
More than five	18 (1)	11 (1)	22 (1)	17 (1)	31 (1)
Don't know	60 (3)	72 (3)	76 (4)	101 (4)	85 (3)
Not reported	116 (5)	63 (3)	78 (4)	85 (4)	95 (4)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	132 (6)	117 (6)	155 (8)	131 (6)	172 (7)
Casual sex partner	10 (<1)	17 (1)	16 (1)	21 (1)	21 (1)
Close friend	62 (3)	94 (5)	98 (5)	115 (5)	131 (5)
Acquaintance	36 (2)	38 (2)	52 (3)	54 (2)	55 (2)
Other	26 (1)	32 (2)	20 (1)	40 (2)	38 (2)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	460 (21)	461 (22)	428 (21)	506 (22)	513 (21)
Water	362 (17)	358 (17)	379 (19)	435 (19)	484 (20)
Filter	223 (10)	228 (11)	195 (10)	251 (11)	243 (10)
Drug mix	177 (8)	221 (11)	191 (10)	210 (9)	251 (10)
None	1477 (69)	1415 (68)	1354 (68)	1541 (67)	1644 (67)
Injected by someone after that person injected themselves or others last month (%)					
No	1740 (81)	1761 (85)	1638 (82)	1905 (82)	1980 (81)
Yes	316 (15)	288 (14)	329 (17)	377 (16)	431 (18)
Not reported	85 (4)	22 (1)	26 (1)	32 (1)	41 (2)
Source of needle acquisition					
Needle Syringe Program	1916 (89)	1865 (90)	1757 (88)	2019 (87)	2140 (87)
Chemist/Pharmacy	456 (21)	465 (22)	495 (25)	539 (23)	588 (24)
Personal sources	230 (11)	255 (12)	268 (13)	272 (12)	306 (12)
Dispensing/Vending Machine	279 (13)	280 (14)	324 (16)	351 (15)	400 (16)
Other sources	37 (2)	52 (3)	49 (2)	71 (3)	100 (4)

Table 1.1.4 Number (percentage) of respondents by treatment for drug use and survey year

National	2014	2015	2016	2017	2018
N° surveyed	N=2378	N=2304	N=2210	N=2600	N=2742
Ever any treatment/therapy for drug use (%)					
No	582 (24)	590 (26)	566 (26)	693 (27)	748 (27)
Yes	1750 (74)	1672 (73)	1566 (71)	1837 (71)	1901 (69)
Not reported	46 (2)	42 (2)	78 (4)	70 (3)	93 (3)
History of methadone maintenance treatment (%)					
Currently	641 (27)	600 (26)	538 (24)	617 (24)	583 (21)
Previously	565 (24)	550 (24)	522 (24)	575 (22)	645 (24)
Never	1123 (47)	1105 (48)	1048 (47)	1343 (52)	1411 (51)
Not reported	49 (2)	49 (2)	102 (5)	65 (3)	103 (4)
History of buprenorphine (Subutex®) treatment (%)					
Currently	197 (8)	177 (8)	143 (6)	184 (7)	196 (7)
Previously	653 (27)	655 (28)	575 (26)	638 (25)	703 (26)
Never	1472 (62)	1422 (62)	1408 (64)	1715 (66)	1759 (64)
Not reported	56 (2)	50 (2)	84 (4)	63 (2)	84 (3)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	196 (8)	187 (8)	164 (7)	196 (8)	212 (8)
Previously	526 (22)	533 (23)	482 (22)	568 (22)	645 (24)
Never	1597 (67)	1530 (66)	1487 (67)	1775 (68)	1799 (66)
Not reported	59 (2)	54 (2)	77 (3)	61 (2)	86 (3)

Table 1.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year

National	2014	2015	2016	2017	2018
N° surveyed	N=2378	N=2304	N=2210	N=2600	N=2742
Previous HIV test (%)					
Yes, ever	1951 (82)	1950 (85)	1840 (83)	2097 (81)	2211 (81)
Yes, last year	1170 (49)	1151 (50)	1120 (51)	1273 (49)	1363 (50)
>1 year ago	781 (33)	799 (35)	720 (33)	824 (32)	848 (31)
Never tested	332 (14)	297 (13)	293 (13)	369 (14)	390 (14)
Not reported	95 (4)	57 (2)	77 (3)	134 (5)	141 (5)
Previous HCV test (%)					
Yes, ever	2047 (86)	2016 (88)	1825 (83)	2099 (81)	2201 (80)
Yes, last year	1276 (54)	1244 (54)	1203 (54)	1420 (55)	1455 (53)
>1 year ago	771 (32)	772 (34)	622 (28)	679 (26)	746 (27)
Never tested	214 (9)	187 (8)	185 (8)	253 (10)	251 (9)
Not reported	117 (5)	101 (4)	200 (9)	248 (10)	290 (11)
Lifetime treatment for HCV (%)#					
N° self-reported HCV diagnosis	N=709	N=713	N=643	N=697	N=738
Antiviral treatment	89 (13)	79 (11)	184 (29)	314 (45)	409 (55)
No antiviral treatment	603 (85)	604 (85)	454 (71)	376 (54)	322 (44)
Not reported	17 (2)	30 (4)	5 (1)	7 (1)	7 (1)
Treatment for HCV in past 12 months (%)#*					
N° self-reported HCV diagnosis	N=669	N=685	N=617	N=639	N=603
Antiviral treatment	7 (1)	14 (2)	137 (22)	227 (36)	236 (39)
No antiviral treatment	645 (96)	641 (94)	475 (77)	405 (63)	360 (60)
Not reported	17 (3)	30 (4)	5 (1)	7 (1)	7 (1)

among people who tested HCV antibody positive and did not report spontaneous clearance

* excludes people who reported treatment induced clearance more than 12 months previously

Table 1.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year

National	2014	2015	2016	2017	2018
N° surveyed	N=2378	N=2304	N=2210	N=2600	N=2742
Sex with a regular partner last month (%)					
No	1166 (49)	1116 (48)	1089 (49)	1329 (51)	1374 (50)
Yes	1114 (47)	1086 (47)	1039 (47)	1129 (43)	1228 (45)
Not reported	98 (4)	102 (4)	82 (4)	142 (5)	140 (5)
Condom used with regular partner last month (%)					
N° surveyed	N=1114	N=1086	N=1039	N=1129	N=1228
Never	800 (72)	832 (77)	746 (72)	822 (73)	924 (75)
Sometimes	145 (13)	106 (10)	135 (13)	136 (12)	137 (11)
Every time	110 (10)	113 (10)	105 (10)	126 (11)	95 (8)
Not reported	59 (5)	35 (3)	53 (5)	45 (4)	72 (6)
Sex with other partner(s) last month (%)					
No	1895 (80)	1901 (83)	1777 (80)	2074 (80)	2137 (78)
Yes	357 (15)	319 (14)	331 (15)	349 (13)	420 (15)
Not reported	126 (5)	84 (4)	102 (5)	177 (7)	185 (7)
Condom used with other partner(s) last month (%)					
N° surveyed	N=357	N=319	N=331	N=349	N=420
Never	118 (33)	112 (35)	124 (37)	126 (36)	179 (43)
Sometimes	98 (27)	99 (31)	105 (32)	123 (35)	117 (28)
Every time	101 (28)	95 (30)	95 (29)	84 (24)	105 (25)
Not reported	40 (11)	13 (4)	7 (2)	16 (5)	19 (5)
Sex work last month (%)					
No	2050 (86)	2137 (93)	1969 (89)	2274 (87)	2394 (87)
Yes	133 (6)	96 (4)	121 (5)	133 (5)	154 (6)
Not reported	195 (8)	71 (3)	120 (5)	193 (7)	194 (7)
Condom used at last sex work (%)					
Yes	83 (62)	66 (69)	82 (68)	94 (71)	100 (65)

HIV antibody prevalence

Table 1.2.1 HIV antibody prevalence by gender and survey year

National Survey year	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014	1558	33 (2.1)	702	3 (0.4)	2273	39 (1.7)
2015	1502	33 (2.2)	696	3 (0.4)	2217	38 (1.7)
2016	1412	24 (1.7)	727	5 (0.7)	2160	31 (1.4)
2017	1641	45 (2.7)	820	7 (0.9)	2492	53 (2.1)
2018	1784	37 (2.1)	888	8 (0.9)	2686	46 (1.7)
X ² p trend		0.710		0.145		0.641

Table 1.2.2 HIV antibody prevalence by sexual identity, gender and survey year

National Sexual identity	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
Heterosexual	1332	8 (0.6)	497	3 (0.6)	1832	11 (0.6)
Bisexual	58	5 (8.6)	134	0 (0.0)	199	8 (4.0)
Homosexual	64	19 (29.7)	23	0 (0.0)	88	19 (21.6)
p value		<0.001		1.000		<0.001
2015						
Heterosexual	1315	7 (0.5)	514	2 (0.4)	1835	9 (0.5)
Bisexual	69	4 (5.8)	110	1 (0.9)	185	6 (3.2)
Homosexual	53	21 (39.6)	28	0 (0.0)	84	21 (25.0)
p value		<0.001		0.511		<0.001
2016						
Heterosexual	1193	6 (0.5)	492	3 (0.6)	1691	9 (0.5)
Bisexual	61	3 (4.9)	148	1 (0.7)	214	5 (2.3)
Homosexual	58	14 (24.1)	27	0 (0.0)	90	15 (16.7)
p value		<0.001		1.000		<0.001
2017						
Heterosexual	1352	12 (0.9)	577	3 (0.5)	1934	16 (0.8)
Bisexual	82	6 (7.3)	135	3 (2.2)	227	9 (4.0)
Homosexual	68	24 (35.3)	44	0 (0.0)	122	24 (19.7)
p value		<0.001		0.165		<0.001
2018						
Heterosexual	1473	12 (0.8)	611	6 (1.0)	2086	18 (0.9)
Bisexual	90	6 (6.7)	162	2 (1.2)	255	8 (3.1)
Homosexual	80	16 (20.0)	35	0 (0.0)	120	17 (14.2)
p value		<0.001		0.773		<0.001

Table 1.2.3 HIV antibody prevalence by age group, gender and survey year

National Age group	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
<25 years	98	1 (1.0)	33	0 (0.0)	133	1 (0.8)
25-34 years	363	7 (1.9)	204	0 (0.0)	570	8 (1.4)
35-44 years	596	8 (1.3)	273	2 (0.7)	874	12 (1.4)
45+ years	495	17 (3.4)	190	1 (0.5)	688	18 (2.6)
p value		0.114		0.681		0.224
2015						
<25 years	67	0 (0.0)	32	1 (3.1)	101	1 (1.0)
25-34 years	347	10 (2.9)	187	1 (0.5)	540	13 (2.4)
35-44 years	545	6 (1.1)	248	0 (0.0)	796	6 (0.8)
45+ years	539	17 (3.2)	229	1 (0.4)	776	18 (2.3)
p value		0.055		0.092		0.033
2016						
<25 years	51	1 (2.0)	32	0 (0.0)	86	1 (1.2)
25-34 years	262	7 (2.7)	169	1 (0.6)	433	8 (1.9)
35-44 years	528	3 (0.6)	274	1 (0.4)	808	4 (0.5)
45+ years	568	13 (2.3)	251	3 (1.2)	829	18 (2.2)
p value		0.039		0.640		0.016
2017						
<25 years	76	1 (1.3)	40	0 (0.0)	118	1 (0.9)
25-34 years	275	7 (2.6)	166	0 (0.0)	454	8 (1.8)
35-44 years	587	14 (2.4)	302	2 (0.7)	894	16 (1.8)
45+ years	695	23 (3.3)	308	5 (1.6)	1014	28 (2.8)
p value		0.716		0.329		0.390
2018						
<25 years	60	1 (1.7)	49	0 (0.0)	111	1 (0.9)
25-34 years	284	12 (4.2)	194	2 (1.0)	480	14 (2.9)
35-44 years	643	6 (0.9)	338	1 (0.3)	987	7 (0.7)
45+ years	791	18 (2.3)	304	5 (1.6)	1099	24 (2.2)
p value		0.013		0.313		0.005

Table 1.2.4 HIV antibody prevalence by last drug injected, gender and survey year

National Last drug injected	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
Heroin	460	6 (1.3)	233	1 (0.4)	696	8 (1.2)
Methamphetamine	472	20 (4.2)	265	1 (0.4)	741	21 (2.8)
Other opioids	326	3 (0.9)	145	0 (0.0)	474	3 (0.6)
PIEDs	144	2 (1.4)	5	0 (0.0)	150	2 (1.3)
Other drugs	149	2 (1.3)	52	1 (1.9)	203	5 (2.5)
p value		0.011		0.416		0.024
2015						
Heroin	468	9 (1.9)	230	1 (0.4)	704	11 (1.6)
Methamphetamine	516	21 (4.1)	271	2 (0.7)	798	24 (3.0)
Other opioids	300	2 (0.7)	142	0 (0.0)	444	2 (0.5)
PIEDs	140	1 (0.7)	6	0 (0.0)	146	1 (0.7)
Other drugs	78	0 (0.0)	47	0 (0.0)	125	0 (0.0)
p value		0.008		0.842		0.005
2016						
Heroin	384	5 (1.3)	207	4 (1.9)	595	9 (1.5)
Methamphetamine	582	16 (2.8)	339	1 (0.3)	929	19 (2.1)
Other opioids	254	0 (0.0)	125	0 (0.0)	381	0 (0.0)
PIEDs	80	1 (1.3)	0	0 (0.0)	82	1 (1.2)
Other drugs	112	2 (1.8)	56	0 (0.0)	173	2 (1.2)
p value		0.035		0.146		0.028
2017						
Heroin	468	7 (1.5)	274	3 (1.1)	751	10 (1.3)
Methamphetamine	651	31 (4.8)	356	3 (0.8)	1016	35 (3.4)
Other opioids	292	3 (1.0)	131	0 (0.0)	428	3 (0.7)
PIEDs	99	0 (0.0)	3	0 (0.0)	105	0 (0.0)
Other drugs	131	4 (3.1)	56	1 (1.8)	192	5 (2.6)
p value		0.001		0.479		0.001
2018						
Heroin	460	8 (1.7)	238	2 (0.8)	701	10 (1.4)
Methamphetamine	828	25 (3.0)	452	6 (1.3)	1287	32 (2.5)
Other opioids	274	1 (0.4)	137	0 (0.0)	412	1 (0.2)
PIEDs	90	0 (0.0)	5	0 (0.0)	96	0 (0.0)
Other drugs	126	3 (2.4)	53	0 (0.0)	181	3 (1.7)
p value		0.035		0.671		0.012

Table 1.2.5 HIV antibody prevalence by years of injection, gender and survey year

National Years of injection	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
<3 years	116	3 (2.6)	41	0 (0.0)	158	3 (1.9)
3 to 10 years	215	10 (4.7)	119	0 (0.0)	335	10 (3.0)
11+ years	1176	19 (1.6)	526	3 (0.6)	1712	24 (1.4)
p value		0.020		1.000		0.097
2015						
<3 years	110	4 (3.6)	32	0 (0.0)	143	4 (2.8)
3 to 10 years	222	10 (4.5)	108	1 (0.9)	337	11 (3.3)
11+ years	1130	18 (1.6)	537	2 (0.4)	1678	22 (1.3)
p value		0.013		0.502		0.020
2016						
<3 years	67	0 (0.0)	39	0 (0.0)	108	0 (0.0)
3 to 10 years	191	10 (5.2)	102	1 (1.0)	296	11 (3.7)
11+ years	1097	12 (1.1)	564	4 (0.7)	1676	18 (1.1)
p value		0.001		0.673		0.003
2017						
<3 years	97	1 (1.0)	44	0 (0.0)	143	1 (0.7)
3 to 10 years	212	10 (4.7)	122	0 (0.0)	339	11 (3.2)
11+ years	1332	34 (2.6)	654	7 (1.1)	2010	41 (2.0)
p value		0.129		0.731		0.215
2018						
<3 years	83	3 (3.6)	46	0 (0.0)	129	3 (2.3)
3 to 10 years	235	9 (3.8)	148	0 (0.0)	384	9 (2.3)
11+ years	1466	25 (1.7)	694	8 (1.2)	2173	34 (1.6)
p value		0.046		0.584		0.420

Table 1.2.6 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

National Receptively shared syringe last month	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
No receptive sharing	1163	22 (1.9)	520	2 (0.4)	1693	26 (1.5)
Receptive sharing	213	4 (1.9)	102	1 (1.0)	316	6 (1.9)
p value		1.000		0.416		0.636
2015						
No receptive sharing	1117	29 (2.6)	535	3 (0.6)	1665	34 (2.0)
Receptive sharing	217	3 (1.4)	96	0 (0.0)	315	3 (1.0)
p value		0.464		1.000		0.257
2016						
No receptive sharing	1018	18 (1.8)	527	4 (0.8)	1559	23 (1.5)
Receptive sharing	243	4 (1.7)	124	0 (0.0)	370	4 (1.1)
p value		1.000		1.000		0.805
2017						
No receptive sharing	1190	31 (2.6)	603	5 (0.8)	1817	36 (2.0)
Receptive sharing	250	7 (2.8)	119	2 (1.7)	372	10 (2.7)
p value		0.861		0.325		0.386
2018						
No receptive sharing	1309	29 (2.2)	637	6 (0.9)	1951	35 (1.8)
Receptive sharing	293	5 (1.7)	148	0 (0.0)	444	5 (1.1)
p value		0.822		0.601		0.322

Table 1.2.7 HIV antibody prevalence by frequency of drug injection last month, gender and survey year

National Frequency of injection	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
Less than daily	641	11 (1.7)	301	0 (0.0)	946	11 (1.2)
Daily or more	753	16 (2.1)	336	3 (0.9)	1096	22 (2.0)
Not last month	144	6 (4.2)	55	0 (0.0)	201	6 (3.0)
p value		0.186		0.416		0.127
2015						
Less than daily	652	18 (2.8)	276	2 (0.7)	937	21 (2.2)
Daily or more	690	14 (2.0)	357	1 (0.3)	1053	16 (1.5)
Not last month	136	1 (0.7)	54	0 (0.0)	194	1 (0.5)
p value		0.339		0.674		0.215
2016						
Less than daily	559	12 (2.2)	300	1 (0.3)	868	14 (1.6)
Daily or more	715	10 (1.4)	358	3 (0.8)	1081	13 (1.2)
Not last month	110	1 (0.9)	54	1 (1.9)	166	2 (1.2)
p value		0.581		0.347		0.712
2017						
Less than daily	643	22 (3.4)	292	3 (1.0)	944	25 (2.7)
Daily or more	817	17 (2.1)	440	4 (0.9)	1276	22 (1.7)
Not last month	153	5 (3.3)	81	0 (0.0)	236	5 (2.1)
p value		0.240		1.000		0.310
2018						
Less than daily	717	13 (1.8)	324	4 (1.2)	1044	17 (1.6)
Daily or more	899	21 (2.3)	472	3 (0.6)	1376	24 (1.7)
Not last month	137	3 (2.2)	82	1 (1.2)	223	5 (2.2)
p value		0.760		0.466		0.817

Table 1.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year

National Imprisonment last year	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
No imprisonment	1260	26 (2.1)	609	3 (0.5)	1874	29 (1.6)
Imprisonment	180	0 (0.0)	51	0 (0.0)	236	3 (1.3)
p value		0.065		1.000		1.000
2015						
No imprisonment	1249	29 (2.3)	625	2 (0.3)	1890	33 (1.8)
Imprisonment	168	1 (0.6)	48	0 (0.0)	219	1 (0.5)
p value		0.247		1.000		0.250
2016						
No imprisonment	1135	16 (1.4)	632	1 (0.2)	1781	18 (1.0)
Imprisonment	200	6 (3.0)	59	2 (3.4)	261	8 (3.1)
p value		0.125		0.020		0.013
2017						
No imprisonment	1300	40 (3.1)	698	5 (0.7)	2023	46 (2.3)
Imprisonment	229	2 (0.9)	67	1 (1.5)	299	3 (1.0)
p value		0.076		0.424		0.196
2018						
No imprisonment	1421	30 (2.1)	748	7 (0.9)	2179	38 (1.7)
Imprisonment	249	7 (2.8)	92	0 (0.0)	343	7 (2.0)
p value		0.489		1.000		0.699

Table 1.2.9 HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year

National Condom use at last sex	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
No condom use	468	7 (1.5)	302	1 (0.3)	771	8 (1.0)
Condom use	177	5 (2.8)	66	0 (0.0)	246	7 (2.9)
p value		0.265		1.000		0.041
2015						
No condom use	495	9 (1.8)	303	0 (0.0)	802	11 (1.4)
Condom use	139	2 (1.4)	66	1 (1.5)	208	3 (1.4)
p value		1.000		0.179		1.000
2016						
No condom use	429	10 (2.3)	289	1 (0.4)	724	11 (1.5)
Condom use	151	2 (1.3)	83	1 (1.2)	237	4 (1.7)
p value		0.740		0.397		0.771
2017						
No condom use	462	17 (3.7)	319	2 (0.6)	786	19 (2.4)
Condom use	170	7 (4.1)	81	1 (1.2)	254	8 (3.2)
p value		0.798		0.494		0.523
2018						
No condom use	545	11 (2.0)	369	1 (0.3)	917	12 (1.3)
Condom use	154	7 (4.6)	67	0 (0.0)	226	7 (3.1)
p value		0.080		1.000		0.060

Table 1.2.10 HIV antibody prevalence by sex work last month, gender and survey year

National Sex work last month	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
No sex work	1364	21 (1.5)	599	3 (0.5)	1969	25 (1.3)
Sex work	58	5 (8.6)	60	0 (0.0)	124	7 (5.7)
p value		<0.001		1.000		<0.001
2015						
No sex work	1415	25 (1.8)	631	3 (0.5)	2059	29 (1.4)
Sex work	34	6 (17.7)	54	0 (0.0)	94	7 (7.5)
p value		<0.001		1.000		<0.001
2016						
No sex work	1286	18 (1.4)	621	3 (0.5)	1921	23 (1.2)
Sex work	50	3 (6.0)	65	1 (1.5)	121	4 (3.3)
p value		0.041		0.329		0.072
2017						
No sex work	1464	39 (2.7)	696	6 (0.9)	2182	45 (2.1)
Sex work	57	4 (7.0)	61	0 (0.0)	126	5 (4.0)
p value		0.074		1.000		0.192
2018						
No sex work	1614	31 (1.9)	740	6 (0.8)	2363	38 (1.6)
Sex work	65	2 (3.1)	81	0 (0.0)	150	2 (1.3)
p value		0.368		1.000		1.000

Table 1.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

National Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
Non Indigenous	1352	26 (1.9)	558	2 (0.4)	1922	30 (1.6)
Indigenous	174	4 (2.3)	132	1 (0.8)	307	6 (2.0)
p value		0.769		0.472		0.612
2015						
Non Indigenous	1282	28 (2.2)	565	1 (0.2)	1864	31 (1.7)
Indigenous	197	5 (2.5)	122	2 (1.6)	319	7 (2.2)
p value		0.754		0.083		0.503
2016						
Non Indigenous	1127	14 (1.2)	555	2 (0.4)	1696	17 (1.0)
Indigenous	233	9 (3.9)	152	2 (1.3)	391	11 (2.8)
p value		0.010		0.204		0.012
2017						
Non Indigenous	1341	33 (2.5)	627	3 (0.5)	1991	37 (1.9)
Indigenous	266	12 (4.5)	172	4 (2.3)	446	16 (3.6)
p value		0.064		0.042		0.024
2018						
Non Indigenous	1439	20 (1.4)	662	3 (0.5)	2111	23 (1.1)
Indigenous	311	15 (4.8)	209	3 (1.4)	523	19 (3.6)
p value		<0.001		0.153		<0.001

Table 1.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and survey year

National Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
English speaking	1426	29 (2.0)	659	2 (0.3)	2096	34 (1.6)
Non-English speaking	120	2 (1.7)	38	1 (2.6)	160	3 (1.9)
p value		1.000		0.155		0.744
2015						
English speaking	1390	31 (2.2)	666	3 (0.5)	2075	36 (1.7)
Non-English speaking	92	2 (2.2)	25	0 (0.0)	117	2 (1.7)
p value		1.000		1.000		1.000
2016						
English speaking	1283	22 (1.7)	688	4 (0.6)	1990	28 (1.4)
Non-English speaking	102	1 (1.0)	26	0 (0.0)	130	1 (0.8)
p value		1.000		1.000		1.000
2017						
English speaking	1534	43 (2.8)	790	7 (0.9)	2352	51 (2.2)
Non-English speaking	96	2 (2.1)	27	0 (0.0)	126	2 (1.6)
p value		1.000		1.000		1.000
2018						
English speaking	1653	36 (2.2)	846	4 (0.5)	2508	41 (1.6)
Non-English speaking	120	1 (0.8)	39	2 (5.1)	164	3 (1.8)
p value		0.511		0.025		0.750

Table 1.2.13 HIV antibody prevalence by region/country of birth, gender and survey year

National Region/country of birth	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
Australia	1304	26 (2.0)	620	2 (0.3)	1934	29 (1.5)
Other Oceania	63	1 (1.6)	20	0 (0.0)	85	3 (3.5)
Asia	35	1 (2.9)	4	1 (25.0)	39	2 (5.1)
UK & Ireland	70	0 (0.0)	28	0 (0.0)	98	0 (0.0)
Other	72	3 (4.2)	26	0 (0.0)	99	3 (3.0)
p value		0.372		0.048		0.056
2015						
Australia	1266	29 (2.3)	606	3 (0.5)	1888	33 (1.8)
Other Oceania	61	1 (1.6)	18	0 (0.0)	80	2 (2.5)
Asia	32	1 (3.1)	9	0 (0.0)	42	1 (2.4)
UK & Ireland	63	1 (1.6)	40	0 (0.0)	104	1 (1.0)
Other	51	0 (0.0)	18	0 (0.0)	69	0 (0.0)
p value		0.878		1.000		0.699
2016						
Australia	1216	22 (1.8)	632	4 (0.6)	1864	27 (1.5)
Other Oceania	46	0 (0.0)	24	0 (0.0)	72	1 (1.4)
Asia	21	0 (0.0)	2	0 (0.0)	24	0 (0.0)
UK & Ireland	47	0 (0.0)	30	0 (0.0)	78	0 (0.0)
Other	50	1 (2.0)	23	0 (0.0)	74	1 (1.4)
p value		0.947		1.000		0.890
2017						
Australia	1415	39 (2.8)	729	6 (0.8)	2167	46 (2.1)
Other Oceania	43	1 (2.3)	31	0 (0.0)	77	1 (1.3)
Asia	18	1 (5.6)	9	0 (0.0)	27	1 (3.7)
UK & Ireland	73	1 (1.4)	33	0 (0.0)	107	1 (0.9)
Other	68	1 (1.5)	10	0 (0.0)	82	1 (1.2)
p value		0.740		1.000		0.820
2018						
Australia	1518	33 (2.2)	793	6 (0.8)	2320	39 (1.7)
Other Oceania	57	1 (1.8)	23	0 (0.0)	82	2 (2.4)
Asia	26	0 (0.0)	4	0 (0.0)	30	0 (0.0)
UK & Ireland	83	2 (2.4)	38	0 (0.0)	121	2 (1.7)
Other	90	1 (1.1)	24	0 (0.0)	117	1 (0.9)
p value		0.964		1.000		0.936

HCV antibody prevalence

Table 1.3.1 HCV antibody prevalence by gender and survey year

National Survey year	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014	1506	802 (53)	684	380 (56)	2203	1188 (54)
2015	1382	790 (57)	654	375 (57)	2054	1173 (57)
2016	1326	695 (52)	672	315 (47)	2016	1019 (51)
2017	1577	786 (50)	799	381 (48)	2404	1178 (49)
2018	1770	817 (46)	884	376 (43)	2668	1200 (45)
X ² p trend		0.002		<0.001		<0.001

Table 1.3.2 HCV antibody prevalence by sexual identity, gender and survey year

National Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
Heterosexual	1286	692 (54)	481	266 (55)	1770	959 (54)
Bisexual	57	28 (49)	133	72 (54)	197	104 (53)
Homosexual	64	22 (34)	23	12 (52)	88	34 (39)
p value		0.008		0.936		0.017
2015						
Heterosexual	1214	698 (58)	481	273 (57)	1701	974 (57)
Bisexual	58	34 (59)	103	63 (61)	167	98 (59)
Homosexual	50	19 (38)	27	15 (56)	80	36 (45)
p value		0.023		0.699		0.085
2016						
Heterosexual	1115	597 (54)	451	207 (46)	1570	806 (51)
Bisexual	58	24 (41)	145	76 (52)	208	103 (50)
Homosexual	57	22 (39)	23	6 (26)	84	30 (36)
p value		0.021		0.051		0.020
2017						
Heterosexual	1292	657 (51)	560	265 (47)	1856	923 (50)
Bisexual	80	40 (50)	132	66 (50)	221	109 (49)
Homosexual	70	15 (21)	45	16 (36)	125	36 (29)
p value		<0.001		0.239		<0.001
2018						
Heterosexual	1462	690 (47)	610	264 (43)	2074	955 (46)
Bisexual	89	34 (38)	161	64 (40)	253	101 (40)
Homosexual	80	28 (35)	35	15 (43)	120	44 (37)
p value		0.032		0.723		0.031

Table 1.3.3 HCV antibody prevalence by age group, gender and survey year

National Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
<25 years	98	12 (12)	33	8 (24)	133	20 (15)
25-34 years	355	136 (38)	198	109 (55)	556	247 (44)
35-44 years	572	336 (59)	266	144 (54)	843	482 (57)
45+ years	475	315 (66)	185	117 (63)	663	434 (65)
p value		<0.001		<0.001		<0.001
2015						
<25 years	60	11 (18)	29	5 (17)	91	16 (18)
25-34 years	325	127 (39)	176	102 (58)	507	232 (46)
35-44 years	507	302 (60)	232	120 (52)	742	423 (57)
45+ years	486	347 (71)	217	148 (68)	710	499 (70)
p value		<0.001		<0.001		<0.001
2016						
<25 years	50	10 (20)	29	12 (41)	82	24 (29)
25-34 years	248	92 (37)	159	67 (42)	408	160 (39)
35-44 years	502	286 (57)	254	123 (48)	761	410 (54)
45+ years	523	306 (59)	229	113 (49)	761	424 (56)
p value		<0.001		0.459		<0.001
2017						
<25 years	73	6 (8)	40	9 (23)	115	15 (13)
25-34 years	264	104 (39)	163	72 (44)	438	180 (41)
35-44 years	558	278 (50)	296	143 (48)	859	422 (49)
45+ years	674	394 (58)	296	155 (52)	980	555 (57)
p value		<0.001		0.003		<0.001
2018						
<25 years	58	10 (17)	49	10 (20)	109	21 (19)
25-34 years	283	96 (34)	192	75 (39)	477	172 (36)
35-44 years	638	296 (46)	337	150 (45)	981	449 (46)
45+ years	785	411 (52)	303	140 (46)	1092	553 (51)
p value		<0.001		0.005		<0.001

Table 1.3.4 HCV antibody prevalence by years since first injection, gender and survey year

National Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
<3 years	116	7 (6)	41	5 (12)	158	12 (8)
3 to 10 years	212	67 (32)	119	54 (45)	332	121 (37)
11+ years	1126	704 (63)	508	311 (61)	1644	1021 (62)
p value		<0.001		<0.001		<0.001
2015						
<3 years	101	14 (14)	27	6 (22)	128	20 (16)
3 to 10 years	206	67 (33)	101	40 (40)	314	108 (34)
11+ years	1040	693 (67)	508	321 (63)	1559	1021 (65)
p value		<0.001		<0.001		<0.001
2016						
<3 years	67	5 (7)	38	8 (21)	107	14 (13)
3 to 10 years	184	55 (30)	93	34 (37)	280	91 (33)
11+ years	1022	601 (59)	522	265 (51)	1556	872 (56)
p value		<0.001		<0.001		<0.001
2017						
<3 years	96	4 (4)	44	5 (11)	142	9 (6)
3 to 10 years	207	55 (27)	122	37 (30)	333	93 (28)
11+ years	1199	684 (57)	594	323 (54)	1813	1016 (56)
p value		<0.001		<0.001		<0.001
2018						
<3 years	83	9 (11)	46	2 (4)	129	11 (9)
3 to 10 years	233	51 (22)	146	47 (32)	380	99 (26)
11+ years	1373	713 (52)	659	312 (47)	2043	1031 (50)
p value		<0.001		<0.001		<0.001

Table 1.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

National Receptively shared syringe last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
No receptive sharing	113	10 (9)	1496	840 (56)	1647	869 (53)
Receptive sharing	9	1 (11)	282	195 (69)	302	205 (68)
p value		0.586		<0.001		<0.001
2015						
No receptive sharing	92	13 (14)	1428	862 (60)	1545	888 (57)
Receptive sharing	13	4 (31)	275	180 (65)	294	190 (65)
p value		0.218		0.113		0.023
2016						
No receptive sharing	75	10 (13)	1341	699 (52)	1460	736 (50)
Receptive sharing	18	2 (11)	318	177 (56)	347	187 (54)
p value		1.000		0.256		0.244
2017						
No receptive sharing	106	6 (6)	1580	801 (51)	1747	841 (48)
Receptive sharing	18	2 (11)	317	188 (59)	359	204 (57)
p value		0.328		0.005		0.003
2018						
No receptive sharing	86	6 (7)	1787	813 (46)	1935	849 (44)
Receptive sharing	23	4 (17)	391	219 (56)	442	244 (55)
p value		0.214		<0.001		<0.001

Table 1.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year

National Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
Heroin	17	4 (24)	639	429 (67)	674	444 (66)
Methamphetamine	46	4 (9)	568	336 (51)	717	347 (48)
Other opioids	11	3 (27)	437	272 (62)	456	279 (61)
PIEDs	68	0 (0)	72	1 (1)	149	2 (1)
Other drugs	15	1 (7)	168	102 (61)	198	113 (57)
p value		0.001		<0.001		<0.001
2015						
Heroin	10	2 (20)	646	475 (74)	663	483 (73)
Methamphetamine	51	10 (20)	665	321 (48)	729	340 (47)
Other opioids	9	3 (33)	388	263 (68)	402	271 (67)
PIEDs	49	1 (2)	69	2 (3)	127	3 (2)
Other drugs	7	3 (43)	90	59 (66)	104	64 (62)
p value		0.007		<0.001		<0.001
2016						
Heroin	7	2 (29)	518	346 (67)	539	354 (66)
Methamphetamine	59	8 (14)	783	336 (43)	870	362 (42)
Other opioids	5	3 (60)	326	192 (59)	340	202 (59)
PIEDs	26	0 (0)	46	0 (0)	75	0 (0)
Other drugs	7	1 (14)	130	68 (52)	152	78 (51)
p value		0.005		<0.001		<0.001
2017						
Heroin	16	4 (25)	653	442 (68)	703	473 (67)
Methamphetamine	70	4 (6)	883	343 (39)	987	363 (37)
Other opioids	8	1 (13)	380	229 (60)	412	240 (58)
PIEDs	36	0 (0)	64	2 (3)	103	2 (2)
Other drugs	12	0 (0)	144	80 (56)	166	84 (51)
p value		0.010		<0.001		<0.001
2018						
Heroin	12	2 (17)	650	381 (59)	685	399 (58)
Methamphetamine	82	7 (9)	1127	433 (38)	1260	463 (37)
Other opioids	3	1 (33)	385	212 (55)	404	223 (55)
PIEDs	20	0 (0)	68	1 (1)	95	1 (1)
Other drugs	11	1 (9)	149	81 (55)	172	88 (51)
p value		0.266		<0.001		<0.001

Table 1.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

National Frequency of injection last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
Less than daily	63	3 (5)	840	464 (55)	926	480 (52)
Daily or more	61	8 (13)	966	589 (61)	1055	612 (58)
Not last month	33	1 (3)	147	75 (51)	194	79 (41)
p value		0.165		0.011		<0.001
2015						
Less than daily	65	7 (11)	792	467 (59)	875	483 (55)
Daily or more	41	10 (24)	919	578 (63)	973	598 (61)
Not last month	20	2 (10)	147	75 (51)	177	80 (45)
p value		0.181		0.015		<0.001
2016						
Less than daily	56	7 (13)	743	391 (53)	815	407 (50)
Daily or more	37	5 (14)	933	498 (53)	1010	529 (52)
Not last month	11	2 (18)	127	53 (42)	151	60 (40)
p value		0.840		0.046		0.014
2017						
Less than daily	66	4 (6)	815	398 (49)	913	416 (46)
Daily or more	59	4 (7)	1107	607 (55)	1223	647 (53)
Not last month	17	1 (6)	202	91 (45)	235	99 (42)
p value		1.000		0.005		<0.001
2018						
Less than daily	60	6 (10)	948	432 (46)	1040	453 (44)
Daily or more	50	4 (8)	1253	611 (49)	1362	652 (48)
Not last month	18	1 (6)	185	68 (37)	223	74 (33)
p value		0.914		0.007		<0.001

Table 1.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

National Imprisonment last year	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
No imprisonment	143	8 (6)	1618	908 (56)	1814	942 (52)
Imprisonment	7	2 (29)	215	144 (67)	228	149 (65)
p value		0.070		0.003		<0.001
2015						
No imprisonment	113	17 (15)	1590	914 (54)	1750	950 (54)
Imprisonment	7	3 (43)	188	152 (76)	200	152 (76)
p value		0.090		<0.001		<0.001
2016						
No imprisonment	87	9 (10)	1519	760 (50)	1663	801 (48)
Imprisonment	11	2 (18)	222	151 (68)	245	160 (65)
p value		0.607		<0.001		<0.001
2017						
No imprisonment	126	8 (6)	1742	860 (49)	1955	908 (46)
Imprisonment	8	0 (0)	258	166 (64)	285	182 (64)
p value		1.000		<0.001		<0.001
2018						
No imprisonment	109	8 (7)	1979	889 (45)	2166	932 (43)
Imprisonment	16	1 (6)	300	172 (57)	338	186 (55)
p value		1.000		<0.001		<0.001

Table 1.3.9 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

National Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
Non Indigenous	1307	675 (52)	545	293 (54)	1864	974 (52)
Indigenous	169	112 (66)	127	79 (62)	297	191 (64)
p value		<0.001		0.085		<0.001
2015						
Non Indigenous	1190	654 (55)	529	298 (56)	1735	958 (55)
Indigenous	173	129 (75)	116	73 (63)	289	202 (70)
p value		<0.001		0.193		<0.001
2016						
Non Indigenous	1056	544 (52)	513	236 (46)	1580	786 (50)
Indigenous	218	122 (56)	141	68 (48)	365	193 (53)
p value		0.231		0.639		0.281
2017						
Non Indigenous	1290	603 (47)	611	288 (47)	1922	899 (47)
Indigenous	254	163 (64)	167	83 (50)	428	249 (58)
p value		<0.001		0.556		<0.001
2018						
Non Indigenous	1431	625 (44)	660	270 (41)	2101	899 (43)
Indigenous	305	175 (57)	208	99 (48)	516	276 (53)
p value		<0.001		0.089		<0.001

Table 1.3.10 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

National Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
English speaking	1381	732 (53)	641	355 (55)	2033	1092 (54)
Non-English speaking	114	65 (57)	38	21 (55)	154	87 (56)
p value		0.409		0.989		0.505
2015						
English speaking	1275	723 (57)	625	356 (57)	1918	1087 (57)
Non-English speaking	89	56 (63)	24	16 (67)	113	72 (64)
p value		0.252		0.345		0.142
2016						
English speaking	1201	626 (52)	638	294 (46)	1855	928 (50)
Non-English speaking	99	54 (55)	22	14 (64)	123	69 (56)
p value		0.643		0.105		0.192
2017						
English speaking	1476	729 (49)	769	366 (48)	2270	1106 (49)
Non-English speaking	91	51 (56)	27	14 (52)	121	65 (54)
p value		0.218		0.663		0.284
2018						
English speaking	1640	752 (46)	843	360 (43)	2492	1116 (45)
Non-English speaking	118	61 (52)	39	16 (41)	162	80 (49)
p value		0.219		0.836		0.254

Table 1.3.11 HCV antibody prevalence by region/country of birth, gender and survey year

National Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
Australia	1257	687 (55)	602	327 (54)	1869	1018 (54)
Other Oceania	63	26 (41)	19	10 (53)	84	37 (44)
Asia	35	22 (63)	4	3 (75)	39	25 (64)
UK & Ireland	68	35 (51)	29	21 (72)	97	56 (58)
Other	70	28 (40)	26	16 (62)	97	45 (46)
p value		0.027		0.318		0.095
2015						
Australia	1167	674 (58)	571	339 (59)	1753	1020 (58)
Other Oceania	54	26 (48)	15	6 (40)	70	33 (47)
Asia	32	16 (50)	8	3 (38)	41	19 (46)
UK & Ireland	55	31 (56)	37	17 (46)	93	48 (52)
Other	49	28 (57)	18	8 (44)	67	36 (54)
p value		0.619		0.117		0.132
2016						
Australia	1141	596 (52)	588	271 (46)	1743	874 (50)
Other Oceania	45	27 (60)	23	12 (52)	69	40 (58)
Asia	19	11 (58)	2	0 (0)	22	11 (50)
UK & Ireland	44	22 (50)	25	12 (48)	70	35 (50)
Other	49	24 (49)	19	12 (63)	69	36 (52)
p value		0.806		0.422		0.788
2017						
Australia	1357	665 (49)	709	344 (49)	2086	1017 (49)
Other Oceania	41	21 (51)	30	11 (37)	74	34 (46)
Asia	17	9 (53)	9	6 (67)	26	15 (58)
UK & Ireland	71	40 (56)	33	13 (39)	105	54 (51)
Other	67	35 (52)	10	3 (30)	81	38 (47)
p value		0.775		0.287		0.832
2018						
Australia	1504	689 (46)	790	342 (43)	2303	1035 (45)
Other Oceania	57	23 (40)	23	6 (26)	82	29 (35)
Asia	26	17 (65)	4	4 (100)	30	21 (70)
UK & Ireland	82	39 (48)	38	14 (37)	120	53 (44)
Other	90	44 (49)	24	8 (33)	117	55 (47)
p value		0.282		0.052		0.028

HCV RNA prevalence

Table 1.4.1 HCV RNA prevalence by gender and survey year *

National Survey year	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015	658	350 (53)	311	141 (45)	978	496 (51)
2016	504	188 (37)	257	68 (26)	767	256 (33)
2017	1073	305 (28)	529	110 (21)	1621	416 (26)
2018	932	195 (21)	458	89 (19)	1397	284 (20)
X ² p trend		<0.001		<0.001		<0.001

* Weighted for gender and HCV antibody status

Table 1.4.2 HCV RNA prevalence by sexual identity, gender and survey year *

National Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
Heterosexual	573	307 (54)	226	108 (48)	802	415 (52)
Bisexual	37	20 (54)	54	23 (43)	94	45 (48)
Homosexual	21	7 (33)	12	4 (33)	33	11 (33)
p value		0.220		0.525		0.095
2016						
Heterosexual	423	168 (40)	161	38 (24)	584	206 (35)
Bisexual	23	5 (22)	61	22 (36)	85	28 (33)
Homosexual	24	5 (21)	14	2 (14)	40	7 (18)
p value		0.065		0.039		0.032
2017						
Heterosexual	903	256 (28)	369	75 (20)	1275	331 (26)
Bisexual	58	22 (38)	84	18 (21)	147	40 (27)
Homosexual	31	3 (10)	31	7 (23)	68	11 (16)
p value		0.039		0.891		0.169
2018						
Heterosexual	764	166 (22)	309	65 (21)	1074	231 (22)
Bisexual	44	7 (16)	85	13 (15)	131	21 (16)
Homosexual	44	5 (11)	21	3 (14)	68	8 (12)
p value		0.155		0.439		0.062

Table 1.4.3 HCV RNA prevalence by age group, gender and survey year *

National Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
<25 years	23	7 (30)	14	4 (29)	38	11 (29)
25-34 years	136	58 (43)	91	39 (43)	231	99 (43)
35-44 years	255	136 (53)	112	47 (42)	368	183 (50)
45+ years	244	149 (61)	94	51 (54)	341	203 (60)
p value		0.002		0.094		<0.001
2016						
<25 years	13	2 (15)	11	3 (27)	27	5 (19)
25-34 years	85	23 (27)	55	18 (33)	140	42 (30)
35-44 years	195	80 (41)	104	30 (29)	300	110 (37)
45+ years	209	82 (39)	86	17 (20)	298	99 (33)
p value		0.093		0.264		0.233
2017						
<25 years	52	5 (10)	27	5 (19)	81	10 (12)
25-34 years	191	57 (30)	105	23 (22)	304	80 (26)
35-44 years	398	118 (30)	189	42 (22)	590	160 (27)
45+ years	428	124 (29)	206	40 (19)	641	166 (26)
p value		0.060		0.908		0.092
2018						
<25 years	33	6 (18)	25	6 (24)	59	12 (20)
25-34 years	138	22 (16)	102	23 (23)	241	45 (19)
35-44 years	345	81 (23)	172	34 (20)	521	116 (22)
45+ years	410	84 (20)	157	26 (17)	570	110 (19)
p value		0.571		0.633		0.686

Table 1.4.4 HCV RNA prevalence by years since first injection, gender and survey year *

National Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
<3 years	35	8 (23)	14	3 (21)	49	11 (22)
3 to 10 years	87	36 (41)	50	18 (36)	140	56 (40)
11+ years	525	300 (57)	241	118 (49)	772	421 (55)
p value		<0.001		0.022		<0.001
2016						
<3 years	21	2 (10)	10	2 (20)	32	4 (13)
3 to 10 years	70	13 (19)	32	9 (28)	103	22 (21)
11+ years	388	162 (42)	209	57 (27)	602	219 (36)
p value		<0.001		0.648		<0.001
2017						
<3 years	66	2 (3)	27	1 (4)	94	3 (3)
3 to 10 years	138	28 (20)	76	18 (24)	216	46 (21)
11+ years	824	258 (31)	402	84 (21)	1243	344 (28)
p value		<0.001		0.081		<0.001
2018						
<3 years	37	3 (8)	23	3 (13)	60	6 (10)
3 to 10 years	118	20 (17)	66	15 (23)	184	35 (19)
11+ years	733	159 (22)	351	67 (19)	1090	227 (21)
p value		0.163		0.537		0.164

Table 1.4.5 HCV RNA prevalence by re-use of someone else's used needle and syringe last month, gender and survey year *

National	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
Receptively shared syringe last month						
2015						
No receptive sharing	504	263 (52)	232	103 (44)	741	369 (50)
Receptive sharing	91	59 (65)	48	26 (54)	139	85 (61)
p value		0.037		0.189		0.017
2016						
No receptive sharing	364	132 (36)	181	44 (24)	551	177 (32)
Receptive sharing	74	37 (50)	47	17 (36)	121	54 (45)
p value		0.040		0.085		0.010
2017						
No receptive sharing	792	218 (28)	400	89 (22)	1207	307 (25)
Receptive sharing	167	62 (37)	68	10 (15)	235	72 (31)
p value		0.020		0.209		0.109
2018						
No receptive sharing	685	133 (19)	325	60 (18)	1012	193 (19)
Receptive sharing	143	48 (34)	69	18 (26)	214	66 (31)
p value		<0.001		0.164		<0.001

Table 1.4.6 HCV RNA prevalence by last drug injected, gender and survey year *

National	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
Last drug injected						
2015						
Heroin	222	128 (58)	113	68 (60)	338	199 (59)
Methamphetamine	265	126 (48)	119	39 (33)	389	167 (43)
Other opioids	126	69 (55)	58	24 (41)	185	93 (50)
PIEDs	3	1 (33)	0	0 (0)	3	1 (33)
Other drugs	36	22 (61)	16	8 (50)	52	30 (58)
p value		0.162		<0.001		0.001
2016						
Heroin	168	70 (42)	83	24 (29)	251	94 (37)
Methamphetamine	174	63 (36)	110	21 (19)	285	84 (29)
Other opioids	85	33 (39)	41	17 (41)	126	50 (40)
PIEDs	24	0 (0)	0	0 (0)	25	0 (0)
Other drugs	38	14 (37)	21	5 (24)	62	20 (32)
p value		0.005		0.018		0.001
2017						
Heroin	288	99 (34)	184	53 (29)	482	154 (32)
Methamphetamine	421	110 (26)	216	37 (17)	641	147 (23)
Other opioids	209	59 (28)	91	17 (19)	302	76 (25)
PIEDs	66	2 (3)	2	0 (0)	70	2 (3)
Other drugs	79	31 (39)	32	3 (9)	112	34 (30)
p value		<0.001		0.012		<0.001
2018						
Heroin	294	59 (20)	139	26 (19)	435	85 (20)
Methamphetamine	363	87 (24)	205	35 (17)	572	122 (21)
Other opioids	142	28 (20)	71	17 (24)	214	45 (21)
PIEDs	50	1 (2)	1	0 (0)	51	1 (2)
Other drugs	64	16 (25)	33	9 (27)	98	25 (26)
p value		0.038		0.531		0.026

Table 1.4.7 HCV RNA prevalence by frequency of drug injection last month, gender and survey year *

National Frequency of injection last month	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2015						
Less than daily	292	146 (50)	131	66 (50)	427	214 (50)
Daily or more	304	176 (58)	148	63 (43)	454	239 (53)
Not last month	57	25 (44)	27	11 (41)	87	37 (43)
p value		0.069		0.324		0.202
2016						
Less than daily	198	64 (32)	111	29 (26)	313	93 (30)
Daily or more	242	106 (44)	119	33 (28)	363	139 (38)
Not last month	48	10 (21)	25	6 (24)	73	16 (22)
p value		0.005		0.888		0.007
2017						
Less than daily	423	104 (25)	197	39 (20)	625	143 (23)
Daily or more	547	182 (33)	277	63 (23)	837	245 (29)
Not last month	93	16 (17)	51	8 (16)	145	26 (18)
p value		0.001		0.541		0.003
2018						
Less than daily	368	71 (19)	173	35 (20)	542	106 (20)
Daily or more	468	110 (24)	227	44 (19)	696	154 (22)
Not last month	81	12 (15)	52	8 (15)	134	20 (15)
p value		0.144		0.733		0.141

Table 1.4.8 HCV RNA prevalence by imprisonment last year, gender and survey year *

National Imprisonment last year	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2015						
No imprisonment	543	280 (52)	274	120 (44)	824	404 (49)
Imprisonment	77	48 (62)	26	16 (62)	105	65 (62)
p value		0.095		0.071		0.018
2016						
No imprisonment	413	142 (34)	230	59 (26)	647	201 (31)
Imprisonment	57	34 (60)	16	6 (38)	75	40 (53)
p value		<0.001		0.179		<0.001
2017						
No imprisonment	857	228 (27)	458	91 (20)	1329	320 (24)
Imprisonment	148	60 (41)	38	10 (26)	189	70 (37)
p value		0.002		0.283		<0.001
2018						
No imprisonment	732	147 (20)	388	76 (20)	1125	223 (20)
Imprisonment	134	32 (24)	41	9 (22)	176	41 (23)
p value		0.326		0.674		0.287

Table 1.4.9 HCV RNA prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year *

National Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
Non Indigenous	561	295 (53)	254	121 (48)	823	419 (51)
Indigenous	88	52 (59)	54	20 (37)	142	72 (51)
p value		0.273		0.122		0.895
2016						
Non Indigenous	413	147 (36)	215	54 (25)	633	201 (32)
Indigenous	76	35 (46)	37	12 (32)	114	47 (41)
p value		0.090		0.257		0.041
2017						
Non Indigenous	878	238 (27)	401	76 (19)	1293	315 (24)
Indigenous	171	57 (33)	116	32 (28)	292	90 (31)
p value		0.107		0.043		0.033
2018						
Non Indigenous	750	144 (19)	339	66 (19)	1094	210 (19)
Indigenous	163	47 (29)	107	20 (19)	272	67 (25)
p value		0.020		0.880		0.073

Table 1.4.10 HCV RNA prevalence by main language spoken at home by parents, gender and survey year *

National Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
English speaking	609	319 (52)	297	134 (45)	914	457 (50)
Non-English speaking	44	27 (61)	13	7 (54)	57	34 (60)
p value		0.253		0.738		0.200
2016						
English speaking	459	163 (36)	245	66 (27)	710	229 (32)
Non-English speaking	37	21 (57)	9	2 (22)	47	23 (49)
p value		0.009		0.435		0.018
2017						
English speaking	1003	283 (28)	510	105 (21)	1530	389 (25)
Non-English speaking	62	19 (31)	18	5 (28)	82	24 (29)
p value		0.716		0.368		0.436
2018						
English speaking	859	178 (21)	432	85 (20)	1296	263 (20)
Non-English speaking	66	17 (26)	23	4 (17)	90	21 (23)
p value		0.364		0.956		0.484

Table 1.4.11 HCV RNA prevalence by region/country of birth, gender and survey year *

National Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
Australia	584	308 (53)	276	127 (46)	866	438 (51)
Other Oceania	15	7 (47)	6	2 (33)	21	9 (43)
Asia	10	7 (70)	5	2 (40)	15	10 (67)
UK & Ireland	25	11 (44)	15	7 (47)	41	19 (46)
Other	14	9 (64)	8	3 (38)	22	12 (55)
p value		0.494		0.793		0.537
2016						
Australia	431	166 (39)	226	58 (26)	661	224 (34)
Other Oceania	12	3 (25)	6	5 (83)	20	8 (40)
Asia	11	5 (45)	2	0 (0)	13	5 (38)
UK & Ireland	17	3 (18)	13	2 (15)	30	5 (17)
Other	21	6 (29)	7	2 (29)	28	9 (32)
p value		0.322		0.055		0.318
2017						
Australia	931	259 (28)	471	97 (21)	1416	357 (25)
Other Oceania	27	8 (30)	22	5 (23)	51	14 (27)
Asia	10	5 (50)	4	1 (25)	14	6 (43)
UK & Ireland	49	15 (31)	21	3 (14)	70	18 (26)
Other	42	11 (26)	8	2 (25)	52	14 (27)
p value		0.800		0.930		0.765
2018						
Australia	806	166 (21)	400	80 (20)	1211	247 (20)
Other Oceania	26	3 (12)	12	2 (17)	39	5 (13)
Asia	9	5 (56)	1	0 (0)	10	5 (50)
UK & Ireland	35	5 (14)	20	5 (25)	55	10 (18)
Other	49	14 (29)	18	2 (11)	69	16 (23)
p value		0.014		0.650		0.060

Australian Capital Territory

Table 2.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Australian Capital Territory	2014	2015	2016	2017	2018
Number of sites	1	1	1	1	1
N° surveyed	N=99	N=110	N=112	N=119	N=127
Response rate (%)	69%	71%	82%	89%	93%
Gender (%)					
Male	76 (77)	77 (70)	78 (70)	80 (67)	90 (71)
Female	23 (23)	33 (30)	32 (29)	38 (32)	35 (28)
Transgender	0 (0)	0 (0)	2 (2)	1 (1)	2 (2)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Sexual identity (%)					
Heterosexual	81 (82)	98 (89)	93 (83)	92 (77)	100 (79)
Bisexual	9 (9)	7 (6)	12 (11)	15 (13)	13 (10)
Homosexual	2 (2)	2 (2)	1 (1)	1 (1)	3 (2)
Not reported	7 (7)	3 (3)	6 (5)	11 (9)	11 (9)
Aboriginal and Torres Strait Islander origin (%)					
No	87 (88)	85 (77)	84 (75)	90 (76)	98 (77)
Yes	11 (11)	25 (23)	23 (21)	28 (24)	27 (21)
Not reported	1 (1)	0 (0)	5 (4)	1 (1)	2 (2)
Region/country of birth (%)					
Australia	88 (89)	95 (86)	101 (90)	105 (88)	110 (87)
Other Oceania	3 (3)	1 (1)	1 (1)	3 (3)	1 (1)
Asia	2 (2)	3 (3)	1 (1)	2 (2)	1 (1)
UK & Ireland	4 (4)	5 (5)	6 (5)	2 (2)	6 (5)
Other	1 (1)	4 (4)	2 (2)	5 (4)	7 (6)
Not reported	1 (1)	2 (2)	1 (1)	2 (2)	2 (2)
Main language spoken at home by parents (%)					
English	92 (93)	101 (92)	104 (93)	114 (96)	114 (90)
Non-English	6 (6)	8 (7)	8 (7)	3 (3)	11 (9)
Not reported	1 (1)	1 (1)	0 (0)	2 (2)	2 (2)
Age and time since first injection (years)					
<i>Median age</i>	41	42	44	41.5	41
<i>Age range</i>	19-60	21-61	19-64	18-64	20-67
Age group (%)					
<25 years	6 (6)	3 (3)	4 (4)	3 (3)	4 (3)
25+ years	92 (93)	106 (96)	107 (96)	115 (97)	123 (97)
Not reported	1 (1)	1 (1)	1 (1)	1 (1)	0 (0)
<i>Median age first injection</i>	17	18	19	18	18
<i>Age range</i>	12-55	11-45	12-55	10-49	10-50
N° not reported	1	2	4	0	5
<i>Median yrs since first injection</i>	22	22	24	20	21
<i>Range</i>	<1-38	<1-47	<1-48	<1-46	<1-46
Years since first injection					
<3 years	5 (5)	3 (3)	2 (2)	3 (3)	3 (2)
3+ years	92 (93)	105 (95)	106 (95)	110 (92)	119 (94)
Not reported	2 (2)	2 (2)	4 (4)	6 (5)	5 (4)
Imprisonment last year (%)					
No	83 (84)	103 (94)	97 (87)	95 (80)	99 (78)
Yes	9 (9)	5 (5)	14 (13)	18 (15)	11 (9)
Not reported	7 (7)	2 (2)	1 (1)	6 (5)	17 (13)
N° in prison					
Injected in prison	3 (33)	2 (40)	4 (29)	6 (33)	5 (45)

Table 2.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year

Australian Capital Territory	2014	2015	2016	2017	2018
N° surveyed	N=99	N=110	N=112	N=119	N=127
Drug last injected (%)					
Cocaine	0 (0)	0 (0)	1 (1)	3 (3)	1 (1)
Methamphetamine	31 (31)	45 (41)	41 (37)	48 (40)	60 (47)
Heroin	44 (44)	50 (45)	45 (40)	58 (49)	51 (40)
Pharm. opioids	6 (6)	1 (1)	4 (4)	1 (1)	4 (3)
Methadone	6 (6)	7 (6)	8 (7)	3 (3)	3 (2)
Buprenorphine	2 (2)	2 (2)	5 (4)	1 (1)	0 (0)
Buprenorphine/naloxone	2 (2)	0 (0)	3 (3)	2 (2)	1 (1)
PIEDs	0 (0)	3 (3)	0 (0)	0 (0)	0 (0)
More than one	4 (4)	2 (2)	3 (3)	3 (3)	5 (4)
Other	4 (4)	0 (0)	2 (2)	0 (0)	1 (1)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
Ever injected opioids					
No	-	-	13 (12)	7 (6)	15 (12)
Yes	-	-	98 (88)	110 (92)	110 (87)
Not reported	-	-	1 (1)	2 (2)	2 (2)
Frequency of injection last month (%)					
Not last month	3 (3)	5 (5)	9 (8)	16 (13)	11 (9)
Less than weekly	13 (13)	11 (10)	14 (13)	16 (13)	17 (13)
Weekly not daily	40 (40)	47 (43)	29 (26)	27 (23)	30 (24)
Daily or more	43 (43)	46 (42)	58 (52)	57 (48)	66 (52)
Not reported	0 (0)	1 (1)	2 (2)	3 (3)	3 (2)
Present when someone injected for the first time in the last 12 months (%)					
No	82 (83)	92 (84)	96 (86)	100 (84)	103 (81)
Yes	14 (14)	17 (15)	15 (13)	15 (13)	20 (16)
Not reported	3 (3)	1 (1)	1 (1)	4 (3)	4 (3)
Overdosed in last 12 months					
No	78 (79)	94 (85)	87 (78)	90 (76)	93 (73)
Yes	18 (18)	13 (12)	24 (21)	24 (20)	30 (24)
Not reported	3 (3)	3 (3)	1 (1)	5 (4)	4 (3)

Table 2.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year

Australian Capital Territory	2014	2015	2016	2017	2018
N° injected last month	N=96	N=104	N=101	N=100	N=113
Places injected last month (%)					
All private	69 (72)	65 (63)	52 (51)	52 (52)	50 (44)
Any public	27 (28)	39 (38)	49 (49)	47 (47)	63 (56)
Not reported	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)
Use of new and sterile needles and syringes last month (%)					
All injections	77 (80)	78 (75)	75 (74)	64 (64)	76 (67)
Most of the time	16 (17)	23 (22)	16 (16)	31 (31)	30 (27)
Half of the time	1 (1)	2 (2)	4 (4)	2 (2)	4 (4)
Some of the time	1 (1)	0 (0)	2 (2)	2 (2)	2 (2)
Not last month	0 (0)	1 (1)	2 (2)	0 (0)	0 (0)
Not reported	1 (1)	0 (0)	2 (2)	1 (1)	1 (1)
Re-used someone else's used needle & syringe last month (%)					
None	82 (85)	88 (85)	81 (80)	71 (71)	83 (73)
Once	6 (6)	4 (4)	5 (5)	12 (12)	8 (7)
Twice	3 (3)	3 (3)	6 (6)	8 (8)	9 (8)
3-5 times	3 (3)	8 (8)	5 (5)	7 (7)	6 (5)
>5 times	0 (0)	1 (1)	3 (3)	2 (2)	6 (5)
Not reported	2 (2)	0 (0)	1 (1)	0 (0)	1 (1)
Number of people needle & syringe was re-used after last month (%)					
None	82 (85)	88 (85)	81 (80)	71 (71)	83 (73)
One	5 (5)	4 (4)	8 (8)	10 (10)	11 (10)
Two	3 (3)	1 (1)	2 (2)	2 (2)	1 (1)
Three to five	0 (0)	1 (1)	3 (3)	0 (0)	2 (2)
More than five	0 (0)	0 (0)	1 (1)	1 (1)	2 (2)
Don't know	2 (2)	6 (6)	2 (2)	13 (13)	10 (9)
Not reported	4 (4)	4 (4)	4 (4)	3 (3)	4 (4)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	6 (6)	6 (6)	8 (8)	10 (10)	10 (9)
Casual sex partner	0 (0)	1 (1)	1 (1)	2 (2)	0 (0)
Close friend	1 (1)	3 (3)	5 (5)	7 (7)	5 (4)
Acquaintance	2 (2)	1 (1)	1 (1)	6 (6)	5 (4)
Other	1 (1)	2 (2)	1 (1)	2 (2)	1 (1)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	32 (33)	23 (22)	26 (26)	31 (31)	33 (29)
Water	10 (10)	10 (10)	18 (18)	21 (21)	21 (19)
Filter	9 (9)	5 (5)	10 (10)	16 (16)	11 (10)
Drug mix	11 (11)	8 (8)	12 (12)	10 (10)	14 (12)
None	57 (59)	71 (68)	63 (62)	65 (65)	74 (65)
Injected by someone after that person injected themselves or others last month (%)					
No	79 (82)	92 (88)	85 (84)	85 (85)	90 (80)
Yes	14 (15)	12 (12)	16 (16)	15 (15)	23 (20)
Not reported	3 (3)	0 (0)	0 (0)	0 (0)	0 (0)
Source of needle acquisition					
Needle Syringe Program	83 (86)	92 (88)	87 (86)	90 (90)	101 (89)
Chemist/Pharmacy	29 (30)	28 (27)	36 (36)	36 (36)	37 (33)
Personal sources	13 (14)	14 (13)	20 (20)	22 (22)	24 (21)
Dispensing/Vending Machine	23 (24)	20 (19)	23 (23)	28 (28)	29 (26)
Other sources	2 (2)	2 (2)	3 (3)	0 (0)	5 (4)

Table 2.1.4 Number (percentage) of respondents by treatment for drug use and survey year

Australian Capital Territory	2014	2015	2016	2017	2018
N° surveyed	N=99	N=110	N=112	N=119	N=127
Ever any treatment/therapy for drug use (%)					
No	9 (9)	23 (21)	26 (23)	21 (18)	31 (24)
Yes	90 (91)	87 (79)	86 (77)	96 (81)	93 (73)
Not reported	0 (0)	0 (0)	0 (0)	2 (2)	3 (2)
History of methadone maintenance treatment (%)					
Currently	37 (38)	46 (42)	41 (37)	44 (37)	33 (26)
Previously	29 (29)	31 (28)	23 (21)	20 (17)	29 (23)
Never	32 (32)	31 (28)	46 (41)	51 (43)	58 (46)
Not reported	1 (1)	2 (2)	2 (2)	4 (3)	7 (6)
History of buprenorphine (Subutex®) treatment (%)					
Currently	11 (11)	10 (9)	8 (7)	12 (10)	7 (6)
Previously	27 (27)	27 (25)	24 (21)	32 (27)	31 (24)
Never	59 (60)	72 (65)	76 (68)	74 (62)	86 (68)
Not reported	2 (2)	1 (1)	4 (4)	1 (1)	3 (2)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	10 (10)	7 (6)	9 (8)	11 (9)	8 (6)
Previously	25 (25)	18 (16)	23 (21)	29 (24)	33 (26)
Never	63 (64)	84 (76)	77 (69)	75 (63)	83 (65)
Not reported	1 (1)	1 (1)	3 (3)	4 (3)	3 (2)

Table 2.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year

Australian Capital Territory	2014	2015	2016	2017	2018
N° surveyed	N=99	N=110	N=112	N=119	N=127
Previous HIV test (%)					
Yes, ever	82 (83)	91 (83)	98 (88)	97 (82)	102 (80)
Yes, last year	50 (51)	51 (46)	49 (44)	59 (50)	62 (49)
>1 year ago	32 (32)	40 (36)	49 (44)	38 (32)	40 (32)
Never tested	12 (12)	19 (17)	11 (10)	19 (16)	15 (12)
Not reported	5 (5)	0 (0)	3 (3)	3 (3)	10 (8)
Previous HCV test (%)					
Yes, ever	88 (89)	99 (90)	94 (84)	92 (77)	104 (82)
Yes, last year	53 (54)	53 (48)	57 (51)	63 (53)	68 (54)
>1 year ago	35 (35)	46 (42)	37 (33)	29 (24)	36 (28)
Never tested	7 (7)	4 (4)	11 (10)	11 (9)	11 (9)
Not reported	4 (4)	7 (6)	7 (6)	16 (13)	12 (9)
Lifetime treatment for HCV (%)[#]					
N° self-reported HCV diagnosis	N=41	N=51	N=34	N=35	N=46
Antiviral treatment	4 (10)	4 (8)	8 (24)	16 (46)	21 (46)
No antiviral treatment	36 (88)	46 (90)	26 (76)	19 (54)	25 (54)
Not reported	1 (2)	1 (2)	0 (0)	0 (0)	0 (0)
Treatment for HCV in past 12 months (%)^{##}					
N° self-reported HCV diagnosis	N=40	N=51	N=33	N=28	N=40
Antiviral treatment	0 (0)	2 (4)	7 (21)	9 (32)	14 (35)
No antiviral treatment	39 (98)	48 (94)	26 (79)	19 (68)	26 (65)
Not reported	1 (3)	0 (0)	0 (0)	0 (0)	0 (0)

[#] among people who tested HCV antibody positive and did not report spontaneous clearance

^{*} excludes people who reported treatment induced clearance more than 12 months previously

Table 2.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year

Australian Capital Territory	2014	2015	2016	2017	2018
N° surveyed	N=99	N=110	N=112	N=119	N=127
Sex with a regular partner last month (%)					
No	58 (59)	61 (55)	73 (65)	75 (63)	75 (59)
Yes	35 (35)	45 (41)	38 (34)	39 (33)	43 (34)
Not reported	6 (6)	4 (4)	1 (1)	5 (4)	9 (7)
Condom used with regular partner last month (%)					
N° surveyed	N=35	N=45	N=38	N=39	N=43
Never	27 (77)	36 (87)	22 (58)	29 (74)	34 (79)
Sometimes	5 (14)	3 (7)	7 (18)	4 (10)	4 (9)
Every time	2 (6)	4 (9)	7 (18)	5 (13)	2 (5)
Not reported	1 (3)	2 (4)	2 (5)	1 (3)	3 (7)
Sex with other partner(s) last month (%)					
No	86 (87)	92 (84)	101 (90)	107 (90)	103 (81)
Yes	8 (8)	14 (13)	8 (7)	7 (6)	12 (9)
Not reported	5 (5)	4 (4)	3 (3)	5 (4)	12 (9)
Condom used with other partner(s) last month (%)					
N° surveyed	N=8	N=14	N=8	N=7	N=12
Never	3 (38)	5 (36)	2 (25)	3 (43)	7 (58)
Sometimes	3 (38)	5 (36)	5 (63)	1 (14)	0 (0)
Every time	2 (25)	3 (21)	1 (13)	1 (14)	4 (33)
Not reported	0 (0)	1 (7)	0 (0)	2 (29)	1 (8)
Sex work last month (%)					
No	89 (90)	106 (96)	105 (94)	111 (93)	108 (85)
Yes	4 (4)	3 (3)	3 (3)	3 (3)	8 (6)
Not reported	6 (6)	1 (1)	4 (4)	5 (4)	11 (9)
Condom used at last sex work (%)					
Yes	3 (75)	1 (33)	1 (33)	1 (33)	7 (88)

HIV antibody prevalence

Table 2.2.1 HIV antibody prevalence by gender and survey year

Aust. Capital Territory	Male		Female		Total	
Survey year	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014	73	0 (0.0)	23	0 (0.0)	96	0 (0.0)
2015	76	0 (0.0)	33	0 (0.0)	109	0 (0.0)
2016	72	0 (0.0)	31	0 (0.0)	105	0 (0.0)
2017	80	0 (0.0)	38	0 (0.0)	119	0 (0.0)
2018	90	0 (0.0)	35	0 (0.0)	127	0 (0.0)
X ² p trend		--		--		--

HCV antibody prevalence

Table 2.3.1 HCV antibody prevalence by gender and survey year

Aust. Capital Territory	Male		Female		Total	
Survey year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014	71	49 (69)	23	12 (52)	94	61 (65)
2015	70	54 (77)	29	21 (72)	99	75 (76)
2016	68	39 (57)	27	14 (52)	97	54 (56)
2017	77	46 (60)	38	23 (61)	116	70 (60)
2018	90	51 (57)	35	22 (63)	127	73 (57)
X ² p trend		0.255		0.904		0.323

Table 2.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Aust. Capital Territory	Male		Female		Total	
Sexual identity	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
Heterosexual	65	45 (69)	12	5 (42)	77	50 (65)
Bisexual	1	0 (0)	8	5 (63)	9	5 (56)
Homosexual	1	1 (100)	1	0 (0)	2	1 (50)
p value		0.532		0.513		0.755
2015						
Heterosexual	65	50 (77)	24	18 (75)	89	68 (76)
Bisexual	2	2 (100)	3	1 (33)	5	3 (60)
Homosexual	0	0 (0)	2	2 (100)	2	2 (100)
p value		1.000		0.237		0.765
2016						
Heterosexual	60	34 (57)	21	11 (52)	81	45 (56)
Bisexual	5	3 (60)	5	2 (40)	11	6 (55)
Homosexual	1	1 (100)	0	0 (0)	1	1 (100)
p value		1.000		1.000		1.000
2017						
Heterosexual	66	42 (64)	23	15 (65)	89	57 (64)
Bisexual	5	1 (20)	9	3 (33)	15	5 (33)
Homosexual	0	0 (0)	1	0 (0)	1	0 (0)
p value		0.075		0.126		0.031
2018						
Heterosexual	77	43 (56)	22	14 (64)	100	57 (57)
Bisexual	6	2 (33)	7	4 (57)	13	6 (46)
Homosexual	2	1 (50)	0	0 (0)	3	1 (33)
p value		0.701		1.000		0.594

Table 2.3.3 HCV antibody prevalence by age group, gender and survey year

Aust. Capital Territory Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
<25 years	4	1 (25)	2	0 (0)	6	1 (17)
25-34 years	11	5 (45)	5	3 (60)	16	8 (50)
35-44 years	29	22 (76)	10	9 (90)	39	31 (79)
45+ years	26	20 (77)	6	0 (0)	32	20 (63)
p value		0.053		<0.001		0.009
2015						
<25 years	1	0 (0)	1	0 (0)	2	0 (0)
25-34 years	14	8 (57)	7	4 (57)	21	12 (57)
35-44 years	28	25 (89)	10	7 (70)	38	32 (84)
45+ years	26	20 (77)	11	10 (91)	37	30 (81)
p value		0.030		0.132		0.010
2016						
<25 years	0	0 (0)	4	3 (75)	4	3 (75)
25-34 years	7	4 (57)	6	2 (33)	13	6 (46)
35-44 years	24	16 (67)	7	4 (57)	33	21 (64)
45+ years	36	19 (53)	10	5 (50)	46	24 (52)
p value		0.592		0.704		0.560
2017						
<25 years	0	0 (0)	3	1 (33)	3	1 (33)
25-34 years	15	7 (47)	10	5 (50)	26	13 (50)
35-44 years	27	19 (70)	12	7 (58)	39	26 (67)
45+ years	34	19 (56)	13	10 (77)	47	29 (62)
p value		0.287		0.393		0.417
2018						
<25 years	2	0 (0)	2	1 (50)	4	1 (25)
25-34 years	13	7 (54)	9	6 (67)	22	13 (59)
35-44 years	40	28 (70)	14	8 (57)	56	36 (64)
45+ years	35	16 (46)	10	7 (70)	45	23 (51)
p value		0.056		0.952		0.321

Table 2.3.4 HCV antibody prevalence by years since first injection, gender and survey year

Aust. Capital Territory Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
<3 years	4	1 (25)	1	0 (0)	5	1 (20)
3 to 10 years	8	4 (50)	4	0 (0)	12	4 (33)
11+ years	57	42 (74)	18	12 (52)	75	54 (72)
p value		0.043		0.014		0.003
2015						
<3 years	2	1 (50)	1	0 (0)	3	1 (33)
3 to 10 years	12	6 (50)	4	2 (50)	16	8 (50)
11+ years	54	45 (83)	24	19 (79)	78	64 (82)
p value		0.017		0.112		0.005
2016						
<3 years	1	0 (0)	1	1 (100)	2	1 (50)
3 to 10 years	3	1 (33)	7	3 (43)	10	4 (40)
11+ years	60	36 (60)	19	10 (53)	81	47 (58)
p value		0.384		1.000		0.510
2017						
<3 years	1	0 (0)	2	1 (50)	3	1 (33)
3 to 10 years	10	5 (50)	6	2 (33)	16	7 (44)
11+ years	63	39 (62)	28	18 (64)	92	58 (63)
p value		0.383		0.391		0.213
2018						
<3 years	3	2 (67)	0	0 (0)	3	2 (67)
3 to 10 years	9	2 (22)	7	4 (57)	16	6 (38)
11+ years	74	43 (58)	27	17 (63)	103	60 (58)
p value		0.106		1.000		0.286

Table 2.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

Aust. Capital Territory Receptively shared syringe last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
No receptive sharing	4	1 (25)	71	47 (66)	77	50 (65)
Receptive sharing	0	0 (0)	12	8 (67)	12	8 (67)
p value		--		0.975		0.907
2015						
No receptive sharing	3	1 (33)	74	57 (77)	79	60 (76)
Receptive sharing	0	0 (0)	14	11 (79)	14	11 (79)
p value		--		1.000		1.000
2016						
No receptive sharing	2	1 (50)	70	41 (59)	74	44 (59)
Receptive sharing	0	0 (0)	13	6 (46)	13	6 (46)
p value		--		0.407		0.371
2017						
No receptive sharing	3	1 (33)	65	37 (57)	71	41 (58)
Receptive sharing	0	0 (0)	26	16 (62)	27	17 (63)
p value		--		0.687		0.639
2018						
No receptive sharing	2	1 (50)	79	46 (58)	83	49 (59)
Receptive sharing	1	1 (100)	27	15 (56)	29	17 (59)
p value		1.000		0.808		0.969

Table 2.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year

Aust. Capital Territory Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
Heroin	0	0 (0)	40	25 (63)	42	27 (64)
Methamphetamine	2	0 (0)	27	15 (56)	29	15 (52)
Other opioids	2	1 (50)	13	11 (85)	15	12 (80)
Other drugs	1	0 (0)	7	7 (100)	8	7 (88)
p value		0.392		0.066		0.138
2015						
Heroin	1	0 (0)	43	37 (86)	44	37 (84)
Methamphetamine	2	1 (50)	38	26 (68)	41	28 (68)
Other opioids	0	0 (0)	8	6 (75)	9	7 (78)
Other drugs	0	0 (0)	4	3 (75)	4	3 (75)
p value		0.386		0.304		0.397
2016						
Heroin	2	1 (50)	36	26 (72)	40	28 (70)
Methamphetamine	0	0 (0)	34	14 (41)	35	14 (40)
Other opioids	0	0 (0)	15	8 (53)	15	8 (53)
Other drugs	0	0 (0)	4	2 (50)	5	3 (60)
p value		--		0.072		0.076
2017						
Heroin	1	1 (100)	49	33 (67)	52	36 (69)
Methamphetamine	2	0 (0)	45	22 (49)	48	23 (48)
Other opioids	0	0 (0)	6	3 (50)	7	4 (57)
Other drugs	0	0 (0)	6	5 (83)	6	5 (83)
p value		0.083		0.172		0.104
2018						
Heroin	0	0 (0)	49	28 (57)	51	30 (59)
Methamphetamine	2	1 (50)	54	28 (52)	58	31 (53)
Other opioids	0	0 (0)	7	5 (71)	7	5 (71)
Other drugs	1	1 (100)	6	5 (83)	7	6 (86)
p value		0.386		0.411		0.358

Table 2.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

Aust. Capital Territory Frequency of injection last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
Less than daily	3	0 (0)	46	30 (65)	50	31 (62)
Daily or more	2	1 (50)	38	26 (68)	41	28 (68)
Not last month	0	0 (0)	3	2 (67)	3	2 (67)
p value		0.400		0.918		0.847
2015						
Less than daily	2	1 (50)	51	38 (75)	55	41 (75)
Daily or more	1	0 (0)	37	30 (81)	38	30 (79)
Not last month	0	0 (0)	5	4 (80)	5	4 (80)
p value		1.000		0.837		0.920
2016						
Less than daily	2	1 (50)	36	23 (64)	39	25 (64)
Daily or more	0	0 (0)	47	24 (51)	49	25 (51)
Not last month	0	0 (0)	6	3 (50)	7	3 (43)
p value		--		0.500		0.425
2017						
Less than daily	0	0 (0)	39	19 (49)	43	23 (53)
Daily or more	3	1 (33)	52	34 (65)	55	35 (64)
Not last month	0	0 (0)	15	10 (67)	15	10 (67)
p value		--		0.244		0.511
2018						
Less than daily	3	2 (67)	41	22 (54)	47	27 (57)
Daily or more	0	0 (0)	66	40 (61)	66	40 (61)
Not last month	0	0 (0)	9	4 (44)	11	6 (55)
p value		--		0.541		0.902

Table 2.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

Aust. Capital Territory Imprisonment last year	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
No imprisonment	5	1 (20)	72	49 (68)	79	52 (66)
Imprisonment	0	0 (0)	8	5 (63)	8	5 (63)
p value		--		0.750		0.851
2015						
No imprisonment	1	1 (100)	89	68 (76)	92	71 (77)
Imprisonment	1	0 (0)	4	3 (75)	5	3 (60)
p value		--		1.000		0.589
2016						
No imprisonment	2	1 (50)	78	43 (55)	84	46 (55)
Imprisonment	0	0 (0)	12	7 (58)	12	7 (58)
p value		--		0.835		0.816
2017						
No imprisonment	3	1 (33)	85	48 (56)	92	52 (57)
Imprisonment	0	0 (0)	17	11 (65)	18	12 (67)
p value		--		0.530		0.425
2018						
No imprisonment	2	1 (50)	95	50 (53)	99	53 (54)
Imprisonment	0	0 (0)	10	6 (60)	11	7 (64)
p value		--		0.748		0.751

Table 2.3.9 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Aust. Capital Territory Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
Non Indigenous	62	41 (66)	21	41 (66)	83	51 (61)
Indigenous	8	7 (88)	8	7 (88)	10	9 (90)
p value		0.220		0.478		0.075
2015						
Non Indigenous	57	42 (74)	20	14 (70)	77	56 (73)
Indigenous	13	12 (93)	9	7 (78)	22	19 (86)
p value		0.272		1.000		0.263
2016						
Non Indigenous	52	31 (60)	18	9 (50)	71	40 (56)
Indigenous	13	5 (38)	7	3 (43)	21	9 (43)
p value		0.170		1.000		0.277
2017						
Non Indigenous	62	38 (61)	25	15 (60)	88	54 (61)
Indigenous	14	7 (50)	13	8 (62)	27	15 (56)
p value		0.438		1.000		0.590
2018						
Non Indigenous	74	41 (55)	22	12 (55)	98	53 (54)
Indigenous	15	9 (60)	12	9 (75)	27	18 (67)
p value		0.744		0.292		0.242

Table 2.3.10 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Aust. Capital Territory Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
English speaking	67	48 (72)	20	12 (60)	87	60 (69)
Non-English speaking	3	0 (0)	3	0 (0)	6	0 (0)
p value		0.028		0.093		0.001
2015						
English speaking	62	49 (79)	28	21 (75)	90	70 (78)
Non-English speaking	7	4 (57)	1	0 (0)	8	4 (50)
p value		0.340		0.276		0.098
2016						
English speaking	62	37 (60)	27	14 (52)	91	52 (57)
Non-English speaking	6	2 (33)	0	0 (0)	6	2 (33)
p value		0.390		--		0.401
2017						
English speaking	73	43 (59)	37	22 (59)	111	66 (59)
Non-English speaking	3	2 (67)	0	0 (0)	3	2 (67)
p value		1.000		--		1.000
2018						
English speaking	81	47 (58)	31	20 (65)	114	67 (59)
Non-English speaking	7	3 (43)	4	2 (50)	11	5 (45)
p value		0.459		0.618		0.393

Table 2.3.11 HCV antibody prevalence by region/country of birth, gender and survey year

Aust. Capital Territory Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
Australia	62	43 (69)	21	11 (52)	83	54 (65)
Other Oceania	3	3 (100)	0	0 (0)	3	3 (100)
Asia	2	0 (0)	0	0 (0)	2	0 (0)
UK & Ireland	3	2 (67)	1	1 (100)	4	3 (75)
Other	0	0 (0)	0	0 (0)	1	0 (0)
p value		0.128		1.000		0.105
2015						
Australia	59	45 (76)	26	19 (73)	85	64 (75)
Other Oceania	1	1 (100)	0	0 (0)	1	1 (100)
Asia	3	2 (67)	0	0 (0)	3	2 (67)
UK & Ireland	2	1 (50)	2	2 (100)	4	3 (75)
Other	3	3 (100)	1	0 (0)	4	3 (75)
p value		0.681		0.330		1.000
2016						
Australia	64	37 (58)	25	13 (52)	91	51 (56)
Other Oceania	1	1 (100)	0	0 (0)	1	1 (100)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	2	1 (50)	2	1 (50)	4	2 (50)
Other	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.837		1.000		0.884
2017						
Australia	64	38 (59)	37	22 (59)	102	61 (60)
Other Oceania	3	0 (0)	0	0 (0)	3	0 (0)
Asia	2	2 (100)	0	0 (0)	2	2 (100)
UK & Ireland	2	1 (50)	0	0 (0)	2	1 (50)
Other	4	3 (75)	1	1 (100)	5	4 (80)
p value		0.180		1.000		0.134
2018						
Australia	76	45 (59)	32	21 (66)	110	66 (60)
Other Oceania	1	0 (0)	0	0 (0)	1	0 (0)
Asia	1	0 (0)	0	0 (0)	1	0 (0)
UK & Ireland	5	2 (40)	1	0 (0)	6	2 (33)
Other	6	3 (50)	1	0 (0)	7	3 (43)
p value		0.472		0.139		0.212

HCV RNA prevalence

Table 2.4.1 HCV RNA prevalence by gender and survey year *

Australian Capital Territory	Male		Female		Total	
Survey year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015	30	24 (81)	12	8 (67)	42	32 (76)
2016 [#]	6	2 (33)	1	0 (0)	7	2 (29)
2017	56	18 (32)	27	8 (30)	84	26 (31)
2018	67	17 (25)	26	9 (35)	95	26 (27)
X ² p trend		0.002		0.265		0.001

* Weighted for gender and HCV antibody status

A number of ACT samples were subject to a failed run due to incompatibility with the HCV RNA testing platform in 2016

Table 2.4.2 HCV RNA prevalence by sexual identity, gender and survey year *

Australian Capital Territory	Male		Female		Total	
Sexual identity	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
Heterosexual	28	22 (79)	8	6 (75)	36	28 (78)
Bisexual	0	0 (0)	3	1 (33)	3	1 (33)
Homosexual	0	0 (0)	1	1 (100)	1	1 (100)
p value		--		0.609		0.405
2016						
Heterosexual	6	2 (33)	1	0 (0)	7	2 (29)
Bisexual	0	0 (0)	0	0 (0)	0	0 (0)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2017						
Heterosexual	45	13 (29)	14	4 (29)	59	17 (29)
Bisexual	5	2 (40)	7	1 (14)	13	3 (23)
Homosexual	0	0 (0)	1	1 (100)	1	1 (100)
p value		0.860		0.243		0.270
2018						
Heterosexual	62	14 (23)	17	5 (29)	80	20 (25)
Bisexual	2	1 (50)	6	3 (50)	8	4 (50)
Homosexual	1	0 (0)	0	0 (0)	2	0 (0)
p value		0.608		0.598		0.315

Table 2.4.3 HCV RNA prevalence by age group, gender and survey year *

Australian Capital Territory	Male		Female		Total	
Age group	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
<25 years	1	0 (0)	2	0 (0)	3	0 (0)
25-34 years	7	6 (86)	2	1 (50)	9	7 (78)
35-44 years	12	10 (83)	3	2 (67)	15	12 (80)
45+ years	10	8 (80)	4	4 (100)	15	13 (87)
p value		0.239		0.202		0.049
2016						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	0	0 (0)	1	0 (0)	1	0 (0)
35-44 years	3	2 (67)	0	0 (0)	3	2 (67)
45+ years	3	0 (0)	0	0 (0)	3	0 (0)
p value		0.153		--		0.243
2017						
<25 years	0	0 (0)	2	1 (50)	2	1 (50)
25-34 years	12	4 (33)	6	1 (17)	18	5 (28)
35-44 years	24	7 (29)	7	2 (29)	31	9 (29)
45+ years	20	7 (35)	12	4 (33)	32	11 (34)
p value		0.830		0.882		0.845
2018						
<25 years	2	0 (0)	1	1 (100)	3	1 (33)
25-34 years	9	3 (33)	6	4 (67)	16	8 (50)
35-44 years	29	7 (24)	12	3 (25)	42	10 (24)
45+ years	26	6 (23)	7	1 (14)	34	7 (21)
p value		0.803		0.045		0.212

Table 2.4.4 HCV RNA prevalence by years since first injection, gender and survey year *

Australian Capital Territory	Male		Female		Total	
Years of injection	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
<3 years	0	0 (0)	1	0 (0)	1	0 (0)
3 to 10 years	4	3 (75)	4	2 (50)	8	5 (63)
11+ years	26	21 (81)	7	6 (86)	33	27 (82)
p value		0.742		0.272		0.107
2016						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 10 years	2	0 (0)	1	0 (0)	3	0 (0)
11+ years	3	1 (33)	0	0 (0)	3	1 (33)
p value		0.414		--		0.361
2017						
<3 years	1	1 (100)	1	0 (0)	2	1 (50)
3 to 10 years	8	3 (38)	5	3 (60)	13	6 (46)
11+ years	45	14 (31)	19	3 (16)	65	18 (28)
p value		0.482		0.110		0.384
2018						
<3 years	1	1 (100)	0	0 (0)	1	1 (100)
3 to 10 years	8	2 (25)	4	3 (75)	12	5 (42)
11+ years	56	13 (23)	22	6 (27)	79	20 (25)
p value		0.233		0.091		0.161

Table 2.4.5 HCV RNA prevalence by re-use of someone else's used needle and syringe last month, gender and survey year *

Australian Capital Territory	Male		Female		Total	
Receptively shared syringe last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
No receptive sharing	23	19 (83)	10	7 (70)	33	26 (79)
Receptive sharing	5	4 (80)	1	1 (100)	6	5 (83)
p value		0.819		0.528		0.797
2016						
No receptive sharing	3	2 (67)	1	0 (0)	4	2 (50)
Receptive sharing	3	0 (0)	0	0 (0)	3	0 (0)
p value		0.277		--		0.225
2017						
No receptive sharing	34	12 (35)	16	4 (25)	51	16 (31)
Receptive sharing	16	6 (38)	5	3 (60)	21	9 (43)
p value		0.862		0.169		0.392
2018						
No receptive sharing	40	10 (25)	20	8 (40)	61	19 (31)
Receptive sharing	19	5 (26)	4	1 (25)	23	6 (26)
p value		0.917		0.554		0.680

Table 2.4.6 HCV RNA prevalence by last drug injected, gender and survey year *

Australian Capital Territory	Male		Female		Total	
Last drug injected	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
Heroin	13	11 (85)	8	6 (75)	21	17 (81)
Methamphetamine	14	11 (79)	3	1 (33)	18	12 (67)
Other opioids	2	2 (100)	1	1 (100)	3	3 (100)
Other drugs	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.577		0.609		0.505
2016						
Heroin	2	1 (50)	1	0 (0)	3	1 (33)
Methamphetamine	3	1 (33)	0	0 (0)	3	1 (33)
Other opioids	1	0 (0)	0	0 (0)	1	0 (0)
Other drugs	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.755		--		0.863
2017						
Heroin	18	7 (39)	15	3 (20)	33	11 (33)
Methamphetamine	31	7 (23)	10	4 (40)	41	11 (27)
Other opioids	3	1 (33)	1	0 (0)	4	1 (25)
Other drugs	4	3 (75)	1	0 (0)	5	3 (60)
p value		0.203		0.648		0.439
2018						
Heroin	29	7 (24)	10	4 (40)	41	12 (29)
Methamphetamine	32	9 (28)	11	2 (18)	43	11 (26)
Other opioids	4	0 (0)	2	1 (50)	6	1 (17)
Other drugs	0	0 (0)	3	2 (67)	3	2 (67)
p value		0.441		0.333		0.419

Table 2.4.7 HCV RNA prevalence by frequency of drug injection last month, gender and survey year *

Australian Capital Territory	Male		Female		Total	
Frequency of injection last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
Less than daily	17	14 (82)	5	5 (100)	22	19 (86)
Daily or more	11	9 (82)	6	2 (33)	17	11 (65)
Not last month	2	1 (50)	1	0 (0)	3	1 (33)
p value		0.513		0.086		0.088
2016						
Less than daily	4	0 (0)	0	0 (0)	4	0 (0)
Daily or more	2	2 (100)	1	0 (0)	3	2 (67)
Not last month	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.009		--		0.072
2017						
Less than daily	24	8 (33)	9	3 (33)	33	11 (33)
Daily or more	27	9 (33)	11	4 (36)	39	14 (36)
Not last month	5	0 (0)	5	1 (20)	11	1 (9)
p value		0.308		0.829		0.288
2018						
Less than daily	25	5 (20)	10	4 (40)	35	9 (26)
Daily or more	35	10 (29)	13	5 (38)	50	16 (32)
Not last month	5	1 (20)	3	0 (0)	8	1 (13)
p value		0.701		0.406		0.504

Table 2.4.8 HCV RNA prevalence by imprisonment last year, gender and survey year *

Australian Capital Territory	Male		Female		Total	
Imprisonment last year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
No imprisonment	28	22 (79)	10	8 (80)	38	30 (79)
Imprisonment	2	2 (100)	2	0 (0)	4	2 (50)
p value		0.478		0.179		0.355
2016						
No imprisonment	6	2 (33)	1	0 (0)	7	2 (29)
Imprisonment	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2017						
No imprisonment	48	15 (31)	24	7 (29)	72	22 (31)
Imprisonment	5	2 (40)	3	1 (33)	8	3 (38)
p value		0.901		0.890		0.980
2018						
No imprisonment	50	12 (24)	20	7 (35)	71	20 (28)
Imprisonment	6	1 (17)	2	1 (50)	8	2 (25)
p value		0.636		0.706		0.812

Table 2.4.9 HCV RNA prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year *

Australian Capital Territory	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
Non Indigenous	25	19 (76)	8	6 (75)	33	25 (76)
Indigenous	4	4 (100)	4	2 (50)	9	7 (78)
p value		0.235		0.799		0.782
2016						
Non Indigenous	5	1 (20)	1	0 (0)	6	1 (17)
Indigenous	1	1 (100)	0	0 (0)	1	1 (100)
p value		0.192		--		0.284
2017						
Non Indigenous	48	18 (38)	17	4 (24)	66	22 (33)
Indigenous	8	0 (0)	10	4 (40)	18	4 (22)
p value		0.042		0.401		0.322
2018						
Non Indigenous	55	11 (20)	17	4 (24)	73	16 (22)
Indigenous	12	5 (42)	8	5 (63)	20	10 (50)
p value		0.099		0.156		0.017

Table 2.4.10 HCV RNA prevalence by main language spoken at home by parents, gender and survey year *

Australian Capital Territory	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
English speaking	25	21 (84)	11	8 (73)	36	29 (81)
Non-English speaking	5	3 (60)	1	0 (0)	6	3 (50)
p value		0.195		0.179		0.057
2016						
English speaking	6	2 (33)	1	0 (0)	7	2 (29)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2017						
English speaking	53	17 (32)	27	8 (30)	80	25 (31)
Non-English speaking	3	1 (33)	0	0 (0)	3	1 (33)
p value		0.790		--		0.750
2018						
English speaking	61	16 (26)	22	8 (36)	85	24 (28)
Non-English speaking	4	1 (25)	4	1 (25)	8	2 (25)
p value		0.964		0.678		0.856

Table 2.4.11 HCV RNA prevalence by region/country of birth, gender and survey year *

Australian Capital Territory	Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
Australia	25	19 (76)	9	7 (78)	35	26 (74)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	2	2 (100)	0	0 (0)	2	2 (100)
UK & Ireland	1	1 (100)	1	1 (100)	2	2 (100)
Other	1	1 (100)	2	0 (0)	3	1 (33)
p value		0.769		0.270		0.348
2016						
Australia	6	2 (33)	1	0 (0)	7	2 (29)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2017						
Australia	49	15 (31)	26	7 (27)	75	22 (29)
Other Oceania	2	0 (0)	0	0 (0)	2	0 (0)
Asia	1	1 (100)	0	0 (0)	1	1 (100)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	4	2 (50)	1	1 (100)	5	3 (60)
p value		0.326		0.121		0.207
2018						
Australia	58	16 (28)	24	9 (38)	83	25 (30)
Other Oceania	1	0 (0)	0	0 (0)	1	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	1	0 (0)	1	0 (0)	2	0 (0)
Other	6	1 (17)	1	0 (0)	7	1 (14)
p value		0.799		0.551		0.588

New South Wales

Table 3.1.1 Number (percentage) of respondents by demographic characteristics and survey year

New South Wales	2014	2015	2016	2017	2018
Number of sites	19	16	17	17	19
N° surveyed	N=761	N=639	N=532	N=575	N=574
Response rate (%)	45%	35%	36%	31%	37%
Gender (%)					
Male	539 (71)	464 (73)	372 (70)	402 (70)	420 (73)
Female	212 (28)	167 (26)	153 (29)	159 (28)	147 (26)
Transgender	9 (1)	7 (1)	6 (1)	11 (2)	5 (1)
Not reported	1 (<1)	1 (<1)	1 (<1)	3 (1)	2 (<1)
Sexual identity (%)					
Heterosexual	610 (80)	515 (81)	417 (78)	443 (77)	417 (73)
Bisexual	69 (9)	61 (10)	52 (10)	45 (8)	65 (11)
Homosexual	44 (6)	33 (5)	32 (6)	43 (7)	36 (6)
Not reported	38 (5)	30 (5)	31 (6)	44 (8)	56 (10)
Aboriginal and Torres Strait Islander origin (%)					
No	609 (80)	510 (80)	418 (79)	466 (81)	446 (78)
Yes	136 (18)	117 (18)	99 (19)	97 (17)	94 (16)
Not reported	16 (2)	12 (2)	15 (3)	12 (2)	34 (6)
Region/country of birth (%)					
Australia	646 (85)	548 (86)	455 (86)	492 (86)	470 (82)
Other Oceania	30 (4)	25 (4)	25 (5)	23 (4)	22 (4)
Asia	11 (1)	11 (2)	10 (2)	11 (2)	6 (1)
UK & Ireland	27 (4)	27 (4)	11 (2)	18 (3)	16 (3)
Other	37 (5)	18 (3)	22 (4)	21 (4)	38 (7)
Not reported	10 (1)	10 (2)	9 (2)	10 (2)	22 (4)
Main language spoken at home by parents (%)					
English	698 (92)	602 (94)	495 (93)	546 (95)	512 (89)
Non-English	56 (7)	32 (5)	31 (6)	26 (5)	43 (7)
Not reported	7 (1)	5 (1)	6 (1)	3 (1)	19 (3)
Age and time since first injection (years)					
<i>Median age</i>	40	41	42	43	44
<i>Age range</i>	17-67	18-70	18-75	17-76	18-69
Age group (%)					
<25 years	57 (7)	27 (4)	20 (4)	28 (5)	24 (4)
25+ years	702 (92)	612 (96)	512 (96)	545 (95)	550 (96)
Not reported	2 (<1)	0 (0)	0 (0)	2 (<1)	0 (0)
Median age first injection					
<i>Median age first injection</i>	19	19	19	19	19
<i>Age range</i>	10-47	10-63	10-76	10-76	10-54
N° not reported	25	18	16	36	41
Median yrs since first injection					
<i>Median yrs since first injection</i>	19	19	21	22	23
<i>Range</i>	<1-47	<1-52	<1-49	<1-50	<1-53
Years since first injection					
<3 years	66 (9)	60 (9)	30 (6)	46 (8)	28 (5)
3+ years	670 (88)	561 (88)	485 (91)	493 (86)	505 (88)
Not reported	25 (3)	18 (3)	17 (3)	36 (6)	41 (7)
Imprisonment last year (%)					
No	601 (79)	531 (83)	430 (81)	455 (79)	459 (80)
Yes	99 (13)	76 (12)	71 (13)	69 (12)	68 (12)
Not reported	61 (8)	32 (5)	31 (6)	51 (9)	47 (8)
N° in prison					
N° in prison	N=99	N=76	N=71	N=69	N=68
Injected in prison	38 (38)	31 (41)	34 (48)	26 (38)	26 (38)

Table 3.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year

New South Wales	2014	2015	2016	2017	2018
N° surveyed	N=761	N=639	N=532	N=575	N=574
Drug last injected (%)					
Cocaine	19 (3)	9 (1)	12 (2)	13 (2)	11 (2)
Methamphetamine	259 (34)	204 (32)	189 (36)	205 (36)	203 (35)
Heroin	216 (28)	194 (30)	170 (32)	190 (33)	175 (30)
Pharm. opioids	40 (5)	48 (8)	16 (3)	20 (3)	26 (5)
Methadone	70 (9)	60 (9)	49 (9)	39 (7)	41 (7)
Buprenorphine	9 (1)	10 (2)	5 (1)	5 (1)	5 (1)
Buprenorphine/naloxone	3 (<1)	5 (1)	1 (<1)	2 (<1)	3 (1)
PIEDs	77 (10)	76 (12)	52 (10)	57 (10)	64 (11)
More than one	33 (4)	25 (4)	33 (6)	29 (5)	37 (6)
Other	32 (4)	8 (1)	5 (1)	9 (2)	4 (1)
Not reported	3 (<1)	0 (0)	0 (0)	6 (1)	5 (1)
Ever injected opioids					
No	-	-	103 (19)	144 (25)	135 (24)
Yes	-	-	428 (80)	429 (75)	419 (73)
Not reported	-	-	1 (<1)	2 (<1)	20 (3)
Frequency of injection last month (%)					
Not last month	89 (12)	71 (11)	46 (9)	73 (13)	94 (16)
Less than weekly	138 (18)	111 (17)	95 (18)	99 (17)	90 (16)
Weekly not daily	186 (24)	159 (25)	140 (26)	131 (23)	136 (24)
Daily or more	339 (44)	286 (45)	240 (45)	263 (46)	232 (40)
Not reported	9 (1)	12 (2)	11 (2)	9 (2)	22 (4)
Present when someone injected for the first time in the last 12 months (%)					
No	604 (79)	512 (80)	420 (79)	463 (81)	464 (81)
Yes	130 (17)	114 (18)	99 (19)	82 (14)	77 (13)
Not reported	27 (4)	13 (2)	13 (2)	30 (5)	33 (6)
Overdosed in last 12 months					
No	610 (80)	539 (84)	431 (81)	453 (79)	436 (76)
Yes	122 (16)	82 (13)	86 (16)	88 (15)	103 (18)
Not reported	29 (4)	19 (3)	15 (3)	34 (6)	35 (6)

Table 3.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year

New South Wales	2014	2015	2016	2017	2018
N° injected last month	N=663	N=556	N=475	N=493	N=458
Places injected last month (%)					
All private	447 (67)	385 (69)	284 (60)	321 (65)	298 (65)
Any public	212 (32)	166 (30)	186 (39)	169 (34)	158 (35)
Not reported	4 (<1)	5 (1)	5 (1)	3 (1)	2 (<1)
Use of new and sterile needles and syringes last month (%)					
All injections	527 (79)	429 (77)	362 (76)	406 (82)	363 (79)
Most of the time	103 (16)	98 (18)	83 (17)	67 (14)	71 (16)
Half of the time	10 (2)	13 (2)	8 (2)	6 (1)	7 (2)
Some of the time	4 (<1)	7 (1)	13 (3)	4 (1)	6 (1)
Not last month	6 (1)	3 (1)	2 (<1)	3 (1)	6 (1)
Not reported	13 (2)	6 (1)	7 (1)	7 (1)	5 (1)
Re-used someone else's used needle & syringe last month (%)					
None	548 (83)	478 (86)	415 (87)	428 (87)	384 (84)
Once	45 (7)	23 (4)	19 (4)	19 (4)	25 (5)
Twice	27 (4)	18 (3)	16 (3)	21 (4)	13 (3)
3-5 times	20 (3)	16 (3)	9 (2)	9 (2)	20 (4)
>5 times	13 (2)	18 (3)	13 (3)	8 (2)	7 (2)
Not reported	10 (2)	3 (1)	3 (1)	8 (2)	9 (2)
Number of people needle & syringe was re-used after last month (%)					
None	548 (83)	478 (86)	415 (87)	428 (87)	384 (84)
One	45 (7)	24 (4)	22 (5)	19 (4)	31 (7)
Two	8 (1)	11 (2)	5 (1)	5 (1)	5 (1)
Three to five	4 (<1)	3 (1)	5 (1)	3 (1)	5 (1)
More than five	6 (1)	5 (1)	6 (1)	5 (1)	3 (1)
Don't know	18 (3)	18 (3)	11 (2)	14 (3)	12 (3)
Not reported	34 (5)	17 (3)	11 (2)	19 (4)	18 (4)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	44 (7)	27 (5)	23 (5)	23 (5)	25 (5)
Casual sex partner	7 (1)	4 (1)	5 (1)	1 (<1)	0 (0)
Close friend	16 (2)	16 (3)	12 (3)	16 (3)	15 (3)
Acquaintance	14 (2)	8 (1)	8 (2)	5 (1)	8 (2)
Other	7 (1)	4 (1)	3 (1)	3 (1)	8 (2)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	128 (19)	97 (17)	81 (17)	95 (19)	87 (19)
Water	99 (15)	76 (14)	64 (13)	59 (12)	72 (16)
Filter	63 (10)	42 (8)	36 (8)	30 (6)	35 (8)
Drug mix	47 (7)	60 (11)	35 (7)	31 (6)	33 (7)
None	480 (72)	403 (72)	356 (75)	367 (74)	330 (72)
Injected by someone after that person injected themselves or others last month (%)					
No	544 (82)	491 (88)	419 (88)	432 (88)	394 (86)
Yes	89 (13)	54 (10)	48 (10)	57 (12)	56 (12)
Not reported	30 (5)	11 (2)	8 (2)	4 (1)	8 (2)
Source of needle acquisition					
Needle Syringe Program	585 (88)	494 (89)	427 (90)	428 (87)	393 (86)
Chemist/Pharmacy	132 (20)	103 (19)	93 (20)	80 (16)	83 (18)
Personal sources	70 (11)	65 (12)	59 (12)	39 (8)	56 (12)
Dispensing/Vending Machine	190 (29)	133 (24)	143 (30)	111 (23)	124 (27)
Other sources	16 (2)	14 (3)	19 (4)	16 (3)	26 (6)

Table 3.1.4 Number (percentage) of respondents by treatment for drug use and survey year

New South Wales	2014	2015	2016	2017	2018
N° surveyed	N=761	N=639	N=532	N=575	N=574
Ever any treatment/therapy for drug use (%)					
No	200 (26)	158 (25)	121 (23)	151 (26)	144 (25)
Yes	543 (71)	466 (73)	397 (75)	408 (71)	402 (70)
Not reported	18 (2)	15 (2)	14 (3)	16 (3)	28 (5)
History of methadone maintenance treatment (%)					
Currently	251 (33)	225 (35)	196 (37)	192 (33)	183 (32)
Previously	158 (21)	122 (19)	105 (20)	104 (18)	132 (23)
Never	336 (44)	278 (44)	216 (41)	262 (46)	225 (39)
Not reported	16 (2)	14 (2)	15 (3)	17 (3)	34 (6)
History of buprenorphine (Subutex®) treatment (%)					
Currently	47 (6)	46 (7)	21 (4)	39 (7)	47 (8)
Previously	182 (24)	147 (23)	155 (29)	122 (21)	147 (26)
Never	511 (67)	428 (67)	338 (64)	396 (69)	348 (61)
Not reported	21 (3)	18 (3)	18 (3)	18 (3)	32 (6)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	45 (6)	54 (8)	21 (4)	41 (7)	35 (6)
Previously	127 (17)	118 (18)	112 (21)	98 (17)	130 (23)
Never	571 (75)	451 (71)	379 (71)	420 (73)	374 (65)
Not reported	18 (2)	16 (3)	20 (4)	16 (3)	35 (6)

Table 3.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year

New South Wales	2014	2015	2016	2017	2018
N° surveyed	N=761	N=639	N=532	N=575	N=574
Previous HIV test (%)					
Yes, ever	610 (80)	545 (85)	471 (89)	461 (80)	463 (81)
Yes, last year	374 (49)	328 (51)	283 (53)	283 (49)	307 (53)
>1 year ago	236 (31)	217 (34)	188 (35)	178 (31)	156 (27)
Never tested	116 (15)	78 (12)	48 (9)	69 (12)	70 (12)
Not reported	35 (5)	16 (3)	13 (2)	45 (8)	41 (7)
Previous HCV test (%)					
Yes, ever	648 (85)	550 (86)	448 (84)	456 (79)	452 (79)
Yes, last year	389 (51)	339 (53)	282 (53)	316 (55)	315 (55)
>1 year ago	259 (34)	211 (33)	166 (31)	140 (24)	137 (24)
Never tested	80 (11)	60 (9)	36 (7)	56 (10)	53 (9)
Not reported	33 (4)	29 (5)	48 (9)	63 (11)	69 (12)
Lifetime treatment for HCV (%)[#]					
N° self-reported HCV diagnosis	N=231	N=202	N=169	N=157	N=163
Antiviral treatment	29 (13)	32 (16)	53 (31)	77 (49)	97 (60)
No antiviral treatment	197 (85)	165 (82)	116 (69)	78 (50)	65 (40)
Not reported	5 (2)	5 (2)	0 (0)	2 (1)	1 (1)
Treatment for HCV in past 12 months (%)^{##}					
N° self-reported HCV diagnosis	N=218	N=190	N=163	N=142	N=131
Antiviral treatment	4 (2)	5 (3)	44 (27)	57 (40)	57 (44)
No antiviral treatment	209 (96)	180 (95)	119 (73)	83 (58)	73 (56)
Not reported	5 (2)	5 (3)	0 (0)	2 (1)	1 (1)

[#] among people who tested HCV antibody positive and did not report spontaneous clearance

* excludes people who reported treatment induced clearance more than 12 months previously

Table 3.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year

New South Wales	2014	2015	2016	2017	2018
N° surveyed	N=761	N=639	N=532	N=575	N=574
Sex with a regular partner last month (%)					
No	355 (47)	292 (46)	257 (48)	286 (50)	279 (49)
Yes	377 (50)	319 (50)	257 (48)	247 (43)	255 (44)
Not reported	29 (4)	28 (4)	18 (3)	42 (7)	40 (7)
Condom used with regular partner last month (%)					
N° surveyed	N=377	N=319	N=257	N=247	N=255
Never	265 (70)	250 (78)	186 (72)	187 (76)	182 (71)
Sometimes	49 (13)	28 (9)	28 (11)	24 (10)	26 (10)
Every time	43 (11)	29 (9)	29 (11)	27 (11)	32 (13)
Not reported	20 (5)	12 (4)	14 (5)	9 (4)	15 (6)
Sex with other partner(s) last month (%)					
No	588 (77)	527 (82)	416 (78)	441 (77)	437 (76)
Yes	133 (17)	95 (15)	92 (17)	78 (14)	82 (14)
Not reported	40 (5)	17 (3)	24 (5)	56 (10)	55 (10)
Condom used with other partner(s) last month (%)					
N° surveyed	N=133	N=95	N=92	N=78	N=82
Never	45 (34)	35 (37)	29 (32)	31 (40)	33 (40)
Sometimes	34 (26)	30 (32)	28 (30)	23 (29)	21 (26)
Every time	43 (32)	27 (28)	35 (38)	22 (28)	25 (30)
Not reported	11 (8)	3 (3)	0 (0)	2 (3)	3 (4)
Sex work last month (%)					
No	642 (84)	595 (93)	479 (90)	482 (84)	487 (85)
Yes	51 (7)	29 (5)	29 (5)	35 (6)	30 (5)
Not reported	68 (9)	15 (2)	24 (5)	58 (10)	57 (10)
Condom used at last sex work (%)					
Yes	35 (69)	21 (72)	17 (59)	24 (69)	19 (63)

HIV antibody prevalence

Table 3.2.1 HIV antibody prevalence by gender and survey year

New South Wales Survey year	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014	505	15 (3.0)	202	0 (0.0)	714	18 (2.5)
2015	436	16 (3.7)	164	2 (1.2)	608	19 (3.1)
2016	354	11 (3.1)	148	1 (0.7)	509	13 (2.6)
2017	369	17 (4.6)	150	3 (2.0)	533	21 (3.9)
2018	395	15 (3.8)	144	1 (0.7)	546	17 (3.1)
X ² p trend		0.375		0.281		0.368

Table 3.2.2 HIV antibody prevalence by sexual identity, gender and survey year

New South Wales Sexual identity	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
Heterosexual	434	3 (0.7)	135	0 (0.0)	571	3 (0.5)
Bisexual	17	2 (11.8)	44	0 (0.0)	65	5 (7.7)
Homosexual	31	10 (32.3)	10	0 (0.0)	42	10 (23.8)
p value		<0.001		--		<0.001
2015						
Heterosexual	369	2 (0.5)	125	1 (0.8)	497	3 (0.6)
Bisexual	26	2 (7.7)	28	1 (3.6)	56	4 (7.1)
Homosexual	23	12 (52.2)	2	0 (0.0)	26	12 (46.2)
p value		<0.001		0.351		<0.001
2016						
Heterosexual	293	0 (0.0)	106	0 (0.0)	401	0 (0.0)
Bisexual	16	1 (6.3)	32	1 (3.1)	48	2 (4.2)
Homosexual	25	9 (36.0)	0	0 (0.0)	29	10 (34.5)
p value		<0.001		0.232		<0.001
2017						
Heterosexual	293	3 (1.0)	119	1 (0.8)	415	5 (1.2)
Bisexual	24	2 (4.2)	15	2 (13.3)	41	3 (7.3)
Homosexual	25	12 (48.0)	5	0 (0.0)	36	12 (33.3)
p value		<0.001		0.054		<0.001
2018						
Heterosexual	301	0 (0.0)	90	1 (1.1)	392	1 (0.3)
Bisexual	26	2 (7.7)	36	0 (0.0)	64	2 (3.1)
Homosexual	26	10 (38.5)	7	0 (0.0)	34	11 (32.4)
p value		<0.001		1.000		<0.001

Table 3.2.3 HIV antibody prevalence by age group, gender and survey year

New South Wales Age group	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
<25 years	42	1 (2.4)	7	0 (0.0)	50	1 (2.0)
25-34 years	105	3 (2.9)	59	0 (0.0)	167	4 (2.4)
35-44 years	187	3 (1.6)	81	0 (0.0)	271	5 (1.9)
45+ years	171	8 (4.7)	53	0 (0.0)	224	8 (3.6)
p value		0.393		--		0.674
2015						
<25 years	21	0 (0.0)	6	1 (16.7)	27	1 (3.7)
25-34 years	101	2 (2.0)	51	1 (2.0)	155	4 (2.6)
35-44 years	138	3 (2.2)	52	0 (0.0)	192	3 (2.6)
45+ years	176	11 (6.3)	55	0 (0.0)	234	11 (4.7)
p value		0.179		0.024		0.249
2016						
<25 years	18	0 (0.0)	2	0 (0.0)	20	0 (0.0)
25-34 years	59	4 (6.8)	32	0 (0.0)	93	4 (4.3)
35-44 years	131	2 (1.5)	54	1 (1.9)	186	3 (1.6)
45+ years	146	5 (3.4)	60	0 (0.0)	210	6 (2.9)
p value		0.249		0.595		0.498
2017						
<25 years	19	0 (0.0)	5	0 (0.0)	24	0 (0.0)
25-34 years	55	0 (0.0)	21	0 (0.0)	80	1 (1.3)
35-44 years	114	6 (5.3)	61	2 (3.3)	177	8 (4.5)
45+ years	180	11 (6.1)	62	1 (1.6)	250	12 (4.8)
p value		0.230		0.786		0.462
2018						
<25 years	14	1 (7.1)	7	0 (0.0)	22	1 (4.6)
25-34 years	54	5 (9.3)	24	0 (0.0)	79	5 (6.3)
35-44 years	127	3 (2.4)	55	1 (1.8)	184	4 (2.2)
45+ years	200	6 (3.0)	58	0 (0.0)	261	7 (2.7)
p value		0.094		0.597		0.229

Table 3.2.4 HIV antibody prevalence by last drug injected, gender and survey year

New South Wales Last drug injected	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
Heroin	130	1 (0.8)	70	0 (0.0)	202	2 (1.0)
Methamphetamine	164	9 (5.5)	80	0 (0.0)	245	9 (3.7)
Other opioids	81	2 (2.5)	33	0 (0.0)	115	2 (1.7)
PIEDs	69	1 (1.5)	2	0 (0.0)	72	1 (1.4)
Other drugs	60	2 (3.3)	16	0 (0.0)	78	4 (5.1)
p value		0.173		--		0.187
2015						
Heroin	124	3 (2.4)	60	0 (0.0)	187	4 (2.1)
Methamphetamine	134	10 (7.5)	54	2 (3.7)	191	12 (6.3)
Other opioids	85	2 (2.4)	32	0 (0.0)	119	2 (1.7)
PIEDs	70	1 (1.4)	4	0 (0.0)	74	1 (1.4)
Other drugs	23	0 (0.0)	14	0 (0.0)	37	0 (0.0)
p value		0.165		0.352		0.098
2016						
Heroin	106	1 (0.9)	57	1 (1.8)	165	2 (1.2)
Methamphetamine	121	9 (7.4)	56	0 (0.0)	180	10 (5.6)
Other opioids	47	0 (0.0)	21	0 (0.0)	68	0 (0.0)
PIEDs	48	0 (0.0)	0	0 (0.0)	49	0 (0.0)
Other drugs	32	1 (3.1)	14	0 (0.0)	47	1 (2.1)
p value		0.024		1.000		0.046
2017						
Heroin	110	3 (2.7)	61	1 (1.6)	177	4 (2.3)
Methamphetamine	134	11 (8.2)	51	2 (3.9)	188	14 (7.5)
Other opioids	43	1 (2.3)	21	0 (0.0)	65	1 (1.5)
PIEDs	43	0 (0.0)	3	0 (0.0)	47	0 (0.0)
Other drugs	39	2 (5.1)	14	0 (0.0)	56	2 (3.6)
p value		0.134		0.831		0.051
2018						
Heroin	107	3 (2.8)	56	0 (0.0)	165	3 (1.8)
Methamphetamine	140	9 (6.4)	47	1 (2.1)	191	11 (5.8)
Other opioids	47	1 (2.1)	27	0 (0.0)	74	1 (1.4)
PIEDs	56	0 (0.0)	3	0 (0.0)	60	0 (0.0)
Other drugs	42	2 (4.8)	10	0 (0.0)	52	2 (3.9)
p value		0.247		0.608		0.106

Table 3.2.5 HIV antibody prevalence by years of injection, gender and survey year

New South Wales Years of injection	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
<3 years	53	1 (1.9)	8	0 (0.0)	62	1 (1.6)
3 to 10 years	81	6 (7.4)	39	0 (0.0)	120	6 (5.0)
11+ years	355	7 (2.0)	149	0 (0.0)	509	9 (1.8)
p value		0.042		--		0.111
2015						
<3 years	45	2 (4.4)	12	0 (0.0)	58	2 (3.5)
3 to 10 years	61	4 (6.6)	21	1 (4.8)	84	5 (6.0)
11+ years	317	9 (2.8)	126	1 (0.8)	448	11 (2.5)
p value		0.287		0.373		0.193
2016						
<3 years	21	0 (0.0)	7	0 (0.0)	29	0 (0.0)
3 to 10 years	59	4 (6.8)	21	0 (0.0)	81	4 (4.9)
11+ years	263	6 (2.3)	116	1 (0.9)	384	8 (2.1)
p value		0.189		1.000		0.349
2017						
<3 years	34	0 (0.0)	8	0 (0.0)	42	0 (0.0)
3 to 10 years	50	4 (8.0)	11	0 (0.0)	63	5 (7.9)
11+ years	285	13 (4.6)	131	3 (2.3)	428	16 (3.7)
p value		0.236		1.000		0.114
2018						
<3 years	19	1 (5.3)	5	0 (0.0)	24	1 (4.2)
3 to 10 years	60	5 (8.3)	13	0 (0.0)	73	5 (6.9)
11+ years	316	9 (2.9)	126	1 (0.8)	449	11 (2.5)
p value		0.090		1.000		0.098

Table 3.2.6 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

New South Wales Receptively shared syringe last month	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
No receptive sharing	362	9 (2.5)	143	0 (0.0)	510	11 (2.2)
Receptive sharing	70	2 (2.9)	28	0 (0.0)	99	3 (3.0)
p value		0.695		--		0.485
2015						
No receptive sharing	329	13 (4.0)	119	2 (1.7)	453	16 (3.5)
Receptive sharing	49	2 (4.1)	20	0 (0.0)	71	2 (2.8)
p value		1.000		1.000		1.000
2016						
No receptive sharing	279	9 (3.2)	114	1 (0.9)	398	10 (2.5)
Receptive sharing	37	0 (0.0)	18	0 (0.0)	55	0 (0.0)
p value		0.606		1.000		0.618
2017						
No receptive sharing	277	13 (4.7)	112	2 (1.8)	398	15 (3.8)
Receptive sharing	38	1 (2.6)	15	1 (6.7)	54	3 (5.6)
p value		1.000		0.316		0.463
2018						
No receptive sharing	284	12 (4.2)	87	0 (0.0)	374	12 (3.2)
Receptive sharing	48	2 (4.2)	17	0 (0.0)	65	2 (3.1)
p value		1.000		--		1.000

Table 3.2.7 HIV antibody prevalence by frequency of drug injection last month, gender and survey year

New South Wales Frequency of injection	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
Less than daily	221	4 (1.8)	87	0 (0.0)	309	4 (1.3)
Daily or more	218	8 (3.7)	86	0 (0.0)	309	11 (3.6)
Not last month	60	3 (5.0)	26	0 (0.0)	87	3 (3.4)
p value		0.257		--		0.138
2015						
Less than daily	194	8 (4.1)	55	1 (1.8)	252	9 (3.6)
Daily or more	187	7 (3.7)	84	1 (1.2)	275	9 (3.3)
Not last month	47	1 (2.1)	21	0 (0.0)	69	1 (1.5)
p value		1.000		1.000		0.845
2016						
Less than daily	165	5 (3.0)	60	0 (0.0)	229	5 (2.2)
Daily or more	153	4 (2.6)	73	1 (1.4)	227	5 (2.2)
Not last month	30	1 (3.3)	12	0 (0.0)	43	1 (2.3)
p value		1.000		1.000		1.000
2017						
Less than daily	169	7 (4.1)	45	2 (4.4)	215	9 (4.2)
Daily or more	150	7 (4.7)	85	1 (1.2)	245	9 (3.7)
Not last month	44	2 (4.6)	19	0 (0.0)	65	2 (3.1)
p value		1.000		0.520		0.949
2018						
Less than daily	166	6 (3.6)	52	0 (0.0)	220	6 (2.7)
Daily or more	169	8 (4.7)	57	0 (0.0)	227	8 (3.5)
Not last month	56	1 (1.8)	33	1 (3.0)	92	3 (3.3)
p value		0.725		0.232		0.898

Table 3.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year

New South Wales Imprisonment last year	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
No imprisonment	399	12 (3.0)	167	0 (0.0)	568	12 (2.1)
Imprisonment	65	0 (0.0)	22	0 (0.0)	91	3 (3.3)
p value		0.389		--		0.448
2015						
No imprisonment	355	13 (3.7)	143	2 (1.4)	504	16 (3.2)
Imprisonment	56	1 (1.8)	16	0 (0.0)	74	1 (1.4)
p value		0.703		1.000		0.711
2016						
No imprisonment	278	6 (2.2)	131	0 (0.0)	412	6 (1.5)
Imprisonment	58	3 (5.2)	10	1 (10.0)	68	4 (5.9)
p value		0.190		0.071		0.040
2017						
No imprisonment	283	16 (5.7)	128	1 (0.8)	421	18 (4.3)
Imprisonment	51	0 (0.0)	10	1 (10.0)	63	1 (1.6)
p value		0.145		0.140		0.491
2018						
No imprisonment	320	14 (4.4)	123	1 (0.8)	448	16 (3.6)
Imprisonment	52	1 (1.9)	15	0 (0.0)	68	1 (1.5)
p value		0.705		1.000		0.712

Table 3.2.9 HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year

New South Wales		Male		Female		Total	
Condom use at last sex	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2014							
No condom use	157	1 (0.6)	96	0 (0.0)	253	1 (0.4)	
Condom use	65	2 (3.1)	20	0 (0.0)	88	4 (4.6)	
p value		0.206		--		0.017	
2015							
No condom use	166	6 (3.6)	73	0 (0.0)	240	7 (2.9)	
Condom use	42	1 (2.4)	13	1 (7.7)	55	2 (3.6)	
p value		1.000		0.151		0.676	
2016							
No condom use	116	5 (4.3)	60	0 (0.0)	176	5 (2.8)	
Condom use	35	0 (0.0)	17	1 (5.9)	54	2 (3.7)	
p value		0.590		0.221		0.668	
2017							
No condom use	107	11 (10.3)	63	1 (1.6)	171	12 (7.0)	
Condom use	37	0 (0.0)	11	0 (0.0)	49	0 (0.0)	
p value		0.066		1.000		0.073	
2018							
No condom use	128	3 (2.3)	49	0 (0.0)	178	3 (1.7)	
Condom use	37	5 (13.5)	16	0 (0.0)	56	5 (8.9)	
p value		0.015		--		0.021	

Table 3.2.10 HIV antibody prevalence by sex work last month, gender and survey year

New South Wales		Male		Female		Total	
Sex work last month	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2014							
No sex work	439	8 (1.8)	165	0 (0.0)	606	9 (1.5)	
Sex work	17	3 (17.7)	22	0 (0.0)	44	5 (11.4)	
p value		0.006		--		<0.001	
2015							
No sex work	414	11 (2.7)	147	2 (1.4)	567	13 (2.3)	
Sex work	11	3 (27.3)	15	0 (0.0)	28	4 (14.3)	
p value		0.004		1.000		0.006	
2016							
No sex work	324	6 (1.9)	129	1 (0.8)	457	8 (1.8)	
Sex work	15	3 (20.0)	11	0 (0.0)	29	3 (10.3)	
p value		0.005		1.000		0.023	
2017							
No sex work	316	14 (4.4)	124	2 (1.6)	447	16 (3.6)	
Sex work	15	2 (13.3)	12	0 (0.0)	33	3 (9.1)	
p value		0.159		1.000		0.135	
2018							
No sex work	354	10 (2.8)	117	1 (0.9)	476	12 (2.5)	
Sex work	13	2 (15.4)	15	0 (0.0)	30	2 (6.7)	
p value		0.063		1.000		0.199	

Table 3.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

New South Wales Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
Non Indigenous	421	12 (2.9)	142	0 (0.0)	569	14 (2.5)
Indigenous	73	1 (1.4)	57	0 (0.0)	131	2 (1.5)
p value		0.703		--		0.749
2015						
Non Indigenous	358	15 (4.2)	122	0 (0.0)	486	16 (3.3)
Indigenous	71	1 (1.4)	41	2 (4.9)	112	3 (2.7)
p value		0.489		0.062		1.000
2016						
Non Indigenous	283	7 (2.5)	109	0 (0.0)	399	8 (2.0)
Indigenous	59	3 (5.1)	37	1 (2.7)	96	4 (4.2)
p value		0.386		0.253		0.260
2017						
Non Indigenous	306	14 (4.6)	110	1 (0.9)	428	16 (3.7)
Indigenous	56	3 (5.4)	37	2 (5.4)	95	5 (5.3)
p value		0.734		0.156		0.561
2018						
Non Indigenous	321	9 (2.8)	110	0 (0.0)	437	9 (2.1)
Indigenous	62	5 (8.1)	30	0 (0.0)	93	6 (6.5)
p value		0.043		--		0.020

Table 3.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and survey year

New South Wales Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
English speaking	459	13 (2.8)	189	0 (0.0)	654	16 (2.5)
Non-English speaking	41	0 (0.0)	11	0 (0.0)	53	0 (0.0)
p value		0.613		--		0.624
2015						
English speaking	408	15 (3.7)	157	2 (1.3)	573	18 (3.1)
Non-English speaking	25	1 (4.0)	7	0 (0.0)	32	1 (3.1)
p value		1.000		1.000		1.000
2016						
English speaking	324	10 (3.1)	142	1 (0.7)	472	12 (2.5)
Non-English speaking	25	0 (0.0)	5	0 (0.0)	31	0 (0.0)
p value		1.000		1.000		1.000
2017						
English speaking	350	17 (4.9)	143	3 (2.1)	507	21 (4.1)
Non-English speaking	17	0 (0.0)	7	0 (0.0)	24	0 (0.0)
p value		1.000		1.000		0.616
2018						
English speaking	361	15 (4.2)	135	0 (0.0)	501	16 (3.2)
Non-English speaking	33	0 (0.0)	8	0 (0.0)	43	0 (0.0)
p value		0.625		--		0.628

Table 3.2.13 HIV antibody prevalence by region/country of birth, gender and survey year

New South Wales		Male		Female		Total	
Region/country of birth	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2014							
Australia	421	11 (2.6)	179	0 (0.0)	604	12 (2.0)	
Other Oceania	20	0 (0.0)	7	0 (0.0)	29	2 (6.9)	
Asia	10	0 (0.0)	1	0 (0.0)	11	0 (0.0)	
UK & Ireland	19	0 (0.0)	7	0 (0.0)	26	0 (0.0)	
Other	28	2 (7.1)	5	0 (0.0)	34	2 (5.9)	
p value		0.508		--			0.169
2015							
Australia	373	13 (3.5)	143	2 (1.4)	523	15 (2.9)	
Other Oceania	17	1 (5.9)	6	0 (0.0)	24	2 (8.3)	
Asia	8	0 (0.0)	3	0 (0.0)	11	0 (0.0)	
UK & Ireland	19	1 (5.3)	7	0 (0.0)	26	1 (3.9)	
Other	12	0 (0.0)	5	0 (0.0)	17	0 (0.0)	
p value		0.704		1.000			0.401
2016							
Australia	304	10 (3.3)	125	1 (0.8)	434	11 (2.5)	
Other Oceania	14	0 (0.0)	10	0 (0.0)	25	1 (4.0)	
Asia	8	0 (0.0)	1	0 (0.0)	10	0 (0.0)	
UK & Ireland	7	0 (0.0)	4	0 (0.0)	11	0 (0.0)	
Other	14	0 (0.0)	7	0 (0.0)	21	0 (0.0)	
p value		1.000		1.000			0.825
2017							
Australia	317	14 (4.4)	131	2 (1.5)	459	17 (3.7)	
Other Oceania	14	1 (7.1)	6	0 (0.0)	21	1 (4.8)	
Asia	6	0 (0.0)	3	0 (0.0)	9	0 (0.0)	
UK & Ireland	11	0 (0.0)	5	0 (0.0)	17	0 (0.0)	
Other	14	1 (7.1)	4	0 (0.0)	19	1 (5.3)	
p value		0.651		1.000			0.743
2018							
Australia	330	12 (3.6)	125	0 (0.0)	460	12 (2.6)	
Other Oceania	14	1 (7.1)	7	0 (0.0)	22	2 (9.1)	
Asia	5	0 (0.0)	0	0 (0.0)	5	0 (0.0)	
UK & Ireland	13	1 (7.7)	3	0 (0.0)	16	1 (6.3)	
Other	31	1 (3.2)	6	0 (0.0)	38	1 (2.6)	
p value		0.478		--			0.240

HCV antibody prevalence

Table 3.3.1 HCV antibody prevalence by gender and survey year

New South Wales Survey year	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014	502	264 (53)	200	123 (62)	709	390 (55)
2015	371	215 (58)	143	96 (67)	521	316 (61)
2016	331	174 (53)	137	75 (55)	473	252 (53)
2017	357	172 (48)	146	73 (50)	515	252 (49)
2018	395	183 (46)	144	60 (42)	546	247 (45)
X ² p trend		0.128		0.018		0.011

Table 3.3.2 HCV antibody prevalence by sexual identity, gender and survey year

New South Wales Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
Heterosexual	432	233 (54)	133	80 (60)	567	314 (55)
Bisexual	17	8 (47)	44	27 (61)	65	37 (57)
Homosexual	31	10 (32)	10	6 (60)	42	16 (38)
p value		0.060		0.989		0.087
2015						
Heterosexual	313	185 (59)	108	71 (66)	424	258 (61)
Bisexual	21	12 (57)	25	18 (72)	48	31 (65)
Homosexual	22	9 (41)	2	1 (50)	25	11 (44)
p value		0.247		0.737		0.202
2016						
Heterosexual	271	147 (54)	96	51 (53)	368	199 (54)
Bisexual	16	6 (38)	32	20 (63)	48	26 (54)
Homosexual	25	9 (36)	0	0 (0)	28	11 (39)
p value		0.108		0.355		0.315
2017						
Heterosexual	281	149 (53)	115	62 (54)	398	212 (53)
Bisexual	24	8 (33)	15	6 (40)	40	15 (38)
Homosexual	25	3 (12)	5	3 (60)	36	10 (28)
p value		<0.001		0.628		0.004
2018						
Heterosexual	301	143 (48)	90	34 (38)	392	178 (45)
Bisexual	26	12 (46)	36	17 (47)	64	31 (48)
Homosexual	26	8 (31)	7	3 (43)	34	11 (32)
p value		0.259		0.616		0.282

Table 3.3.3 HCV antibody prevalence by age group, gender and survey year

New South Wales Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
<25 years	42	5 (12)	7	2 (29)	50	7 (14)
25-34 years	104	39 (38)	59	38 (64)	166	79 (48)
35-44 years	187	116 (62)	79	44 (56)	269	161 (60)
45+ years	169	104 (62)	53	37 (70)	222	141 (64)
p value		<0.001		0.116		<0.001
2015						
<25 years	16	2 (13)	3	0 (0)	19	2 (11)
25-34 years	87	31 (36)	46	30 (65)	136	63 (46)
35-44 years	126	82 (65)	45	30 (67)	173	113 (65)
45+ years	142	100 (70)	49	36 (73)	193	138 (72)
p value		<0.001		0.089		<0.001
2016						
<25 years	17	4 (24)	2	1 (50)	19	5 (26)
25-34 years	56	14 (25)	31	18 (58)	88	33 (38)
35-44 years	125	74 (59)	49	23 (47)	175	97 (55)
45+ years	133	82 (62)	55	33 (60)	191	117 (61)
p value		<0.001		0.566		<0.001
2017						
<25 years	17	0 (0)	5	1 (20)	22	1 (5)
25-34 years	52	17 (33)	20	9 (45)	75	27 (36)
35-44 years	110	48 (44)	60	33 (55)	172	82 (48)
45+ years	177	107 (60)	60	30 (50)	244	142 (58)
p value		<0.001		0.489		<0.001
2018						
<25 years	14	2 (14)	7	0 (0)	22	2 (9)
25-34 years	54	12 (22)	24	11 (46)	79	24 (30)
35-44 years	126	66 (52)	55	24 (44)	183	91 (50)
45+ years	201	103 (51)	58	25 (43)	262	130 (50)
p value		<0.001		0.151		<0.001

Table 3.3.4 HCV antibody prevalence by years since first injection, gender and survey year

New South Wales Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
<3 years	53	1 (20)	8	1 (13)	62	2 (3)
3 to 10 years	80	22 (28)	39	22 (56)	19	44 (37)
11+ years	353	231 (65)	147	96 (65)	505	330 (65)
p value		<0.001		0.009		<0.001
2015						
<3 years	36	5 (14)	8	2 (25)	44	7 (16)
3 to 10 years	50	16 (32)	17	8 (57)	69	25 (36)
11+ years	275	191 (69)	113	84 (74)	393	279 (71)
p value		<0.001		0.002		<0.001
2016						
<3 years	21	2 (10)	7	1 (14)	29	4 (14)
3 to 10 years	55	15 (27)	18	8 (44)	74	23 (31)
11+ years	245	152 (62)	109	65 (60)	357	219 (61)
p value		<0.001		0.048		<0.001
2017						
<3 years	34	2 (6)	8	0 (0)	42	2 (5)
3 to 10 years	48	17 (35)	11	4 (36)	60	21 (35)
11+ years	252	142 (56)	118	67 (57)	380	216 (57)
p value		<0.001		0.002		<0.001
2018						
<3 years	19	1 (5)	5	0 (0)	24	1 (4)
3 to 10 years	60	6 (10)	13	3 (23)	73	9 (12)
11+ years	288	164 (57)	119	55 (46)	413	223 (54)
p value		<0.001		0.040		<0.001

Table 3.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

New South Wales Receptively shared syringe last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
No receptive sharing	44	2 (5)	454	259 (57)	507	267 (53)
Receptive sharing	2	0 (0)	90	69 (77)	99	75 (76)
p value		1.000		0.001		<0.001
2015						
No receptive sharing	32	5 (16)	350	232 (66)	389	238 (61)
Receptive sharing	3	1 (33)	56	36 (64)	60	38 (63)
p value		0.442		0.769		0.750
2016						
No receptive sharing	23	4 (17)	337	190 (56)	369	197 (53)
Receptive sharing	3	0 (0)	47	28 (60)	52	30 (58)
p value		1.000		0.679		0.560
2017						
No receptive sharing	28	2 (7)	337	178 (53)	383	188 (49)
Receptive sharing	3	0 (0)	43	25 (58)	52	27 (52)
p value		1.000		0.510		0.701
2018						
No receptive sharing	16	0 (0)	338	160 (47)	374	168 (45)
Receptive sharing	0	0 (0)	59	36 (61)	65	40 (62)
p value		--		0.052		0.013

Table 3.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year

New South Wales Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
Heroin	4	1 (25)	192	130 (68)	200	133 (67)
Methamphetamine	14	1 (7)	221	130 (59)	243	135 (56)
Other opioids	2	0 (0)	111	73 (66)	114	74 (65)
PIEDs	36	0 (0)	33	1 (3)	72	2 (3)
Other drugs	5	0 (0)	67	40 (60)	78	46 (59)
p value		0.089		<0.001		<0.001
2015						
Heroin	5	1 (20)	158	120 (76)	165	123 (75)
Methamphetamine	12	2 (17)	145	86 (59)	161	90 (56)
Other opioids	3	2 (67)	96	74 (77)	99	76 (77)
PIEDs	20	1 (5)	32	0 (0)	56	1 (2)
Other drugs	3	1 (33)	26	21 (81)	30	22 (73)
p value		0.086		<0.001		<0.001
2016						
Heroin	1	0 (0)	151	94 (62)	156	95 (61)
Methamphetamine	10	3 (30)	148	81 (55)	162	86 (53)
Other opioids	1	1 (100)	60	45 (75)	62	47 (76)
PIEDs	15	0 (0)	28	0 (0)	45	0 (0)
Other drugs	1	0 (0)	37	19 (51)	40	21 (53)
p value		0.028		<0.001		<0.001
2017						
Heroin	4	0 (0)	152	100 (66)	170	110 (65)
Methamphetamine	15	2 (13)	156	67 (43)	179	70 (39)
Other opioids	0	0 (0)	59	39 (66)	62	40 (65)
PIEDs	20	0 (0)	24	0 (0)	46	0 (0)
Other drugs	3	0 (0)	45	28 (62)	50	28 (56)
p value		0.286		<0.001		<0.001
2018						
Heroin	2	0 (0)	156	94 (60)	162	96 (59)
Methamphetamine	10	1 (10)	167	71 (43)	190	77 (41)
Other opioids	1	0 (0)	65	40 (62)	73	44 (60)
PIEDs	11	0 (0)	43	1 (2)	60	1 (2)
Other drugs	0	0 (0)	46	21 (46)	50	23 (46)
p value		0.691		<0.001		<0.001

Table 3.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

New South Wales Frequency of injection last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
Less than daily	26	1 (4)	275	151 (55)	307	157 (51)
Daily or more	20	1 (5)	277	183 (66)	308	191 (62)
Not last month	15	0 (0)	65	35 (54)	85	36 (42)
p value		1.000		0.016		0.001
2015						
Less than daily	22	2 (9)	186	113 (61)	213	115 (54)
Daily or more	13	4 (31)	222	156 (70)	238	162 (68)
Not last month	8	1 (13)	49	32 (65)	60	35 (58)
p value		0.291		0.125		0.008
2016						
Less than daily	15	2 (13)	195	101 (52)	212	104 (49)
Daily or more	11	2 (18)	192	120 (63)	212	126 (59)
Not last month	2	0 (0)	37	18 (49)	41	19 (46)
p value		1.000		0.064		0.063
2017						
Less than daily	20	2 (10)	182	89 (49)	209	91 (44)
Daily or more	11	0 (0)	205	119 (58)	234	129 (55)
Not last month	11	0 (0)	49	26 (53)	64	28 (44)
p value		0.489		0.197		0.035
2018						
Less than daily	10	0 (0)	202	93 (46)	221	95 (43)
Daily or more	6	0 (0)	203	105 (52)	226	115 (51)
Not last month	8	1 (13)	75	30 (40)	92	33 (36)
p value		0.583		0.190		0.037

Table 3.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

New South Wales Imprisonment last year	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
No imprisonment	58	1 (2)	492	275 (56)	564	285 (51)
Imprisonment	3	1 (33)	84	67 (80)	91	71 (78)
p value		0.097		<0.001		<0.001
2015						
No imprisonment	38	6 (16)	376	235 (63)	427	244 (57)
Imprisonment	2	1 (50)	64	53 (83)	67	55 (82)
p value		0.323		0.002		<0.001
2016						
No imprisonment	24	2 (8)	349	193 (55)	382	200 (52)
Imprisonment	3	1 (33)	58	36 (62)	64	37 (58)
p value		0.308		0.336		0.418
2017						
No imprisonment	40	2 (5)	343	174 (51)	406	183 (45)
Imprisonment	0	0 (0)	52	43 (83)	61	49 (80)
p value		--		<0.001		<0.001
2018						
No imprisonment	18	0 (0)	401	185 (46)	448	194 (43)
Imprisonment	6	1 (17)	57	32 (56)	68	36 (53)
p value		0.250		0.157		0.136

Table 3.3.9 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

New South Wales	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
Non Indigenous	418	206 (49)	140	84 (60)	564	293 (52)
Indigenous	73	53 (73)	57	36 (63)	131	89 (68)
p value		<0.001		0.680		0.001
2015						
Non Indigenous	311	167 (54)	105	67 (64)	421	237 (56)
Indigenous	55	44 (80)	37	28 (76)	92	72 (78)
p value		<0.001		0.187		<0.001
2016						
Non Indigenous	263	130 (49)	101	55 (54)	369	188 (51)
Indigenous	56	37 (66)	34	19 (56)	90	56 (62)
p value		0.024		0.885		0.055
2017						
Non Indigenous	297	128 (43)	107	50 (47)	414	184 (44)
Indigenous	53	38 (72)	36	21 (58)	91	60 (66)
p value		<0.001		0.228		<0.001
2018						
Non Indigenous	321	144 (45)	110	41 (37)	437	189 (43)
Indigenous	62	34 (55)	30	16 (53)	93	50 (54)
p value		0.149		0.112		0.064

Table 3.3.10 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

New South Wales	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
English speaking	456	242 (53)	187	114 (61)	649	358 (55)
Non-English speaking	41	20 (49)	11	7 (64)	53	28 (53)
p value		0.598		0.860		0.743
2015						
English speaking	346	201 (58)	137	93 (68)	490	299 (61)
Non-English speaking	23	13 (57)	6	3 (50)	29	16 (55)
p value		0.883		0.395		0.531
2016						
English speaking	303	164 (54)	132	71 (54)	439	238 (54)
Non-English speaking	23	8 (35)	4	3 (75)	28	11 (39)
p value		0.073		0.625		0.125
2017						
English speaking	340	166 (49)	139	69 (50)	491	242 (49)
Non-English speaking	15	5 (33)	7	4 (57)	22	9 (41)
p value		0.296		1.000		0.442
2018						
English speaking	361	169 (47)	135	58 (43)	501	230 (46)
Non-English speaking	33	14 (42)	8	2 (25)	43	17 (40)
p value		0.628		0.468		0.421

Table 3.3.11 HCV antibody prevalence by region/country of birth, gender and survey year

New South Wales		Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2014							
Australia	420	230 (55)	177	108 (61)	601	339 (56)	
Other Oceania	20	10 (50)	7	3 (43)	29	14 (48)	
Asia	10	5 (50)	1	0 (0)	11	5 (45)	
UK & Ireland	18	7 (39)	7	5 (71)	25	12 (48)	
Other	27	10 (37)	5	5 (100)	33	16 (49)	
p value		0.305		0.179		0.635	
2015							
Australia	324	198 (61)	127	89 (70)	457	291 (64)	
Other Oceania	11	4 (36)	4	1 (25)	16	6 (38)	
Asia	8	1 (13)	2	2 (100)	10	3 (30)	
UK & Ireland	14	7 (50)	5	2 (40)	19	9 (47)	
Other	10	4 (40)	5	2 (40)	15	6 (40)	
p value		0.016		0.057		0.009	
2016							
Australia	285	150 (53)	116	62 (53)	405	215 (53)	
Other Oceania	14	7 (50)	10	5 (50)	24	12 (50)	
Asia	6	2 (33)	1	0 (0)	8	2 (25)	
UK & Ireland	7	4 (57)	3	3 (100)	10	7 (70)	
Other	13	8 (62)	6	4 (67)	19	12 (63)	
p value		0.851		0.440		0.356	
2017							
Australia	306	144 (47)	127	64 (50)	442	213 (48)	
Other Oceania	13	9 (69)	6	3 (50)	20	13 (65)	
Asia	5	2 (40)	3	1 (33)	8	3 (38)	
UK & Ireland	11	6 (55)	5	3 (60)	17	10 (59)	
Other	14	6 (43)	4	2 (50)	19	8 (42)	
p value		0.576		1.000		0.466	
2018							
Australia	330	154 (47)	125	52 (42)	460	209 (45)	
Other Oceania	14	7 (50)	7	3 (43)	22	10 (45)	
Asia	5	4 (80)	0	0 (0)	5	4 (80)	
UK & Ireland	13	6 (46)	3	2 (67)	16	8 (50)	
Other	31	11 (35)	6	2 (33)	38	14 (37)	
p value		0.445		0.860		0.474	

HCV RNA prevalence

Table 3.4.1 HCV RNA prevalence by gender and survey year *

New South Wales Survey year	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015	184	95 (52)	71	36 (51)	259	132 (51)
2016 [#]	89	32 (36)	32	7 (22)	122	39 (32)
2017	186	52 (28)	74	13 (18)	265	65 (25)
2018	270	50 (19)	98	20 (20)	373	71 (19)
X ² p trend		<0.001		0.002		<0.001

* Weighted for gender and HCV antibody status

A number of NSW samples were subject to a failed run due to incompatibility with the HCV RNA testing platform in 2016

Table 3.4.2 HCV RNA prevalence by sexual identity, gender and survey year *

New South Wales Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
Heterosexual	151	81 (54)	55	27 (49)	208	109 (52)
Bisexual	12	6 (50)	12	8 (67)	26	14 (54)
Homosexual	14	6 (43)	1	0 (0)	15	6 (40)
p value		0.636		0.347		0.611
2016						
Heterosexual	74	30 (41)	20	2 (10)	95	32 (34)
Bisexual	2	0 (0)	11	4 (36)	13	4 (31)
Homosexual	8	2 (25)	0	0 (0)	8	2 (25)
p value		0.330		0.067		0.814
2017						
Heterosexual	165	49 (30)	63	11 (17)	229	60 (26)
Bisexual	8	1 (13)	5	1 (20)	13	2 (15)
Homosexual	6	0 (0)	2	1 (50)	11	1 (9)
p value		0.186		0.487		0.350
2018						
Heterosexual	202	37 (18)	59	12 (20)	262	49 (19)
Bisexual	17	5 (29)	22	4 (18)	41	9 (22)
Homosexual	20	3 (15)	6	3 (50)	27	6 (22)
p value		0.501		0.266		0.842

Table 3.4.3 HCV RNA prevalence by age group, gender and survey year *

New South Wales Age group	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2015						
<25 years	9	2 (22)	1	0 (0)	10	2 (20)
25-34 years	33	13 (39)	27	12 (44)	62	26 (42)
35-44 years	61	32 (52)	21	10 (48)	83	42 (51)
45+ years	81	48 (59)	22	13 (59)	104	62 (60)
p value		0.161		0.538		0.080
2016						
<25 years	6	3 (50)	0	0 (0)	6	3 (50)
25-34 years	15	1 (7)	5	4 (80)	20	5 (25)
35-44 years	24	9 (38)	14	2 (14)	38	11 (29)
45+ years	44	18 (41)	13	1 (8)	58	20 (34)
p value		0.228		0.005		0.648
2017						
<25 years	8	0 (0)	3	0 (0)	11	0 (0)
25-34 years	31	11 (35)	8	1 (13)	40	12 (30)
35-44 years	47	7 (15)	26	8 (31)	75	15 (20)
45+ years	99	33 (33)	35	4 (11)	137	38 (28)
p value		0.082		0.227		0.249
2018						
<25 years	12	1 (8)	5	0 (0)	18	1 (6)
25-34 years	31	5 (16)	13	2 (15)	44	7 (16)
35-44 years	81	21 (26)	35	7 (20)	117	30 (26)
45+ years	146	23 (16)	45	10 (22)	193	33 (17)
p value		0.132		0.588		0.109

Table 3.4.4 HCV RNA prevalence by years since first injection, gender and survey year *

New South Wales Years of injection	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2015						
<3 years	12	4 (33)	4	1 (25)	16	5 (31)
3 to 10 years	20	6 (30)	9	3 (33)	29	10 (34)
11+ years	146	84 (58)	55	30 (55)	204	115 (56)
p value		0.078		0.133		0.032
2016						
<3 years	5	1 (20)	1	0 (0)	6	1 (17)
3 to 10 years	17	4 (24)	5	1 (20)	22	5 (23)
11+ years	59	24 (41)	26	5 (19)	87	29 (33)
p value		0.403		0.706		0.647
2017						
<3 years	19	0 (0)	4	0 (0)	24	0 (0)
3 to 10 years	19	6 (32)	5	1 (20)	24	7 (29)
11+ years	136	43 (32)	60	12 (20)	202	56 (28)
p value		0.024		0.588		0.018
2018						
<3 years	15	1 (7)	5	0 (0)	20	1 (5)
3 to 10 years	37	2 (5)	5	2 (40)	42	4 (10)
11+ years	197	44 (22)	83	16 (19)	284	60 (21)
p value		0.030		0.304		0.045

Table 3.4.5 HCV RNA prevalence by re-use of someone else's used needle and syringe last month, gender and survey year *

New South Wales Receptively shared syringe last month	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
No receptive sharing	145	76 (52)	50	24 (48)	197	101 (51)
Receptive sharing	18	9 (50)	8	6 (75)	26	15 (58)
p value		0.687		0.051		0.694
2016						
No receptive sharing	64	22 (34)	23	4 (17)	87	26 (30)
Receptive sharing	11	7 (64)	5	1 (20)	16	8 (50)
p value		0.091		0.939		0.163
2017						
No receptive sharing	142	38 (27)	50	11 (22)	196	49 (25)
Receptive sharing	16	6 (38)	5	0 (0)	21	6 (29)
p value		0.395		0.207		0.762
2018						
No receptive sharing	193	32 (17)	57	10 (18)	252	42 (17)
Receptive sharing	34	14 (41)	13	3 (23)	47	17 (36)
p value		0.002		0.767		0.004

Table 3.4.6 HCV RNA prevalence by last drug injected, gender and survey year *

New South Wales Last drug injected	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
Heroin	65	32 (49)	25	16 (64)	91	49 (54)
Methamphetamine	59	28 (47)	24	10 (42)	84	38 (45)
Other opioids	41	24 (59)	16	6 (38)	57	30 (53)
PIEDs	3	0 (0)	0	0 (0)	3	0 (0)
Other drugs	15	9 (60)	4	3 (75)	19	13 (68)
p value		0.533		0.061		0.363
2016						
Heroin	27	12 (44)	15	2 (13)	45	14 (31)
Methamphetamine	19	8 (42)	7	2 (29)	26	10 (38)
Other opioids	12	6 (50)	6	2 (33)	18	9 (50)
PIEDs	10	0 (0)	0	0 (0)	10	0 (0)
Other drugs	15	4 (27)	3	1 (33)	19	5 (26)
p value		0.186		0.681		0.194
2017						
Heroin	50	16 (32)	29	8 (28)	83	25 (30)
Methamphetamine	75	16 (21)	19	2 (11)	95	18 (19)
Other opioids	23	11 (48)	16	2 (13)	39	13 (33)
PIEDs	24	0 (0)	2	0 (0)	26	0 (0)
Other drugs	14	8 (57)	7	1 (14)	22	9 (41)
p value		0.001		0.494		0.013
2018						
Heroin	79	16 (20)	38	8 (21)	119	24 (20)
Methamphetamine	91	22 (24)	31	5 (16)	125	27 (22)
Other opioids	27	6 (22)	18	4 (22)	45	10 (22)
PIEDs	34	1 (3)	0	0 (0)	36	1 (3)
Other drugs	31	4 (13)	2	2 (100)	40	6 (15)
p value		0.080		0.972		0.095

Table 3.4.7 HCV RNA prevalence by frequency of drug injection last month, gender and survey year *

New South Wales	Male		Female		Total	
Frequency of injection last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
Less than daily	73	32 (44)	22	12 (55)	97	45 (46)
Daily or more	89	53 (60)	36	18 (50)	126	71 (56)
Not last month	20	8 (40)	11	5 (45)	31	14 (45)
p value		0.185		0.920		0.346
2016						
Less than daily	33	7 (21)	13	2 (15)	46	10 (22)
Daily or more	44	22 (50)	14	2 (14)	59	25 (42)
Not last month	10	1 (10)	5	2 (40)	15	4 (27)
p value		0.027		0.218		0.068
2017						
Less than daily	96	19 (20)	22	3 (14)	118	22 (19)
Daily or more	64	26 (41)	37	9 (24)	106	35 (33)
Not last month	25	6 (24)	15	1 (7)	41	8 (20)
p value		0.043		0.287		0.070
2018						
Less than daily	119	20 (17)	33	7 (21)	154	27 (18)
Daily or more	111	27 (24)	39	5 (13)	151	32 (21)
Not last month	36	3 (8)	25	6 (24)	62	9 (15)
p value		0.086		0.419		0.508

Table 3.4.8 HCV RNA prevalence by imprisonment last year, gender and survey year *

New South Wales	Male		Female		Total	
Imprisonment last year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
No imprisonment	146	72 (49)	60	29 (48)	209	101 (48)
Imprisonment	27	15 (56)	8	6 (75)	36	21 (58)
p value		0.634		0.140		0.299
2016						
No imprisonment	69	24 (35)	29	7 (24)	98	31 (32)
Imprisonment	15	7 (47)	2	0 (0)	17	7 (41)
p value		0.471		0.327		0.569
2017						
No imprisonment	138	32 (23)	63	10 (16)	203	43 (21)
Imprisonment	34	17 (50)	5	2 (40)	40	19 (48)
p value		0.087		0.170		0.011
2018						
No imprisonment	213	37 (17)	84	19 (23)	301	56 (19)
Imprisonment	40	9 (23)	10	1 (10)	51	10 (20)
p value		0.465		0.300		0.943

Table 3.4.9 HCV RNA prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year *

New South Wales	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
Non Indigenous	145	74 (51)	51	26 (51)	199	100 (50)
Indigenous	37	21 (57)	19	9 (47)	56	30 (54)
p value		0.604		0.976		0.634
2016						
Non Indigenous	67	23 (34)	27	6 (22)	95	29 (31)
Indigenous	18	7 (39)	5	1 (20)	23	8 (35)
p value		0.769		0.692		0.816
2017						
Non Indigenous	156	37 (24)	52	8 (15)	213	45 (21)
Indigenous	28	12 (43)	21	5 (24)	50	17 (34)
p value		0.095		0.412		0.126
2018						
Non Indigenous	222	38 (17)	72	15 (21)	299	53 (18)
Indigenous	39	12 (31)	23	3 (13)	63	15 (24)
p value		0.048		0.317		0.318

Table 3.4.10 HCV RNA prevalence by main language spoken at home by parents, gender and survey year *

New South Wales	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
English speaking	173	85 (49)	68	34 (50)	245	121 (49)
Non-English speaking	10	9 (90)	3	1 (33)	13	11 (85)
p value		0.009		0.853		0.019
2016						
English speaking	85	30 (35)	30	6 (20)	117	36 (31)
Non-English speaking	2	1 (50)	2	1 (50)	4	2 (50)
p value		0.673		0.357		0.443
2017						
English speaking	179	51 (28)	68	12 (18)	253	63 (25)
Non-English speaking	7	1 (14)	5	1 (20)	12	2 (17)
p value		0.257		0.973		0.344
2018						
English speaking	252	48 (19)	92	19 (21)	347	68 (20)
Non-English speaking	18	2 (11)	6	1 (17)	26	3 (12)
p value		0.364		0.695		0.273

Table 3.4.11 HCV RNA prevalence by region/country of birth, gender and survey year *

New South Wales						
Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
Australia	168	90 (54)	62	32 (52)	233	123 (53)
Other Oceania	4	1 (25)	2	0 (0)	7	1 (14)
Asia	1	1 (100)	1	1 (100)	2	2 (100)
UK & Ireland	7	2 (29)	2	1 (50)	9	3 (33)
Other	2	1 (50)	3	1 (33)	5	2 (40)
p value		0.477		0.162		0.096
2016						
Australia	73	27 (37)	27	5 (19)	101	32 (32)
Other Oceania	2	1 (50)	1	1 (100)	4	3 (75)
Asia	2	0 (0)	1	0 (0)	3	0 (0)
UK & Ireland	1	0 (0)	2	0 (0)	3	0 (0)
Other	5	2 (40)	1	1 (100)	7	3 (43)
p value		0.636		0.066		0.125
2017						
Australia	165	48 (29)	62	11 (18)	232	59 (25)
Other Oceania	10	1 (10)	3	1 (33)	13	3 (23)
Asia	1	0 (0)	2	0 (0)	3	0 (0)
UK & Ireland	6	2 (33)	3	0 (0)	9	2 (22)
Other	3	0 (0)	4	1 (25)	8	1 (13)
p value		0.536		0.765		0.836
2018						
Australia	225	43 (19)	84	18 (21)	312	62 (20)
Other Oceania	9	1 (11)	5	1 (20)	15	2 (13)
Asia	4	2 (50)	0	0 (0)	4	2 (50)
UK & Ireland	11	2 (18)	2	1 (50)	13	3 (23)
Other	20	2 (10)	6	0 (0)	26	2 (8)
p value		0.440		0.430		0.268

Northern Territory

Table 4.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Northern Territory	2014	2015	2016	2017	2018
Number of sites	3	3	3	3	3
N° surveyed	N=70	N=60	N=87	N=66	N=67
Response rate (%)	39%	27%	49%	39%	37%
Gender (%)					
Male	54 (77)	46 (77)	59 (68)	34 (52)	41 (61)
Female	16 (23)	14 (23)	26 (30)	30 (45)	26 (39)
Transgender	0 (0)	0 (0)	2 (2)	2 (3)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Sexual identity (%)					
Heterosexual	63 (90)	54 (90)	67 (77)	46 (70)	60 (90)
Bisexual	3 (4)	3 (5)	9 (10)	8 (12)	3 (4)
Homosexual	0 (0)	1 (2)	4 (5)	2 (3)	4 (6)
Not reported	4 (6)	2 (3)	7 (8)	10 (15)	0 (0)
Aboriginal and Torres Strait Islander origin (%)					
No	55 (79)	42 (70)	52 (60)	42 (64)	41 (61)
Yes	14 (20)	16 (27)	31 (36)	18 (27)	25 (37)
Not reported	1 (1)	2 (3)	4 (5)	6 (9)	1 (1)
Region/country of birth (%)					
Australia	61 (87)	53 (88)	75 (86)	59 (89)	62 (93)
Other Oceania	2 (3)	3 (5)	1 (1)	2 (3)	2 (3)
Asia	1 (1)	1 (2)	1 (1)	0 (0)	1 (1)
UK & Ireland	3 (4)	2 (3)	0 (0)	1 (2)	0 (0)
Other	3 (4)	0 (0)	5 (6)	1 (2)	1 (1)
Not reported	0 (0)	1 (2)	5 (6)	3 (5)	1 (1)
Main language spoken at home by parents (%)					
English	66 (94)	57 (95)	79 (91)	63 (95)	64 (96)
Non-English	4 (6)	2 (3)	4 (5)	0 (0)	1 (1)
Not reported	0 (0)	1 (2)	4 (5)	3 (5)	2 (3)
Age and time since first injection (years)					
<i>Median age</i>	42	42	43	43	43
<i>Age range</i>	21-61	26-57	21-65	19-62	24-61
<i>Age group (%)</i>					
<25 years	3 (4)	0 (0)	2 (2)	5 (8)	1 (1)
25+ years	67 (96)	60 (100)	85 (98)	61 (92)	65 (97)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
<i>Median age first injection</i>	20	18	19	20	17.5
<i>Age range</i>	10-45	12-43	11-45	14-40	10-43
N° not reported	0	2	2	4	5
<i>Median yrs since first injection</i>	21	20	21	20.5	23.5
<i>Range</i>	0-45	2-41	2-46	0-44	1-47
<i>Years since first injection</i>					
<3 years	4 (6)	1 (2)	4 (5)	3 (5)	2 (3)
3+ years	65 (93)	57 (95)	81 (93)	59 (89)	60 (90)
Not reported	1 (1)	2 (3)	2 (2)	4 (6)	5 (7)
Imprisonment last year (%)					
No	63 (90)	50 (83)	72 (83)	57 (86)	59 (88)
Yes	2 (3)	7 (12)	8 (9)	3 (5)	4 (6)
Not reported	5 (7)	3 (5)	7 (8)	6 (9)	4 (6)
N° in prison	N=2	N=7	N=8	N=3	N=4
Injected in prison	0 (0)	0 (0)	1 (13)	0 (0)	1 (25)

Table 4.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year

Northern Territory	2014	2015	2016	2017	2018
N° surveyed	N=70	N=60	N=87	N=66	N=67
Drug last injected (%)					
Cocaine	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)
Methamphetamine	19 (27)	21 (35)	37 (43)	31 (47)	27 (40)
Heroin	6 (9)	1 (2)	4 (5)	3 (5)	1 (1)
Pharm. opioids	35 (50)	25 (42)	30 (34)	22 (33)	24 (36)
Methadone	6 (9)	4 (7)	2 (2)	3 (5)	1 (1)
Buprenorphine	1 (1)	5 (8)	2 (2)	0 (0)	5 (7)
Buprenorphine/naloxone	1 (1)	3 (5)	4 (5)	3 (5)	2 (3)
PIEDs	1 (1)	0 (0)	1 (1)	1 (2)	2 (3)
More than one	0 (0)	1 (2)	7 (8)	1 (2)	5 (7)
Other	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)
Ever injected opioids					
No	-	-	13 (15)	10 (15)	12 (18)
Yes	-	-	73 (84)	56 (85)	53 (79)
Not reported	-	-	1 (1)	0 (0)	2 (3)
Frequency of injection last month (%)					
Not last month	3 (4)	2 (3)	8 (9)	8 (12)	1 (1)
Less than weekly	9 (13)	7 (12)	10 (11)	5 (8)	6 (9)
Weekly not daily	9 (13)	8 (13)	15 (17)	11 (17)	14 (21)
Daily or more	48 (69)	43 (72)	54 (62)	42 (64)	44 (66)
Not reported	1 (1)	0 (0)	0 (0)	0 (0)	2 (3)
Present when someone injected for the first time in the last 12 months (%)					
No	63 (90)	50 (83)	69 (79)	54 (82)	54 (81)
Yes	7 (10)	7 (12)	13 (15)	8 (12)	8 (12)
Not reported	0 (0)	3 (5)	5 (6)	4 (6)	5 (7)
Overdosed in last 12 months					
No	68 (97)	50 (83)	68 (78)	56 (85)	56 (84)
Yes	2 (3)	9 (15)	13 (15)	6 (9)	6 (9)
Not reported	0 (0)	1 (2)	6 (7)	4 (6)	5 (7)

Table 4.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year

Northern Territory	2014	2015	2016	2017	2018
N° injected last month	N=66	N=58	N=79	N=58	N=64
Places injected last month (%)					
All private	52 (79)	38 (66)	52 (66)	31 (53)	40 (63)
Any public	14 (21)	20 (34)	27 (34)	27 (47)	24 (38)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Use of new and sterile needles and syringes last month (%)					
All injections	56 (85)	47 (81)	67 (85)	50 (86)	53 (83)
Most of the time	7 (11)	9 (16)	9 (11)	3 (5)	11 (17)
Half of the time	1 (2)	1 (2)	0 (0)	1 (2)	0 (0)
Some of the time	2 (3)	0 (0)	0 (0)	0 (0)	0 (0)
Not last month	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)
Not reported	0 (0)	1 (2)	2 (3)	4 (7)	0 (0)
Re-used someone else's used needle & syringe last month (%)					
None	62 (94)	56 (97)	70 (89)	52 (90)	55 (86)
Once	2 (3)	1 (2)	3 (4)	2 (3)	6 (9)
Twice	1 (2)	1 (2)	3 (4)	0 (0)	1 (2)
3-5 times	1 (2)	0 (0)	0 (0)	3 (5)	1 (2)
>5 times	0 (0)	0 (0)	1 (1)	1 (2)	1 (2)
Not reported	0 (0)	0 (0)	2 (3)	0 (0)	0 (0)
Number of people needle & syringe was re-used after last month (%)					
None	62 (94)	56 (97)	70 (89)	52 (90)	55 (86)
One	1 (2)	0 (0)	2 (3)	0 (0)	5 (8)
Two	2 (3)	0 (0)	0 (0)	2 (3)	1 (2)
Three to five	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)
More than five	0 (0)	0 (0)	1 (1)	0 (0)	1 (2)
Don't know	0 (0)	1 (2)	2 (3)	1 (2)	1 (2)
Not reported	1 (2)	1 (2)	4 (5)	2 (3)	1 (2)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	0 (0)	1 (2)	2 (3)	2 (3)	6 (9)
Casual sex partner	0 (0)	0 (0)	1 (1)	1 (2)	1 (2)
Close friend	0 (0)	0 (0)	1 (1)	2 (3)	2 (3)
Acquaintance	3 (5)	0 (0)	1 (1)	1 (2)	0 (0)
Other	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	11 (17)	10 (17)	21 (27)	9 (16)	8 (13)
Water	2 (3)	7 (12)	18 (23)	13 (22)	10 (16)
Filter	9 (14)	4 (7)	7 (9)	5 (9)	8 (13)
Drug mix	1 (2)	4 (7)	9 (11)	5 (9)	8 (13)
None	55 (83)	43 (74)	50 (63)	40 (69)	50 (78)
Injected by someone after that person injected themselves or others last month (%)					
No	57 (86)	54 (93)	67 (85)	46 (79)	54 (84)
Yes	7 (11)	4 (7)	10 (13)	9 (16)	10 (16)
Not reported	2 (3)	0 (0)	2 (3)	3 (5)	0 (0)
Source of needle acquisition					
Needle Syringe Program	62 (94)	57 (98)	75 (95)	46 (79)	58 (91)
Chemist/Pharmacy	7 (11)	9 (16)	9 (11)	10 (17)	11 (17)
Personal sources	9 (14)	5 (9)	12 (15)	10 (17)	5 (8)
Dispensing/Vending Machine	1 (2)	0 (0)	0 (0)	12 (21)	15 (23)
Other sources	3 (5)	1 (2)	1 (1)	0 (0)	0 (0)

Table 4.1.4 Number (percentage) of respondents by treatment for drug use and survey year

Northern Territory	2014	2015	2016	2017	2018
N° surveyed	N=70	N=60	N=87	N=66	N=67
Ever any treatment/therapy for drug use (%)					
No	24 (34)	18 (30)	37 (43)	28 (42)	29 (43)
Yes	45 (64)	40 (67)	45 (52)	35 (53)	35 (52)
Not reported	1 (1)	2 (3)	5 (6)	3 (5)	3 (4)
History of methadone maintenance treatment (%)					
Currently	2 (3)	5 (8)	1 (1)	1 (2)	1 (1)
Previously	15 (21)	18 (30)	19 (22)	10 (15)	11 (16)
Never	48 (69)	36 (60)	60 (69)	51 (77)	50 (75)
Not reported	5 (7)	1 (2)	7 (8)	4 (6)	5 (7)
History of buprenorphine (Subutex®) treatment (%)					
Currently	3 (4)	2 (3)	9 (10)	2 (3)	6 (9)
Previously	22 (31)	15 (25)	15 (17)	13 (20)	15 (22)
Never	43 (61)	43 (72)	58 (67)	48 (73)	44 (66)
Not reported	2 (3)	0 (0)	5 (6)	3 (5)	2 (3)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	5 (7)	4 (7)	12 (14)	7 (11)	2 (3)
Previously	19 (27)	16 (27)	13 (15)	10 (15)	16 (24)
Never	45 (64)	36 (60)	56 (64)	46 (70)	46 (69)
Not reported	1 (1)	4 (7)	6 (7)	3 (5)	3 (4)

Table 4.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year

Northern Territory	2014	2015	2016	2017	2018
N° surveyed	N=70	N=60	N=87	N=66	N=67
Previous HIV test (%)					
Yes, ever	60 (86)	51 (85)	72 (83)	50 (76)	54 (81)
Yes, last year	28 (40)	22 (37)	48 (55)	34 (52)	34 (51)
>1 year ago	32 (46)	29 (48)	24 (28)	16 (24)	20 (30)
Never tested	10 (14)	8 (13)	10 (11)	10 (15)	10 (15)
Not reported	0 (0)	1 (2)	5 (6)	6 (9)	3 (4)
Previous HCV test (%)					
Yes, ever	66 (94)	50 (83)	74 (85)	49 (74)	51 (76)
Yes, last year	31 (44)	26 (43)	49 (56)	32 (48)	34 (51)
>1 year ago	35 (50)	24 (40)	25 (29)	17 (26)	17 (25)
Never tested	4 (6)	5 (8)	5 (6)	8 (12)	6 (9)
Not reported	0 (0)	5 (8)	8 (9)	9 (14)	10 (15)
Lifetime treatment for HCV (%)[#]					
N° self-reported HCV diagnosis	N=24	N=17	N=21	N=15	N=19
Antiviral treatment	11 (46)	1 (6)	4 (19)	3 (20)	3 (16)
No antiviral treatment	13 (54)	16 (94)	17 (81)	9 (60)	16 (84)
Not reported	0 (0)	0 (0)	0 (0)	3 (20)	0 (0)
Treatment for HCV in past 12 months (%)^{##}					
N° self-reported HCV diagnosis	N=17	N=17	N=21	N=14	N=19
Antiviral treatment	0 (0)	0 (0)	4 (19)	1 (7)	3 (16)
No antiviral treatment	17 (100)	17 (100)	17 (81)	10 (71)	16 (84)
Not reported	0 (0)	0 (0)	0 (0)	3 (21)	0 (0)

[#] among people who tested HCV antibody positive and did not report spontaneous clearance

^{*} excludes people who reported treatment induced clearance more than 12 months previously

Table 4.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year

Northern Territory	2014	2015	2016	2017	2018
N° surveyed	N=70	N=60	N=87	N=66	N=67
Sex with a regular partner last month (%)					
No	41 (59)	40 (67)	52 (60)	36 (55)	29 (43)
Yes	29 (41)	19 (32)	28 (32)	25 (38)	33 (49)
Not reported	0 (0)	1 (2)	7 (8)	5 (8)	5 (7)
Condom used with regular partner last month (%)					
N° surveyed	N=29	N=19	N=28	N=25	N=33
Never	16 (55)	15 (79)	16 (57)	16 (64)	22 (67)
Sometimes	5 (17)	1 (5)	6 (21)	5 (20)	4 (12)
Every time	4 (14)	3 (16)	5 (18)	2 (8)	4 (12)
Not reported	4 (14)	0 (0)	1 (4)	2 (8)	3 (9)
Sex with other partner(s) last month (%)					
No	60 (86)	52 (87)	69 (79)	49 (74)	44 (66)
Yes	10 (14)	6 (10)	15 (17)	12 (18)	17 (25)
Not reported	0 (0)	2 (3)	3 (3)	5 (8)	6 (9)
Condom used with other partner(s) last month (%)					
N° surveyed	N=10	N=6	N=15	N=12	N=17
Never	1 (10)	2 (33)	3 (20)	2 (17)	7 (41)
Sometimes	6 (60)	1 (17)	6 (40)	4 (33)	1 (6)
Every time	3 (30)	3 (50)	5 (33)	6 (50)	7 (41)
Not reported	0 (0)	0 (0)	1 (7)	0 (0)	2 (12)
Sex work last month (%)					
No	64 (91)	56 (93)	70 (80)	52 (79)	53 (79)
Yes	6 (9)	2 (3)	9 (10)	7 (11)	6 (9)
Not reported	0 (0)	2 (3)	8 (9)	7 (11)	8 (12)
Condom used at last sex work (%)					
Yes	4 (67)	1 (50)	8 (90)	6 (86)	3 (50)

HIV antibody prevalence

Table 4.2.1 HIV antibody prevalence by gender and survey year

Northern Territory Survey year	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014	54	0 (0.0)	16	0 (0.0)	70	0 (0.0)
2015	45	0 (0.0)	14	0 (0.0)	59	0 (0.0)
2016	59	0 (0.0)	26	0 (0.0)	87	0 (0.0)
2017	34	0 (0.0)	29	0 (0.0)	65	0 (0.0)
2018	41	0 (0.0)	25	0 (0.0)	66	0 (0.0)
X ² p trend		--		--		--

HCV antibody prevalence

Table 4.3.1 HCV antibody prevalence by gender and survey year

Northern Territory Survey year	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014	53	30 (57)	16	8 (50)	69	38 (55)
2015	31	19 (61)	12	7 (58)	43	26 (60)
2016	59	23 (39)	26	12 (46)	87	35 (40)
2017	32	15 (47)	29	8 (28)	63	23 (37)
2018	41	15 (37)	25	11 (44)	66	26 (39)
X ² p trend		0.184		0.473		0.108

Table 4.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Northern Territory Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
Heterosexual	50	29 (58)	12	6 (50)	62	35 (56)
Bisexual	2	0 (0)	1	0 (0)	3	0 (0)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.191		1.000		0.093
2015						
Heterosexual	31	19 (61)	7	5 (71)	38	24 (63)
Bisexual	0	0 (0)	2	1 (50)	2	1 (50)
Homosexual	0	0 (0)	1	1 (100)	1	1 (100)
p value		--		1.000		1.000
2016						
Heterosexual	49	19 (39)	17	9 (53)	67	28 (42)
Bisexual	2	0 (0)	6	1 (17)	9	1 (11)
Homosexual	3	2 (67)	1	1 (100)	4	3 (75)
p value		0.486		0.166		0.071
2017						
Heterosexual	28	12 (43)	15	2 (13)	43	14 (33)
Bisexual	0	0 (0)	7	1 (14)	8	1 (13)
Homosexual	0	0 (0)	2	2 (100)	2	2 (100)
p value		--		0.051		0.079
2018						
Heterosexual	40	15 (38)	20	9 (45)	60	24 (40)
Bisexual	0	0 (0)	2	0 (0)	2	0 (0)
Homosexual	1	0 (0)	3	2 (67)	4	2 (50)
p value		1		0.480		0.656

Table 4.3.3 HCV antibody prevalence by age group, gender and survey year

Northern Territory Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
<25 years	1	0 (0)	2	1 (50)	3	1 (33)
25-34 years	10	4 (40)	3	2 (67)	13	6 (46)
35-44 years	20	11 (55)	5	3 (60)	25	14 (56)
45+ years	22	15 (68)	6	2 (33)	28	17 (61)
p value		0.311		0.814		0.722
2015						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	11	3 (27)	1	0 (0)	12	3 (25)
35-44 years	11	10 (91)	5	3 (60)	16	13 (81)
45+ years	9	6 (67)	6	4 (67)	15	10 (67)
p value		0.010		0.747		0.008
2016						
<25 years	1	0 (0)	0	0 (0)	2	0 (0)
25-34 years	7	4 (57)	2	0 (0)	9	4 (44)
35-44 years	23	3 (13)	10	6 (60)	33	9 (27)
45+ years	28	16 (57)	14	6 (43)	43	22 (51)
p value		0.003		0.443		0.111
2017						
<25 years	2	1 (50)	3	0 (0)	5	1 (20)
25-34 years	5	0 (0)	2	1 (50)	8	1 (13)
35-44 years	13	4 (31)	10	3 (30)	23	7 (30)
45+ years	12	10 (83)	14	4 (29)	27	14 (52)
p value		0.003		0.729		0.152
2018						
<25 years	1	0 (0)	0	0 (0)	1	0 (0)
25-34 years	5	1 (20)	4	1 (25)	9	2 (22)
35-44 years	18	5 (28)	7	4 (57)	25	9 (36)
45+ years	16	8 (50)	14	6 (43)	30	14 (47)
p value		0.417		0.654		0.501

Table 4.3.4 HCV antibody prevalence by years since first injection, gender and survey year

Northern Territory Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
<3 years	1	0 (0)	3	0 (0)	4	0 (0)
3 to 10 years	6	3 (50)	2	2 (100)	8	5 (63)
11+ years	45	27 (60)	11	6 (55)	56	33 (59)
p value		0.509		0.097		0.070
2015						
<3 years	0	0 (0)	1	0 (0)	1	0 (0)
3 to 10 years	8	3 (38)	0	0 (0)	8	3 (38)
11+ years	26	16 (70)	9	5 (56)	32	21 (66)
p value		0.206		1.000		0.158
2016						
<3 years	1	0 (0)	2	1 (50)	4	1 (25)
3 to 10 years	4	0 (0)	2	1 (50)	6	1 (17)
11+ years	54	23 (43)	21	9 (43)	75	32 (43)
p value		0.200		1.000		0.507
2017						
<3 years	1	0 (0)	2	0 (0)	3	0 (0)
3 to 10 years	4	2 (50)	5	0 (0)	9	2 (22)
11+ years	25	11 (44)	20	8 (40)	47	19 (40)
p value		1.000		0.197		0.282
2018						
<3 years	2	0 (0)	0	0 (0)	2	0 (0)
3 to 10 years	6	3 (50)	2	1 (50)	8	4 (50)
11+ years	31	10 (32)	21	8 (38)	52	18 (35)
p value		0.555		1.000		0.419

Table 4.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

Northern Territory Receptively shared syringe last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
No receptive sharing	3	0 (0)	57	34 (60)	61	34 (56)
Receptive sharing	0	0 (0)	4	3 (75)	4	3 (75)
p value		--		1.000		0.628
2015						
No receptive sharing	1	0 (0)	36	23 (64)	39	25 (64)
Receptive sharing	0	0 (0)	2	0 (0)	2	0 (0)
p value		--		0.149		0.146
2016						
No receptive sharing	4	1 (25)	65	29 (45)	70	31 (44)
Receptive sharing	0	0 (0)	6	3 (50)	7	3 (43)
p value		--		1.000		1.000
2017						
No receptive sharing	3	3 (100)	42	17 (40)	49	19 (39)
Receptive sharing	0	0 (0)	6	1 (17)	6	1 (17)
p value		--		0.388		0.399
2018						
No receptive sharing	2	2 (100)	49	20 (41)	55	24 (44)
Receptive sharing	0	0 (0)	9	2 (22)	9	2 (22)
p value		--		0.459		0.291

Table 4.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year

Northern Territory Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
Methamphetamine	3	0 (0)	16	8 (50)	19	8 (42)
Pharm. Opioids	0	0 (0)	33	25 (76)	34	25 (74)
OST*	1	0 (0)	7	2 (29)	8	2 (25)
Other drugs	0	0 (0)	8	3 (38)	8	3 (38)
p value		--		0.035		0.019
2015						
Methamphetamine	1	0 (0)	14	6 (43)	15	6 (40)
Pharm. Opioids	0	0 (0)	15	10 (67)	17	12 (71)
OST*	0	0 (0)	10	7 (70)	10	7 (70)
Other drugs	0	0 (0)	1	1 (100)	1	1 (100)
p value		--		0.380		0.222
2016						
Methamphetamine	2	1 (50)	35	10 (29)	37	11 (30)
Pharm. Opioids	0	0 (0)	29	14 (48)	30	15 (50)
OST*	1	0 (0)	7	4 (57)	8	4 (50)
Other drugs	1	0 (0)	10	5 (50)	12	5 (42)
p value		0.513		0.265		0.360
2017						
Methamphetamine	1	1 (100)	28	7 (25)	30	7 (23)
Pharm. Opioids	0	0 (0)	19	10 (53)	22	12 (55)
OST*	1	1 (100)	4	2 (50)	5	2 (40)
Other drugs	1	1 (100)	5	2 (40)	6	2 (33)
p value		--		0.261		0.146
2018						
Methamphetamine	1	1 (100)	24	11 (46)	26	12 (46)
Pharm. Opioids	0	0 (0)	21	6 (29)	23	8 (35)
OST*	0	0 (0)	7	4 (57)	8	5 (63)
Other drugs	1	1 (100)	7	1 (14)	8	1 (13)
p value		--		0.241		0.181

*OST = methadone, buprenorphine & burpenorphine/naloxone

Table 4.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

Northern Territory Frequency of injection last month	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2014						
Less than daily	1	0 (0)	17	11 (65)	18	11 (61)
Daily or more	2	0 (0)	44	26 (59)	47	26 (55)
Not last month	1	0 (0)	2	1 (50)	3	1 (33)
p value		--		0.891		0.677
2015						
Less than daily	1	0 (0)	8	5 (63)	11	7 (64)
Daily or more	0	0 (0)	30	18 (60)	30	18 (60)
Not last month	0	0 (0)	2	1 (50)	2	1 (50)
p value		--		1.000		1.000
2016						
Less than daily	2	0 (0)	22	9 (41)	25	10 (40)
Daily or more	2	1 (50)	51	23 (45)	54	24 (44)
Not last month	0	0 (0)	8	1 (13)	8	1 (13)
p value		1		0.229		0.248
2017						
Less than daily	2	2 (100)	12	5 (42)	15	5 (33)
Daily or more	1	1 (100)	36	13 (36)	40	15 (38)
Not last month	0	0 (0)	8	3 (38)	8	3 (38)
p value		--		0.922		1.000
2018						
Less than daily	1	1 (100)	18	9 (50)	20	10 (50)
Daily or more	1	1 (100)	40	13 (33)	44	16 (36)
Not last month	0	0 (0)	1	0 (0)	1	0 (0)
p value		--		0.363		0.481

Table 4.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

Northern Territory Imprisonment last year	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2014						
No imprisonment	2	0 (0)	59	36 (61)	62	36 (58)
Imprisonment	0	0 (0)	2	0 (0)	2	0 (0)
p value		--		0.164		0.187
2015						
No imprisonment	1	0 (0)	32	18 (56)	35	20 (57)
Imprisonment	0	0 (0)	5	4 (80)	5	5 (4)
p value		--		0.629		0.631
2016						
No imprisonment	4	1 (25)	67	29 (43)	72	31 (43)
Imprisonment	0	0 (0)	7	2 (29)	8	2 (25)
p value		--		0.692		0.459
2017						
No imprisonment	3	3 (100)	50	19 (38)	56	21 (38)
Imprisonment	0	0 (0)	2	0 (0)	2	0 (0)
p value		--		0.527		0.530
2018						
No imprisonment	2	2 (100)	54	20 (37)	59	23 (39)
Imprisonment	0	0 (0)	3	2 (67)	4	3 (75)
p value		--		0.553		0.297

Table 4.3.9 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Northern Territory Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
Non Indigenous	44	24 (55)	11	5 (45)	55	29 (53)
Indigenous	9	6 (67)	4	2 (50)	13	8 (62)
p value		0.504		1.000		0.566
2015						
Non Indigenous	21	16 (76)	7	5 (71)	28	21 (75)
Indigenous	10	3 (30)	4	2 (50)	14	5 (36)
p value		0.021		0.576		0.020
2016						
Non Indigenous	35	19 (54)	17	8 (47)	52	27 (52)
Indigenous	21	4 (19)	8	4 (50)	31	8 (26)
p value		0.012		1.000		0.020
2017						
Non Indigenous	24	12 (50)	15	5 (33)	40	17 (43)
Indigenous	5	1 (20)	11	2 (18)	17	3 (18)
p value		0.343		0.658		0.128
2018						
Non Indigenous	27	9 (33)	14	7 (50)	41	16 (39)
Indigenous	14	6 (43)	11	4 (36)	25	10 (40)
p value		0.548		0.689		0.937

Table 4.3.10 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Northern Territory Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
English speaking	49	27 (55)	16	8 (50)	65	35 (54)
Non-English speaking	4	3 (75)	0	0 (0)	4	3 (75)
p value		0.624		--		0.622
2015						
English speaking	30	18 (60)	11	6 (55)	41	24 (59)
Non-English speaking	1	1 (100)	0	0 (0)	1	1 (100)
p value		1.000		--		1.000
2016						
English speaking	52	22 (42)	25	12 (48)	79	34 (43)
Non-English speaking	4	1 (25)	0	0 (0)	4	1 (25)
p value		0.636		--		0.635
2017						
English speaking	30	14 (47)	28	8 (29)	60	22 (37)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2018						
English speaking	39	14 (36)	25	11 (44)	64	25 (39)
Non-English speaking	1	0 (0)	0	0 (0)	1	0 (0)
p value		1.000		--		1.000

Table 4.3.11 HCV antibody prevalence by region/country of birth, gender and survey year

Northern Territory Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
Australia	47	28 (60)	13	7 (54)	60	35 (58)
Other Oceania	2	0 (0)	0	0 (0)	2	0 (0)
Asia	1	1 (100)	0	0 (0)	1	1 (100)
UK & Ireland	2	0 (0)	1	1 (100)	3	1 (33)
Other	1	1 (100)	2	0 (0)	3	1 (33)
p value		0.053		0.467		0.353
2015						
Australia	28	17 (61)	10	6 (60)	38	23 (61)
Other Oceania	2	1 (50)	0	0 (0)	2	1 (50)
Asia	0	0 (0)	1	0 (0)	1	0 (0)
UK & Ireland	1	1 (100)	0	0 (0)	1	1 (100)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		1.000		0.455		0.828
2016						
Australia	51	20 (39)	23	11 (48)	75	31 (41)
Other Oceania	1	1 (100)	0	0 (0)	1	1 (100)
Asia	1	1 (100)	0	0 (0)	1	1 (100)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	3	1 (33)	1	1 (100)	5	2 (40)
p value		0.527		1.000		0.552
2017						
Australia	26	11 (42)	28	8 (29)	56	19 (34)
Other Oceania	2	2 (100)	0	0 (0)	2	2 (100)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	1	0 (0)	0	0 (0)	1	0 (0)
Other	1	1 (100)	0	0 (0)	1	1 (100)
p value		0.143		--		0.075
2018						
Australia	38	14 (37)	24	11 (46)	62	25 (40)
Other Oceania	2	1 (50)	0	0 (0)	2	1 (50)
Asia	1	0 (0)	0	0 (0)	1	0 (0)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	0	0 (0)	1	0 (0)	1	0 (0)
p value		1.000		1.000		1.000

HCV RNA prevalence

Table 4.4.1 HCV RNA prevalence by gender and survey year *

Northern Territory Survey year	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015	12	7 (58)	4	0 (0)	16	7 (44)
2016	19	3 (16)	8	4 (50)	28	7 (25)
2017	26	5 (19)	22	4 (18)	50	9 (18)
2018	27	6 (22)	16	4 (25)	43	10 (23)
X ² p trend		0.209		1.000		0.288

* Weighted for gender and HCV antibody status

Table 4.4.2 HCV RNA prevalence by sexual identity, gender and survey year *

Northern Territory Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
Heterosexual	12	7 (58)	3	0 (0)	15	7 (47)
Bisexual	0	0 (0)	0	0 (0)	0	0 (0)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2016						
Heterosexual	16	2 (13)	4	3 (75)	20	5 (25)
Bisexual	1	0 (0)	3	0 (0)	5	0 (0)
Homosexual	1	0 (0)	1	1 (100)	2	1 (50)
p value		0.834		0.227		0.241
2017						
Heterosexual	23	4 (17)	10	2 (20)	34	6 (18)
Bisexual	0	0 (0)	7	1 (14)	8	1 (13)
Homosexual	0	0 (0)	1	1 (100)	1	1 (100)
p value		--		0.141		0.109
2018						
Heterosexual	27	6 (22)	12	3 (25)	39	9 (23)
Bisexual	0	0 (0)	2	0 (0)	2	0 (0)
Homosexual	0	0 (0)	2	1 (50)	2	1 (50)
p value		--		0.566		0.549

Table 4.4.3 HCV RNA prevalence by age group, gender and survey year *

Northern Territory Age group	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2015						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	3	1 (33)	1	0 (0)	4	1 (25)
35-44 years	4	3 (75)	2	0 (0)	6	3 (50)
45+ years	5	3 (60)	1	0 (0)	6	3 (50)
p value	0.345		--		0.494	
2016						
<25 years	0	0 (0)	0	0 (0)	1	0 (0)
25-34 years	1	0 (0)	0	0 (0)	1	0 (0)
35-44 years	9	0 (0)	2	2 (100)	11	2 (18)
45+ years	9	3 (33)	6	1 (17)	15	5 (33)
p value	0.109		0.141		0.704	
2017						
<25 years	2	0 (0)	4	0 (0)	6	0 (0)
25-34 years	5	0 (0)	1	0 (0)	7	0 (0)
35-44 years	11	3 (27)	6	3 (50)	17	6 (35)
45+ years	8	2 (25)	11	1 (9)	20	3 (15)
p value	0.477		0.227		0.126	
2018						
<25 years	1	0 (0)	0	0 (0)	1	0 (0)
25-34 years	2	0 (0)	3	1 (33)	5	1 (20)
35-44 years	11	2 (18)	4	2 (50)	16	4 (25)
45+ years	11	4 (36)	9	1 (11)	20	5 (25)
p value	0.575		0.200		0.889	

Table 4.4.4 HCV RNA prevalence by years since first injection, gender and survey year *

Northern Territory Years of injection	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2015						
<3 years	0	0 (0)	1	0 (0)	1	0 (0)
3 to 10 years	3	1 (33)	0	0 (0)	3	1 (33)
11+ years	8	6 (75)	3	0 (0)	12	6 (50)
p value	0.172		--		0.553	
2016						
<3 years	0	0 (0)	0	0 (0)	1	0 (0)
3 to 10 years	1	0 (0)	0	0 (0)	1	0 (0)
11+ years	18	3 (17)	8	4 (50)	26	7 (27)
p value	0.640		--		0.704	
2017						
<3 years	1	0 (0)	1	0 (0)	2	0 (0)
3 to 10 years	4	1 (25)	4	0 (0)	8	1 (13)
11+ years	21	4 (19)	15	4 (27)	38	8 (21)
p value	0.836		0.548		0.727	
2018						
<3 years	1	0 (0)	0	0 (0)	1	0 (0)
3 to 10 years	2	1 (50)	1	0 (0)	3	1 (33)
11+ years	22	4 (18)	13	4 (31)	35	8 (23)
p value	0.539		0.562		0.790	

Table 4.4.5 HCV RNA prevalence by re-use of someone else's used needle and syringe last month, gender and survey year *

Northern Territory Receptively shared syringe last month	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
No receptive sharing	12	7 (58)	3	0 (0)	15	7 (47)
Receptive sharing	0	0 (0)	1	0 (0)	1	0 (0)
p value		--		--		--
2016						
No receptive sharing	15	3 (20)	7	4 (57)	26	7 (27)
Receptive sharing	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2017						
No receptive sharing	22	5 (23)	17	4 (24)	41	9 (22)
Receptive sharing	2	0 (0)	2	0 (0)	4	0 (0)
p value		0.454		0.493		0.311
2018						
No receptive sharing	20	5 (25)	12	3 (25)	33	8 (24)
Receptive sharing	5	1 (20)	3	1 (33)	8	2 (25)
p value		0.808		0.956		0.869

Table 4.4.6 HCV RNA prevalence by last drug injected, gender and survey year *

Northern Territory Last drug injected	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
Methamphetamine	5	2 (40)	1	0 (0)	6	2 (33)
Pharm. Opioids	4	4 (100)	3	0 (0)	7	4 (57)
OST*	3	1 (33)	0	0 (0)	3	1 (33)
Other drugs	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.177		--		0.620
2016						
Methamphetamine	9	0 (0)	3	0 (0)	12	0 (0)
Pharm. Opioids	9	3 (33)	3	3 (100)	13	7 (54)
OST*	0	0 (0)	0	0 (0)	0	0 (0)
Other drugs	1	0 (0)	2	0 (0)	3	0 (0)
p value		0.097		0.084		0.007
2017						
Methamphetamine	10	2 (20)	10	1 (10)	21	3 (14)
Pharm. Opioids	9	2 (22)	8	1 (13)	17	3 (18)
OST*	3	1 (33)	2	1 (50)	6	2 (33)
Other drugs	4	0 (0)	2	1 (50)	6	1 (17)
p value		0.659		0.469		0.696
2018						
Methamphetamine	13	4 (31)	5	1 (20)	18	5 (28)
Pharm. Opioids	8	2 (25)	7	2 (29)	16	4 (25)
OST*	4	0 (0)	2	1 (50)	6	1 (17)
Other drugs	0	0 (0)	2	0 (0)	2	0 (0)
p value		0.467		0.651		0.755

Table 4.4.7 HCV RNA prevalence by frequency of drug injection last month, gender and survey year *

Northern Territory Frequency of injection last month	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
Less than daily	4	2 (50)	1	0 (0)	5	2 (40)
Daily or more	8	5 (63)	3	0 (0)	11	5 (45)
Not last month	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.365		--		0.723
2016						
Less than daily	3	0 (0)	1	1 (100)	5	1 (20)
Daily or more	15	3 (20)	6	3 (50)	21	6 (29)
Not last month	1	0 (0)	1	0 (0)	2	0 (0)
p value		0.526		0.399		0.660
2017						
Less than daily	7	1 (14)	7	1 (14)	15	2 (13)
Daily or more	17	4 (24)	12	3 (25)	30	7 (23)
Not last month	2	0 (0)	3	0 (0)	5	0 (0)
p value		0.645		0.630		0.386
2018						
Less than daily	8	3 (38)	6	1 (17)	14	4 (29)
Daily or more	18	3 (17)	9	3 (33)	27	6 (22)
Not last month	0	0 (0)	1	0 (0)	1	0 (0)
p value		0.289		0.533		0.816

Table 4.4.8 HCV RNA prevalence by imprisonment last year, gender and survey year *

Northern Territory Imprisonment last year	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
No imprisonment	11	7 (64)	4	0 (0)	16	7 (44)
Imprisonment	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2016						
No imprisonment	16	3 (19)	8	4 (50)	25	7 (28)
Imprisonment	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.620		--		0.544
2017						
No imprisonment	23	5 (22)	16	4 (25)	43	9 (21)
Imprisonment	2	0 (0)	0	0 (0)	2	0 (0)
p value		0.463		--		0.492
2018						
No imprisonment	24	4 (17)	14	3 (21)	38	8 (21)
Imprisonment	2	1 (50)	1	1 (100)	3	2 (67)
p value		0.395		0.134		0.129

Table 4.4.9 HCV RNA prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year *

Northern Territory	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
Non Indigenous	9	6 (67)	4	0 (0)	13	6 (46)
Indigenous	2	1 (50)	0	0 (0)	3	1 (33)
p value		0.682		--		0.776
2016						
Non Indigenous	13	3 (23)	7	3 (43)	20	6 (30)
Indigenous	5	0 (0)	1	1 (100)	7	1 (14)
p value		0.213		0.315		0.675
2017						
Non Indigenous	19	4 (21)	10	2 (20)	29	6 (21)
Indigenous	4	0 (0)	10	2 (20)	16	2 (13)
p value		0.261		0.941		0.432
2018						
Non Indigenous	20	4 (20)	7	2 (29)	27	6 (22)
Indigenous	7	2 (29)	9	2 (22)	16	4 (25)
p value		0.681		0.733		0.525

Table 4.4.10 HCV RNA prevalence by main language spoken at home by parents, gender and survey year *

Northern Territory	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
English speaking	11	6 (55)	4	0 (0)	15	6 (40)
Non-English speaking	1	1 (100)	0	0 (0)	1	1 (100)
p value		0.457		--		0.289
2016						
English speaking	15	3 (20)	8	4 (50)	27	7 (26)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2017						
English speaking	24	4 (17)	22	4 (18)	48	8 (17)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2018						
English speaking	26	6 (23)	16	4 (25)	42	10 (24)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--

Table 4.4.11 HCV RNA prevalence by region/country of birth, gender and survey year *

Northern Territory		Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2015							
Australia	11	6 (55)	3	0 (0)	14	6 (43)	
Other Oceania	1	1 (100)	0	0 (0)	1	1 (100)	
Asia	0	0 (0)	1	0 (0)	1	0 (0)	
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)	
Other	0	0 (0)	0	0 (0)	0	0 (0)	
p value		0.457		--		0.400	
2016							
Australia	17	2 (12)	8	4 (50)	26	6 (23)	
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)	
Asia	1	1 (100)	0	0 (0)	1	1 (100)	
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)	
Other	0	0 (0)	0	0 (0)	0	0 (0)	
p value		0.045		--		0.114	
2017							
Australia	21	2 (10)	22	4 (18)	45	6 (13)	
Other Oceania	1	1 (100)	0	0 (0)	1	1 (100)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	1	0 (0)	0	0 (0)	1	0 (0)	
Other	1	1 (100)	0	0 (0)	1	1 (100)	
p value		0.016		--		0.010	
2018							
Australia	26	6 (23)	15	4 (27)	41	10 (24)	
Other Oceania	1	0 (0)	0	0 (0)	1	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)	
Other	0	0 (0)	1	0 (0)	1	0 (0)	
p value		0.597		0.533		0.719	

Queensland

Table 5.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Queensland	2014	2015	2016	2017	2018
Number of sites	7	8	8	8	9
N° surveyed	N=490	N=532	N=349	N=619	N=633
Response rate (%)	51%	36%	30%	33%	41%
Gender (%)					
Male	356 (73)	386 (73)	230 (66)	447 (72)	441 (70)
Female	133 (27)	144 (27)	117 (34)	171 (28)	191 (30)
Transgender	1 (<1)	2 (<1)	1 (<1)	1 (<1)	1 (<1)
Not reported	0 (0)	0 (0)	1 (<1)	0 (0)	0 (0)
Sexual identity (%)					
Heterosexual	398 (81)	453 (85)	258 (74)	483 (78)	506 (80)
Bisexual	36 (7)	41 (8)	47 (13)	55 (9)	62 (10)
Homosexual	22 (4)	19 (4)	18 (5)	33 (5)	25 (4)
Not reported	34 (7)	19 (4)	26 (7)	48 (8)	40 (6)
Aboriginal and Torres Strait Islander origin (%)					
No	428 (87)	459 (86)	294 (84)	501 (81)	511 (81)
Yes	49 (10)	67 (13)	44 (13)	100 (16)	115 (18)
Not reported	13 (3)	6 (1)	11 (3)	18 (3)	7 (1)
Region/country of birth (%)					
Australia	421 (86)	467 (88)	304 (87)	548 (89)	570 (90)
Other Oceania	30 (6)	24 (5)	13 (4)	32 (5)	20 (3)
Asia	2 (<1)	5 (1)	2 (1)	2 (<1)	0 (0)
UK & Ireland	15 (3)	17 (3)	16 (5)	19 (3)	24 (4)
Other	17 (3)	9 (2)	5 (1)	11 (2)	15 (2)
Not reported	5 (1)	10 (2)	9 (3)	7 (1)	4 (1)
Main language spoken at home by parents (%)					
English	468 (96)	515 (97)	329 (94)	594 (96)	612 (97)
Non-English	17 (3)	9 (2)	12 (3)	22 (4)	18 (3)
Not reported	5 (1)	8 (2)	8 (2)	3 (<1)	3 (<1)
Age and time since first injection (years)					
<i>Median age</i>	37	38	40	41	41
<i>Age range</i>	14-64	16-62	17-76	16-75	14-78
<i>Age group (%)</i>					
<25 years	52 (11)	44 (8)	21 (6)	37 (6)	37 (6)
25+ years	436 (89)	487 (92)	328 (94)	581 (94)	595 (94)
Not reported	2 (<1)	1 (<1)	0 (0)	1 (<1)	1 (<1)
<i>Median age first injection</i>					
<i>Age range</i>	10-49	11-50	11-55	10-65	10-64
N° not reported	15	13	16	16	22
<i>Median yrs since first injection</i>					
<i>Range</i>	<1-47	<1-44	<1-53	<1-59	<1-52
<i>Years since first injection</i>					
<3 years	55 (11)	46 (9)	22 (6)	47 (8)	42 (7)
3+ years	420 (86)	472 (89)	311 (89)	556 (90)	569 (90)
Not reported	15 (3)	14 (3)	16 (5)	16 (3)	22 (3)
Imprisonment last year (%)					
No	415 (85)	468 (88)	299 (86)	528 (85)	535 (85)
Yes	48 (10)	43 (8)	39 (11)	69 (11)	72 (11)
Not reported	27 (6)	21 (4)	11 (3)	22 (4)	26 (4)
N° in prison					
Injected in prison	18 (38)	22 (51)	16 (41)	27 (39)	29 (40)

Table 5.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year

Queensland	2014	2015	2016	2017	2018
N° surveyed	N=490	N=532	N=349	N=619	N=633
Drug last injected (%)					
Cocaine	3 (<1)	5 (1)	1 (<1)	5 (1)	10 (2)
Methamphetamine	155 (31)	183 (34)	136 (39)	265 (43)	304 (48)
Heroin	75 (15)	107 (20)	56 (16)	89 (14)	84 (13)
Pharm. opioids	94 (19)	92 (17)	53 (15)	117 (19)	104 (16)
Methadone	22 (4)	31 (6)	28 (8)	27 (4)	28 (4)
Buprenorphine	20 (4)	21 (4)	11 (3)	23 (4)	33 (5)
Buprenorphine/naloxone	14 (3)	6 (1)	13 (4)	11 (2)	17 (3)
PIEDs	71 (14)	62 (12)	21 (6)	49 (8)	28 (4)
More than one	16 (3)	18 (3)	22 (6)	22 (4)	21 (3)
Other	16 (3)	7 (1)	8 (2)	6 (1)	3 (<1)
Not reported	4 (<1)	0 (0)	0 (0)	5 (1)	1 (<1)
Ever injected opioids					
No	-	-	74 (21)	173 (28)	151 (24)
Yes	-	-	274 (79)	446 (72)	480 (76)
Not reported	-	-	1 (<1)	0 (0)	2 (<1)
Frequency of injection last month (%)					
Not last month	47 (10)	54 (10)	31 (9)	54 (9)	41 (6)
Less than weekly	64 (13)	92 (17)	49 (14)	94 (15)	90 (14)
Weekly not daily	134 (27)	114 (21)	80 (23)	150 (24)	160 (25)
Daily or more	238 (49)	268 (50)	177 (51)	316 (51)	332 (52)
Not reported	7 (1)	4 (1)	12 (3)	5 (1)	10 (2)
Present when someone injected for the first time in the last 12 months (%)					
No	392 (80)	442 (83)	287 (82)	496 (80)	499 (79)
Yes	88 (18)	80 (15)	57 (16)	106 (17)	117 (18)
Not reported	10 (2)	10 (2)	5 (1)	17 (3)	17 (3)
Overdosed in last 12 months					
No	415 (85)	458 (86)	285 (82)	512 (83)	521 (82)
Yes	65 (13)	67 (13)	57 (16)	93 (15)	96 (15)
Not reported	10 (2)	7 (1)	7 (2)	14 (2)	16 (3)

Table 5.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year

Queensland	2014	2015	2016	2017	2018
N° injected last month	N=436	N=474	N=306	N=560	N=582
Places injected last month (%)					
All private	294 (67)	326 (69)	208 (68)	375 (67)	378 (65)
Any public	140 (32)	146 (31)	96 (31)	182 (33)	198 (34)
Not reported	2 (<1)	2 (<1)	2 (1)	3 (1)	6 (1)
Use of new and sterile needles and syringes last month (%)					
All injections	340 (78)	350 (74)	240 (78)	434 (78)	445 (76)
Most of the time	84 (19)	98 (21)	52 (17)	98 (18)	107 (18)
Half of the time	3 (1)	14 (3)	5 (2)	8 (1)	8 (1)
Some of the time	3 (1)	2 (<1)	3 (1)	12 (2)	14 (2)
Not last month	0 (0)	3 (1)	2 (1)	4 (1)	2 (<1)
Not reported	6 (1)	7 (1)	4 (1)	4 (1)	6 (1)
Re-used someone else's used needle & syringe last month (%)					
None	361 (83)	400 (84)	245 (80)	471 (84)	490 (84)
Once	24 (6)	26 (5)	14 (5)	27 (5)	29 (5)
Twice	18 (4)	10 (2)	18 (6)	22 (4)	17 (3)
3-5 times	15 (3)	18 (4)	11 (4)	19 (3)	23 (4)
>5 times	11 (3)	17 (4)	15 (5)	16 (3)	18 (3)
Not reported	7 (2)	3 (1)	3 (1)	5 (1)	5 (1)
Number of people needle & syringe was re-used after last month (%)					
None	361 (83)	400 (84)	245 (80)	471 (84)	490 (84)
One	27 (6)	33 (7)	24 (8)	32 (6)	37 (6)
Two	6 (1)	5 (1)	7 (2)	7 (1)	7 (1)
Three to five	4 (1)	6 (1)	1 (<1)	5 (1)	5 (1)
More than five	2 (<1)	3 (1)	3 (1)	3 (1)	10 (2)
Don't know	13 (3)	14 (3)	13 (4)	27 (5)	20 (3)
Not reported	23 (5)	13 (3)	13 (4)	15 (3)	13 (2)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	27 (6)	25 (5)	20 (7)	24 (4)	29 (5)
Casual sex partner	0 (0)	3 (1)	3 (1)	4 (1)	5 (1)
Close friend	10 (2)	21 (4)	14 (5)	25 (4)	33 (6)
Acquaintance	5 (1)	9 (2)	12 (4)	12 (2)	17 (3)
Other	3 (1)	10 (2)	4 (1)	9 (2)	7 (1)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	75 (17)	97 (20)	59 (19)	102 (18)	116 (20)
Water	82 (19)	82 (17)	45 (15)	106 (19)	105 (18)
Filter	36 (8)	53 (11)	33 (11)	69 (12)	63 (11)
Drug mix	38 (9)	46 (10)	37 (12)	52 (9)	51 (9)
None	305 (70)	332 (70)	223 (73)	381 (68)	413 (71)
Injected by someone after that person injected themselves or others last month (%)					
No	351 (81)	404 (85)	249 (81)	474 (85)	475 (82)
Yes	72 (17)	68 (14)	51 (17)	81 (14)	97 (17)
Not reported	13 (3)	2 (<1)	6 (2)	5 (1)	10 (2)
Source of needle acquisition					
Needle Syringe Program	394 (90)	437 (92)	274 (90)	502 (90)	533 (92)
Chemist/Pharmacy	107 (25)	122 (26)	88 (29)	138 (25)	143 (25)
Personal sources	36 (8)	38 (8)	27 (9)	53 (9)	44 (8)
Dispensing/Vending Machine	38 (9)	70 (15)	50 (16)	76 (14)	66 (11)
Other sources	6 (1)	9 (2)	6 (2)	16 (3)	21 (4)

Table 5.1.4 Number (percentage) of respondents by treatment for drug use and survey year

Queensland	2014	2015	2016	2017	2018
N° surveyed	N=490	N=532	N=349	N=619	N=633
Ever any treatment/therapy for drug use (%)					
No	168 (34)	171 (32)	98 (28)	196 (32)	170 (27)
Yes	308 (63)	351 (66)	241 (69)	412 (67)	443 (70)
Not reported	14 (3)	10 (2)	10 (3)	11 (2)	20 (3)
History of methadone maintenance treatment (%)					
Currently	80 (16)	79 (15)	63 (18)	89 (14)	87 (14)
Previously	94 (19)	117 (22)	83 (24)	125 (20)	141 (22)
Never	303 (62)	329 (62)	193 (55)	394 (64)	391 (62)
Not reported	13 (3)	7 (1)	10 (3)	11 (2)	14 (2)
History of buprenorphine (Subutex®) treatment (%)					
Currently	48 (10)	41 (8)	30 (9)	41 (7)	56 (9)
Previously	100 (20)	144 (27)	93 (27)	138 (22)	147 (23)
Never	330 (67)	340 (64)	214 (61)	429 (69)	415 (66)
Not reported	12 (2)	7 (1)	12 (3)	11 (2)	15 (2)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	35 (7)	42 (8)	23 (7)	37 (6)	54 (9)
Previously	99 (20)	119 (22)	89 (26)	128 (21)	139 (22)
Never	340 (69)	362 (68)	229 (66)	442 (71)	428 (68)
Not reported	16 (3)	9 (2)	8 (2)	12 (2)	12 (2)

Table 5.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year

Queensland	2014	2015	2016	2017	2018
N° surveyed	N=490	N=532	N=349	N=619	N=619
Previous HIV test (%)					
Yes, ever	408 (83)	437 (82)	292 (84)	510 (82)	534 (84)
Yes, last year	253 (52)	250 (47)	186 (53)	302 (49)	312 (49)
>1 year ago	155 (32)	187 (35)	106 (30)	208 (34)	222 (35)
Never tested	68 (14)	82 (15)	45 (13)	90 (15)	78 (12)
Not reported	14 (3)	13 (2)	12 (3)	19 (3)	21 (3)
Previous HCV test (%)					
Yes, ever	414 (84)	449 (84)	294 (84)	516 (83)	540 (85)
Yes, last year	273 (56)	279 (52)	211 (60)	343 (55)	342 (54)
>1 year ago	141 (29)	170 (32)	83 (24)	173 (28)	198 (31)
Never tested	52 (11)	64 (12)	28 (8)	63 (10)	37 (6)
Not reported	24 (5)	19 (4)	27 (8)	40 (6)	56 (9)
Lifetime treatment for HCV (%)#					
N° self-reported HCV diagnosis	N=112	N=126	N=104	N=156	N=172
Antiviral treatment	13 (12)	11 (9)	34 (33)	69 (44)	101 (59)
No antiviral treatment	94 (84)	109 (87)	69 (66)	87 (56)	69 (40)
Not reported	5 (4)	6 (5)	1 (1)	0 (0)	2 (1)
Treatment for HCV in past 12 months (%)#*					
N° self-reported HCV diagnosis	N=102	N=121	N=102	N=143	N=129
Antiviral treatment	2 (2)	1 (1)	28 (27)	52 (36)	50 (39)
No antiviral treatment	85 (96)	80 (92)	57 (71)	91 (64)	77 (60)
Not reported	2 (2)	6 (7)	1 (1)	0 (0)	2 (2)

among people who tested HCV antibody positive and did not report spontaneous clearance

* excludes people who reported treatment induced clearance more than 12 months previously

Table 5.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year

Queensland	2014	2015	2016	2017	2018
N° surveyed	N=490	N=532	N=349	N=619	N=633
Sex with a regular partner last month (%)					
No	229 (47)	239 (45)	165 (47)	316 (51)	319 (50)
Yes	250 (51)	274 (52)	175 (50)	279 (45)	297 (47)
Not reported	11 (2)	19 (4)	9 (3)	24 (4)	17 (3)
Condom used with regular partner last month (%)					
N° surveyed	N=250	N=274	N=175	N=279	N=297
Never	174 (70)	212 (77)	130 (74)	198 (71)	230 (77)
Sometimes	39 (16)	30 (11)	24 (14)	37 (13)	32 (11)
Every time	25 (10)	26 (9)	15 (9)	33 (12)	16 (5)
Not reported	12 (5)	6 (2)	6 (3)	11 (4)	19 (6)
Sex with other partner(s) last month (%)					
No	398 (81)	440 (83)	294 (84)	497 (80)	500 (79)
Yes	74 (15)	79 (15)	44 (13)	92 (15)	108 (17)
Not reported	18 (4)	13 (2)	11 (3)	30 (5)	25 (4)
Condom used with other partner(s) last month (%)					
N° surveyed	N=74	N=79	N=44	N=92	N=108
Never	23 (31)	26 (33)	21 (48)	31 (34)	49 (45)
Sometimes	25 (34)	25 (32)	11 (25)	33 (36)	36 (33)
Every time	13 (18)	24 (30)	11 (25)	23 (25)	17 (16)
Not reported	13 (18)	4 (5)	1 (2)	5 (5)	6 (6)
Sex work last month (%)					
No	439 (90)	508 (95)	314 (90)	568 (92)	581 (92)
Yes	19 (4)	14 (3)	18 (5)	22 (4)	30 (5)
Not reported	32 (7)	10 (2)	17 (5)	29 (5)	22 (3)
Condom used at last sex work (%)					
Yes	10 (53)	9 (64)	12 (67)	17 (77)	16 (53)

HIV antibody prevalence

Table 5.2.1 HIV antibody prevalence by gender and survey year

Queensland Survey year	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014	349	11 (3.2)	131	0 (0.0)	481	11 (2.3)
2015	382	6 (1.6)	144	0 (0.0)	528	7 (1.3)
2016	224	4 (1.8)	115	0 (0.0)	341	4 (1.2)
2017	441	14 (3.2)	167	1 (0.6)	609	15 (2.5)
2018	437	6 (1.4)	189	2 (1.1)	627	8 (1.3)
X ² p trend		0.445		0.077		0.650

Table 5.2.2 HIV antibody prevalence by sexual identity, gender and survey year

Queensland Sexual identity	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
Heterosexual	297	1 (0.3)	95	0 (0.0)	392	1 (0.3)
Bisexual	11	1 (9.1)	24	0 (0.0)	35	1 (2.9)
Homosexual	17	8 (47.1)	3	0 (0.0)	20	8 (40.0)
p value		<0.001		--		<0.001
2015						
Heterosexual	339	1 (0.3)	111	0 (0.0)	450	1 (0.2)
Bisexual	18	1 (5.6)	22	0 (0.0)	41	1 (2.4)
Homosexual	14	4 (28.6)	5	0 (0.0)	19	4 (21.1)
p value		<0.001		--		<0.001
2016						
Heterosexual	184	0 (0.0)	67	0 (0.0)	253	0 (0.0)
Bisexual	13	1 (7.7)	33	0 (0.0)	46	1 (2.2)
Homosexual	10	3 (30.0)	8	0 (0.0)	18	3 (16.7)
p value		<0.001		--		<0.001
2017						
Heterosexual	358	3 (0.8)	118	0 (0.0)	476	3 (0.6)
Bisexual	27	3 (11.1)	28	1 (3.6)	55	4 (7.3)
Homosexual	22	7 (31.8)	7	0 (0.0)	30	7 (23.3)
p value		<0.001		0.229		<0.001
2018						
Heterosexual	365	1 (0.3)	136	2 (1.5)	501	3 (0.6)
Bisexual	25	2 (8.0)	36	0 (0.0)	61	2 (3.3)
Homosexual	21	3 (14.3)	3	0 (0.0)	25	3 (12.0)
p value		<0.001		1.000		0.001

Table 5.2.3 HIV antibody prevalence by age group, gender and survey year

Queensland Age group	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
<25 years	35	0 (0.0)	16	0 (0.0)	51	0 (0.0)
25-34 years	110	1 (0.9)	45	0 (0.0)	155	1 (0.7)
35-44 years	107	4 (3.7)	45	0 (0.0)	152	4 (2.6)
45+ years	95	6 (6.3)	25	0 (0.0)	121	6 (5.0)
p value		0.119		--		0.091
2015						
<25 years	32	0 (0.0)	12	0 (0.0)	44	0 (0.0)
25-34 years	120	2 (1.7)	44	0 (0.0)	165	3 (1.8)
35-44 years	135	1 (0.7)	47	0 (0.0)	182	1 (0.6)
45+ years	94	3 (3.2)	41	0 (0.0)	136	3 (2.2)
p value		0.489		--		0.529
2016						
<25 years	14	0 (0.0)	7	0 (0.0)	21	0 (0.0)
25-34 years	56	0 (0.0)	29	0 (0.0)	85	0 (0.0)
35-44 years	79	0 (0.0)	41	0 (0.0)	121	0 (0.0)
45+ years	75	4 (5.3)	38	0 (0.0)	114	4 (3.5)
p value		0.060		--		0.060
2017						
<25 years	25	0 (0.0)	11	0 (0.0)	37	0 (0.0)
25-34 years	86	3 (3.5)	41	0 (0.0)	127	3 (2.4)
35-44 years	157	5 (3.2)	53	0 (0.0)	210	5 (2.4)
45+ years	172	6 (3.5)	62	1 (1.6)	234	7 (3.0)
p value		1.000		1.000		0.935
2018						
<25 years	21	0 (0.0)	15	0 (0.0)	36	0 (0.0)
25-34 years	75	1 (1.3)	46	2 (4.4)	122	3 (2.5)
35-44 years	158	2 (1.3)	67	0 (0.0)	225	2 (0.9)
45+ years	182	3 (1.7)	61	0 (0.0)	243	3 (1.2)
p value		1.000		0.211		0.671

Table 5.2.4 HIV antibody prevalence by last drug injected, gender and survey year

Queensland Last drug injected	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
Heroin	53	1 (1.9)	21	0 (0.0)	74	1 (1.4)
Methamphetamine	98	8 (8.2)	54	0 (0.0)	152	8 (5.3)
Other opioids	103	1 (1.0)	44	0 (0.0)	148	1 (0.7)
PIEDs	67	1 (1.5)	3	0 (0.0)	70	1 (1.4)
Other drugs	25	0 (0.0)	9	0 (0.0)	34	0 (0.0)
p value		0.051		--		0.106
2015						
Heroin	76	1 (1.3)	31	0 (0.0)	107	1 (0.9)
Methamphetamine	120	5 (4.2)	60	0 (0.0)	182	6 (3.3)
Other opioids	107	0 (0.0)	42	0 (0.0)	149	0 (0.0)
PIEDs	61	0 (0.0)	1	0 (0.0)	62	0 (0.0)
Other drugs	18	0 (0.0)	10	0 (0.0)	28	0 (0.0)
p value		0.126		--		0.108
2016						
Heroin	32	0 (0.0)	22	0 (0.0)	54	0 (0.0)
Methamphetamine	88	3 (3.4)	44	0 (0.0)	133	3 (2.3)
Other opioids	65	0 (0.0)	37	0 (0.0)	103	0 (0.0)
PIEDs	20	1 (5.0)	0	0 (0.0)	20	1 (5.0)
Other drugs	19	0 (0.0)	12	0 (0.0)	31	0 (0.0)
p value		0.313		--		0.199
2017						
Heroin	57	0 (0.0)	31	1 (3.2)	88	1 (1.1)
Methamphetamine	176	11 (6.3)	84	0 (0.0)	261	11 (4.2)
Other opioids	132	1 (0.8)	45	0 (0.0)	177	1 (0.6)
PIEDs	48	0 (0.0)	0	0 (0.0)	48	0 (0.0)
Other drugs	28	2 (7.1)	7	0 (0.0)	35	2 (5.7)
p value		0.011		0.228		0.045
2018						
Heroin	56	0 (0.0)	27	0 (0.0)	83	0 (0.0)
Methamphetamine	200	6 (3.0)	100	2 (2.0)	301	8 (2.7)
Other opioids	130	0 (0.0)	50	0 (0.0)	180	0 (0.0)
PIEDs	27	0 (0.0)	1	0 (0.0)	28	0 (0.0)
Other drugs	23	0 (0.0)	11	0 (0.0)	34	0 (0.0)
p value		0.218		0.719		0.119

Table 5.2.5 HIV antibody prevalence by years of injection, gender and survey year

Queensland Years of injection	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
<3 years	39	2 (5.1)	15	0 (0.0)	54	2 (3.7)
3 to 10 years	59	1 (1.7)	27	0 (0.0)	86	1 (1.2)
11+ years	238	8 (3.4)	88	0 (0.0)	327	8 (2.5)
p value		0.555		--		0.559
2015						
<3 years	41	1 (2.4)	4	0 (0.0)	45	1 (2.2)
3 to 10 years	81	2 (2.5)	28	0 (0.0)	110	2 (1.8)
11+ years	250	3 (1.2)	108	0 (0.0)	359	4 (1.1)
p value		0.526		--		0.533
2016						
<3 years	16	0 (0.0)	5	0 (0.0)	21	0 (0.0)
3 to 10 years	46	3 (6.5)	12	0 (0.0)	58	3 (5.2)
11+ years	151	1 (0.7)	94	0 (0.0)	247	1 (0.4)
p value		0.061		--		0.041
2017						
<3 years	31	0 (0.0)	15	0 (0.0)	46	0 (0.0)
3 to 10 years	63	4 (6.4)	35	0 (0.0)	98	4 (4.1)
11+ years	347	10 (2.9)	117	1 (0.9)	465	11 (2.4)
p value		0.280		1.000		0.302
2018						
<3 years	28	1 (3.6)	13	0 (0.0)	41	1 (2.4)
3 to 10 years	61	2 (3.3)	34	0 (0.0)	95	2 (2.1)
11+ years	348	3 (0.9)	142	2 (1.4)	491	5 (1.0)
p value		0.126		1.000		0.268

Table 5.2.6 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

Queensland Receptively shared syringe last month	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
No receptive sharing	258	8 (3.1)	96	0 (0.0)	355	8 (2.3)
Receptive sharing	46	0 (0.0)	22	0 (0.0)	68	0 (0.0)
p value		0.612		--		0.365
2015						
No receptive sharing	284	5 (1.8)	110	0 (0.0)	396	6 (1.5)
Receptive sharing	49	1 (2.0)	22	0 (0.0)	71	1 (1.4)
p value		1.000		--		1.000
2016						
No receptive sharing	153	3 (2.0)	86	0 (0.0)	239	3 (1.3)
Receptive sharing	41	1 (2.4)	15	0 (0.0)	57	1 (1.8)
p value		1.000		--		0.577
2017						
No receptive sharing	337	11 (3.3)	129	1 (0.8)	467	12 (2.6)
Receptive sharing	55	1 (1.8)	28	0 (0.0)	83	1 (1.2)
p value		1.000		1.000		0.703
2018						
No receptive sharing	337	4 (1.2)	147	2 (1.4)	485	6 (1.2)
Receptive sharing	62	2 (3.2)	25	0 (0.0)	87	2 (2.3)
p value		0.236		1.000		0.350

Table 5.2.7 HIV antibody prevalence by frequency of drug injection last month, gender and survey year

Queensland	Male		Female		Total	
Frequency of injection	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
Less than daily	144	5 (3.5)	53	0 (0.0)	197	5 (2.5)
Daily or more	162	3 (1.9)	69	0 (0.0)	232	3 (1.3)
Not last month	38	3 (7.9)	7	0 (0.0)	45	3 (6.7)
p value		0.139		--		0.090
2015						
Less than daily	154	3 (2.0)	48	0 (0.0)	204	4 (2.0)
Daily or more	182	3 (1.7)	84	0 (0.0)	266	3 (1.1)
Not last month	43	0 (0.0)	11	0 (0.0)	54	0 (0.0)
p value		1.000		--		0.532
2016						
Less than daily	82	4 (4.9)	44	0 (0.0)	126	4 (3.2)
Daily or more	113	0 (0.0)	59	0 (0.0)	173	0 (0.0)
Not last month	21	0 (0.0)	10	0 (0.0)	31	0 (0.0)
p value		0.046		--		0.045
2017						
Less than daily	179	11 (6.2)	60	0 (0.0)	240	11 (4.6)
Daily or more	217	1 (0.5)	97	1 (1.0)	314	2 (0.6)
Not last month	40	2 (5.0)	10	0 (0.0)	50	2 (4.0)
p value		0.002		1.000		0.004
2018						
Less than daily	176	2 (1.1)	72	2 (2.8)	248	4 (1.6)
Daily or more	226	4 (1.8)	102	0 (0.0)	329	4 (1.2)
Not last month	27	0 (0.0)	13	0 (0.0)	40	0 (0.0)
p value		0.797		0.282		0.843

Table 5.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year

Queensland	Male		Female		Total	
Imprisonment last year	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
No imprisonment	289	7 (2.4)	118	0 (0.0)	407	7 (1.7)
Imprisonment	38	0 (0.0)	10	0 (0.0)	48	0 (0.0)
p value		1.000		--		1.000
2015						
No imprisonment	334	6 (1.8)	129	0 (0.0)	465	7 (1.5)
Imprisonment	30	0 (0.0)	12	0 (0.0)	42	0 (0.0)
p value		1.000		--		1.000
2016						
No imprisonment	192	3 (1.6)	98	0 (0.0)	292	3 (1.0)
Imprisonment	27	1 (3.7)	11	0 (0.0)	38	1 (2.6)
p value		0.412		--		0.388
2017						
No imprisonment	367	13 (3.5)	152	1 (0.7)	520	14 (2.7)
Imprisonment	57	1 (1.8)	10	0 (0.0)	67	1 (1.5)
p value		0.704		1.000		1.000
2018						
No imprisonment	365	5 (1.4)	165	2 (1.2)	531	7 (1.3)
Imprisonment	55	1 (1.8)	16	0 (0.0)	71	1 (1.4)
p value		0.572		1.000		1.000

Table 5.2.9 HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year

Queensland	Male		Female		Total	
Condom use at last sex	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
No condom use	121	4 (3.3)	48	0 (0.0)	170	4 (2.4)
Condom use	48	2 (4.2)	16	0 (0.0)	64	2 (3.1)
p value		1.000		--		0.666
2015						
No condom use	140	2 (1.4)	70	0 (0.0)	211	3 (1.4)
Condom use	41	0 (0.0)	14	0 (0.0)	55	0 (0.0)
p value		1.000		--		1.000
2016						
No condom use	77	2 (2.6)	46	0 (0.0)	125	2 (1.6)
Condom use	28	1 (3.6)	11	0 (0.0)	39	1 (2.6)
p value		1.000		--		0.560
2017						
No condom use	134	3 (2.2)	63	1 (1.6)	197	4 (2.0)
Condom use	49	4 (8.2)	18	0 (0.0)	68	4 (5.9)
p value		0.840		1.000		0.210
2018						
No condom use	145	3 (2.1)	84	0 (0.0)	229	3 (1.3)
Condom use	35	1 (2.9)	11	0 (0.0)	47	1 (2.1)
p value		0.582		--		0.528

Table 5.2.10 HIV antibody prevalence by sex work last month, gender and survey year

Queensland	Male		Female		Total	
Sex work last month	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
No sex work	312	7 (2.2)	118	0 (0.0)	431	7 (1.6)
Sex work	13	2 (15.4)	6	0 (0.0)	19	2 (10.5)
p value		0.045		--		0.051
2015						
No sex work	368	5 (1.4)	135	0 (0.0)	505	6 (1.2)
Sex work	5	1 (20.0)	9	0 (0.0)	14	1 (7.1)
p value		0.078		--		0.175
2016						
No sex work	208	4 (1.9)	97	0 (0.0)	307	4 (1.3)
Sex work	9	0 (0.0)	9	0 (0.0)	18	0 (0.0)
p value		1.000		--		1.000
2017						
No sex work	413	13 (3.2)	146	1 (0.7)	559	14 (2.5)
Sex work	10	1 (10.0)	11	0 (0.0)	22	1 (4.6)
p value		0.288		1.000		0.444
2018						
No sex work	409	6 (1.5)	168	2 (1.2)	577	8 (1.4)
Sex work	14	0 (0.0)	14	0 (0.0)	29	0 (0.0)
p value		1.000		1.000		1.000

Table 5.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Queensland Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
Non Indigenous	311	10 (3.2)	108	0 (0.0)	420	10 (2.4)
Indigenous	30	0 (0.0)	19	0 (0.0)	49	0 (0.0)
p value		1.000		--		0.609
2015						
Non Indigenous	337	6 (1.8)	118	0 (0.0)	457	7 (1.5)
Indigenous	41	0 (0.0)	21	0 (0.0)	65	0 (0.0)
p value		1.000		--		0.605
2016						
Non Indigenous	193	4 (2.1)	94	0 (0.0)	289	4 (1.4)
Indigenous	25	0 (0.0)	19	0 (0.0)	44	0 (0.0)
p value		1.000		--		1.000
2017						
Non Indigenous	358	11 (3.1)	135	1 (0.7)	493	12 (2.4)
Indigenous	69	3 (4.4)	30	0 (0.0)	100	3 (3.0)
p value		0.482		1.000		0.727
2018						
Non Indigenous	362	3 (0.8)	143	2 (1.4)	506	5 (1.0)
Indigenous	71	3 (4.2)	44	0 (0.0)	115	3 (2.6)
p value		0.058		1.000		0.170

Table 5.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and survey year

Queensland Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
English speaking	334	10 (3.0)	125	0 (0.0)	460	10 (2.2)
Non-English speaking	12	1 (8.3)	5	0 (0.0)	17	1 (5.9)
p value		0.326		--		0.332
2015						
English speaking	367	6 (1.6)	142	0 (0.0)	511	7 (1.4)
Non-English speaking	8	0 (0.0)	1	0 (0.0)	9	0 (0.0)
p value		1.000		--		1.000
2016						
English speaking	210	3 (1.4)	111	0 (0.0)	323	3 (0.9)
Non-English speaking	9	1 (11.1)	2	0 (0.0)	11	1 (9.1)
p value		0.156		--		0.126
2017						
English speaking	425	14 (3.3)	159	1 (0.6)	584	15 (2.6)
Non-English speaking	13	0 (0.0)	8	0 (0.0)	22	0 (0.0)
p value		1.000		1.000		1.000
2018						
English speaking	425	6 (1.4)	183	0 (0.0)	608	6 (1.0)
Non-English speaking	11	0 (0.0)	6	2 (33.3)	18	2 (11.1)
p value		1.000		0.001		0.020

Table 5.2.13 HIV antibody prevalence by region/country of birth, gender and survey year

Queensland	Male		Female		Total	
Region/country of birth	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
Australia	298	9 (3.0)	116	0 (0.0)	415	9 (2.2)
Other Oceania	21	1 (4.8)	7	0 (0.0)	28	1 (3.6)
Asia	2	0 (0.0)	0	0 (0.0)	2	0 (0.0)
UK & Ireland	11	0 (0.0)	4	0 (0.0)	15	0 (0.0)
Other	14	1 (7.1)	3	0 (0.0)	17	1 (5.9)
p value		0.480		--		0.441
2015						
Australia	333	6 (1.8)	129	0 (0.0)	464	7 (1.5)
Other Oceania	18	0 (0.0)	6	0 (0.0)	24	0 (0.0)
Asia	4	0 (0.0)	1	0 (0.0)	5	0 (0.0)
UK & Ireland	10	0 (0.0)	6	0 (0.0)	16	0 (0.0)
Other	8	0 (0.0)	1	0 (0.0)	9	0 (0.0)
p value		1.000		--		1.000
2016						
Australia	196	3 (1.5)	101	0 (0.0)	298	3 (1.0)
Other Oceania	8	0 (0.0)	4	0 (0.0)	12	0 (0.0)
Asia	2	0 (0.0)	0	0 (0.0)	2	0 (0.0)
UK & Ireland	7	0 (0.0)	8	0 (0.0)	16	0 (0.0)
Other	5	1 (20.0)	0	0 (0.0)	5	1 (20.0)
p value		0.146		--		0.117
2017						
Australia	398	14 (3.5)	141	1 (0.7)	539	15 (2.8)
Other Oceania	13	0 (0.0)	17	0 (0.0)	31	0 (0.0)
Asia	1	0 (0.0)	1	0 (0.0)	2	0 (0.0)
UK & Ireland	14	0 (0.0)	5	0 (0.0)	19	0 (0.0)
Other	9	0 (0.0)	2	0 (0.0)	11	0 (0.0)
p value		1.000		1.000		1.000
2018						
Australia	391	5 (1.3)	175	2 (1.1)	566	7 (1.2)
Other Oceania	16	0 (0.0)	3	0 (0.0)	20	0 (0.0)
Asia	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)
UK & Ireland	17	1 (5.9)	7	0 (0.0)	24	1 (4.2)
Other	11	0 (0.0)	4	0 (0.0)	15	0 (0.0)
p value		0.475		1.000		0.550

HCV antibody prevalence

Table 5.3.1 HCV antibody prevalence by gender and survey year

Queensland	Male		Female		Total	
Survey year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014	327	120 (37)	123	49 (40)	451	169 (37)
2015	379	161 (42)	139	64 (46)	520	226 (43)
2016	204	98 (48)	101	54 (53)	306	153 (50)
2017	425	179 (42)	161	66 (41)	587	245 (42)
2018	436	182 (42)	188	84 (45)	625	266 (43)
X ² p trend		0.502		0.889		0.519

Table 5.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Queensland	Male		Female		Total	
Sexual identity	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
Heterosexual	275	103 (37)	87	36 (41)	362	139 (38)
Bisexual	11	6 (55)	24	8 (33)	35	14 (40)
Homosexual	18	3 (17)	3	2 (67)	21	5 (24)
p value		0.094		0.565		0.416
2015						
Heterosexual	336	144 (43)	107	47 (44)	443	191 (43)
Bisexual	18	11 (61)	22	12 (55)	41	23 (56)
Homosexual	14	0 (0)	4	2 (50)	18	2 (11)
p value		<0.001		0.655		0.004
2016						
Heterosexual	165	80 (48)	58	31 (53)	224	112 (50)
Bisexual	12	3 (25)	32	19 (59)	44	22 (50)
Homosexual	10	6 (60)	4	1 (25)	14	7 (50)
p value		0.205		0.408		1.000
2017						
Heterosexual	343	142 (41)	113	46 (41)	456	188 (41)
Bisexual	26	17 (65)	27	12 (44)	53	29 (55)
Homosexual	24	7 (29)	8	2 (25)	33	9 (27)
p value		0.024		0.642		0.038
2018						
Heterosexual	364	160 (44)	136	61 (45)	500	221 (44)
Bisexual	25	8 (32)	36	17 (47)	61	25 (41)
Homosexual	21	7 (33)	3	1 (33)	25	8 (32)
p value		0.340		0.939		0.450

Table 5.3.3 HCV antibody prevalence by age group, gender and survey year

Queensland Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
<25 years	35	2 (6)	16	2 (13)	51	4 (8)
25-34 years	105	25 (24)	42	18 (43)	147	43 (29)
35-44 years	97	44 (45)	44	16 (36)	141	60 (43)
45+ years	88	49 (56)	21	13 (62)	110	62 (56)
p value		<0.001		0.020		<0.001
2015						
<25 years	32	7 (22)	12	4 (33)	44	11 (25)
25-34 years	120	37 (31)	43	19 (44)	164	57 (35)
35-44 years	133	56 (42)	46	18 (39)	179	74 (41)
45+ years	93	61 (66)	38	23 (61)	132	84 (64)
p value		<0.001		0.185		<0.001
2016						
<25 years	14	3 (21)	5	2 (40)	19	5 (26)
25-34 years	52	19 (37)	28	14 (50)	80	33 (41)
35-44 years	76	41 (54)	36	21 (58)	112	62 (55)
45+ years	62	35 (56)	32	17 (53)	95	53 (56)
p value		0.023		0.848		0.026
2017						
<25 years	24	2 (8)	11	2 (18)	36	4 (11)
25-34 years	84	30 (36)	42	22 (52)	126	52 (41)
35-44 years	148	65 (44)	53	17 (32)	201	82 (41)
45+ years	168	82 (49)	55	25 (45)	223	107 (48)
p value		0.001		0.081		<0.001
2018						
<25 years	20	2 (10)	15	3 (20)	35	5 (14)
25-34 years	76	23 (30)	45	18 (40)	122	41 (34)
35-44 years	158	59 (37)	67	34 (51)	225	93 (41)
45+ years	181	97 (54)	61	29 (48)	242	126 (52)
p value		<0.001		0.153		<0.001

Table 5.3.4 HCV antibody prevalence by years since first injection, gender and survey year

Queensland Years of injection	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2014						
<3 years	39	3 (8)	15	1 (7)	54	4 (7)
3 to 10 years	59	9 (15)	27	7 (26)	86	16 (19)
11+ years	215	106 (49)	80	41 (51)	296	147 (50)
p value		<0.001		0.001		<0.001
2015						
<3 years	42	4 (10)	4	1 (25)	46	5 (11)
3 to 10 years	81	16 (20)	28	10 (36)	110	26 (24)
11+ years	246	138 (56)	103	52 (50)	350	191 (55)
p value		<0.001		0.293		<0.001
2016						
<3 years	16	0 (0)	4	1 (25)	20	1 (5)
3 to 10 years	45	13 (29)	11	3 (27)	56	16 (29)
11+ years	132	77 (58)	82	50 (61)	215	128 (60)
p value		<0.001		0.045		<0.001
2017						
<3 years	31	1 (3)	15	2 (13)	46	3 (7)
3 to 10 years	62	10 (16)	35	7 (20)	97	17 (18)
11+ years	318	161 (51)	111	57 (51)	430	218 (51)
p value		<0.001		<0.001		<0.001
2018						
<3 years	28	1 (4)	13	1 (8)	41	2 (5)
3 to 10 years	60	11 (18)	33	8 (24)	93	19 (20)
11+ years	333	164 (49)	137	73 (53)	470	237 (50)
p value		<0.001		<0.001		<0.001

Table 5.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

Queensland Receptively shared syringe last month	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2014						
No receptive sharing	38	3 (8)	288	113 (39)	336	118 (35)
Receptive sharing	2	1 (50)	57	38 (67)	59	39 (66)
p value		0.192		<0.001		<0.001
2015						
No receptive sharing	35	4 (11)	349	171 (49)	391	177 (45)
Receptive sharing	4	1 (25)	62	34 (55)	68	37 (54)
p value		0.436		0.397		0.163
2016						
No receptive sharing	10	0 (0)	198	102 (52)	217	107 (49)
Receptive sharing	4	0 (0)	47	27 (57)	52	28 (54)
p value		--		0.464		0.557
2017						
No receptive sharing	34	1 (3)	407	182 (45)	449	186 (41)
Receptive sharing	8	2 (25)	68	36 (53)	80	41 (51)
p value		0.088		0.208		0.102
2018						
No receptive sharing	30	1 (3)	441	189 (43)	483	194 (40)
Receptive sharing	7	1 (14)	75	45 (60)	87	50 (57)
p value		0.347		0.006		0.003

Table 5.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year

Queensland Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
Heroin	1	1 (100)	64	41 (64)	66	42 (64)
Methamphetamine	17	2 (12)	123	43 (35)	141	46 (33)
Other opioids	4	1 (25)	135	71 (53)	141	72 (51)
PIEDs	27	0 (0)	36	0 (0)	69	0 (0)
Other drugs	5	0 (0)	23	7 (30)	31	7 (23)
p value		0.002		<0.001		<0.001
2015						
Heroin	0	0 (0)	105	64 (61)	106	64 (60)
Methamphetamine	14	3 (21)	162	57 (35)	178	61 (34)
Other opioids	5	1 (20)	140	88 (63)	146	90 (62)
PIEDs	25	0 (0)	33	0 (0)	62	0 (0)
Other drugs	2	1 (50)	19	8 (42)	24	11 (46)
p value		0.041		<0.001		<0.001
2016						
Heroin	1	0 (0)	41	27 (66)	43	27 (63)
Methamphetamine	10	0 (0)	105	51 (49)	120	55 (46)
Other opioids	1	0 (0)	81	49 (60)	85	51 (60)
PIEDs	3	0 (0)	15	0 (0)	19	0 (0)
Other drugs	4	1 (25)	21	11 (52)	30	14 (47)
p value		0.412		<0.001		<0.001
2017						
Heroin	4	1 (25)	77	44 (57)	82	46 (56)
Methamphetamine	20	1 (5)	230	87 (38)	255	91 (36)
Other opioids	6	1 (17)	160	93 (58)	170	96 (56)
PIEDs	12	0 (0)	34	2 (6)	47	2 (4)
Other drugs	4	0 (0)	23	7 (30)	30	8 (27)
p value		0.349		<0.001		<0.001
2018						
Heroin	3	1 (33)	74	36 (49)	80	40 (50)
Methamphetamine	25	1 (4)	262	99 (38)	297	102 (34)
Other opioids	1	0 (0)	172	99 (58)	177	101 (57)
PIEDs	7	0 (0)	19	0 (0)	27	0 (0)
Other drugs	4	0 (0)	27	16 (59)	33	17 (52)
p value		0.218		<0.001		<0.001

Table 5.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

Queensland	<3 years		3+ years		Total	
Frequency of injection last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
Less than daily	20	2 (10)	163	59 (36)	189	63 (33)
Daily or more	21	2 (10)	186	94 (51)	212	96 (45)
Not last month	13	0 (0)	27	8 (30)	44	8 (18)
p value		0.663		0.009		0.001
2015						
Less than daily	26	3 (12)	173	81 (47)	202	84 (42)
Daily or more	13	2 (15)	241	124 (51)	260	130 (50)
Not last month	7	0 (0)	45	12 (27)	54	12 (22)
p value		0.827		0.009		0.001
2016						
Less than daily	10	0 (0)	101	54 (53)	116	57 (49)
Daily or more	4	0 (0)	146	77 (53)	155	80 (52)
Not last month	5	1 (20)	16	7 (44)	26	10 (38)
p value		0.474		0.766		0.461
2017						
Less than daily	23	1 (4)	201	81 (40)	229	84 (37)
Daily or more	19	2 (11)	278	138 (50)	304	144 (47)
Not last month	4	0 (0)	45	14 (31)	51	15 (29)
p value		0.683		0.022		0.008
2018						
Less than daily	22	2 (9)	217	91 (42)	246	96 (39)
Daily or more	15	0 (0)	304	146 (48)	329	151 (46)
Not last month	3	0 (0)	34	13 (38)	40	13 (33)
p value		0.577		0.276		0.111

Table 5.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

Queensland	<3 years		3+ years		Total	
Imprisonment last year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
No imprisonment	49	3 (6)	322	139 (43)	384	144 (38)
Imprisonment	2	0 (0)	39	19 (49)	42	19 (45)
p value		1.000		0.509		0.327
2015						
No imprisonment	42	4 (10)	403	175 (43)	459	183 (40)
Imprisonment	1	1 (100)	39	29 (74)	40	30 (75)
p value		0.116		<0.001		<0.001
2016						
No imprisonment	16	0 (0)	233	115 (49)	263	122 (46)
Imprisonment	1	0 (0)	33	26 (79)	35	27 (77)
p value		--		0.002		0.001
2017						
No imprisonment	40	2 (5)	450	190 (42)	501	196 (39)
Imprisonment	3	0 (0)	58	34 (59)	64	37 (58)
p value		1.000		0.018		0.004
2018						
No imprisonment	39	2 (5)	472	210 (44)	529	218 (41)
Imprisonment	2	0 (0)	65	35 (54)	70	37 (53)
p value		1.000		0.156		0.064

Table 5.3.9 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Queensland Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
Non Indigenous	293	105 (36)	104	43 (41)	398	148 (37)
Indigenous	27	14 (52)	15	6 (40)	42	20 (48)
p value		0.099		0.921		0.186
2015						
Non Indigenous	334	135 (40)	114	51 (45)	450	187 (42)
Indigenous	41	25 (61)	23	12 (52)	64	37 (59)
p value		0.012		0.514		0.014
2016						
Non Indigenous	176	80 (45)	82	39 (48)	259	120 (46)
Indigenous	22	14 (64)	18	14 (78)	40	28 (70)
p value		0.107		0.035		0.005
2017						
Non Indigenous	346	134 (39)	130	51 (39)	476	185 (39)
Indigenous	66	41 (62)	29	15 (52)	96	56 (58)
p value		<0.001		0.217		<0.001
2018						
Non Indigenous	362	145 (40)	142	63 (44)	505	208 (41)
Indigenous	69	35 (51)	44	21 (48)	113	56 (50)
p value		0.100		0.695		0.104

Table 5.3.10 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Queensland Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
English speaking	313	115 (37)	117	47 (40)	431	162 (38)
Non-English speaking	12	5 (42)	5	2 (40)	17	7 (41)
p value		0.729		1.000		0.765
2015						
English speaking	364	153 (42)	137	62 (45)	503	216 (43)
Non-English speaking	8	4 (50)	1	1 (100)	9	5 (56)
p value		0.726		0.457		0.449
2016						
English speaking	191	90 (47)	98	51 (52)	290	142 (49)
Non-English speaking	9	5 (56)	2	2 (100)	11	7 (64)
p value		0.738		0.497		0.375
2017						
English speaking	410	175 (43)	153	61 (40)	563	236 (42)
Non-English speaking	13	3 (23)	8	5 (63)	22	8 (36)
p value		0.253		0.274		0.604
2018						
English speaking	423	176 (42)	182	82 (45)	605	258 (43)
Non-English speaking	11	5 (45)	6	2 (33)	18	7 (39)
p value		0.798		0.693		0.751

Table 5.3.11 HCV antibody prevalence by region/country of birth, gender and survey year

Queensland	Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
Australia	277	111 (40)	109	42 (39)	387	153 (40)
Other Oceania	22	5 (23)	6	3 (50)	28	8 (29)
Asia	2	0 (0)	0	0 (0)	2	0 (0)
UK & Ireland	10	3 (30)	4	2 (50)	14	5 (36)
Other	14	1 (7)	3	1 (33)	17	2 (12)
p value		0.044		0.858		0.095
2015						
Australia	330	143 (43)	124	62 (50)	456	206 (45)
Other Oceania	18	7 (39)	6	1 (17)	24	8 (33)
Asia	4	0 (0)	1	0 (0)	5	0 (0)
UK & Ireland	10	5 (50)	6	1 (17)	16	6 (38)
Other	8	2 (25)	1	0 (0)	9	2 (22)
p value		0.401		0.111		0.132
2016						
Australia	178	87 (49)	90	47 (52)	268	134 (50)
Other Oceania	7	3 (43)	3	2 (67)	10	5 (50)
Asia	2	1 (50)	0	0 (0)	2	1 (50)
UK & Ireland	7	4 (57)	7	4 (57)	15	9 (60)
Other	5	1 (20)	0	0 (0)	5	1 (20)
p value		0.812		1.000		0.682
2017						
Australia	383	162 (42)	136	61 (45)	519	223 (43)
Other Oceania	13	6 (46)	16	3 (19)	30	9 (30)
Asia	1	0 (0)	1	1 (100)	2	1 (50)
UK & Ireland	14	8 (57)	5	1 (20)	19	9 (47)
Other	9	1 (11)	2	0 (0)	11	1 (9)
p value		0.194		0.069		0.087
2018						
Australia	389	164 (42)	174	80 (46)	563	244 (43)
Other Oceania	16	6 (38)	3	1 (33)	20	7 (35)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	17	9 (53)	7	2 (29)	24	11 (46)
Other	11	2 (18)	4	1 (25)	15	3 (20)
p value		0.319		0.694		0.285

HCV RNA prevalence

Table 5.4.1 HCV RNA prevalence by gender and survey year *

Queensland	Male		Female		Total	
Survey year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015	161	68 (42)	59	22 (37)	220	91 (41)
2016	90	25 (28)	46	14 (30)	136	39 (29)
2017	368	83 (23)	141	20 (14)	509	103 (20)
2018	196	43 (22)	84	16 (19)	280	59 (21)
X ² p trend		<0.001		0.013		<0.001

* Weighted for gender and HCV antibody status

Table 5.4.2 HCV RNA prevalence by sexual identity, gender and survey year *

Queensland	Male		Female		Total	
Sexual identity	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
Heterosexual	140	59 (42)	44	17 (39)	185	76 (41)
Bisexual	13	8 (62)	11	4 (36)	24	12 (50)
Homosexual	4	0 (0)	1	0 (0)	5	1 (20)
p value		0.152		0.474		0.322
2016						
Heterosexual	76	22 (29)	26	8 (31)	102	30 (29)
Bisexual	3	1 (33)	13	5 (38)	17	6 (35)
Homosexual	5	2 (40)	4	0 (0)	9	2 (22)
p value		0.924		0.292		0.659
2017						
Heterosexual	303	68 (22)	101	10 (10)	404	78 (19)
Bisexual	24	9 (38)	20	5 (25)	44	14 (32)
Homosexual	14	1 (7)	7	2 (29)	21	3 (14)
p value		0.135		0.085		0.150
2018						
Heterosexual	172	39 (23)	62	12 (19)	234	51 (22)
Bisexual	8	1 (13)	14	3 (21)	22	4 (18)
Homosexual	6	0 (0)	3	0 (0)	9	0 (0)
p value		0.332		0.680		0.228

Table 5.4.3 HCV RNA prevalence by age group, gender and survey year *

Queensland Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
<25 years	10	4 (40)	7	1 (14)	17	6 (35)
25-34 years	48	16 (33)	18	6 (33)	66	22 (33)
35-44 years	66	27 (41)	20	7 (35)	86	34 (40)
45+ years	36	21 (58)	14	8 (57)	50	29 (58)
p value		0.198		0.234		0.078
2016						
<25 years	2	0 (0)	4	1 (25)	6	1 (17)
25-34 years	19	5 (26)	9	4 (44)	29	9 (31)
35-44 years	29	8 (28)	16	4 (25)	45	12 (27)
45+ years	39	12 (31)	16	4 (25)	56	17 (30)
p value		0.752		0.549		0.782
2017						
<25 years	22	1 (5)	10	2 (20)	33	3 (9)
25-34 years	71	22 (31)	35	8 (23)	106	30 (28)
35-44 years	138	33 (24)	45	3 (7)	183	36 (20)
45+ years	135	27 (20)	50	7 (14)	185	34 (18)
p value		0.098		0.232		0.101
2018						
<25 years	10	2 (20)	6	1 (17)	16	3 (19)
25-34 years	43	5 (12)	23	3 (13)	66	8 (12)
35-44 years	74	18 (24)	26	5 (19)	100	23 (23)
45+ years	69	18 (26)	28	7 (25)	97	25 (26)
p value		0.407		0.612		0.222

Table 5.4.4 HCV RNA prevalence by years since first injection, gender and survey year *

Queensland Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
<3 years	11	1 (9)	3	0 (0)	14	1 (7)
3 to 10 years	30	11 (37)	14	3 (21)	44	14 (32)
11+ years	117	55 (47)	42	19 (45)	160	75 (47)
p value		0.035		0.149		0.006
2016						
<3 years	5	0 (0)	3	0 (0)	8	0 (0)
3 to 10 years	19	4 (21)	3	1 (33)	22	5 (23)
11+ years	59	17 (29)	38	12 (32)	97	29 (30)
p value		0.293		0.440		0.149
2017						
<3 years	28	1 (4)	12	1 (8)	40	2 (5)
3 to 10 years	51	6 (12)	31	4 (13)	82	10 (12)
11+ years	278	72 (26)	98	15 (15)	376	87 (23)
p value		0.003		0.773		0.003
2018						
<3 years	11	0 (0)	7	0 (0)	18	0 (0)
3 to 10 years	33	7 (21)	15	1 (7)	48	8 (17)
11+ years	149	36 (24)	59	14 (24)	208	50 (24)
p value		0.225		0.086		0.052

Table 5.4.5 HCV RNA prevalence by re-use of someone else's used needle and syringe last month, gender and survey year *

Queensland	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
Receptively shared syringe last month						
2015						
No receptive sharing	122	49 (40)	45	19 (42)	167	68 (41)
Receptive sharing	20	13 (65)	11	2 (18)	31	15 (48)
p value		0.059		0.137		0.415
2016						
No receptive sharing	60	16 (27)	33	10 (30)	94	26 (28)
Receptive sharing	13	4 (31)	6	2 (33)	19	6 (32)
p value		0.886		0.752		0.777
2017						
No receptive sharing	281	64 (23)	109	17 (16)	390	81 (21)
Receptive sharing	47	12 (26)	23	3 (13)	70	15 (21)
p value		0.708		0.741		0.915
2018						
No receptive sharing	150	29 (19)	60	12 (20)	210	42 (20)
Receptive sharing	29	11 (38)	15	3 (20)	45	14 (31)
p value		0.039		0.750		0.122

Table 5.4.6 HCV RNA prevalence by last drug injected, gender and survey year *

Queensland	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
Last drug injected						
2015						
Heroin	33	15 (45)	13	6 (46)	46	22 (48)
Methamphetamine	75	32 (43)	26	6 (23)	102	38 (37)
Other opioids	43	17 (40)	19	10 (53)	62	27 (44)
PIEDs	0	0 (0)	0	0 (0)	0	0 (0)
Other drugs	7	4 (57)	1	0 (0)	8	4 (50)
p value		0.925		0.064		0.669
2016						
Heroin	9	1 (11)	8	2 (25)	17	3 (18)
Methamphetamine	26	8 (31)	17	5 (29)	43	13 (30)
Other opioids	34	13 (38)	14	4 (29)	48	18 (38)
PIEDs	9	0 (0)	0	0 (0)	9	0 (0)
Other drugs	8	2 (25)	7	2 (29)	15	4 (27)
p value		0.145		0.993		0.173
2017						
Heroin	39	13 (33)	25	7 (28)	65	20 (31)
Methamphetamine	147	37 (25)	71	10 (14)	219	47 (21)
Other opioids	114	24 (21)	38	3 (8)	152	27 (18)
PIEDs	41	2 (5)	0	0 (0)	41	2 (5)
Other drugs	23	6 (26)	7	0 (0)	30	6 (20)
p value		0.045		0.112		0.033
2018						
Heroin	22	6 (27)	9	2 (22)	31	8 (26)
Methamphetamine	87	21 (24)	47	9 (19)	134	30 (22)
Other opioids	58	10 (17)	21	4 (19)	79	15 (19)
PIEDs	13	0 (0)	0	0 (0)	13	0 (0)
Other drugs	13	4 (31)	5	0 (0)	18	4 (22)
p value		0.271		0.677		0.420

Table 5.4.7 HCV RNA prevalence by frequency of drug injection last month, gender and survey year *

Queensland Frequency of injection last month	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2015						
Less than daily	72	31 (43)	23	10 (43)	95	41 (43)
Daily or more	70	31 (44)	33	11 (33)	103	42 (41)
Not last month	17	6 (35)	3	1 (33)	20	7 (35)
p value		0.749		0.647		0.818
2016						
Less than daily	31	8 (26)	17	6 (35)	48	14 (29)
Daily or more	42	12 (29)	23	6 (26)	65	18 (28)
Not last month	14	4 (29)	5	1 (20)	19	6 (32)
p value		0.955		0.856		0.977
2017						
Less than daily	149	34 (23)	52	8 (15)	201	42 (21)
Daily or more	183	44 (24)	80	12 (15)	263	56 (21)
Not last month	33	4 (12)	9	0 (0)	42	4 (10)
p value		0.441		0.420		0.281
2018						
Less than daily	84	19 (23)	30	8 (27)	114	27 (24)
Daily or more	95	21 (22)	45	7 (16)	140	29 (21)
Not last month	14	2 (14)	6	0 (0)	20	2 (10)
p value		0.753		0.181		0.354

Table 5.4.8 HCV RNA prevalence by imprisonment last year, gender and survey year *

Queensland Imprisonment last year	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2015						
No imprisonment	139	59 (42)	51	17 (33)	191	77 (40)
Imprisonment	14	7 (50)	7	4 (57)	21	11 (52)
p value		0.648		0.101		0.236
2016						
No imprisonment	83	20 (24)	43	13 (30)	126	33 (26)
Imprisonment	6	4 (67)	1	1 (100)	7	5 (71)
p value		0.015		0.144		0.008
2017						
No imprisonment	305	65 (21)	128	16 (13)	434	81 (19)
Imprisonment	47	14 (30)	7	3 (43)	54	17 (31)
p value		0.163		0.044		0.026
2018						
No imprisonment	162	35 (22)	74	14 (19)	236	50 (21)
Imprisonment	27	7 (26)	7	1 (14)	35	8 (23)
p value		0.759		0.621		0.911

Table 5.4.9 HCV RNA prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year *

Queensland	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
Non Indigenous	143	59 (41)	47	20 (43)	190	80 (42)
Indigenous	17	8 (47)	12	2 (17)	29	10 (34)
p value		0.725		0.065		0.399
2016						
Non Indigenous	83	22 (27)	38	10 (26)	121	32 (26)
Indigenous	4	2 (50)	8	4 (50)	12	6 (50)
p value		0.110		0.237		0.051
2017						
Non Indigenous	298	61 (20)	113	13 (12)	411	74 (18)
Indigenous	59	22 (37)	26	7 (27)	85	29 (34)
p value		0.009		0.046		0.002
2018						
Non Indigenous	159	34 (21)	65	11 (17)	224	45 (20)
Indigenous	33	9 (27)	18	4 (22)	52	14 (27)
p value		0.497		0.496		0.367

Table 5.4.10 HCV RNA prevalence by main language spoken at home by parents, gender and survey year *

Queensland	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
English speaking	158	66 (42)	58	21 (36)	217	88 (41)
Non-English speaking	1	1 (100)	1	1 (100)	2	2 (100)
p value		0.241		0.205		0.091
2016						
English speaking	84	22 (26)	45	13 (29)	129	35 (27)
Non-English speaking	4	3 (75)	1	1 (100)	5	4 (80)
p value		0.065		0.133		0.030
2017						
English speaking	354	82 (23)	134	17 (13)	488	99 (20)
Non-English speaking	12	1 (8)	7	3 (43)	19	4 (21)
p value		0.283		0.021		0.922
2018						
English speaking	188	42 (22)	80	16 (20)	268	58 (22)
Non-English speaking	6	1 (17)	4	0 (0)	10	1 (10)
p value		0.661		0.999		0.349

Table 5.4.11 HCV RNA prevalence by region/country of birth, gender and survey year *

Queensland	Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
Australia	148	62 (42)	54	22 (41)	203	85 (42)
Other Oceania	4	2 (50)	1	0 (0)	5	2 (40)
Asia	1	0 (0)	0	0 (0)	1	0 (0)
UK & Ireland	4	2 (50)	2	0 (0)	6	2 (33)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.678		0.363		0.758
2016						
Australia	80	22 (28)	39	11 (28)	119	33 (28)
Other Oceania	3	1 (33)	3	1 (33)	6	2 (33)
Asia	1	1 (100)	0	0 (0)	1	1 (100)
UK & Ireland	2	0 (0)	4	1 (25)	6	1 (17)
Other	2	0 (0)	0	0 (0)	2	0 (0)
p value		0.414		0.546		0.406
2017						
Australia	326	74 (23)	120	17 (14)	447	91 (20)
Other Oceania	12	3 (25)	14	2 (14)	27	5 (19)
Asia	1	0 (0)	0	0 (0)	1	0 (0)
UK & Ireland	13	4 (31)	4	1 (25)	17	5 (29)
Other	8	0 (0)	2	0 (0)	10	0 (0)
p value		0.454		0.849		0.370
2018						
Australia	180	40 (22)	75	15 (20)	255	55 (22)
Other Oceania	6	1 (17)	1	0 (0)	7	1 (14)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	5	1 (20)	4	1 (25)	9	2 (22)
Other	3	1 (33)	4	0 (0)	7	1 (14)
p value		0.952		0.727		0.908

South Australia

Table 6.1.1 Number (percentage) of respondents by demographic characteristics and survey year

South Australia	2014	2015	2016	2017	2018
Number of sites	7	7	7	7	7
N° surveyed	N=228	N=238	N=247	N=270	N=321
Response rate (%)	51%	55%	52%	54%	53%
Gender (%)					
Male	143 (63)	137 (58)	151 (61)	138 (51)	197 (61)
Female	83 (36)	98 (41)	95 (38)	127 (47)	123 (38)
Transgender	2 (1)	3 (1)	0 (0)	5 (2)	1 (<1)
Not reported	0 (0)	0 (0)	1 (<1)	0 (0)	0 (0)
Sexual identity (%)					
Heterosexual	177 (78)	187 (79)	196 (79)	190 (70)	248 (77)
Bisexual	28 (12)	26 (11)	20 (8)	37 (14)	30 (9)
Homosexual	5 (2)	12 (5)	10 (4)	25 (9)	20 (6)
Not reported	18 (8)	13 (5)	21 (9)	18 (7)	23 (7)
Aboriginal and Torres Strait Islander origin (%)					
No	197 (86)	210 (88)	192 (78)	210 (78)	264 (82)
Yes	28 (1)	25 (11)	49 (20)	49 (18)	51 (16)
Not reported	3 (1)	3 (1)	6 (2)	11 (4)	6 (2)
Region/country of birth (%)					
Australia	202 (87)	214 (90)	215 (87)	238 (88)	277 (86)
Other Oceania	4 (2)	0 (0)	9 (4)	3 (1)	4 (1)
Asia	2 (1)	2 (1)	0 (0)	2 (1)	6 (2)
UK & Ireland	11 (5)	9 (4)	12 (5)	12 (4)	21 (7)
Other	8 (4)	8 (3)	9 (4)	12 (4)	11 (3)
Not reported	1 (<1)	5 (2)	2 (1)	3 (1)	2 (1)
Main language spoken at home by parents (%)					
English	213 (93)	221 (93)	228 (92)	255 (94)	293 (91)
Non-English	13 (6)	14 (6)	17 (7)	14 (5)	25 (8)
Not reported	2 (1)	3 (1)	2 (1)	1 (<1)	3 (1)
Age and time since first injection (years)					
<i>Median age</i>	40	43	43	43	43
<i>Age range</i>	18-68	17-70	17-67	18-69	18-71
Age group (%)					
<25 years	6 (3)	7 (3)	12 (5)	21 (8)	10 (3)
25+ years	222 (97)	231 (97)	235 (95)	249 (92)	310 (97)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	1 (<1)
Median age first injection					
<i>Median age first injection</i>	18	19	19	18	18
<i>Age range</i>	10-57	12-51	10-55	10-60	10-64
N° not reported	1	5	5	17	11
Median yrs since first injection					
<i>Median yrs since first injection</i>	20	22	21	22	23
<i>Range</i>	<1-41	<1-51	<1-47	1-47	1-49
Years since first injection					
<3 years	8 (4)	10 (4)	15 (6)	10 (4)	8 (2)
3+ years	218 (96)	223 (94)	227 (92)	243 (90)	302 (94)
Not reported	2 (1)	5 (2)	5 (2)	17 (6)	11 (3)
Imprisonment last year (%)					
No	195 (86)	214 (90)	211 (85)	224 (83)	261 (81)
Yes	19 (8)	13 (5)	24 (10)	32 (12)	33 (10)
Not reported	14 (6)	11 (5)	12 (5)	14 (5)	27 (8)
N° in prison					
N° in prison	N=19	N=13	N=24	N=32	N=33
Injected in prison	1 (5)	2 (15)	4 (17)	6 (19)	9 (27)

Table 6.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year

South Australia	2014	2015	2016	2017	2018
N° surveyed	N=228	N=238	N=247	N=270	N=321
Drug last injected (%)					
Cocaine	0 (0)	1 (<1)	1 (<1)	4 (1)	2 (1)
Methamphetamine	116 (51)	125 (53)	147 (60)	133 (49)	183 (57)
Heroin	65 (29)	73 (31)	45 (18)	89 (33)	98 (31)
Pharm. opioids	14 (6)	12 (5)	24 (10)	17 (6)	5 (2)
Methadone	9 (4)	11 (5)	11 (4)	11 (4)	16 (5)
Buprenorphine	2 (1)	1 (<1)	3 (1)	2 (1)	2 (1)
Buprenorphine/naloxone	1 (<1)	1 (<1)	1 (<1)	1 (<1)	0 (0)
PIEDs	1 (<1)	1 (<1)	2 (1)	2 (1)	0 (0)
More than one	18 (8)	10 (4)	13 (5)	8 (3)	13 (4)
Other	2 (1)	3 (1)	0 (0)	2 (1)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	1 (<1)	2 (1)
Ever injected opioids					
No	-	-	67 (27)	68 (25)	84 (26)
Yes	-	-	178 (72)	199 (74)	234 (73)
Not reported	-	-	2 (1)	3 (1)	3 (1)
Frequency of injection last month (%)					
Not last month	9 (4)	17 (7)	11 (4)	28 (10)	15 (5)
Less than weekly	42 (18)	48 (20)	40 (16)	37 (14)	56 (17)
Weekly not daily	66 (29)	82 (34)	79 (32)	69 (26)	94 (29)
Daily or more	106 (46)	90 (38)	114 (46)	130 (48)	151 (47)
Not reported	5 (2)	1 (<1)	3 (1)	6 (2)	5 (2)
Present when someone injected for the first time in the last 12 months (%)					
No	190 (83)	202 (85)	202 (82)	208 (77)	252 (79)
Yes	34 (15)	34 (14)	43 (17)	59 (22)	57 (18)
Not reported	4 (2)	2 (1)	2 (1)	3 (1)	12 (4)
Overdosed in last 12 months					
No	198 (87)	218 (92)	194 (79)	220 (81)	258 (80)
Yes	25 (11)	18 (8)	48 (19)	44 (16)	49 (15)
Not reported	5 (2)	2 (1)	5 (2)	6 (2)	14 (4)

Table 6.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year

South Australia	2014	2015	2016	2017	2018
N° injected last month	N=214	N=220	N=233	N=236	N=301
Places injected last month (%)					
All private	143 (67)	153 (70)	125 (54)	130 (55)	161 (53)
Any public	69 (32)	67 (30)	106 (45)	104 (44)	136 (45)
Not reported	2 (1)	0 (0)	2 (1)	2 (1)	4 (1)
Use of new and sterile needles and syringes last month (%)					
All injections	174 (81)	178 (81)	180 (77)	188 (80)	232 (77)
Most of the time	30 (14)	36 (16)	40 (17)	40 (17)	59 (20)
Half of the time	4 (2)	2 (1)	6 (3)	4 (2)	3 (1)
Some of the time	2 (1)	1 (<1)	2 (1)	1 (<1)	1 (<1)
Not last month	0 (0)	1 (<1)	1 (<1)	1 (<1)	0 (0)
Not reported	4 (2)	2 (1)	4 (2)	2 (1)	6 (2)
Re-used someone else's used needle & syringe last month (%)					
None	183 (86)	189 (86)	180 (77)	194 (82)	258 (86)
Once	10 (5)	11 (5)	21 (9)	14 (6)	18 (6)
Twice	12 (6)	13 (6)	14 (6)	17 (7)	10 (3)
3-5 times	4 (2)	4 (2)	11 (5)	5 (2)	5 (2)
>5 times	3 (1)	3 (1)	5 (2)	2 (1)	6 (2)
Not reported	2 (1)	0 (0)	2 (1)	4 (2)	4 (1)
Number of people needle & syringe was re-used after last month (%)					
None	183 (86)	189 (86)	180 (77)	194 (82)	258 (86)
One	11 (5)	14 (6)	18 (8)	22 (9)	21 (7)
Two	1 (<1)	2 (1)	5 (2)	2 (1)	3 (1)
Three to five	0 (0)	1 (<1)	5 (2)	4 (2)	0 (0)
More than five	2 (1)	0 (0)	2 (1)	3 (1)	0 (0)
Don't know	10 (5)	10 (5)	9 (4)	5 (2)	7 (2)
Not reported	7 (3)	4 (2)	14 (6)	6 (3)	12 (4)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	14 (7)	14 (6)	24 (10)	18 (8)	17 (6)
Casual sex partner	1 (<1)	3 (1)	1 (<1)	3 (1)	1 (<1)
Close friend	9 (4)	2 (1)	13 (6)	11 (5)	9 (3)
Acquaintance	2 (1)	4 (2)	6 (3)	4 (2)	4 (1)
Other	3 (1)	4 (2)	1 (<1)	3 (1)	1 (<1)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	32 (15)	34 (15)	30 (13)	50 (21)	41 (14)
Water	28 (13)	43 (20)	50 (21)	48 (20)	62 (21)
Filter	12 (6)	19 (9)	17 (7)	23 (10)	23 (8)
Drug mix	12 (6)	19 (9)	20 (9)	22 (9)	32 (11)
None	155 (72)	161 (73)	161 (69)	155 (66)	208 (69)
Injected by someone after that person injected themselves or others last month (%)					
No	166 (78)	178 (81)	187 (80)	183 (78)	250 (83)
Yes	40 (19)	42 (19)	43 (18)	50 (21)	44 (15)
Not reported	8 (4)	0 (0)	3 (1)	3 (1)	7 (2)
Source of needle acquisition					
Needle Syringe Program	191 (89)	201 (91)	203 (87)	210 (89)	266 (88)
Chemist/Pharmacy	34 (16)	44 (20)	41 (18)	45 (19)	60 (20)
Personal sources	18 (8)	23 (10)	37 (16)	32 (14)	53 (18)
Dispensing/Vending Machine	22 (10)	37 (17)	47 (20)	43 (18)	56 (19)
Other sources	1 (<1)	4 (2)	3 (1)	4 (2)	4 (1)

Table 6.1.4 Number (percentage) of respondents by treatment for drug use and survey year

South Australia	2014	2015	2016	2017	2018
N° surveyed	N=228	N=238	N=247	N=270	N=321
Ever any treatment/therapy for drug use (%)					
No	72 (33)	76 (32)	85 (34)	73 (27)	96 (30)
Yes	153 (67)	161 (68)	153 (62)	188 (70)	216 (67)
Not reported	3 (1)	1 (<1)	9 (4)	9 (3)	9 (3)
History of methadone maintenance treatment (%)					
Currently	57 (25)	53 (22)	44 (18)	73 (27)	68 (21)
Previously	46 (20)	56 (24)	47 (19)	48 (18)	81 (25)
Never	122 (54)	125 (53)	144 (58)	142 (53)	160 (50)
Not reported	3 (1)	4 (2)	12 (5)	7 (3)	12 (4)
History of buprenorphine (Subutex®) treatment (%)					
Currently	15 (7)	18 (8)	13 (5)	17 (6)	13 (4)
Previously	54 (24)	74 (31)	54 (22)	78 (29)	86 (27)
Never	157 (69)	143 (60)	170 (69)	164 (61)	214 (67)
Not reported	2 (1)	3 (1)	10 (4)	11 (4)	8 (2)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	23 (10)	16 (7)	23 (9)	23 (9)	22 (7)
Previously	37 (16)	48 (20)	36 (15)	71 (26)	69 (22)
Never	164 (72)	170 (71)	180 (73)	171 (63)	222 (69)
Not reported	4 (2)	4 (2)	8 (3)	5 (2)	8 (2)

Table 6.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year

South Australia	2014	2015	2016	2017	2018
N° surveyed	N=228	N=238	N=247	N=270	N=321
Previous HIV test (%)					
Yes, ever	176 (77)	212 (89)	198 (80)	210 (78)	256 (80)
Yes, last year	98 (43)	127 (53)	112 (45)	122 (45)	149 (46)
>1 year ago	78 (34)	85 (36)	86 (35)	88 (33)	107 (33)
Never tested	45 (20)	22 (9)	45 (18)	55 (20)	52 (16)
Not reported	7 (3)	4 (2)	4 (2)	5 (2)	13 (4)
Previous HCV test (%)					
Yes, ever	183 (80)	211 (89)	201 (81)	220 (81)	241 (75)
Yes, last year	116 (51)	131 (55)	121 (49)	149 (55)	145 (45)
>1 year ago	67 (29)	80 (34)	80 (32)	71 (26)	96 (30)
Never tested	35 (15)	15 (6)	31 (13)	37 (14)	45 (14)
Not reported	10 (4)	12 (5)	15 (6)	13 (5)	35 (11)
Lifetime treatment for HCV (%)#					
N° self-reported HCV diagnosis	N=50	N=58	N=48	N=68	N=68
Antiviral treatment	7 (14)	9 (16)	22 (46)	34 (50)	44 (65)
No antiviral treatment	40 (80)	47 (81)	26 (54)	34 (50)	23 (34)
Not reported	3 (6)	2 (3)	0 (0)	0 (0)	1 (1)
Treatment for HCV in past 12 months (%)#*					
N° self-reported HCV diagnosis	N=48	N=52	N=42	N=64	N=53
Antiviral treatment	1 (2)	1 (2)	13 (31)	25 (39)	22 (42)
No antiviral treatment	44 (92)	49 (94)	29 (69)	39 (61)	30 (57)
Not reported	3 (6)	2 (4)	0 (0)	0 (0)	1 (2)

among people who tested HCV antibody positive and did not report spontaneous clearance

* excludes people who reported treatment induced clearance more than 12 months previously

Table 6.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year

South Australia	2014	2015	2016	2017	2018
N° surveyed	N=228	N=238	N=247	N=270	N=321
Sex with a regular partner last month (%)					
No	102 (45)	108 (45)	94 (38)	130 (48)	152 (47)
Yes	119 (52)	116 (49)	146 (59)	131 (49)	145 (45)
Not reported	7 (3)	14 (6)	7 (3)	9 (3)	24 (7)
Condom used with regular partner last month (%)					
N° surveyed	N=119	N=116	N=146	N=131	N=145
Never	89 (75)	87 (75)	112 (77)	95 (73)	114 (79)
Sometimes	14 (12)	11 (9)	12 (8)	14 (11)	7 (5)
Every time	11 (9)	14 (12)	13 (9)	16 (12)	16 (11)
Not reported	5 (4)	4 (3)	9 (6)	6 (5)	8 (6)
Sex with other partner(s) last month (%)					
No	185 (81)	205 (86)	202 (82)	232 (86)	257 (80)
Yes	34 (15)	21 (9)	39 (16)	29 (11)	38 (12)
Not reported	9 (4)	12 (5)	6 (2)	9 (3)	26 (8)
Condom used with other partner(s) last month (%)					
N° surveyed	N=34	N=21	N=39	N=29	N=38
Never	10 (29)	11 (52)	17 (44)	7 (24)	7 (18)
Sometimes	10 (29)	1 (5)	12 (31)	11 (38)	14 (37)
Every time	11 (32)	9 (43)	9 (23)	9 (31)	17 (45)
Not reported	3 (9)	0 (0)	1 (3)	2 (7)	0 (0)
Sex work last month (%)					
No	207 (91)	221 (93)	228 (92)	232 (86)	286 (89)
Yes	10 (4)	9 (4)	11 (4)	22 (8)	15 (5)
Not reported	11 (5)	8 (3)	8 (3)	16 (6)	20 (6)
Condom used at last sex work (%)					
Yes	8 (80)	6 (67)	9 (82)	16 (73)	10 (67)

HIV antibody prevalence

Table 6.2.1 HIV antibody prevalence by gender and survey year

South Australia	Male		Female		Total	
Survey year	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014	137	2 (1.5)	82	0 (0.0)	220	2 (0.9)
2015	122	0 (0.0)	88	0 (0.0)	213	0 (0.0)
2016	150	1 (0.7)	94	0 (0.0)	245	1 (0.4)
2017	132	5 (3.8)	125	0 (0.0)	262	5 (1.9)
2018	193	2 (1.0)	122	0 (0.0)	315	2 (0.6)
X ² p trend		0.471		--		0.496

Table 6.2.2 HIV antibody prevalence by sexual identity, gender and survey year

South Australia	Male		Female		Total	
Sexual identity	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
Heterosexual	110	0 (0.0)	61	0 (0.0)	171	0 (0.0)
Bisexual	9	1 (11.1)	16	0 (0.0)	26	1 (3.9)
Homosexual	2	1 (50.0)	3	0 (0.0)	5	1 (20.0)
p value		0.003		--		0.007
2015						
Heterosexual	109	0 (0.0)	55	0 (0.0)	165	0 (0.0)
Bisexual	4	0 (0.0)	18	0 (0.0)	24	0 (0.0)
Homosexual	3	0 (0.0)	8	0 (0.0)	11	0 (0.0)
p value		--		--		--
2016						
Heterosexual	129	1 (0.8)	66	0 (0.0)	195	1 (0.5)
Bisexual	7	0 (0.0)	12	0 (0.0)	19	0 (0.0)
Homosexual	3	0 (0.0)	7	0 (0.0)	10	0 (0.0)
p value		1.000		--		1.000
2017						
Heterosexual	103	1 (1.0)	79	0 (0.0)	183	1 (0.6)
Bisexual	7	1 (14.3)	26	0 (0.0)	37	1 (2.7)
Homosexual	9	3 (33.3)	16	0 (0.0)	25	3 (12.0)
p value		0.001		--		0.005
2018						
Heterosexual	167	2 (1.2)	76	0 (0.0)	243	2 (0.8)
Bisexual	4	0 (0.0)	26	0 (0.0)	30	0 (0.0)
Homosexual	9	0 (0.0)	11	0 (0.0)	20	0 (0.0)
p value		1.000		--		1.000

Table 6.2.3 HIV antibody prevalence by age group, gender and survey year

South Australia Age group	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
<25 years	5	0 (0.0)	1	0 (0.0)	6	0 (0.0)
25-34 years	22	0 (0.0)	19	0 (0.0)	41	0 (0.0)
35-44 years	62	1 (1.6)	43	0 (0.0)	105	1 (1.0)
45+ years	48	1 (2.1)	19	0 (0.0)	68	1 (1.5)
p value		1.000		--		1.000
2015						
<25 years	1	0 (0.0)	3	0 (0.0)	4	0 (0.0)
25-34 years	14	0 (0.0)	16	0 (0.0)	31	0 (0.0)
35-44 years	43	0 (0.0)	35	0 (0.0)	78	0 (0.0)
45+ years	64	0 (0.0)	34	0 (0.0)	100	0 (0.0)
p value		--		--		--
2016						
<25 years	9	0 (0.0)	3	0 (0.0)	12	0 (0.0)
25-34 years	24	0 (0.0)	20	0 (0.0)	44	0 (0.0)
35-44 years	44	0 (0.0)	36	0 (0.0)	81	0 (0.0)
45+ years	73	1 (1.4)	35	0 (0.0)	108	1 (0.9)
p value		1.000		--		1.000
2017						
<25 years	11	1 (9.1)	9	0 (0.0)	21	1 (4.8)
25-34 years	17	0 (0.0)	26	0 (0.0)	45	0 (0.0)
35-44 years	41	1 (2.4)	43	0 (0.0)	86	1 (1.2)
45+ years	63	3 (4.8)	47	0 (0.0)	110	3 (2.7)
p value		0.571		--		0.386
2018						
<25 years	4	0 (0.0)	6	0 (0.0)	10	0 (0.0)
25-34 years	34	1 (2.9)	20	0 (0.0)	54	1 (1.9)
35-44 years	65	0 (0.0)	48	0 (0.0)	113	0 (0.0)
45+ years	90	1 (1.1)	47	0 (0.0)	137	1 (0.7)
p value		0.468		--		0.495

Table 6.2.4 HIV antibody prevalence by last drug injected, gender and survey year

South Australia Last drug injected	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
Heroin	37	0 (0.0)	27	0 (0.0)	64	0 (0.0)
Methamphetamine	71	2 (2.8)	39	0 (0.0)	111	2 (1.8)
Other opioids	14	0 (0.0)	11	0 (0.0)	25	0 (0.0)
Other drugs	15	0 (0.0)	5	0 (0.0)	20	0 (0.0)
p value		0.718		--		0.705
2015						
Heroin	40	0 (0.0)	24	0 (0.0)	65	0 (0.0)
Methamphetamine	61	0 (0.0)	50	0 (0.0)	113	0 (0.0)
Other opioids	14	0 (0.0)	9	0 (0.0)	23	0 (0.0)
Other drugs	7	0 (0.0)	5	0 (0.0)	12	0 (0.0)
p value		--		--		--
2016						
Heroin	25	0 (0.0)	18	0 (0.0)	43	0 (0.0)
Methamphetamine	85	1 (1.2)	61	0 (0.0)	147	1 (0.7)
Other opioids	28	0 (0.0)	11	0 (0.0)	39	0 (0.0)
Other drugs	12	0 (0.0)	4	0 (0.0)	16	0 (0.0)
p value		1.000		--		1.000
2017						
Heroin	40	1 (2.5)	46	0 (0.0)	86	1 (1.2)
Methamphetamine	61	4 (6.6)	65	0 (0.0)	128	4 (3.1)
Other opioids	21	0 (0.0)	10	0 (0.0)	31	0 (0.0)
Other drugs	10	0 (0.0)	4	0 (0.0)	17	0 (0.0)
p value		0.715		--		0.781
2018						
Heroin	66	0 (0.0)	32	0 (0.0)	98	0 (0.0)
Methamphetamine	102	2 (2.0)	79	0 (0.0)	181	2 (1.1)
Other opioids	13	0 (0.0)	8	0 (0.0)	21	0 (0.0)
Other drugs	11	0 (0.0)	3	0 (0.0)	14	0 (0.0)
p value		0.633		--		0.639

Table 6.2.5 HIV antibody prevalence by years of injection, gender and survey year

South Australia Years of injection	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
<3 years	3	0 (0.0)	4	0 (0.0)	7	0 (0.0)
3 to 10 years	26	1 (4.4)	10	0 (0.0)	33	1 (3.0)
11+ years	109	1 (0.9)	68	0 (0.0)	178	1 (0.6)
p value		0.349		--		0.334
2015						
<3 years	5	0 (0.0)	5	0 (0.0)	10	0 (0.0)
3 to 10 years	10	0 (0.0)	8	0 (0.0)	18	0 (0.0)
11+ years	106	0 (0.0)	74	0 (0.0)	183	0 (0.0)
p value		--		--		--
2016						
<3 years	9	0 (0.0)	6	0 (0.0)	15	0 (0.0)
3 to 10 years	17	0 (0.0)	8	0 (0.0)	25	0 (0.0)
11+ years	120	1 (0.8)	79	0 (0.0)	200	1 (0.5)
p value		1.000		--		1.000
2017						
<3 years	6	1 (16.7)	4	0 (0.0)	10	1 (10.0)
3 to 10 years	21	1 (4.8)	23	0 (0.0)	47	1 (2.1)
11+ years	105	3 (2.9)	98	0 (0.0)	205	3 (1.5)
p value		0.143		--		0.144
2018						
<3 years	3	0 (0.0)	5	0 (0.0)	8	0 (0.0)
3 to 10 years	24	0 (0.0)	19	0 (0.0)	43	0 (0.0)
11+ years	166	2 (1.2)	98	0 (0.0)	264	2 (0.8)
p value		1.000		--		1.000

Table 6.2.6 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

South Australia Receptively shared syringe last month	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
No receptive sharing	109	2 (1.8)	69	0 (0.0)	179	2 (1.1)
Receptive sharing	21	0 (0.0)	7	0 (0.0)	28	0 (0.0)
p value		1.000		--		1.000
2015						
No receptive sharing	95	0 (0.0)	73	0 (0.0)	170	0 (0.0)
Receptive sharing	16	0 (0.0)	11	0 (0.0)	27	0 (0.0)
p value		--		--		--
2016						
No receptive sharing	106	1 (0.9)	71	0 (0.0)	178	1 (0.6)
Receptive sharing	30	0 (0.0)	21	0 (0.0)	51	0 (0.0)
p value		1.000		--		1.000
2017						
No receptive sharing	94	2 (2.1)	91	0 (0.0)	188	2 (1.1)
Receptive sharing	19	2 (10.5)	16	0 (0.0)	37	2 (5.4)
p value		0.131		--		0.127
2018						
No receptive sharing	159	2 (1.3)	96	0 (0.0)	255	2 (0.8)
Receptive sharing	18	0 (0.0)	19	0 (0.0)	37	0 (0.0)
p value		1.000		--		1.000

Table 6.2.7 HIV antibody prevalence by frequency of drug injection last month, gender and survey year

South Australia	Male		Female		Total	
Frequency of injection	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
Less than daily	58	1 (1.7)	45	0 (0.0)	104	1 (1.0)
Daily or more	72	1 (1.4)	32	0 (0.0)	104	1 (1.0)
Not last month	6	0 (0.0)	2	0 (0.0)	8	0 (0.0)
p value		1.000		--		1.000
2015						
Less than daily	68	0 (0.0)	47	0 (0.0)	116	0 (0.0)
Daily or more	43	0 (0.0)	37	0 (0.0)	81	0 (0.0)
Not last month	10	0 (0.0)	4	0 (0.0)	15	0 (0.0)
p value		--		--		--
2016						
Less than daily	64	1 (1.6)	53	0 (0.0)	118	1 (0.9)
Daily or more	73	0 (0.0)	40	0 (0.0)	113	0 (0.0)
Not last month	11	0 (0.0)	0	0 (0.0)	11	0 (0.0)
p value		0.507		--		1.000
2017						
Less than daily	47	1 (2.1)	55	0 (0.0)	105	1 (1.0)
Daily or more	68	3 (4.4)	53	0 (0.0)	123	3 (2.4)
Not last month	13	1 (7.7)	15	0 (0.0)	28	1 (3.6)
p value		0.390		--		0.414
2018						
Less than daily	91	0 (0.0)	58	0 (0.0)	149	0 (0.0)
Daily or more	89	2 (2.3)	58	0 (0.0)	147	2 (1.4)
Not last month	10	0 (0.0)	4	0 (0.0)	14	0 (0.0)
p value		0.321		--		0.312

Table 6.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year

South Australia	Male		Female		Total	
Imprisonment last year	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
No imprisonment	114	2 (1.8)	73	0 (0.0)	188	2 (1.1)
Imprisonment	15	0 (0.0)	4	0 (0.0)	19	0 (0.0)
p value		1.000		--		1.000
2015						
No imprisonment	106	0 (0.0)	84	0 (0.0)	193	0 (0.0)
Imprisonment	9	0 (0.0)	1	0 (0.0)	10	0 (0.0)
p value		--		--		--
2016						
No imprisonment	122	0 (0.0)	87	0 (0.0)	210	0 (0.0)
Imprisonment	18	1 (5.6)	5	0 (0.0)	23	1 (4.4)
p value		0.129		--		0.099
2017						
No imprisonment	105	4 (3.8)	109	0 (0.0)	219	4 (1.8)
Imprisonment	19	1 (5.3)	10	0 (0.0)	29	1 (3.5)
p value		0.571		--		0.466
2018						
No imprisonment	150	1 (0.7)	106	0 (0.0)	256	1 (0.4)
Imprisonment	25	1 (4.0)	7	0 (0.0)	32	1 (3.1)
p value		0.266		--		0.210

Table 6.2.9 HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year

South Australia		Male		Female		Total	
Condom use at last sex	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2014							
No condom use	48	1 (2.1)	39	0 (0.0)	87	1 (1.2)	
Condom use	18	0 (0.0)	7	0 (0.0)	25	0 (0.0)	
p value		1.000		--		1.000	
2015							
No condom use	37	0 (0.0)	41	0 (0.0)	78	0 (0.0)	
Condom use	8	0 (0.0)	11	0 (0.0)	21	0 (0.0)	
p value		--		--		--	
2016							
No condom use	56	0 (0.0)	54	0 (0.0)	111	0 (0.0)	
Condom use	17	1 (5.9)	8	0 (0.0)	25	1 (4.0)	
p value		0.233		--		0.184	
2017							
No condom use	36	2 (5.6)	54	0 (0.0)	91	2 (2.2)	
Condom use	18	2 (11.1)	12	0 (0.0)	30	2 (6.7)	
p value		0.594		--		0.256	
2018							
No condom use	56	1 (1.8)	57	0 (0.0)	113	1 (0.9)	
Condom use	17	0 (0.0)	6	0 (0.0)	23	0 (0.0)	
p value		1.000		--		1.000	

Table 6.2.10 HIV antibody prevalence by sex work last month, gender and survey year

South Australia		Male		Female		Total	
Sex work last month	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2014							
No sex work	126	2 (1.6)	73	0 (0.0)	200	2 (1.0)	
Sex work	2	0 (0.0)	8	0 (0.0)	10	0 (0.0)	
p value		1.000		--		1.000	
2015							
No sex work	114	0 (0.0)	82	0 (0.0)	197	0 (0.0)	
Sex work	4	0 (0.0)	3	0 (0.0)	9	0 (0.0)	
p value		--		--		--	
2016							
No sex work	139	1 (0.7)	86	0 (0.0)	226	1 (0.4)	
Sex work	5	0 (0.0)	6	0 (0.0)	11	0 (0.0)	
p value		1.000		--		1.000	
2017							
No sex work	114	4 (3.5)	107	0 (0.0)	225	4 (1.8)	
Sex work	10	1 (10.0)	10	0 (0.0)	21	1 (4.8)	
p value		0.348		--		0.362	
2018							
No sex work	180	2 (1.1)	101	0 (0.0)	281	2 (0.7)	
Sex work	3	0 (0.0)	11	0 (0.0)	14	0 (0.0)	
p value		1.000		--		1.000	

Table 6.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

South Australia	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
Non Indigenous	120	2 (1.7)	68	0 (0.0)	189	2 (1.1)
Indigenous	14	0 (0.0)	14	0 (0.0)	28	0 (0.0)
p value		1.000		--		1.000
2015						
Non Indigenous	109	0 (0.0)	77	0 (0.0)	189	0 (0.0)
Indigenous	11	0 (0.0)	10	0 (0.0)	21	0 (0.0)
p value		--		--		--
2016						
Non Indigenous	116	0 (0.0)	74	0 (0.0)	191	0 (0.0)
Indigenous	29	1 (3.5)	19	0 (0.0)	48	1 (2.1)
p value		0.200		--		0.201
2017						
Non Indigenous	105	4 (3.8)	96	0 (0.0)	205	4 (2.0)
Indigenous	23	1 (4.4)	22	0 (0.0)	46	1 (2.2)
p value		1.000		--		1.000
2018						
Non Indigenous	158	1 (0.6)	102	0 (0.0)	260	1 (0.4)
Indigenous	32	1 (3.1)	17	0 (0.0)	49	1 (2.0)
p value		0.309		--		0.292

Table 6.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and survey year

South Australia	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
English speaking	125	2 (1.6)	79	0 (0.0)	205	2 (1.0)
Non-English speaking	10	0 (0.0)	3	0 (0.0)	13	0 (0.0)
p value		1.000		--		1.000
2015						
English speaking	108	0 (0.0)	85	0 (0.0)	196	0 (0.0)
Non-English speaking	12	0 (0.0)	2	0 (0.0)	14	0 (0.0)
p value		--		--		--
2016						
English speaking	136	1 (0.7)	90	0 (0.0)	227	1 (0.4)
Non-English speaking	13	0 (0.0)	3	0 (0.0)	16	0 (0.0)
p value		1.000		--		1.000
2017						
English speaking	122	4 (3.3)	122	0 (0.0)	247	4 (1.6)
Non-English speaking	9	1 (11.1)	3	0 (0.0)	14	1 (7.1)
p value		0.303		--		0.243
2018						
English speaking	171	1 (0.6)	119	0 (0.0)	290	1 (0.3)
Non-English speaking	19	1 (5.3)	3	0 (0.0)	22	1 (4.6)
p value		0.190		--		0.136

Table 6.2.13 HIV antibody prevalence by region/country of birth, gender and survey year

South Australia		Male		Female		Total	
Region/country of birth	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2014							
Australia	116	2 (1.7)	78	0 (0.0)	195	2 (1.0)	
Other Oceania	4	0 (0.0)	0	0 (0.0)	4	0 (0.0)	
Asia	2	0 (0.0)	0	0 (0.0)	2	0 (0.0)	
UK & Ireland	7	0 (0.0)	4	0 (0.0)	11	0 (0.0)	
Other	7	0 (0.0)	0	0 (0.0)	7	0 (0.0)	
p value		1.000		--		1.000	
2015							
Australia	105	0 (0.0)	82	0 (0.0)	190	0 (0.0)	
Other Oceania	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)	
Asia	2	0 (0.0)	0	0 (0.0)	2	0 (0.0)	
UK & Ireland	5	0 (0.0)	4	0 (0.0)	9	0 (0.0)	
Other	6	0 (0.0)	1	0 (0.0)	7	0 (0.0)	
p value		--		--		--	
2016							
Australia	126	1 (0.8)	86	0 (0.0)	213	1 (0.5)	
Other Oceania	6	0 (0.0)	3	0 (0.0)	9	0 (0.0)	
Asia	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)	
UK & Ireland	9	0 (0.0)	3	0 (0.0)	12	0 (0.0)	
Other	8	0 (0.0)	1	0 (0.0)	9	0 (0.0)	
p value		1.000		--		1.000	
2017							
Australia	116	3 (2.6)	112	0 (0.0)	231	3 (1.3)	
Other Oceania	1	0 (0.0)	2	0 (0.0)	3	0 (0.0)	
Asia	1	0 (0.0)	1	0 (0.0)	2	0 (0.0)	
UK & Ireland	3	1 (33.3)	8	0 (0.0)	11	1 (9.1)	
Other	9	0 (0.0)	1	0 (0.0)	12	0 (0.0)	
p value		0.169		--		0.236	
2018							
Australia	164	2 (1.2)	110	0 (0.0)	274	2 (0.7)	
Other Oceania	2	0 (0.0)	2	0 (0.0)	4	0 (0.0)	
Asia	6	0 (0.0)	0	0 (0.0)	6	0 (0.0)	
UK & Ireland	13	0 (0.0)	8	0 (0.0)	21	0 (0.0)	
Other	7	0 (0.0)	2	0 (0.0)	9	0 (0.0)	
p value		1.000		--		1.000	

HCV antibody prevalence

Table 6.3.1 HCV antibody prevalence by gender and survey year

South Australia	Male		Female		Total	
Survey year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014	128	68 (53)	79	40 (51)	208	109 (52)
2015	120	60 (50)	88	40 (45)	211	100 (47)
2016	141	62 (44)	90	27 (30)	232	89 (38)
2017	128	60 (47)	125	54 (43)	258	115 (45)
2018	187	89 (48)	122	34 (28)	309	123 (40)
X ² p trend		0.569		0.049		0.096

Table 6.3.2 HCV antibody prevalence by sexual identity, gender and survey year

South Australia	Male		Female		Total	
Sexual identity	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
Heterosexual	103	55 (53)	59	30 (51)	162	85 (52)
Bisexual	8	1 (13)	16	8 (50)	25	10 (40)
Homosexual	1	1 (100)	3	2 (67)	4	3 (75)
p value		0.030		1.000		0.314
2015						
Heterosexual	107	53 (50)	55	25 (45)	163	78 (48)
Bisexual	4	1 (25)	18	10 (56)	24	11 (46)
Homosexual	3	2 (67)	8	2 (25)	11	4 (36)
p value		0.711		0.389		0.812
2016						
Heterosexual	120	52 (43)	62	22 (35)	182	74 (41)
Bisexual	7	3 (43)	12	1 (8)	19	4 (21)
Homosexual	3	1 (33)	7	0 (0)	10	1 (10)
p value		1.000		0.041		0.048
2017						
Heterosexual	101	47 (47)	79	36 (46)	181	83 (46)
Bisexual	6	2 (33)	26	14 (54)	36	17 (47)
Homosexual	9	4 (44)	16	2 (13)	25	6 (24)
p value		0.915		0.019		0.107
2018						
Heterosexual	161	81 (50)	76	22 (29)	237	103 (43)
Bisexual	4	0 (0)	26	7 (27)	30	7 (23)
Homosexual	9	2 (22)	11	2 (18)	20	4 (20)
p value		0.045		0.847		0.019

Table 6.3.3 HCV antibody prevalence by age group, gender and survey year

South Australia Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
<25 years	5	1 (20)	1	0 (0)	6	1 (17)
25-34 years	22	7 (32)	19	8 (42)	41	15 (37)
35-44 years	56	28 (50)	41	18 (44)	97	46 (47)
45+ years	45	32 (71)	18	14 (78)	64	47 (73)
p value		0.005		0.034		<0.001
2015						
<25 years	1	0 (0)	3	0 (0)	4	0 (0)
25-34 years	14	7 (50)	16	7 (44)	31	14 (45)
35-44 years	43	16 (37)	35	13 (37)	78	29 (37)
45+ years	62	37 (60)	34	20 (59)	98	57 (58)
p value		0.085		0.121		0.007
2016						
<25 years	9	2 (22)	3	0 (0)	12	2 (17)
25-34 years	23	9 (39)	20	5 (25)	43	14 (33)
35-44 years	41	15 (37)	35	11 (31)	77	26 (34)
45+ years	68	36 (53)	32	11 (34)	100	47 (47)
p value		0.178		0.764		0.085
2017						
<25 years	11	0 (0)	9	2 (22)	21	2 (10)
25-34 years	17	4 (24)	26	8 (31)	45	13 (29)
35-44 years	38	20 (53)	43	22 (51)	83	42 (51)
45+ years	62	36 (58)	47	22 (47)	109	58 (53)
p value		<0.001		0.220		<0.001
2018						
<25 years	4	0 (0)	6	0 (0)	10	0 (0)
25-34 years	33	9 (27)	20	4 (20)	53	13 (25)
35-44 years	63	31 (49)	48	15 (31)	111	46 (41)
45+ years	87	49 (56)	47	15 (32)	134	64 (48)
p value		0.006		0.368		0.001

Table 6.3.4 HCV antibody prevalence by years since first injection, gender and survey year

South Australia Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
<3 years	3	1 (33)	4	0 (0)	7	1 (14)
3 to 10 years	22	8 (36)	10	4 (40)	32	12 (38)
11+ years	101	58 (57)	65	36 (55)	167	95 (57)
p value		0.129		0.074		0.016
2015						
<3 years	5	1 (20)	5	2 (40)	10	3 (30)
3 to 10 years	10	3 (30)	8	1 (13)	18	4 (22)
11+ years	104	55 (53)	75	37 (49)	182	92 (51)
p value		0.177		0.129		0.035
2016						
<3 years	9	0 (0)	6	1 (17)	15	1 (7)
3 to 10 years	17	3 (18)	8	1 (13)	25	4 (16)
11+ years	112	57 (51)	75	25 (33)	188	82 (44)
p value		<0.001		0.509		0.001
2017						
<3 years	6	1 (17)	4	1 (25)	10	2 (20)
3 to 10 years	21	1 (5)	23	6 (26)	47	8 (17)
11+ years	90	51 (57)	93	46 (49)	185	97 (52)
p value		<0.001		0.101		<0.001
2018						
<3 years	3	0 (0)	5	0 (0)	8	0 (0)
3 to 10 years	24	3 (13)	19	2 (11)	43	5 (12)
11+ years	154	82 (53)	96	32 (33)	250	114 (46)
p value		<0.001		0.053		<0.001

Table 6.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

South Australia Receptively shared syringe last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
No receptive sharing	5	1 (20)	163	91 (56)	170	93 (55)
Receptive sharing	1	0 (0)	25	10 (40)	26	10 (38)
p value		1.000		0.139		0.122
2015						
No receptive sharing	8	2 (25)	161	77 (48)	170	80 (47)
Receptive sharing	0	0 (0)	26	14 (54)	26	14 (54)
p value		--		0.569		0.519
2016						
No receptive sharing	11	1 (9)	155	63 (41)	168	64 (38)
Receptive sharing	3	0 (0)	45	17 (38)	49	18 (37)
p value		1.000		0.730		0.863
2017						
No receptive sharing	6	2 (33)	173	75 (43)	185	79 (43)
Receptive sharing	4	0 (0)	29	15 (52)	36	17 (47)
p value		0.467		0.401		0.617
2018						
No receptive sharing	4	0 (0)	240	94 (39)	249	97 (39)
Receptive sharing	3	0 (0)	32	18 (56)	37	19 (51)
p value		--		0.065		0.152

Table 6.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year

South Australia Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
Heroin	2	0 (0)	59	36 (61)	62	36 (58)
Methamphetamine	3	0 (0)	103	52 (50)	106	52 (49)
Other opioids	1	1 (100)	19	9 (47)	21	11 (52)
Other drugs	1	0 (0)	18	10 (56)	19	10 (53)
p value		0.072		0.566		0.736
2015						
Heroin	0	0 (0)	63	45 (71)	64	46 (72)
Methamphetamine	8	2 (25)	104	36 (35)	112	38 (34)
Other opioids	1	0 (0)	22	9 (41)	23	9 (39)
Other drugs	1	1 (100)	10	5 (50)	11	6 (55)
p value		0.240		<0.001		<0.001
2016						
Heroin	0	0 (0)	39	22 (56)	40	22 (55)
Methamphetamine	13	1 (8)	125	40 (32)	140	42 (30)
Other opioids	0	0 (0)	35	18 (51)	35	18 (51)
Other drugs	2	0 (0)	12	5 (42)	14	5 (36)
p value		0.685		0.022		0.010
2017						
Heroin	1	1 (100)	80	49 (61)	83	51 (61)
Methamphetamine	7	1 (14)	113	36 (32)	126	40 (32)
Other opioids	0	0 (0)	26	15 (58)	30	17 (57)
Other drugs	2	0 (0)	10	4 (40)	13	4 (31)
p value		0.098		<0.001		<0.001
2018						
Heroin	1	0 (0)	92	48 (52)	95	50 (53)
Methamphetamine	7	0 (0)	163	53 (33)	174	54 (31)
Other opioids	0	0 (0)	21	11 (52)	21	11 (52)
Other drugs	0	0 (0)	12	4 (33)	13	5 (38)
p value		--		0.012		0.004

Table 6.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

South Australia Frequency of injection last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
Less than daily	3	0 (0)	97	55 (57)	100	55 (55)
Daily or more	3	1 (33)	92	46 (50)	97	48 (49)
Not last month	1	0 (0)	7	3 (43)	8	3 (38)
p value		1.000		0.555		0.529
2015						
Less than daily	4	1 (25)	111	58 (52)	116	60 (52)
Daily or more	4	1 (25)	76	33 (43)	80	34 (43)
Not last month	2	1 (50)	12	4 (33)	14	5 (36)
p value		1.000		0.310		0.301
2016						
Less than daily	8	1 (13)	101	44 (44)	110	45 (41)
Daily or more	6	0 (0)	100	37 (37)	108	38 (35)
Not last month	1	0 (0)	10	4 (40)	11	4 (36)
p value		1.000		0.621		0.659
2017						
Less than daily	6	1 (17)	94	42 (45)	105	44 (42)
Daily or more	4	1 (25)	110	49 (45)	119	54 (45)
Not last month	0	0 (0)	25	13 (52)	28	14 (50)
p value		1.000		0.782		0.717
2018						
Less than daily	2	0 (0)	141	56 (40)	147	58 (39)
Daily or more	5	0 (0)	135	58 (43)	143	60 (42)
Not last month	1	0 (0)	13	3 (23)	14	3 (21)
p value		--		0.392		0.335

Table 6.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

South Australia Imprisonment last year	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
No imprisonment	7	1 (14)	167	91 (54)	176	9 (53)
Imprisonment	0	0 (0)	19	8 (42)	19	8 (42)
p value		--		0.305		0.374
2015						
No imprisonment	8	2 (25)	182	84 (46)	191	87 (46)
Imprisonment	2	1 (50)	8	6 (75)	10	7 (70)
p value		1.000		0.110		0.131
2016						
No imprisonment	11	1 (9)	183	72 (39)	198	75 (38)
Imprisonment	3	0 (0)	19	10 (53)	22	10 (45)
p value		1.000		0.262		0.489
2017						
No imprisonment	8	2 (25)	197	90 (46)	217	98 (45)
Imprisonment	2	0 (0)	25	9 (36)	28	10 (36)
p value		1.000		0.359		0.343
2018						
No imprisonment	6	0 (0)	241	93 (39)	251	96 (38)
Imprisonment	2	0 (0)	29	16 (55)	31	16 (52)
p value		--		0.086		0.151

Table 6.3.9 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

South Australia	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
Non Indigenous	111	55 (50)	66	33 (50)	178	89 (50)
Indigenous	14	11 (79)	13	7 (54)	27	18 (67)
p value		0.040		0.800		0.106
2015						
Non Indigenous	108	55 (51)	77	33 (43)	188	88 (47)
Indigenous	10	5 (50)	10	7 (70)	20	12 (60)
p value		0.955		0.105		0.262
2016						
Non Indigenous	108	40 (37)	71	22 (31)	180	62 (34)
Indigenous	28	19 (68)	18	5 (28)	46	24 (52)
p value		0.003		0.791		0.027
2017						
Non Indigenous	103	48 (47)	96	43 (45)	203	91 (45)
Indigenous	21	10 (48)	22	9 (41)	44	20 (45)
p value		0.932		0.741		0.940
2018						
Non Indigenous	154	65 (42)	102	31 (30)	256	96 (38)
Indigenous	30	22 (73)	17	3 (18)	47	25 (53)
p value		0.002		0.389		0.043

Table 6.3.10 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

South Australia	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
English speaking	119	66 (55)	76	39 (51)	196	106 (54)
Non-English speaking	7	1 (14)	3	1 (33)	10	2 (20)
p value		0.050		0.615		0.050
2015						
English speaking	106	53 (50)	85	39 (46)	194	92 (47)
Non-English speaking	12	5 (42)	2	1 (50)	14	6 (43)
p value		0.584		1.000		0.741
2016						
English speaking	127	53 (42)	87	26 (30)	215	79 (37)
Non-English speaking	13	8 (62)	2	1 (50)	15	9 (60)
p value		0.170		0.517		0.073
2017						
English speaking	118	55 (47)	122	54 (44)	243	110 (45)
Non-English speaking	9	4 (44)	3	0 (0)	14	4 (29)
p value		0.900		0.258		0.276
2018						
English speaking	167	81 (49)	119	34 (29)	286	115 (40)
Non-English speaking	17	8 (47)	3	0 (0)	20	8 (40)
p value		0.910		0.559		0.985

Table 6.3.11 HCV antibody prevalence by region/country of birth, gender and survey year

South Australia		Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2014							
Australia	108	61 (56)	75	37 (49)	184	99 (54)	
Other Oceania	4	2 (50)	0	0 (0)	4	2 (50)	
Asia	2	0 (0)	0	0 (0)	2	0 (0)	
UK & Ireland	7	3 (43)	4	3 (75)	11	6 (55)	
Other	6	2 (33)	0	0 (0)	6	2 (33)	
p value		0.440		0.615		0.583	
2015							
Australia	103	50 (49)	82	36 (44)	188	86 (46)	
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)	
Asia	2	2 (100)	0	0 (0)	2	2 (100)	
UK & Ireland	5	0 (0)	4	3 (75)	9	3 (33)	
Other	6	4 (67)	1	1 (100)	7	5 (71)	
p value		0.046		0.214		0.207	
2016							
Australia	119	51 (43)	83	24 (29)	203	75 (37)	
Other Oceania	6	3 (50)	3	2 (67)	9	5 (56)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	7	3 (43)	2	1 (50)	9	4 (44)	
Other	8	4 (50)	1	0 (0)	9	4 (44)	
p value		0.975		0.374		0.633	
2017							
Australia	113	54 (48)	112	47 (42)	228	102 (45)	
Other Oceania	1	1 (100)	2	1 (50)	3	2 (67)	
Asia	1	0 (0)	1	1 (100)	2	1 (50)	
UK & Ireland	2	1 (50)	8	4 (50)	10	5 (50)	
Other	9	2 (22)	1	0 (0)	12	2 (17)	
p value		0.312		0.846		0.273	
2018							
Australia	159	75 (47)	110	30 (27)	269	105 (39)	
Other Oceania	2	0 (0)	2	1 (50)	4	1 (25)	
Asia	6	4 (67)	0	0 (0)	6	4 (67)	
UK & Ireland	12	7 (58)	8	3 (38)	20	10 (50)	
Other	7	3 (43)	2	0 (0)	9	3 (33)	
p value		0.592		0.660		0.547	

HCV RNA prevalence

Table 6.4.1 HCV RNA prevalence by gender and survey year *

South Australia	Male		Female		Total	
Survey year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015	71	38 (54)	52	23 (44)	124	61 (49)
2016	75	27 (36)	47	10 (21)	123	37 (30)
2017	103	30 (29)	95	23 (24)	201	53 (26)
2018	87	21 (24)	56	8 (14)	143	29 (20)
X ² p trend		0.007		0.013		<0.001

* Weighted for gender and HCV antibody status

Table 6.4.2 HCV RNA prevalence by sexual identity, gender and survey year *

South Australia	Male		Female		Total	
Sexual identity	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
Heterosexual	63	35 (56)	33	19 (58)	97	54 (56)
Bisexual	3	2 (67)	10	2 (20)	14	4 (29)
Homosexual	1	0 (0)	5	0 (0)	6	0 (0)
p value		0.511		0.008		0.006
2016						
Heterosexual	65	24 (37)	30	7 (23)	95	31 (33)
Bisexual	6	2 (33)	7	2 (29)	13	4 (31)
Homosexual	1	0 (0)	5	0 (0)	6	0 (0)
p value		0.768		0.453		0.251
2017						
Heterosexual	84	26 (31)	59	14 (24)	143	40 (28)
Bisexual	7	1 (14)	19	4 (21)	29	5 (17)
Homosexual	5	1 (20)	14	3 (21)	19	4 (21)
p value		0.778		0.918		0.521
2018						
Heterosexual	66	17 (26)	35	6 (17)	101	23 (23)
Bisexual	4	0 (0)	12	1 (8)	16	1 (6)
Homosexual	8	0 (0)	5	0 (0)	14	0 (0)
p value		0.178		0.369		0.037

Table 6.4.3 HCV RNA prevalence by age group, gender and survey year *

South Australia Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
<25 years	0	0 (0)	1	0 (0)	1	0 (0)
25-34 years	5	3 (60)	8	5 (63)	14	8 (57)
35-44 years	26	11 (42)	26	9 (35)	52	20 (38)
45+ years	39	23 (59)	17	9 (53)	57	33 (58)
p value		0.426		0.497		0.202
2016						
<25 years	4	0 (0)	1	0 (0)	5	0 (0)
25-34 years	9	2 (22)	11	2 (18)	20	4 (20)
35-44 years	25	8 (32)	20	4 (20)	45	13 (29)
45+ years	37	16 (43)	15	4 (27)	53	20 (38)
p value		0.378		0.820		0.201
2017						
<25 years	6	1 (17)	5	1 (20)	13	2 (15)
25-34 years	12	1 (8)	20	2 (10)	32	3 (9)
35-44 years	40	15 (38)	28	10 (36)	70	25 (36)
45+ years	45	13 (29)	41	8 (20)	86	21 (24)
p value		0.273		0.247		0.560
2018						
<25 years	1	0 (0)	4	0 (0)	6	0 (0)
25-34 years	23	5 (22)	14	3 (21)	37	8 (22)
35-44 years	30	7 (23)	23	5 (22)	53	12 (23)
45+ years	33	9 (27)	14	0 (0)	47	9 (19)
p value		0.903		0.155		0.630

Table 6.4.4 HCV RNA prevalence by years since first injection, gender and survey year *

South Australia Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
<3 years	2	1 (50)	0	0 (0)	2	1 (50)
3 to 10 years	3	2 (67)	5	1 (20)	9	3 (33)
11+ years	65	35 (54)	46	21 (46)	113	57 (50)
p value		0.914		0.305		0.789
2016						
<3 years	5	0 (0)	2	0 (0)	7	0 (0)
3 to 10 years	12	1 (8)	4	0 (0)	16	1 (6)
11+ years	58	26 (45)	41	10 (24)	99	36 (36)
p value		0.015		0.382		0.010
2017						
<3 years	4	0 (0)	2	0 (0)	7	0 (0)
3 to 10 years	16	2 (13)	13	2 (15)	30	4 (13)
11+ years	74	23 (31)	74	18 (24)	150	41 (27)
p value		0.162		0.547		0.092
2018						
<3 years	1	0 (0)	2	0 (0)	3	0 (0)
3 to 10 years	10	0 (0)	12	1 (8)	22	1 (5)
11+ years	72	19 (26)	42	7 (17)	114	26 (23)
p value		0.196		0.565		0.074

Table 6.4.5 HCV RNA prevalence by re-use of someone else's used needle and syringe last month, gender and survey year *

South Australia	Male		Female		Total	
Receptively shared syringe last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
No receptive sharing	57	29 (51)	43	19 (44)	101	48 (48)
Receptive sharing	10	6 (60)	7	4 (57)	18	10 (56)
p value		0.604		0.847		0.596
2016						
No receptive sharing	52	19 (37)	35	7 (20)	88	26 (30)
Receptive sharing	16	6 (38)	12	3 (25)	28	10 (36)
p value		0.912		0.475		0.634
2017						
No receptive sharing	75	23 (31)	68	13 (19)	146	36 (25)
Receptive sharing	16	4 (25)	13	1 (8)	30	5 (17)
p value		0.619		0.443		0.394
2018						
No receptive sharing	70	16 (23)	42	6 (14)	112	22 (20)
Receptive sharing	8	4 (50)	11	1 (9)	20	5 (25)
p value		0.127		0.519		0.611

Table 6.4.6 HCV RNA prevalence by last drug injected, gender and survey year *

South Australia	Male		Female		Total	
Last drug injected	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
Heroin	22	14 (64)	17	12 (71)	39	26 (67)
Methamphetamine	34	15 (44)	27	10 (37)	63	26 (41)
Other opioids	9	5 (56)	3	1 (33)	13	6 (46)
Other drugs	5	3 (60)	4	0 (0)	9	3 (33)
p value		0.517		0.037		0.087
2016						
Heroin	13	6 (46)	8	3 (38)	21	10 (48)
Methamphetamine	44	13 (30)	31	4 (13)	76	17 (22)
Other opioids	12	4 (33)	5	3 (60)	18	7 (39)
Other drugs	5	3 (60)	3	0 (0)	8	3 (38)
p value		0.583		0.090		0.163
2017						
Heroin	33	11 (33)	38	13 (34)	72	24 (33)
Methamphetamine	41	11 (27)	44	6 (14)	87	17 (20)
Other opioids	18	5 (28)	8	1 (13)	26	6 (23)
Other drugs	8	3 (38)	2	0 (0)	12	3 (25)
p value		0.946		0.155		0.308
2018						
Heroin	28	5 (18)	16	2 (13)	44	7 (16)
Methamphetamine	44	11 (25)	35	4 (11)	79	15 (19)
Other opioids	8	3 (38)	3	2 (67)	11	5 (45)
Other drugs	4	1 (25)	2	0 (0)	6	1 (17)
p value		0.810		0.065		0.254

Table 6.4.7 HCV RNA prevalence by frequency of drug injection last month, gender and survey year *

South Australia	Male		Female		Total	
Frequency of injection last month	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2015						
Less than daily	37	16 (43)	31	17 (55)	69	33 (48)
Daily or more	30	18 (60)	19	6 (32)	50	24 (48)
Not last month	3	3 (100)	2	0 (0)	5	3 (60)
p value		0.097		0.124		0.922
2016						
Less than daily	42	13 (31)	26	5 (19)	69	18 (26)
Daily or more	26	13 (50)	21	5 (24)	47	18 (38)
Not last month	6	1 (17)	0	0 (0)	6	1 (17)
p value		0.166		0.716		0.277
2017						
Less than daily	33	8 (24)	43	8 (19)	78	16 (21)
Daily or more	60	19 (32)	38	7 (18)	99	26 (26)
Not last month	8	1 (13)	11	6 (55)	19	8 (42)
p value		0.599		0.025		0.267
2018						
Less than daily	40	6 (15)	30	3 (10)	70	9 (13)
Daily or more	42	14 (33)	23	4 (17)	66	19 (29)
Not last month	3	1 (33)	2	0 (0)	5	1 (20)
p value		0.165		0.618		0.104

Table 6.4.8 HCV RNA prevalence by imprisonment last year, gender and survey year *

South Australia	Male		Female		Total	
Imprisonment last year	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2015						
No imprisonment	61	32 (52)	49	21 (43)	112	53 (47)
Imprisonment	3	3 (100)	0	0 (0)	3	3 (100)
p value		0.101		--		0.075
2016						
No imprisonment	66	25 (38)	46	9 (20)	112	34 (30)
Imprisonment	6	2 (33)	1	0 (0)	7	3 (43)
p value		0.825		0.620		0.709
2017						
No imprisonment	82	21 (26)	84	20 (24)	169	41 (24)
Imprisonment	12	5 (42)	6	0 (0)	18	5 (28)
p value		0.258		0.135		0.792
2018						
No imprisonment	70	14 (20)	49	7 (14)	119	21 (18)
Imprisonment	8	5 (63)	3	0 (0)	12	5 (42)
p value		0.010		0.413		0.035

Table 6.4.9 HCV RNA prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year *

South Australia	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
Non Indigenous	65	38 (58)	47	20 (43)	114	58 (51)
Indigenous	3	0 (0)	4	2 (50)	7	2 (29)
p value		0.052		0.571		0.367
2016						
Non Indigenous	61	20 (33)	41	9 (22)	102	29 (28)
Indigenous	12	7 (58)	6	1 (17)	19	8 (42)
p value		0.151		0.560		0.286
2017						
Non Indigenous	80	24 (30)	75	20 (27)	159	44 (28)
Indigenous	21	5 (24)	13	1 (8)	34	6 (18)
p value		0.682		0.238		0.336
2018						
Non Indigenous	72	15 (21)	47	8 (17)	119	23 (19)
Indigenous	14	5 (36)	7	0 (0)	21	5 (24)
p value		0.204		0.205		0.554

Table 6.4.10 HCV RNA prevalence by main language spoken at home by parents, gender and survey year *

South Australia	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
English speaking	58	33 (57)	50	23 (46)	110	56 (51)
Non-English speaking	11	4 (36)	1	0 (0)	12	4 (33)
p value		0.218		0.375		0.250
2016						
English speaking	68	24 (35)	45	10 (22)	114	34 (30)
Non-English speaking	7	3 (43)	2	0 (0)	9	3 (33)
p value		0.465		0.456		0.561
2017						
English speaking	96	26 (27)	92	21 (23)	189	47 (25)
Non-English speaking	7	3 (43)	2	0 (0)	11	3 (27)
p value		0.202		0.355		0.635
2018						
English speaking	74	18 (24)	54	8 (15)	129	26 (20)
Non-English speaking	11	3 (27)	2	0 (0)	13	3 (23)
p value		0.903		0.564		0.824

Table 6.4.11 HCV RNA prevalence by region/country of birth, gender and survey year *

South Australia		Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2015							
Australia	61	32 (52)	50	21 (42)	113	53 (47)	
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)	
Asia	2	2 (100)	0	0 (0)	2	2 (100)	
UK & Ireland	3	1 (33)	1	1 (100)	4	2 (50)	
Other	2	1 (50)	0	0 (0)	2	1 (50)	
p value		0.529		0.261		0.554	
2016							
Australia	62	25 (40)	43	7 (16)	108	32 (30)	
Other Oceania	2	0 (0)	2	2 (100)	4	2 (50)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	4	1 (25)	2	1 (50)	6	2 (33)	
Other	5	1 (20)	0	0 (0)	5	1 (20)	
p value		0.543		0.014		0.978	
2017							
Australia	90	26 (29)	84	20 (24)	176	46 (26)	
Other Oceania	1	1 (100)	1	0 (0)	2	1 (50)	
Asia	1	0 (0)	0	0 (0)	1	0 (0)	
UK & Ireland	3	0 (0)	7	0 (0)	10	0 (0)	
Other	7	1 (14)	1	0 (0)	9	1 (11)	
p value		0.393		0.404		0.231	
2018							
Australia	73	18 (25)	52	8 (15)	125	26 (21)	
Other Oceania	1	0 (0)	1	0 (0)	2	0 (0)	
Asia	3	1 (33)	0	0 (0)	3	1 (33)	
UK & Ireland	5	0 (0)	2	0 (0)	7	0 (0)	
Other	3	2 (67)	1	0 (0)	4	2 (50)	
p value		0.415		0.831		0.332	

Tasmania

Table 7.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Tasmania	2014	2015	2016	2017	2018
Number of sites	4	4	4	4	4
N° surveyed	N=69	N=48	N=35	N=63	N=62
Response rate (%)	36%	20%	25%	30%	23%
Gender (%)					
Male	37 (54)	30 (62)	17 (49)	33 (52)	40 (65)
Female	31 (45)	18 (38)	18 (51)	30 (48)	21 (34)
Transgender	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)
Not reported	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)
Sexual identity (%)					
Heterosexual	52 (75)	39 (81)	31 (89)	51 (81)	52 (84)
Bisexual	3 (4)	2 (4)	2 (6)	6 (10)	5 (8)
Homosexual	2 (3)	3 (6)	1 (3)	3 (5)	0 (0)
Not reported	12 (17)	4 (8)	1 (3)	3 (5)	5 (8)
Aboriginal and Torres Strait Islander origin (%)					
No	56 (81)	39 (81)	31 (89)	55 (87)	49 (79)
Yes	11 (16)	8 (17)	3 (9)	7 (11)	11 (18)
Not reported	2 (3)	1 (2)	1 (3)	1 (2)	2 (3)
Region/country of birth (%)					
Australia	67 (97)	43 (90)	33 (94)	59 (94)	58 (94)
Other Oceania	0 (0)	1 (2)	0 (0)	0 (0)	1 (2)
Asia	0 (0)	0 (0)	0 (0)	2 (3)	0 (0)
UK & Ireland	2 (3)	2 (4)	1 (3)	1 (2)	2 (3)
Other	0 (0)	0 (0)	0 (0)	1 (2)	1 (2)
Not reported	0 (0)	2 (4)	1 (3)	0 (0)	0 (0)
Main language spoken at home by parents (%)					
English	69 (100)	47 (98)	33 (94)	63 (100)	61 (98)
Non-English	0 (0)	0 (0)	1 (3)	0 (0)	1 (2)
Not reported	0 (0)	1 (2)	1 (3)	0 (0)	0 (0)
Age and time since first injection (years)					
<i>Median age</i>	41	42	42	42	41.5
<i>Age range</i>	21-60	23-61	29-59	21-60	21-59
<i>Age group (%)</i>					
<25 years	1 (1)	1 (2)	0 (0)	2 (3)	2 (3)
25+ years	68 (99)	47 (98)	35 (100)	61 (97)	60 (97)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<i>Median age first injection</i>	20	20	21	20.5	19
<i>Age range</i>	12-53	12-50	14-45	14-57	13-48
N° not reported	2	0	1	3	3
<i>Median yrs since first injection</i>	18	18	19	19	20
<i>Range</i>	1-43	<1-43	7-29	2-46	1-40
<i>Years since first injection</i>					
<3 years	1 (1)	2 (4)	0 (0)	1 (2)	1 (2)
3+ years	66 (96)	46 (96)	34 (97)	59 (94)	59 (95)
Not reported	2 (3)	0 (0)	1 (3)	3 (5)	2 (3)
Imprisonment last year (%)					
No	56 (81)	41 (85)	33 (94)	57 (90)	56 (90)
Yes	3 (4)	3 (6)	1 (3)	4 (6)	3 (5)
Not reported	10 (14)	4 (8)	1 (3)	2 (3)	3 (5)
N° in prison					
Injected in prison	N=3	N=3	N=1	N=4	N=3
	1 (33)	0 (0)	0 (0)	0 (0)	2 (67)

Table 7.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year

Tasmania	2014	2015	2016	2017	2018
N° surveyed	N=69	N=48	N=35	N=63	N=62
Drug last injected (%)					
Cocaine	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Methamphetamine	23 (33)	20 (42)	13 (37)	21 (33)	22 (35)
Heroin	2 (3)	0 (0)	1 (3)	2 (3)	2 (3)
Pharm. opioids	25 (36)	15 (31)	7 (20)	15 (24)	19 (31)
Methadone	10 (14)	11 (23)	10 (29)	15 (24)	12 (19)
Buprenorphine	1 (1)	1 (2)	1 (3)	2 (3)	2 (3)
Buprenorphine/naloxone	0 (0)	0 (0)	1 (3)	1 (2)	2 (3)
PIEDs	0 (0)	1 (2)	0 (0)	1 (2)	0 (0)
More than one	7 (10)	0 (0)	0 (0)	3 (5)	1 (2)
Other	1 (1)	0 (0)	2 (6)	0 (0)	2 (3)
Not reported	0 (0)	0 (0)	0 (0)	3 (5)	0 (0)
Ever injected opioids					
No	-	-	4 (11)	5 (8)	3 (5)
Yes	-	-	30 (86)	57 (90)	59 (95)
Not reported	-	-	1 (3)	1 (2)	0 (0)
Frequency of injection last month (%)					
Not last month	1 (1)	4 (8)	7 (20)	5 (8)	2 (3)
Less than weekly	7 (10)	9 (19)	7 (20)	9 (14)	7 (11)
Weekly not daily	24 (35)	15 (31)	14 (40)	17 (27)	27 (44)
Daily or more	36 (52)	19 (40)	7 (20)	32 (51)	26 (42)
Not reported	1 (1)	1 (2)	0 (0)	0 (0)	0 (0)
Present when someone injected for the first time in the last 12 months (%)					
No	61 (88)	41 (85)	32 (91)	55 (87)	57 (92)
Yes	7 (10)	6 (13)	2 (6)	8 (13)	4 (6)
Not reported	1 (1)	1 (2)	1 (3)	0 (0)	1 (2)
Overdosed in last 12 months					
No	63 (91)	45 (94)	32 (91)	58 (92)	55 (89)
Yes	4 (6)	2 (4)	2 (6)	5 (8)	4 (6)
Not reported	2 (3)	1 (2)	1 (3)	0 (0)	3 (5)

Table 7.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year

Tasmania	2014	2015	2016	2017	2018
N° injected last month	N=67	N=43	N=28	N=58	N=60
Places injected last month (%)					
All private	52 (78)	28 (65)	19 (68)	36 (62)	35 (58)
Any public	15 (22)	15 (35)	9 (32)	22 (38)	25 (42)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Use of new and sterile needles and syringes last month (%)					
All injections	64 (96)	36 (84)	13 (46)	50 (86)	47 (78)
Most of the time	2 (3)	7 (16)	10 (36)	8 (14)	9 (15)
Half of the time	0 (0)	0 (0)	1 (4)	0 (0)	1 (2)
Some of the time	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)
Not last month	0 (0)	0 (0)	4 (14)	0 (0)	2 (3)
Not reported	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)
Re-used someone else's used needle & syringe last month (%)					
None	61 (91)	40 (93)	24 (86)	55 (95)	56 (93)
Once	4 (6)	1 (2)	2 (7)	1 (2)	0 (0)
Twice	1 (1)	1 (2)	1 (4)	1 (2)	1 (2)
3-5 times	0 (0)	1 (2)	0 (0)	0 (0)	1 (2)
>5 times	0 (0)	0 (0)	1 (4)	1 (2)	2 (3)
Not reported	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)
Number of people needle & syringe was re-used after last month (%)					
None	61 (91)	40 (93)	24 (86)	55 (95)	56 (93)
One	0 (0)	1 (2)	2 (7)	2 (3)	1 (2)
Two	0 (0)	0 (0)	1 (4)	0 (0)	1 (2)
Three to five	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)
More than five	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)
Don't know	0 (0)	1 (2)	0 (0)	1 (2)	0 (0)
Not reported	6 (9)	1 (2)	0 (0)	0 (0)	1 (2)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	0 (0)	1 (2)	1 (4)	2 (3)	1 (2)
Casual sex partner	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)
Close friend	0 (0)	0 (0)	3 (11)	0 (0)	2 (3)
Acquaintance	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Other	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	7 (10)	2 (5)	4 (14)	8 (14)	5 (8)
Water	14 (21)	2 (5)	4 (14)	6 (10)	5 (8)
Filter	2 (3)	4 (9)	1 (4)	9 (16)	2 (3)
Drug mix	2 (3)	1 (2)	3 (11)	4 (7)	4 (7)
None	46 (69)	36 (84)	21 (75)	40 (69)	52 (87)
Injected by someone after that person injected themselves or others last month (%)					
No	60 (90)	38 (88)	25 (89)	48 (83)	53 (88)
Yes	5 (7)	5 (12)	3 (11)	7 (12)	7 (12)
Not reported	2 (3)	0 (0)	0 (0)	3 (5)	0 (0)
Source of needle acquisition					
Needle Syringe Program	66 (99)	39 (91)	26 (93)	57 (98)	57 (95)
Chemist/Pharmacy	7 (10)	8 (19)	4 (14)	10 (17)	8 (13)
Personal sources	3 (4)	4 (9)	2 (7)	5 (9)	2 (3)
Dispensing/Vending Machine	1 (1)	12 (28)	5 (18)	16 (28)	9 (15)
Other sources	0 (0)	1 (2)	0 (0)	0 (0)	2 (3)

Table 7.1.4 Number (percentage) of respondents by treatment for drug use and survey year

Tasmania	2014	2015	2016	2017	2018
N° surveyed	N=69	N=48	N=35	N=47	N=62
Ever any treatment/therapy for drug use (%)					
No	17 (25)	14 (29)	6 (17)	15 (24)	11 (18)
Yes	52 (75)	34 (71)	28 (80)	47 (75)	50 (81)
Not reported	0 (0)	0 (0)	1 (3)	1 (2)	1 (2)
History of methadone maintenance treatment (%)					
Currently	21 (30)	14 (29)	17 (49)	24 (38)	16 (26)
Previously	16 (23)	8 (17)	4 (11)	16 (25)	24 (39)
Never	32 (46)	25 (52)	12 (34)	22 (35)	20 (32)
Not reported	0 (0)	1 (2)	2 (6)	1 (2)	2 (3)
History of buprenorphine (Subutex®) treatment (%)					
Currently	9 (13)	5 (10)	3 (9)	7 (11)	6 (10)
Previously	13 (19)	7 (15)	5 (14)	11 (17)	19 (31)
Never	45 (65)	35 (73)	26 (74)	44 (70)	35 (56)
Not reported	2 (3)	1 (2)	1 (3)	1 (2)	2 (3)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	5 (7)	2 (4)	1 (3)	2 (3)	4 (6)
Previously	11 (16)	11 (23)	4 (11)	11 (17)	19 (31)
Never	50 (72)	35 (73)	29 (83)	49 (78)	37 (60)
Not reported	3 (4)	0 (0)	1 (3)	1 (2)	2 (3)

Table 7.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year

Tasmania	2014	2015	2016	2017	2018
N° surveyed	N=69	N=48	N=35	N=63	N=62
Previous HIV test (%)					
Yes, ever	56 (81)	45 (94)	26 (74)	54 (86)	49 (79)
Yes, last year	25 (36)	21 (44)	17 (49)	24 (38)	21 (34)
>1 year ago	31 (45)	24 (50)	9 (26)	30 (48)	28 (45)
Never tested	12 (17)	3 (6)	8 (23)	9 (14)	9 (15)
Not reported	1 (1)	0 (0)	1 (3)	0 (0)	4 (6)
Previous HCV test (%)					
Yes, ever	63 (91)	44 (92)	30 (86)	52 (83)	53 (85)
Yes, last year	38 (55)	23 (48)	21 (60)	31 (49)	35 (56)
>1 year ago	25 (36)	21 (44)	9 (26)	21 (33)	18 (29)
Never tested	3 (4)	2 (4)	3 (9)	8 (13)	5 (8)
Not reported	3 (4)	2 (4)	2 (6)	3 (5)	4 (6)
Lifetime treatment for HCV (%)[#]					
N° self-reported HCV diagnosis	N=13	N=11	N=9	N=20	N=21
Antiviral treatment	4 (31)	2 (18)	2 (22)	11 (55)	15 (71)
No antiviral treatment	9 (69)	9 (82)	5 (56)	9 (45)	6 (29)
Not reported	0 (0)	0 (0)	2 (22)	0 (0)	0 (0)
Treatment for HCV in past 12 months (%)^{##}					
N° self-reported HCV diagnosis	N=13	N=11	N=9	N=18	N=17
Antiviral treatment	0 (0)	0 (0)	2 (22)	7 (39)	9 (53)
No antiviral treatment	13 (100)	11 (100)	5 (56)	11 (61)	8 (47)
Not reported	0 (0)	0 (0)	2 (22)	0 (0)	0 (0)

[#] among people who tested HCV antibody positive and did not report spontaneous clearance

* excludes people who reported treatment induced clearance more than 12 months previously

Table 7.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year

Tasmania	2014	2015	2016	2017	2018
N° surveyed	N=69	N=48	N=35	N=63	N=62
Sex with a regular partner last month (%)					
No	28 (41)	16 (33)	17 (49)	29 (46)	32 (52)
Yes	36 (52)	29 (60)	16 (46)	34 (54)	26 (42)
Not reported	5 (7)	3 (6)	2 (6)	0 (0)	4 (6)
Condom used with regular partner last month (%)					
N° surveyed	N=36	N=29	N=16	N=34	N=26
Never	27 (75)	22 (76)	12 (75)	31 (91)	21 (81)
Sometimes	1 (3)	2 (7)	3 (19)	0 (0)	4 (15)
Every time	6 (17)	4 (14)	1 (6)	3 (9)	0 (0)
Not reported	2 (6)	1 (3)	0 (0)	0 (0)	1 (4)
Sex with other partner(s) last month (%)					
No	59 (86)	39 (81)	30 (86)	62 (98)	51 (82)
Yes	4 (6)	6 (13)	1 (3)	1 (2)	6 (10)
Not reported	6 (9)	3 (6)	4 (11)	0 (0)	5 (8)
Condom used with other partner(s) last month (%)					
N° surveyed	N=4	N=6	N=1	N=1	N=6
Never	2 (50)	0 (0)	0 (0)	0 (0)	4 (67)
Sometimes	0 (0)	3 (50)	0 (0)	1 (100)	2 (33)
Every time	1 (25)	3 (50)	1 (100)	0 (0)	0 (0)
Not reported	1 (25)	0 (0)	0 (0)	0 (0)	0 (0)
Sex work last month (%)					
No	56 (81)	45 (94)	31 (89)	59 (94)	55 (89)
Yes	1 (1)	0 (0)	1 (3)	2 (3)	1 (2)
Not reported	12 (17)	3 (6)	3 (9)	2 (3)	6 (10)
Condom used at last sex work (%)					
Yes	1 (100)	--	1 (100)	1 (50)	0 (0)

HIV antibody prevalence

Table 7.2.1 HIV antibody prevalence by gender and survey year

Tasmania Survey year	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2014	32	0 (0.0)	30	0 (0.0)	63	0 (0.0)
2015	29	0 (0.0)	18	0 (0.0)	47	0 (0.0)
2016	17	0 (0.0)	18	0 (0.0)	35	0 (0.0)
2017	32	0 (0.0)	30	0 (0.0)	62	0 (0.0)
2018	40	0 (0.0)	21	0 (0.0)	62	0 (0.0)
X ² p trend		--		--		--

HCV antibody prevalence

Table 7.3.1 HCV antibody prevalence by gender and survey year

Tasmania Survey year	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2014	30	16 (53)	30	18 (60)	61	35 (57)
2015	26	16 (62)	18	10 (56)	44	26 (59)
2016	17	7 (41)	18	6 (33)	35	13 (37)
2017	32	14 (44)	29	15 (52)	61	29 (48)
2018	40	21 (53)	21	12 (57)	62	34 (55)
X ² p trend		0.744		0.818		0.686

Table 7.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Tasmania Sexual identity	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2014						
Heterosexual	24	14 (58)	24	15 (63)	48	29 (60)
Bisexual	0	0 (0)	3	2 (67)	3	2 (67)
Homosexual	1	0 (0)	1	0 (0)	2	0 (0)
p value		0.440		0.726		0.283
2015						
Heterosexual	23	14 (61)	13	7 (54)	36	21 (58)
Bisexual	0	0 (0)	2	1 (50)	2	1 (50)
Homosexual	2	1 (50)	1	1 (100)	3	2 (67)
p value		1.000		1.000		1.000
2016						
Heterosexual	15	7 (47)	16	6 (38)	31	13 (42)
Bisexual	0	0 (0)	2	0 (0)	2	0 (0)
Homosexual	1	0 (0)	0	0 (0)	1	0 (0)
p value		1.000		0.529		0.696
2017						
Heterosexual	28	13 (46)	23	11 (48)	51	24 (47)
Bisexual	0	0 (0)	4	2 (50)	4	2 (50)
Homosexual	2	0 (0)	1	1 (100)	3	1 (33)
p value		0.492		1.000		1.000
2018						
Heterosexual	34	18 (53)	18	9 (50)	52	27 (52)
Bisexual	2	0 (0)	2	2 (100)	5	3 (60)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.486		0.479		1.000

Table 7.3.3 HCV antibody prevalence by age group, gender and survey year

Tasmania Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	2	1 (50)	8	5 (63)	10	6 (60)
35-44 years	18	9 (50)	12	6 (50)	31	16 (52)
45+ years	10	6 (60)	10	7 (70)	20	13 (65)
p value		0.848		0.651		0.649
2015						
<25 years	1	1 (100)	0	0 (0)	1	1 (100)
25-34 years	4	3 (75)	6	4 (67)	10	7 (70)
35-44 years	12	4 (33)	7	1 (14)	19	5 (26)
45+ years	9	8 (89)	5	5 (100)	14	13 (93)
p value		0.030		0.013		<0.001
2016						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	0	0 (0)	3	1 (33)	3	1 (33)
35-44 years	11	6 (55)	11	5 (45)	22	11 (50)
45+ years	6	1 (17)	4	0 (0)	10	1 (10)
p value		0.304		0.314		0.106
2017						
<25 years	2	0 (0)	0	0 (0)	2	0 (0)
25-34 years	3	1 (33)	6	5 (83)	9	6 (67)
35-44 years	12	6 (50)	12	6 (50)	24	12 (50)
45+ years	15	7 (47)	11	4 (36)	26	11 (42)
p value		0.745		0.223		0.385
2018						
<25 years	1	1 (100)	0	0 (0)	2	2 (100)
25-34 years	6	3 (50)	3	2 (67)	9	5 (56)
35-44 years	19	8 (42)	12	8 (67)	31	16 (52)
45+ years	14	9 (64)	6	2 (33)	20	11 (55)
p value		0.490		0.475		0.798

Table 7.3.4 HCV antibody prevalence by years since first injection, gender and survey year

Tasmania Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 10 years	4	1 (25)	6	4 (67)	10	5 (50)
11+ years	25	15 (60)	23	14 (61)	49	30 (61)
p value		0.299		1.000		0.510
2015						
<3 years	1	0 (0)	1	0 (0)	2	0 (0)
3 to 10 years	6	2 (33)	2	1 (50)	8	3 (38)
11+ years	19	14 (74)	15	9 (60)	34	23 (68)
p value		0.086		0.706		0.078
2016						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 10 years	1	0 (0)	1	0 (0)	2	0 (0)
11+ years	16	7 (44)	16	6 (38)	32	13 (41)
p value		1.000		1.000		0.513
2017						
<3 years	1	0 (0)	0	0 (0)	1	0 (0)
3 to 10 years	4	0 (0)	1	1 (100)	5	1 (20)
11+ years	25	14 (56)	27	14 (52)	52	28 (54)
p value		0.067		1.000		0.194
2018						
<3 years	1	1 (100)	0	0 (0)	1	1 (100)
3 to 10 years	5	2 (40)	3	1 (33)	9	4 (44)
11+ years	33	17 (52)	17	11 (65)	50	28 (56)
p value		1.000		0.537		0.845

Table 7.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

Tasmania Receptively shared syringe last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
No receptive sharing	0	0 (0)	52	32 (61)	54	32 (59)
Receptive sharing	0	0 (0)	4	1 (25)	4	1 (25)
p value		--		0.295		0.305
2015						
No receptive sharing	2	0 (0)	36	21 (58)	38	21 (55)
Receptive sharing	0	0 (0)	2	2 (100)	2	2 (100)
p value		--		0.509		0.499
2016						
No receptive sharing	0	0 (0)	24	9 (38)	24	9 (38)
Receptive sharing	0	0 (0)	4	3 (75)	4	3 (75)
p value		--		0.285		0.285
2017						
No receptive sharing	1	1 (100)	49	25 (51)	53	25 (47)
Receptive sharing	0	0 (0)	3	2 (67)	3	2 (67)
p value		--		1.000		0.605
2018						
No receptive sharing	1	1 (100)	53	30 (57)	56	32 (57)
Receptive sharing	0	0 (0)	4	1 (25)	4	1 (25)
p value		--		0.322		0.318

Table 7.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year

Tasmania Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
Methamphetamine	0	0 (0)	18	10 (56)	18	10 (56)
Pharmaceutical opioids	0	0 (0)	24	13 (54)	25	13 (52)
OST	0	0 (0)	11	9 (82)	11	9 (82)
Other drugs	0	0 (0)	6	3 (50)	7	3 (43)
p value		--		0.408		0.307
2015						
Methamphetamine	1	0 (0)	17	9 (53)	18	9 (50)
Pharmaceutical opioids	0	0 (0)	14	11 (79)	14	11 (79)
OST	0	0 (0)	11	6 (55)	11	6 (55)
Other drugs	1	0 (0)	0	0 (0)	1	0 (0)
p value		--		0.286		0.226
2016						
Methamphetamine	0	0 (0)	13	2 (15)	13	2 (15)
Pharmaceutical opioids	0	0 (0)	7	3 (43)	7	3 (43)
OST	0	0 (0)	12	7 (58)	12	7 (58)
Other drugs	0	0 (0)	2	1 (50)	3	1 (33)
p value		--		0.164		0.167
2017						
Methamphetamine	1	1 (100)	19	6 (32)	20	6 (30)
Pharmaceutical opioids	0	0 (0)	12	7 (58)	15	7 (47)
OST	0	0 (0)	18	12 (67)	18	12 (67)
Other drugs	0	0 (0)	8	4 (50)	8	4 (50)
p value		--		0.180		0.162
2018						
Methamphetamine	0	0 (0)	21	10 (48)	22	10 (45)
Pharmaceutical opioids	1	1 (100)	17	10 (59)	19	12 (63)
OST	0	0 (0)	16	9 (56)	16	9 (56)
Other drugs	0	0 (0)	5	3 (60)	5	3 (60)
p value		--		0.895		0.710

Table 7.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

Tasmania Frequency of injection last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
Less than daily	0	0 (0)	27	15 (56)	28	15 (54)
Daily or more	0	0 (0)	30	19 (63)	31	19 (61)
Not last month	0	0 (0)	1	0 (0)	1	0 (0)
p value		--		0.414		0.429
2015						
Less than daily	2	0 (0)	20	11 (55)	22	11 (50)
Daily or more	0	0 (0)	18	12 (67)	18	12 (67)
Not last month	0	0 (0)	4	3 (75)	4	3 (75)
p value		--		0.649		0.531
2016						
Less than daily	0	0 (0)	21	10 (48)	21	10 (48)
Daily or more	0	0 (0)	7	2 (29)	7	2 (29)
Not last month	0	0 (0)	6	1 (17)	7	1 (14)
p value		--		0.473		0.310
2017						
Less than daily	0	0 (0)	25	11 (44)	25	11 (44)
Daily or more	1	1 (100)	27	16 (59)	31	16 (52)
Not last month	0	0 (0)	5	2 (40)	5	2 (40)
p value		--		0.569		0.802
2018						
Less than daily	0	0 (0)	33	19 (58)	34	19 (56)
Daily or more	1	1 (100)	24	12 (50)	26	14 (54)
Not last month	0	0 (0)	2	1 (50)	2	1 (50)
p value		--		0.798		1.000

Table 7.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

Tasmania Imprisonment last year	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
No imprisonment	0	0 (0)	51	27 (53)	53	27 (51)
Imprisonment	0	0 (0)	1	1 (100)	1	1 (100)
p value		--		1.000		1.000
2015						
No imprisonment	2	0 (0)	36	21 (58)	38	21 (55)
Imprisonment	0	0 (0)	2	1 (50)	2	1 (50)
p value		--		1.000		1.000
2016						
No imprisonment	0	0 (0)	32	13 (41)	33	13 (39)
Imprisonment	0	0 (0)	1	0 (0)	1	0 (0)
p value		--		1.000		1.000
2017						
No imprisonment	1	1 (100)	51	27 (53)	55	27 (49)
Imprisonment	0	0 (0)	4	2 (50)	4	2 (50)
p value		--		1.000		1.000
2018						
No imprisonment	0	0 (0)	55	29 (53)	56	29 (52)
Imprisonment	0	0 (0)	3	3 (100)	3	3 (100)
p value		--		0.245		0.243

Table 7.3.9 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Tasmania	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
Non Indigenous	26	15 (58)	23	12 (52)	50	28 (56)
Indigenous	3	1 (33)	6	5 (83)	9	6 (67)
p value		0.573		0.168		0.551
2015						
Non Indigenous	22	14 (64)	13	6 (46)	35	20 (57)
Indigenous	3	2 (67)	5	4 (80)	8	6 (75)
p value		1.000		0.314		0.351
2016						
Non Indigenous	16	7 (44)	15	4 (27)	31	11 (35)
Indigenous	0	0 (0)	3	2 (67)	3	2 (67)
p value		--		0.245		0.544
2017						
Non Indigenous	28	11 (39)	26	13 (50)	54	24 (44)
Indigenous	4	3 (75)	2	1 (50)	6	4 (67)
p value		0.295		1.000		0.404
2018						
Non Indigenous	32	14 (44)	17	10 (59)	49	24 (49)
Indigenous	7	6 (86)	3	1 (33)	11	8 (73)
p value		0.091		0.566		0.193

Table 7.3.10 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Tasmania	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
English speaking	30	16 (53)	30	18 (60)	61	35 (57)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2015						
English speaking	25	15 (60)	18	10 (56)	43	25 (58)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2016						
English speaking	15	7 (47)	18	6 (33)	33	13 (39)
Non-English speaking	1	0 (0)	0	0 (0)	1	0 (0)
p value		1.000		--		1.000
2017						
English speaking	32	14 (44)	29	15 (52)	61	29 (48)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2018						
English speaking	40	21 (53)	21	12 (57)	61	33 (54)
Non-English speaking	0	0 (0)	0	0 (0)	1	1 (100)
p value		--		--		1.000

Table 7.3.11 HCV antibody prevalence by region/country of birth, gender and survey year

Tasmania Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
Australia	29	15 (52)	29	17 (59)	59	33 (56)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	1	1 (100)	1	1 (100)	2	2 (100)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		1.000		1.000		0.503
2015						
Australia	22	13 (59)	17	9 (53)	39	22 (56)
Other Oceania	1	0 (0)	0	0 (0)	1	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	1	1 (100)	1	1 (100)	2	2 (100)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.670		1.000		0.322
2016						
Australia	16	7 (44)	17	6 (35)	33	13 (39)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	0	0 (0)	1	0 (0)	1	0 (0)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		1.000		1.000
2017						
Australia	29	13 (45)	28	14 (50)	57	27 (47)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	1	0 (0)	1	1 (100)	2	1 (50)
UK & Ireland	1	0 (0)	0	0 (0)	1	0 (0)
Other	1	1 (100)	0	0 (0)	1	1 (100)
p value		0.835		1.000		0.862
2018						
Australia	38	21 (55)	20	12 (60)	58	33 (57)
Other Oceania	1	0 (0)	0	0 (0)	1	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	1	0 (0)	1	0 (0)	2	0 (0)
Other	0	0 (0)	0	0 (0)	1	1 (100)
p value		0.219		0.429		0.137

HCV RNA prevalence

Table 7.4.1 HCV RNA prevalence by gender and survey year *

Tasmania	Male		Female		Total	
Survey year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015	4	4 (100)	5	3 (60)	9	7 (78)
2016	4	2 (50)	2	0 (0)	6	2 (33)
2017	27	8 (30)	26	9 (35)	53	17 (32)
2018	32	6 (19)	17	5 (29)	49	11 (22)
X ² p trend		0.033		0.535		0.044

* Weighted for gender and HCV antibody status

Table 7.4.2 HCV RNA prevalence by sexual identity, gender and survey year *

Tasmania	Male		Female		Total	
Sexual identity	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
Heterosexual	4	0 (0)	4	3 (75)	8	6 (75)
Bisexual	0	0 (0)	1	0 (0)	1	0 (0)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		0.334		0.010
2016						
Heterosexual	2	2 (100)	1	0 (0)	4	2 (50)
Bisexual	0	0 (0)	1	0 (0)	1	0 (0)
Homosexual	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.072		--		0.428
2017						
Heterosexual	25	8 (32)	20	9 (45)	45	17 (38)
Bisexual	0	0 (0)	5	0 (0)	5	0 (0)
Homosexual	2	0 (0)	1	0 (0)	3	0 (0)
p value		0.346		0.150		0.111
2018						
Heterosexual	28	4 (14)	13	4 (31)	41	8 (20)
Bisexual	0	0 (0)	2	1 (50)	3	1 (33)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		0.544		0.445

Table 7.4.3 HCV RNA prevalence by age group, gender and survey year *

Tasmania Age group	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2015						
<25 years	1	0 (0)	0	0 (0)	1	1 (100)
25-34 years	1	0 (0)	2	1 (50)	3	2 (67)
35-44 years	1	0 (0)	1	0 (0)	2	1 (50)
45+ years	1	0 (0)	1	1 (100)	3	2 (67)
p value		--		0.416		0.522
2016						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	0	0 (0)	0	0 (0)	1	0 (0)
35-44 years	1	1 (100)	1	0 (0)	2	1 (50)
45+ years	2	1 (50)	1	0 (0)	3	1 (33)
p value		0.488		--		0.622
2017						
<25 years	1	0 (0)	0	0 (0)	1	0 (0)
25-34 years	3	0 (0)	5	3 (60)	8	3 (38)
35-44 years	11	4 (36)	12	2 (17)	23	6 (26)
45+ years	12	4 (33)	9	4 (44)	21	8 (38)
p value		0.567		0.175		0.821
2018						
<25 years	0	0 (0)	0	0 (0)	1	0 (0)
25-34 years	5	1 (20)	2	1 (50)	7	2 (29)
35-44 years	15	1 (7)	10	2 (20)	25	3 (12)
45+ years	12	4 (33)	4	1 (25)	16	5 (31)
p value		0.227		0.634		0.430

Table 7.4.4 HCV RNA prevalence by years since first injection, gender and survey year *

Tasmania Years of injection	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2015						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 10 years	1	1 (0)	1	0 (0)	2	1 (50)
11+ years	3	3 (100)	4	3 (75)	7	6 (86)
p value		--		0.334		0.296
2016						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 10 years	0	0 (0)	1	0 (0)	1	0 (0)
11+ years	4	2 (50)	1	0 (0)	5	2 (40)
p value		--		--		0.445
2017						
<3 years	1	0 (0)	0	0 (0)	1	0 (0)
3 to 10 years	3	0 (0)	1	1 (100)	4	1 (25)
11+ years	22	8 (36)	24	8 (33)	46	16 (35)
p value		0.357		0.179		0.734
2018						
<3 years	1	1 (100)	0	0 (0)	1	1 (100)
3 to 10 years	4	1 (25)	3	1 (33)	8	2 (25)
11+ years	26	3 (12)	13	4 (31)	39	7 (18)
p value		0.064		0.710		0.127

Table 7.4.5 HCV RNA prevalence by re-use of someone else's used needle and syringe last month, gender and survey year *

Tasmania	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
Receptively shared syringe last month						
2015						
No receptive sharing	4	4 (100)	2	1 (50)	7	6 (86)
Receptive sharing	0	0 (0)	1	1 (100)	1	1 (100)
p value		--		0.558		0.663
2016						
No receptive sharing	3	1 (33)	1	0 (0)	4	2 (50)
Receptive sharing	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2017						
No receptive sharing	24	6 (25)	23	8 (35)	47	14 (30)
Receptive sharing	1	1 (100)	2	1 (50)	3	2 (67)
p value		0.123		0.585		0.094
2018						
No receptive sharing	28	5 (18)	16	5 (31)	44	10 (23)
Receptive sharing	2	0 (0)	0	0 (0)	3	0 (0)
p value		0.525		--		0.375

Table 7.4.6 HCV RNA prevalence by last drug injected, gender and survey year *

Tasmania	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
Last drug injected						
2015						
Methamphetamine	2	2 (100)	3	1 (33)	6	4 (67)
Pharm. Opioids	1	1 (100)	0	0 (0)	1	1 (100)
OST*	1	1 (100)	1	1 (100)	2	2 (100)
Other drugs	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		0.403		0.525
2016						
Methamphetamine	0	0 (0)	1	0 (0)	1	0 (0)
Pharm. Opioids	1	0 (0)	0	0 (0)	1	0 (0)
OST*	2	2 (100)	1	0 (0)	3	2 (67)
Other drugs	0	0 (0)	0	0 (0)	1	0 (0)
p value		0.072		--		0.375
2017						
Methamphetamine	6	0 (0)	10	2 (20)	16	2 (13)
Pharm. Opioids	11	4 (36)	4	2 (50)	15	6 (40)
OST*	7	2 (29)	7	5 (71)	15	7 (47)
Other drugs	2	1 (50)	5	0 (0)	7	1 (14)
p value		0.308		0.070		0.172
2018						
Methamphetamine	7	0 (0)	7	2 (29)	14	2 (14)
Pharm. Opioids	14	3 (21)	3	1 (33)	17	4 (24)
OST*	9	3 (33)	5	1 (20)	14	4 (29)
Other drugs	2	0 (0)	1	0 (0)	4	0 (0)
p value		0.344		0.902		0.650

Table 7.4.7 HCV RNA prevalence by frequency of drug injection last month, gender and survey year *

Tasmania Frequency of injection last month	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
Less than daily	2	2 (100)	2	2 (100)	4	4 (100)
Daily or more	2	2 (100)	1	0 (0)	4	3 (75)
Not last month	0	0 (0)	1	0 (0)	1	0 (0)
p value		--		0.164		0.103
2016						
Less than daily	4	2 (50)	1	0 (0)	5	2 (40)
Daily or more	0	0 (0)	0	0 (0)	0	0 (0)
Not last month	0	0 (0)	1	0 (0)	1	0 (0)
p value		--		--		0.263
2017						
Less than daily	7	0 (0)	13	3 (23)	20	3 (15)
Daily or more	18	7 (39)	12	6 (50)	30	13 (43)
Not last month	2	1 (50)	1	0 (0)	3	1 (33)
p value		0.139		0.270		0.093
2018						
Less than daily	16	1 (6)	12	4 (33)	28	5 (18)
Daily or more	15	4 (27)	4	1 (25)	19	5 (26)
Not last month	1	1 (100)	1	0 (0)	2	1 (50)
p value		0.045		0.837		0.433

Table 7.4.8 HCV RNA prevalence by imprisonment last year, gender and survey year *

Tasmania Imprisonment last year	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
No imprisonment	3	3 (100)	3	1 (33)	6	4 (4)
Imprisonment	1	1 (100)	0	0 (0)	1	1 (1)
p value		--		--		0.535
2016						
No imprisonment	4	2 (50)	2	0 (0)	6	2 (33)
Imprisonment	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2017						
No imprisonment	26	8 (31)	22	8 (36)	48	16 (33)
Imprisonment	1	0 (0)	3	1 (33)	4	1 (25)
p value		0.508		0.988		0.767
2018						
No imprisonment	28	4 (14)	17	5 (29)	45	9 (20)
Imprisonment	1	0 (0)	0	0 (0)	2	0 (0)
p value		0.691		--		0.500

Table 7.4.9 HCV RNA prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year *

Tasmania	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
Non Indigenous	3	3 (100)	5	0 (0)	8	6 (75)
Indigenous	1	1 (100)	0	0 (0)	1	1 (100)
p value		--		--		0.605
2016						
Non Indigenous	4	2 (50)	2	0 (0)	6	2 (33)
Indigenous	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2017						
Non Indigenous	25	8 (32)	22	8 (36)	47	16 (34)
Indigenous	2	0 (0)	3	0 (0)	5	0 (0)
p value		0.333		0.219		0.118
2018						
Non Indigenous	25	4 (16)	12	5 (42)	37	9 (24)
Indigenous	6	1 (17)	3	0 (0)	10	1 (10)
p value		0.962		0.221		0.376

Table 7.4.10 HCV RNA prevalence by main language spoken at home by parents, gender and survey year *

Tasmania	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
English speaking	3	3 (100)	5	3 (60)	8	6 (75)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2016						
English speaking	4	2 (50)	2	0 (0)	6	2 (33)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2017						
English speaking	27	8 (30)	26	9 (35)	53	17 (32)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2018						
English speaking	31	6 (19)	17	5 (29)	48	11 (23)
Non-English speaking	0	0 (0)	0	0 (0)	1	0 (0)
p value		--		--		0.605

Table 7.4.11 HCV RNA prevalence by region/country of birth, gender and survey year *

Tasmania		Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2015							
Australia	2	2 (100)	5	2 (40)	7	4 (57)	
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	1	1 (100)	0	0 (0)	1	1 (0)	
Other	0	0 (0)	0	0 (0)	0	0 (0)	
p value		--		--		0.565	
2016							
Australia	4	2 (50)	2	0 (0)	6	2 (33)	
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)	
Other	0	0 (0)	0	0 (0)	0	0 (0)	
p value		--		--		--	
2017							
Australia	24	7 (29)	25	8 (32)	49	15 (31)	
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)	
Asia	1	0 (0)	1	1 (0)	2	1 (0)	
UK & Ireland	1	0 (0)	0	0 (0)	1	0 (0)	
Other	1	1 (0)	0	0 (0)	1	1 (0)	
p value		0.294		0.168		0.308	
2018							
Australia	29	6 (21)	16	5 (31)	45	11 (24)	
Other Oceania	1	0 (0)	0	0 (0)	1	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	1	0 (0)	1	0 (0)	2	0 (0)	
Other	0	0 (0)	0	0 (0)	1	0 (0)	
p value		0.786		0.540		0.756	

Victoria

Table 8.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Victoria	2014	2015	2016	2017	2018
Number of sites	6	6	6	6	6
N° surveyed	N=436	N=459	N=423	N=380	N=437
Response rate (%)	41%	62%	70%	56%	51%
Gender (%)					
Male	288 (66)	303 (66)	268 (63)	247 (65)	290 (66)
Female	146 (33)	153 (33)	151 (36)	127 (33)	145 (33)
Transgender	2 (<1)	3 (1)	2 (<1)	3 (1)	2 (<1)
Not reported	0 (0)	0 (0)	2 (<1)	3 (1)	0 (0)
Sexual identity (%)					
Heterosexual	349 (81)	381 (83)	329 (78)	293 (77)	342 (78)
Bisexual	36 (8)	36 (8)	45 (11)	35 (9)	33 (8)
Homosexual	11 (3)	17 (4)	13 (3)	16 (4)	18 (4)
Not reported	40 (9)	25 (5)	36 (9)	36 (9)	44 (10)
Aboriginal and Torres Strait Islander origin (%)					
No	378 (87)	401 (87)	341 (81)	320 (84)	359 (82)
Yes	53 (12)	53 (12)	70 (17)	55 (14)	71 (16)
Not reported	5 (1)	5 (1)	12 (3)	5 (1)	7 (2)
Region/country of birth (%)					
Australia	360 (83)	376 (82)	363 (86)	333 (88)	373 (85)
Other Oceania	10 (2)	18 (4)	8 (2)	9 (2)	12 (3)
Asia	20 (5)	16 (3)	7 (2)	5 (1)	6 (1)
UK & Ireland	20 (5)	27 (6)	16 (4)	13 (3)	20 (5)
Other	25 (6)	20 (4)	20 (5)	19 (5)	24 (5)
Not reported	1 (<1)	2 (<1)	9 (2)	1 (<1)	2 (<1)
Main language spoken at home by parents (%)					
English	378 (87)	414 (90)	380 (90)	336 (88)	393 (90)
Non-English	57 (13)	42 (9)	38 (9)	44 (12)	43 (10)
Not reported	1 (<1)	3 (1)	5 (1)	0 (0)	1 (<1)
Age and time since first injection (years)					
<i>Median age</i>	39	40	41	42	42
<i>Age range</i>	16-65	18-64	17-69	19-67	17-69
Age group (%)					
<25 years	12 (3)	8 (2)	13 (3)	7 (2)	8 (2)
25+ years	422 (97)	450 (98)	409 (97)	370 (97)	424 (97)
Not reported	2 (<1)	1 (<1)	1 (<1)	3 (1)	5 (1)
Median age first injection					
<i>Median age first injection</i>	18	18	18	18	18
<i>Age range</i>	10-52	11-54	10-48	10-58	11-52
N° not reported	6	10	18	12	23
Median yrs since first injection					
<i>Median yrs since first injection</i>	20	20	21	23	23
Range					
<i>Range</i>	<1-41	<1-41	<1-49	<1-47	<1-46
Years since first injection					
<3 years	17 (4)	19 (4)	12 (3)	8 (2)	18 (4)
3+ years	399 (92)	429 (93)	393 (93)	360 (95)	396 (91)
Not reported	20 (5)	11 (2)	18 (4)	12 (3)	23 (5)
Imprisonment last year (%)					
No	359 (82)	373 (81)	331 (78)	303 (80)	335 (77)
Yes	50 (11)	61 (13)	60 (14)	50 (13)	75 (17)
Not reported	27 (6)	25 (5)	32 (8)	27 (7)	27 (6)
N° in prison					
<i>N° in prison</i>	N=50	N=61	N=60	N=50	N=75
Injected in prison	19 (38)	15 (25)	17 (28)	15 (30)	19 (25)

Table 8.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year

Victoria	2014	2015	2016	2017	2018
N° surveyed	N=436	N=459	N=423	N=380	N=437
Drug last injected (%)					
Cocaine	6 (1)	5 (1)	2 (<1)	2 (1)	3 (1)
Methamphetamine	98 (22)	142 (31)	134 (32)	92 (24)	158 (36)
Heroin	240 (55)	237 (52)	222 (52)	234 (62)	223 (51)
Pharm. opioids	18 (4)	16 (3)	12 (3)	11 (3)	4 (1)
Methadone	10 (2)	9 (2)	5 (1)	4 (1)	3 (1)
Buprenorphine	14 (3)	16 (3)	11 (3)	7 (2)	7 (2)
Buprenorphine/naloxone	14 (3)	7 (2)	7 (2)	4 (1)	8 (2)
PIEDs	0 (0)	4 (1)	1 (<1)	1 (<1)	2 (<1)
More than one	27 (6)	19 (4)	24 (6)	19 (5)	22 (5)
Other	6 (1)	4 (1)	5 (1)	1 (<1)	5 (1)
Not reported	3 (<1)	0 (0)	0 (0)	5 (1)	2 (<1)
Ever injected opioids					
No	-	-	43 (10)	24 (6)	40 (9)
Yes	-	-	379 (90)	353 (93)	393 (90)
Not reported	-	-	1 (<1)	3 (1)	4 (1)
Frequency of injection last month (%)					
Not last month	38 (9)	35 (8)	31 (7)	25 (7)	36 (8)
Less than weekly	68 (16)	74 (16)	58 (14)	70 (18)	66 (15)
Weekly not daily	122 (28)	129 (28)	99 (23)	79 (21)	104 (24)
Daily or more	204 (47)	216 (47)	226 (53)	202 (53)	224 (51)
Not reported	4 (1)	5 (1)	9 (2)	4 (1)	7 (2)
Present when someone injected for the first time in the last 12 months (%)					
No	349 (80)	379 (83)	339 (80)	309 (81)	356 (81)
Yes	71 (16)	66 (14)	71 (17)	56 (15)	67 (15)
Not reported	16 (4)	14 (3)	13 (3)	15 (4)	14 (3)
Overdosed in last 12 months					
No	339 (78)	353 (77)	298 (70)	272 (72)	297 (68)
Yes	82 (19)	97 (21)	112 (27)	91 (24)	125 (29)
Not reported	15 (3)	9 (2)	13 (3)	17 (4)	15 (3)

Table 8.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year

Victoria	2014	2015	2016	2017	2018
N° injected last month	N=394	N=419	N=383	N=351	N=394
Places injected last month (%)					
All private	177 (45)	183 (44)	148 (39)	128 (36)	152 (39)
Any public	215 (55)	233 (56)	233 (61)	219 (62)	239 (61)
Not reported	2 (<1)	3 (1)	2 (1)	4 (1)	3 (1)
Use of new and sterile needles and syringes last month (%)					
All injections	278 (71)	283 (68)	259 (68)	267 (76)	301 (76)
Most of the time	92 (23)	108 (26)	102 (27)	70 (20)	69 (18)
Half of the time	10 (3)	15 (4)	9 (2)	3 (1)	6 (2)
Some of the time	3 (1)	9 (2)	7 (2)	1 (<1)	6 (2)
Not last month	0 (0)	2 (<1)	3 (1)	0 (0)	5 (1)
Not reported	11 (3)	2 (<1)	3 (1)	10 (3)	7 (2)
Re-used someone else's used needle & syringe last month (%)					
None	318 (81)	333 (79)	302 (79)	288 (82)	321 (81)
Once	23 (6)	23 (5)	27 (7)	18 (5)	22 (6)
Twice	15 (4)	27 (6)	20 (5)	18 (5)	14 (4)
3-5 times	17 (4)	21 (5)	17 (4)	11 (3)	16 (4)
>5 times	12 (3)	12 (3)	15 (4)	8 (2)	18 (5)
Not reported	9 (2)	3 (1)	2 (1)	8 (2)	3 (1)
Number of people needle & syringe was re-used after last month (%)					
None	318 (81)	333 (79)	302 (79)	288 (82)	321 (81)
One	31 (8)	42 (10)	35 (9)	22 (6)	26 (7)
Two	6 (2)	9 (2)	7 (2)	7 (2)	5 (1)
Three to five	1 (<1)	5 (1)	6 (2)	1 (<1)	6 (2)
More than five	2 (<1)	2 (<1)	2 (1)	2 (1)	6 (2)
Don't know	11 (3)	15 (4)	17 (4)	15 (4)	17 (4)
Not reported	25 (6)	13 (3)	14 (4)	16 (5)	13 (3)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	25 (6)	30 (7)	36 (9)	11 (3)	26 (7)
Casual sex partner	0 (0)	5 (1)	2 (1)	6 (2)	6 (2)
Close friend	17 (4)	28 (7)	20 (5)	14 (4)	18 (5)
Acquaintance	7 (2)	12 (3)	7 (2)	10 (3)	4 (1)
Other	5 (1)	5 (1)	6 (2)	11 (3)	6 (2)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	131 (33)	145 (35)	133 (35)	104 (30)	132 (34)
Water	86 (22)	99 (24)	85 (22)	69 (20)	77 (20)
Filter	69 (18)	78 (19)	56 (15)	43 (12)	42 (11)
Drug mix	49 (12)	64 (15)	46 (12)	34 (10)	46 (12)
None	240 (61)	247 (59)	219 (57)	220 (63)	233 (59)
Injected by someone after that person injected themselves or others last month (%)					
No	326 (83)	345 (82)	304 (79)	292 (83)	303 (77)
Yes	53 (13)	67 (16)	75 (20)	54 (15)	84 (21)
Not reported	15 (4)	7 (2)	4 (1)	5 (1)	7 (2)
Source of needle acquisition					
Needle Syringe Program	368 (93)	384 (92)	353 (92)	323 (92)	358 (91)
Chemist/Pharmacy	87 (22)	93 (22)	86 (22)	63 (18)	61 (15)
Personal sources	55 (14)	80 (19)	46 (12)	51 (15)	50 (13)
Dispensing/Vending Machine	1 (<1)	3 (1)	47 (12)	53 (15)	90 (23)
Other sources	4 (1)	16 (4)	6 (2)	11 (3)	21 (5)

Table 8.1.4 Number (percentage) of respondents by treatment for drug use and survey year

Victoria	2014	2015	2016	2017	2018
N° surveyed	N=436	N=459	N=423	N=380	N=437
Ever any treatment/therapy for drug use (%)					
No	36 (8)	67 (15)	45 (11)	41 (11)	48 (11)
Yes	396 (91)	388 (85)	367 (87)	335 (88)	385 (88)
Not reported	4 (1)	4 (1)	11 (3)	4 (1)	4 (1)
History of methadone maintenance treatment (%)					
Currently	152 (35)	137 (30)	128 (30)	123 (32)	139 (32)
Previously	153 (35)	151 (33)	153 (36)	156 (41)	155 (35)
Never	126 (30)	162 (35)	122 (29)	97 (26)	134 (31)
Not reported	5 (1)	9 (2)	20 (5)	4 (1)	9 (2)
History of buprenorphine (Subutex®) treatment (%)					
Currently	48 (11)	40 (9)	45 (11)	31 (8)	33 (8)
Previously	196 (45)	188 (41)	166 (39)	161 (42)	170 (39)
Never	183 (42)	221 (48)	197 (47)	181 (48)	229 (52)
Not reported	9 (2)	10 (2)	15 (4)	7 (2)	5 (1)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	50 (11)	48 (10)	55 (13)	51 (13)	57 (13)
Previously	167 (38)	156 (34)	150 (35)	150 (39)	159 (36)
Never	208 (48)	246 (54)	209 (49)	175 (46)	216 (49)
Not reported	11 (3)	9 (2)	9 (2)	4 (1)	5 (1)

Table 8.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year

Victoria	2014	2015	2016	2017	2018
N° surveyed	N=436	N=459	N=423	N=380	N=437
Previous HIV test (%)					
Yes, ever	386 (89)	397 (86)	356 (84)	331 (87)	364 (83)
Yes, last year	244 (56)	243 (53)	222 (52)	223 (59)	226 (52)
>1 year ago	142 (33)	154 (34)	134 (32)	108 (28)	138 (32)
Never tested	33 (8)	48 (10)	51 (12)	33 (9)	57 (13)
Not reported	17 (4)	14 (3)	16 (4)	16 (4)	16 (4)
Previous HCV test (%)					
Yes, ever	395 (91)	429 (93)	362 (86)	317 (83)	363 (83)
Yes, last year	263 (60)	278 (61)	252 (60)	234 (62)	243 (56)
>1 year ago	132 (30)	151 (33)	110 (26)	83 (22)	120 (27)
Never tested	19 (4)	17 (4)	18 (4)	19 (5)	30 (7)
Not reported	22 (5)	13 (3)	43 (10)	44 (12)	44 (10)
Lifetime treatment for HCV (%)#					
N° self-reported HCV diagnosis	N=177	N=194	N=166	N=149	N=150
Antiviral treatment	11 (6)	13 (7)	35 (21)	70 (50)	86 (57)
No antiviral treatment	166 (94)	170 (88)	130 (78)	78 (52)	63 (42)
Not reported	0 (0)	11 (6)	1 (1)	1 (1)	1 (1)
Treatment for HCV in past 12 months (%)#*					
N° self-reported HCV diagnosis	N=172	N=191	N=161	N=140	N=121
Antiviral treatment	0 (0)	4 (2)	25 (16)	56 (40)	53 (44)
No antiviral treatment	172 (100)	176 (92)	135 (84)	83 (59)	67 (55)
Not reported	0 (0)	11 (6)	1 (1)	1 (1)	1 (1)

among people who tested HCV antibody positive and did not report spontaneous clearance

* excludes people who reported treatment induced clearance more than 12 months previously

Table 8.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year

Victoria	2014	2015	2016	2017	2018
N° surveyed	N=436	N=459	N=423	N=380	N=437
Sex with a regular partner last month (%)					
No	240 (55)	260 (57)	223 (53)	217 (57)	253 (58)
Yes	175 (40)	180 (39)	186 (44)	146 (38)	173 (40)
Not reported	21 (5)	19 (4)	14 (3)	17 (4)	11 (3)
Condom used with regular partner last month (%)					
N° surveyed	N=175	N=180	N=186	N=146	N=173
Never	129 (74)	134 (74)	136 (73)	109 (75)	126 (73)
Sometimes	24 (14)	22 (12)	20 (11)	17 (12)	23 (13)
Every time	12 (7)	20 (11)	17 (9)	15 (10)	10 (6)
Not reported	10 (6)	4 (2)	13 (7)	5 (3)	14 (8)
Sex with other partner(s) last month (%)					
No	350 (80)	377 (82)	341 (81)	301 (79)	355 (81)
Yes	60 (14)	64 (14)	60 (14)	52 (14)	58 (13)
Not reported	26 (6)	18 (4)	22 (5)	27 (7)	24 (5)
Condom used with other partner(s) last month (%)					
N° surveyed	N=60	N=64	N=60	N=52	N=58
Never	20 (33)	22 (34)	22 (37)	15 (29)	22 (38)
Sometimes	11 (18)	23 (36)	20 (33)	23 (44)	18 (31)
Every time	21 (35)	16 (25)	18 (30)	10 (19)	15 (26)
Not reported	8 (13)	3 (5)	0 (0)	4 (8)	3 (5)
Sex work last month (%)					
No	372 (85)	416 (91)	370 (87)	335 (88)	378 (87)
Yes	28 (6)	25 (5)	26 (6)	18 (5)	29 (7)
Not reported	36 (8)	18 (4)	27 (6)	27 (7)	30 (7)
Condom used at last sex work (%)					
Yes	16 (57)	18 (72)	16 (62)	14 (78)	22 (76)

HIV antibody prevalence

Table 8.2.1 HIV antibody prevalence by gender and survey year

Victoria	Male		Female		Total	
Survey year	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014	277	4 (1.4)	143	3 (2.1)	421	7 (1.7)
2015	300	10 (3.3)	152	0 (0.0)	455	10 (2.2)
2016	266	6 (2.3)	149	2 (1.3)	419	8 (1.9)
2017	243	6 (2.5)	127	1 (0.8)	376	7 (1.9)
2018	289	8 (2.8)	145	1 (0.7)	436	9 (2.1)
X ² p trend		0.568		0.458		0.832

Table 8.2.2 HIV antibody prevalence by sexual identity, gender and survey year

Victoria	Male		Female		Total	
Sexual identity	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
Heterosexual	230	4 (1.7)	106	3 (2.8)	337	7 (2.1)
Bisexual	12	0 (0.0)	23	0 (0.0)	35	0 (0.0)
Homosexual	9	0 (0.0)	2	0 (0.0)	11	0 (0.0)
p value		1.000		1.000		1.000
2015						
Heterosexual	259	4 (1.5)	118	0 (0.0)	377	4 (1.1)
Bisexual	17	1 (5.9)	18	0 (0.0)	36	1 (2.8)
Homosexual	9	4 (44.4)	6	0 (0.0)	17	4 (23.5)
p value		<0.001		--		<0.001
2016						
Heterosexual	232	4 (1.7)	94	1 (1.1)	327	5 (1.5)
Bisexual	10	0 (0.0)	34	0 (0.0)	45	0 (0.0)
Homosexual	6	2 (33.3)	6	0 (0.0)	13	2 (15.4)
p value		0.010		1.000		0.029
2017						
Heterosexual	206	3 (1.5)	84	0 (0.0)	290	3 (1.0)
Bisexual	9	0 (0.0)	23	0 (0.0)	34	0 (0.0)
Homosexual	4	2 (50.0)	9	0 (0.0)	16	2 (12.5)
p value		0.004		--		0.037
2018						
Heterosexual	240	5 (2.1)	101	1 (1.0)	341	6 (1.8)
Bisexual	11	1 (9.1)	22	0 (0.0)	33	1 (3.0)
Homosexual	11	2 (18.2)	6	0 (0.0)	18	2 (11.1)
p value		0.022		1.000		0.042

Table 8.2.3 HIV antibody prevalence by age group, gender and survey year

Victoria Age group	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
<25 years	5	0 (0.0)	5	0 (0.0)	11	0 (0.0)
25-34 years	70	3 (4.3)	51	0 (0.0)	121	3 (2.5)
35-44 years	124	0 (0.0)	51	2 (3.9)	175	2 (1.1)
45+ years	76	1 (1.3)	36	1 (2.8)	112	2 (1.8)
p value		0.098		0.531		0.703
2015						
<25 years	4	0 (0.0)	4	0 (0.0)	8	0 (0.0)
25-34 years	60	6 (10.0)	47	0 (0.0)	108	6 (5.6)
35-44 years	125	2 (1.6)	55	0 (0.0)	181	2 (1.1)
45+ years	110	2 (1.8)	46	0 (0.0)	157	2 (1.3)
p value		0.036		--		0.059
2016						
<25 years	4	1 (25.0)	8	0 (0.0)	13	1 (7.7)
25-34 years	49	3 (6.1)	37	1 (2.7)	86	4 (4.7)
35-44 years	114	0 (0.0)	62	0 (0.0)	177	0 (0.0)
45+ years	99	2 (2.0)	42	1 (2.4)	143	3 (2.1)
p value		0.005		0.384		0.008
2017						
<25 years	3	0 (0.0)	4	0 (0.0)	7	0 (0.0)
25-34 years	39	4 (10.3)	22	0 (0.0)	65	4 (6.2)
35-44 years	107	2 (1.9)	51	0 (0.0)	158	2 (1.3)
45+ years	91	0 (0.0)	50	1 (2.0)	143	1 (0.7)
p value		0.014		0.598		0.081
2018						
<25 years	2	0 (0.0)	6	0 (0.0)	8	0 (0.0)
25-34 years	43	4 (9.3)	30	0 (0.0)	73	4 (5.5)
35-44 years	117	0 (0.0)	57	0 (0.0)	175	0 (0.0)
45+ years	123	4 (3.3)	51	1 (2.0)	175	5 (2.9)
p value		0.013		0.604		0.024

Table 8.2.4 HIV antibody prevalence by last drug injected, gender and survey year

Victoria Last drug injected	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
Heroin	157	4 (2.6)	73	1 (1.4)	230	5 (2.1)
Methamphetamine	55	0 (0.0)	39	1 (2.6)	95	1 (1.1)
Other opioids	40	0 (0.0)	16	0 (0.0)	56	0 (0.0)
Other drugs	23	0 (0.0)	14	1 (7.1)	37	1 (2.7)
p value		0.627		0.344		0.628
2015						
Heroin	155	5 (3.2)	79	0 (0.0)	236	5 (2.1)
Methamphetamine	95	5 (5.3)	44	0 (0.0)	140	5 (3.6)
Other opioids	31	0 (0.0)	17	0 (0.0)	48	0 (0.0)
Other drugs	19	0 (0.0)	12	0 (0.0)	31	0 (0.0)
p value		0.554		--		0.544
2016						
Heroin	150	4 (2.7)	70	2 (2.9)	221	6 (2.7)
Methamphetamine	76	1 (1.3)	55	0 (0.0)	131	1 (0.8)
Other opioids	20	0 (0.0)	14	0 (0.0)	35	0 (0.0)
Other drugs	20	1 (5.0)	10	0 (0.0)	32	1 (3.1)
p value		0.560		0.651		0.434
2017						
Heroin	151	3 (2.0)	79	0 (0.0)	232	3 (1.3)
Methamphetamine	57	3 (5.3)	33	0 (0.0)	92	3 (3.3)
Other opioids	15	0 (0.0)	7	0 (0.0)	24	0 (0.0)
Other drugs	20	0 (0.0)	8	1 (12.5)	28	1 (3.6)
p value		0.525		0.118		0.426
2018						
Heroin	145	5 (3.5)	77	1 (1.3)	222	6 (2.7)
Methamphetamine	109	3 (2.8)	48	0 (0.0)	158	3 (1.9)
Other opioids	12	0 (0.0)	9	0 (0.0)	22	0 (0.0)
Other drugs	23	0 (0.0)	9	0 (0.0)	32	0 (0.0)
p value		1.000		1.000		0.922

Table 8.2.5 HIV antibody prevalence by years of injection, gender and survey year

Victoria Years of injection	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
<3 years	8	0 (0.0)	9	0 (0.0)	17	0 (0.0)
3 to 10 years	24	2 (8.3)	22	0 (0.0)	47	2 (4.3)
11+ years	231	2 (0.9)	106	3 (2.8)	337	5 (1.5)
p value		0.074		1.000		0.416
2015						
<3 years	12	0 (0.0)	7	0 (0.0)	19	0 (0.0)
3 to 10 years	32	4 (12.5)	23	0 (0.0)	57	4 (7.0)
11+ years	248	6 (2.4)	119	0 (0.0)	368	6 (1.6)
p value		0.033		--		0.051
2016						
<3 years	5	0 (0.0)	7	0 (0.0)	12	0 (0.0)
3 to 10 years	30	2 (6.7)	26	1 (3.9)	57	3 (5.3)
11+ years	220	4 (1.8)	110	1 (0.9)	333	5 (1.5)
p value		0.250		0.410		0.150
2017						
<3 years	3	0 (0.0)	3	0 (0.0)	8	0 (0.0)
3 to 10 years	22	1 (4.6)	17	0 (0.0)	39	1 (2.6)
11+ years	218	5 (2.3)	107	1 (0.9)	329	6 (1.8)
p value		0.482		1.000		0.610
2018						
<3 years	12	0 (0.0)	6	0 (0.0)	18	0 (0.0)
3 to 10 years	24	2 (8.3)	24	0 (0.0)	48	2 (4.2)
11+ years	253	6 (2.4)	115	1 (0.9)	370	7 (1.9)
p value		0.171		1.000		0.507

Table 8.2.6 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

Victoria Receptively shared syringe last month	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
No receptive sharing	206	2 (1.0)	98	2 (2.0)	305	4 (1.3)
Receptive sharing	37	2 (5.4)	28	1 (3.6)	65	3 (4.6)
p value		0.111		0.533		0.107
2015						
No receptive sharing	212	10 (4.7)	114	0 (0.0)	329	10 (3.0)
Receptive sharing	59	0 (0.0)	24	0 (0.0)	83	0 (0.0)
p value		0.125		--		0.223
2016						
No receptive sharing	191	3 (1.6)	103	2 (1.9)	298	5 (1.7)
Receptive sharing	48	3 (6.3)	31	0 (0.0)	79	3 (3.8)
p value		0.097		1.000		0.372
2017						
No receptive sharing	181	3 (1.7)	97	0 (0.0)	284	3 (1.1)
Receptive sharing	41	2 (4.9)	14	1 (7.1)	55	3 (5.5)
p value		0.230		0.126		0.056
2018						
No receptive sharing	210	7 (3.3)	110	1 (0.9)	320	8 (2.5)
Receptive sharing	48	1 (2.1)	21	0 (0.0)	70	1 (1.4)
p value		1.000		1.000		1.000

Table 8.2.7 HIV antibody prevalence by frequency of drug injection last month, gender and survey year

Victoria	Male		Female		Total	
Frequency of injection	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
Less than daily	119	0 (0.0)	63	0 (0.0)	183	0 (0.0)
Daily or more	129	4 (3.1)	67	3 (4.5)	196	7 (3.6)
Not last month	26	0 (0.0)	12	0 (0.0)	38	0 (0.0)
p value		0.199		0.313		0.031
2015						
Less than daily	126	6 (4.8)	72	0 (0.0)	200	6 (3.0)
Daily or more	146	4 (2.7)	68	0 (0.0)	215	4 (1.9)
Not last month	25	0 (0.0)	10	0 (0.0)	35	0 (0.0)
p value		0.536		--		0.605
2016						
Less than daily	90	1 (1.1)	64	1 (1.6)	156	2 (1.3)
Daily or more	151	5 (3.3)	70	1 (1.4)	223	6 (2.7)
Not last month	18	0 (0.0)	13	0 (0.0)	31	0 (0.0)
p value		0.622		1.000		0.724
2017						
Less than daily	95	1 (1.1)	51	0 (0.0)	148	1 (0.7)
Daily or more	132	5 (3.8)	63	1 (1.6)	199	6 (3.0)
Not last month	15	0 (0.0)	10	0 (0.0)	25	0 (0.0)
p value		0.596		1.000		0.353
2018						
Less than daily	117	3 (2.6)	51	0 (0.0)	169	3 (1.8)
Daily or more	143	5 (3.5)	81	1 (1.2)	224	6 (2.7)
Not last month	24	0 (0.0)	11	0 (0.0)	36	0 (0.0)
p value		0.870		1.000		0.882

Table 8.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year

Victoria	Male		Female		Total	
Imprisonment last year	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
No imprisonment	220	4 (1.8)	129	3 (2.3)	350	7 (2.0)
Imprisonment	38	0 (0.0)	8	0 (0.0)	46	0 (0.0)
p value		1.000		1.000		1.000
2015						
No imprisonment	233	9 (3.9)	135	0 (0.0)	371	9 (2.4)
Imprisonment	48	0 (0.0)	11	0 (0.0)	59	0 (0.0)
p value		0.366		--		0.618
2016						
No imprisonment	201	6 (3.0)	124	0 (0.0)	328	6 (1.8)
Imprisonment	42	0 (0.0)	16	1 (6.3)	59	1 (1.7)
p value		0.594		0.114		1.000
2017						
No imprisonment	189	5 (2.7)	105	1 (1.0)	300	6 (2.0)
Imprisonment	40	0 (0.0)	10	0 (0.0)	50	0 (0.0)
p value		0.590		1.000		0.600
2018						
No imprisonment	218	7 (3.2)	115	1 (0.9)	334	8 (2.4)
Imprisonment	52	1 (1.9)	23	0 (0.0)	75	1 (1.3)
p value		1.000		1.000		1.000

Table 8.2.9 HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year

Victoria	Male		Female		Total	
Condom use at last sex	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
No condom use	67	1 (1.5)	57	1 (1.8)	124	2 (1.6)
Condom use	22	0 (0.0)	13	0 (0.0)	35	0 (0.0)
p value		1.000		1.000		1.000
2015						
No condom use	75	1 (1.3)	57	0 (0.0)	133	1 (0.8)
Condom use	25	1 (4.0)	15	0 (0.0)	41	1 (2.4)
p value		0.439		--		0.417
2016						
No condom use	74	2 (2.7)	59	1 (1.7)	134	3 (2.2)
Condom use	24	0 (0.0)	13	0 (0.0)	37	0 (0.0)
p value		1.000		1.000		1.000
2017						
No condom use	62	1 (1.6)	45	0 (0.0)	109	1 (0.9)
Condom use	22	1 (4.6)	9	1 (11.1)	32	2 (6.3)
p value		0.458		0.167		0.129
2018						
No condom use	73	2 (2.7)	53	0 (0.0)	126	2 (1.6)
Condom use	25	1 (4.0)	8	0 (0.0)	33	1 (3.0)
p value		1.000		--		0.505

Table 8.2.10 HIV antibody prevalence by sex work last month, gender and survey year

Victoria	Male		Female		Total	
Sex work last month	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
No sex work	241	3 (1.2)	119	3 (2.2)	360	6 (1.7)
Sex work	12	0 (0.0)	15	0 (0.0)	28	0 (0.0)
p value		1.000		1.000		1.000
2015						
No sex work	278	8 (2.9)	133	0 (0.0)	412	8 (1.9)
Sex work	6	2 (33.3)	17	0 (0.0)	25	2 (8.0)
p value		0.016		--		0.107
2016						
No sex work	242	5 (2.1)	122	0 (0.0)	366	5 (1.4)
Sex work	8	0 (0.0)	17	1 (5.9)	26	1 (3.9)
p value		1.000		0.122		0.339
2017						
No sex work	223	5 (2.2)	103	1 (1.0)	332	6 (1.8)
Sex work	4	0 (0.0)	14	0 (0.0)	18	0 (0.0)
p value		1.000		1.000		1.000
2018						
No sex work	257	8 (3.1)	118	1 (0.9)	377	9 (2.4)
Sex work	13	0 (0.0)	16	0 (0.0)	29	0 (0.0)
p value		1.000		1.000		1.000

Table 8.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Victoria	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
Non Indigenous	245	2 (0.8)	120	2 (1.7)	366	4 (1.1)
Indigenous	30	2 (6.7)	20	1 (5.0)	50	3 (6.0)
p value		0.060		0.373		0.040
2015						
Non Indigenous	261	6 (2.3)	134	0 (0.0)	398	6 (1.5)
Indigenous	34	4 (11.8)	18	0 (0.0)	52	4 (7.7)
p value		0.019		--		0.020
2016						
Non Indigenous	213	2 (0.9)	121	1 (0.8)	337	3 (0.9)
Indigenous	46	4 (8.7)	23	0 (0.0)	70	4 (5.7)
p value		0.010		1.000		0.019
2017						
Non Indigenous	207	4 (1.9)	104	0 (0.0)	316	4 (1.3)
Indigenous	34	2 (5.9)	20	1 (5.0)	55	3 (5.5)
p value		0.201		0.161		0.070
2018						
Non Indigenous	240	4 (1.7)	117	0 (0.0)	358	4 (1.1)
Indigenous	43	4 (9.3)	27	1 (3.7)	71	5 (7.0)
p value		0.021		0.187		0.008

Table 8.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and survey year

Victoria	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
English speaking	235	3 (1.3)	129	2 (1.6)	364	5 (1.4)
Non-English speaking	42	1 (2.4)	13	1 (7.7)	56	2 (3.6)
p value		0.484		0.252		0.237
2015						
English speaking	266	9 (3.4)	141	0 (0.0)	410	9 (2.2)
Non-English speaking	31	1 (3.2)	11	0 (0.0)	42	1 (2.4)
p value		1.000		--		1.000
2016						
English speaking	233	6 (2.6)	139	1 (0.7)	376	7 (1.9)
Non-English speaking	30	0 (0.0)	8	0 (0.0)	38	0 (0.0)
p value		1.000		1.000		1.000
2017						
English speaking	203	5 (2.5)	124	1 (0.8)	333	6 (1.8)
Non-English speaking	40	1 (2.5)	3	0 (0.0)	43	1 (2.3)
p value		1.000		1.000		0.576
2018						
English speaking	254	8 (3.2)	136	1 (0.7)	392	9 (2.3)
Non-English speaking	34	0 (0.0)	9	0 (0.0)	43	0 (0.0)
p value		0.602		1.000		0.609

Table 8.2.13 HIV antibody prevalence by region/country of birth, gender and survey year

Victoria		Male		Female		Total	
Region/country of birth	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2014							
Australia	220	3 (1.4)	127	2 (1.6)	348	5 (1.4)	
Other Oceania	9	0 (0.0)	1	0 (0.0)	10	0 (0.0)	
Asia	17	1 (5.9)	2	1 (50.0)	19	2 (10.5)	
UK & Ireland	14	0 (0.0)	6	0 (0.0)	20	0 (0.0)	
Other	16	0 (0.0)	7	0 (0.0)	26	0 (0.0)	
p value		0.599		0.083		0.121	
2015							
Australia	243	9 (3.7)	128	0 (0.0)	373	9 (2.4)	
Other Oceania	14	0 (0.0)	3	0 (0.0)	17	0 (0.0)	
Asia	13	1 (7.7)	3	0 (0.0)	16	1 (6.3)	
UK & Ireland	13	0 (0.0)	13	0 (0.0)	27	0 (0.0)	
Other	15	0 (0.0)	5	0 (0.0)	20	0 (0.0)	
p value		0.719		--		0.613	
2016							
Australia	225	6 (2.7)	134	1 (0.8)	362	7 (1.9)	
Other Oceania	5	0 (0.0)	1	0 (0.0)	7	0 (0.0)	
Asia	6	0 (0.0)	1	0 (0.0)	7	0 (0.0)	
UK & Ireland	11	0 (0.0)	4	0 (0.0)	15	0 (0.0)	
Other	13	0 (0.0)	6	0 (0.0)	19	0 (0.0)	
p value		1.000		1.000		1.000	
2017							
Australia	209	5 (2.4)	116	1 (0.9)	329	6 (1.8)	
Other Oceania	5	0 (0.0)	3	0 (0.0)	9	0 (0.0)	
Asia	4	1 (25.0)	1	0 (0.0)	5	1 (20.0)	
UK & Ireland	8	0 (0.0)	5	0 (0.0)	13	0 (0.0)	
Other	17	0 (0.0)	1	0 (0.0)	19	0 (0.0)	
p value		0.246		1.000		0.250	
2018							
Australia	243	8 (3.3)	127	1 (0.8)	372	9 (2.4)	
Other Oceania	9	0 (0.0)	3	0 (0.0)	12	0 (0.0)	
Asia	6	0 (0.0)	0	0 (0.0)	6	0 (0.0)	
UK & Ireland	8	0 (0.0)	12	0 (0.0)	20	0 (0.0)	
Other	21	0 (0.0)	3	0 (0.0)	24	0 (0.0)	
p value		1.000		1.000		1.000	

HCV antibody prevalence

Table 8.3.1 HCV antibody prevalence by gender and survey year

Victoria	Male		Female		Total	
Survey year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014	267	183 (69)	138	90 (65)	406	273 (67)
2015	278	207 (74)	143	98 (69)	424	306 (72)
2016	243	167 (69)	130	85 (65)	377	254 (67)
2017	230	160 (70)	118	85 (72)	353	246 (70)
2018	284	161 (57)	145	81 (56)	431	243 (56)
X ² p trend		0.137		0.534		0.113

Table 8.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Victoria	Male		Female		Total	
Sexual identity	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
Heterosexual	221	149 (67)	102	64 (63)	324	213 (66)
Bisexual	12	9 (75)	22	14 (64)	34	23 (68)
Homosexual	9	6 (67)	2	2 (100)	11	8 (73)
p value		0.859		0.750		0.873
2015						
Heterosexual	245	182 (74)	110	75 (68)	355	257 (72)
Bisexual	12	8 (67)	17	11 (65)	30	19 (63)
Homosexual	7	7 (100)	6	5 (83)	15	13 (87)
p value		0.247		0.695		0.281
2016						
Heterosexual	214	153 (72)	81	51 (63)	296	204 (69)
Bisexual	9	5 (56)	32	21 (66)	42	27 (64)
Homosexual	5	0 (0)	6	4 (67)	12	4 (33)
p value		0.001		0.944		0.038
2017						
Heterosexual	193	135 (70)	76	52 (68)	269	187 (70)
Bisexual	9	6 (67)	23	19 (83)	34	25 (74)
Homosexual	4	1 (25)	9	6 (67)	16	8 (50)
p value		0.185		0.392		0.217
2018						
Heterosexual	236	136 (58)	101	58 (57)	337	194 (58)
Bisexual	10	4 (40)	22	12 (55)	32	16 (50)
Homosexual	11	7 (64)	6	4 (67)	18	11 (61)
p value		0.471		0.889		0.668

Table 8.3.3 HCV antibody prevalence by age group, gender and survey year

Victoria Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
<25 years	5	2 (40)	5	3 (60)	11	5 (45)
25-34 years	69	42 (61)	48	26 (54)	117	68 (58)
35-44 years	120	80 (67)	49	38 (78)	169	118 (70)
45+ years	71	58 (82)	36	23 (64)	107	81 (76)
p value		0.015		0.093		0.013
2015						
<25 years	4	0 (0)	4	0 (0)	8	0 (0)
25-34 years	54	28 (52)	44	30 (68)	99	58 (59)
35-44 years	117	93 (79)	50	34 (68)	168	127 (76)
45+ years	102	85 (83)	45	34 (76)	148	120 (81)
p value		<0.001		0.030		<0.001
2016						
<25 years	4	1 (25)	8	5 (63)	13	7 (54)
25-34 years	44	26 (59)	31	19 (61)	75	45 (60)
35-44 years	104	78 (75)	55	41 (75)	160	119 (74)
45+ years	91	62 (68)	36	20 (56)	129	83 (64)
p value		0.058		0.258		0.070
2017						
<25 years	3	0 (0)	4	3 (75)	7	3 (43)
25-34 years	36	22 (61)	20	13 (65)	59	35 (59)
35-44 years	101	70 (69)	47	34 (72)	148	104 (70)
45+ years	87	67 (77)	47	35 (74)	136	103 (76)
p value		0.019		0.899		0.046
2018						
<25 years	2	0 (0)	6	2 (33)	8	2 (25)
25-34 years	43	22 (51)	30	17 (57)	73	39 (53)
35-44 years	115	69 (60)	57	31 (54)	173	101 (58)
45+ years	120	68 (57)	51	31 (61)	172	99 (58)
p value		0.300		0.647		0.294

Table 8.3.4 HCV antibody prevalence by years since first injection, gender and survey year

Victoria Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
<3 years	8	1 (13)	9	3 (33)	17	4 (24)
3 to 10 years	24	16 (67)	22	11 (50)	47	27 (57)
11+ years	221	159 (72)	101	71 (70)	322	230 (71)
p value		0.002		0.024		<0.001
2015						
<3 years	11	2 (18)	6	1 (17)	17	3 (18)
3 to 10 years	31	16 (52)	21	11 (52)	54	27 (50)
11+ years	230	183 (80)	113	84 (74)	344	268 (78)
p value		<0.001		0.003		<0.001
2016						
<3 years	5	2 (40)	7	2 (29)	12	4 (33)
3 to 10 years	28	15 (54)	23	15 (65)	52	31 (60)
11+ years	200	142 (71)	96	65 (68)	299	208 (70)
p value		0.050		0.139		0.017
2017						
<3 years	3	0 (0)	3	1 (33)	8	1 (13)
3 to 10 years	20	9 (45)	17	12 (71)	37	21 (57)
11+ years	201	147 (73)	93	69 (74)	297	217 (73)
p value		0.001		0.264		<0.001
2018						
<3 years	12	2 (17)	6	0 (0)	18	2 (11)
3 to 10 years	24	13 (54)	24	13 (54)	48	26 (54)
11+ years	233	137 (59)	107	64 (60)	342	202 (59)
p value		0.014		0.013		<0.001

Table 8.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

Victoria Receptively shared syringe last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
No receptive sharing	13	3 (23)	273	182 (67)	296	192 (65)
Receptive sharing	3	0 (0)	56	49 (88)	63	52 (83)
p value		1.000		0.002		0.006
2015						
No receptive sharing	9	1 (11)	291	210 (72)	305	216 (71)
Receptive sharing	5	2 (40)	75	61 (81)	81	64 (79)
p value		0.505		0.106		0.142
2016						
No receptive sharing	9	3 (33)	251	171 (68)	269	182 (68)
Receptive sharing	2	0 (0)	66	48 (73)	71	50 (70)
p value		1.000		0.472		0.656
2017						
No receptive sharing	6	0 (0)	256	177 (69)	265	180 (68)
Receptive sharing	1	0 (0)	50	39 (78)	53	40 (75)
p value		--		0.209		0.277
2018						
No receptive sharing	14	1 (7)	291	174 (60)	315	180 (57)
Receptive sharing	3	1 (33)	60	39 (65)	70	46 (66)
p value		0.331		0.452		0.188

Table 8.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year

Victoria Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
Heroin	9	2 (22)	204	150 (74)	223	159 (71)
Methamphetamine	4	1 (25)	84	47 (56)	91	50 (55)
Other opioids	1	0 (0)	48	35 (73)	51	37 (73)
Other drugs	3	1 (33)	33	25 (76)	38	27 (71)
p value		0.923		0.021		0.031
2015						
Heroin	4	1 (25)	220	171 (78)	227	175 (77)
Methamphetamine	9	2 (22)	109	73 (67)	122	79 (65)
Other opioids	0	0 (0)	42	29 (69)	42	29 (69)
Other drugs	4	0 (0)	23	18 (78)	28	18 (64)
p value		0.567		0.163		0.070
2016						
Heroin	2	1 (50)	189	138 (73)	195	142 (73)
Methamphetamine	7	1 (14)	105	66 (63)	119	73 (61)
Other opioids	2	2 (100)	27	16 (59)	30	19 (63)
Other drugs	1	0 (0)	23	13 (57)	25	14 (56)
p value		0.117		0.124		0.099
2017						
Heroin	3	1 (33)	206	158 (77)	217	165 (76)
Methamphetamine	4	0 (0)	83	49 (59)	88	50 (57)
Other opioids	0	0 (0)	21	15 (71)	21	15 (71)
Other drugs	1	0 (0)	23	15 (65)	24	15 (63)
p value		0.386		0.024		0.008
2018						
Heroin	6	1 (17)	200	134 (67)	216	141 (65)
Methamphetamine	8	1 (13)	142	68 (48)	156	72 (46)
Other opioids	0	0 (0)	19	8 (42)	20	8 (40)
Other drugs	4	0 (0)	22	15 (68)	30	17 (57)
p value		0.704		0.001		0.001

Table 8.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

Victoria	<3 years		3+ years		Total	
Frequency of injection last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
Less than daily	5	0 (0)	166	112 (67)	178	116 (65)
Daily or more	11	3 (27)	171	125 (73)	189	134 (71)
Not last month	1	1 (100)	30	19 (63)	35	21 (60)
p value		0.168		0.386		0.312
2015						
Less than daily	7	0 (0)	178	125 (70)	188	128 (68)
Daily or more	8	3 (38)	190	148 (78)	201	154 (77)
Not last month	2	0 (0)	26	18 (69)	30	19 (63)
p value		0.300		0.211		0.098
2016						
Less than daily	5	2 (40)	133	90 (68)	140	93 (66)
Daily or more	6	1 (17)	186	131 (70)	202	141 (70)
Not last month	1	1 (100)	25	12 (48)	27	14 (52)
p value		0.343		0.079		0.170
2017						
Less than daily	5	0 (0)	132	95 (72)	139	96 (69)
Daily or more	2	0 (0)	180	127 (71)	186	131 (70)
Not last month	1	1 (100)	21	15 (71)	25	18 (72)
p value		0.125		0.963		0.966
2018						
Less than daily	11	0 (0)	153	89 (58)	168	91 (54)
Daily or more	6	2 (33)	201	125 (62)	220	136 (62)
Not last month	1	0 (0)	31	12 (39)	36	12 (33)
p value		0.209		0.046		0.005

Table 8.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

Victoria	<3 years		3+ years		Total	
Imprisonment last year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
No imprisonment	13	2 (15)	307	206 (67)	336	218 (65)
Imprisonment	2	1 (50)	42	33 (79)	45	34 (76)
p value		0.371		0.133		0.155
2015						
No imprisonment	17	3 (18)	324	233 (72)	348	242 (70)
Imprisonment	0	0 (0)	50	42 (84)	52	44 (85)
p value		--		0.071		0.031
2016						
No imprisonment	11	3 (27)	279	176 (63)	298	185 (62)
Imprisonment	0	0 (0)	49	46 (94)	52	49 (94)
p value		--		<0.001		<0.001
2017						
No imprisonment	6	1 (17)	268	183 (68)	283	189 (67)
Imprisonment	2	0 (0)	44	37 (84)	46	37 (80)
p value		1.000		0.033		0.064
2018						
No imprisonment	16	2 (13)	304	165 (54)	332	173 (52)
Imprisonment	2	0 (0)	64	50 (78)	72	53 (74)
p value		1.000		<0.001		0.001

Table 8.3.9 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Victoria	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
Non Indigenous	236	165 (70)	115	70 (61)	352	235 (67)
Indigenous	29	16 (55)	20	17 (85)	49	33 (67)
p value		0.107		0.037		0.935
2015						
Non Indigenous	242	176 (73)	127	87 (70)	369	264 (72)
Indigenous	31	29 (94)	19	11 (58)	50	40 (80)
p value		0.012		0.284		0.209
2016						
Non Indigenous	197	134 (68)	107	68 (64)	307	204 (66)
Indigenous	39	27 (69)	19	13 (68)	59	40 (68)
p value		0.882		0.683		0.841
2017						
Non Indigenous	195	133 (68)	97	67 (69)	297	201 (68)
Indigenous	33	25 (76)	18	15 (83)	51	40 (78)
p value		0.384		0.269		0.124
2018						
Non Indigenous	237	131 (55)	117	64 (55)	355	195 (55)
Indigenous	42	27 (64)	27	17 (63)	70	45 (64)
p value		0.277		0.435		0.149

Table 8.3.10 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Victoria	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
English speaking	228	153 (67)	124	80 (65)	352	233 (66)
Non-English speaking	39	30 (77)	13	9 (69)	53	39 (74)
p value		0.222		0.735		0.285
2015						
English speaking	245	181 (74)	132	88 (67)	380	270 (71)
Non-English speaking	31	25 (81)	11	10 (91)	42	35 (83)
p value		0.415		0.096		0.092
2016						
English speaking	211	140 (66)	121	79 (65)	336	221 (66)
Non-English speaking	29	24 (83)	7	4 (57)	36	28 (78)
p value		0.075		0.696		0.146
2017						
English speaking	192	130 (68)	115	83 (72)	312	214 (69)
Non-English speaking	38	30 (79)	3	2 (67)	41	32 (78)
p value		0.169		1.000		0.215
2018						
English speaking	249	137 (55)	136	75 (55)	387	213 (55)
Non-English speaking	34	24 (71)	9	6 (67)	43	30 (70)
p value		0.086		0.731		0.065

Table 8.3.11 HCV antibody prevalence by region/country of birth, gender and survey year

Victoria	Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
Australia	211	142 (67)	122	78 (64)	334	220 (66)
Other Oceania	8	5 (63)	1	1 (100)	9	6 (67)
Asia	17	16 (94)	2	2 (100)	19	18 (95)
UK & Ireland	14	8 (57)	6	4 (67)	20	12 (60)
Other	16	12 (75)	7	5 (71)	23	17 (74)
p value		0.157		0.969		0.101
2015						
Australia	224	167 (75)	119	86 (72)	345	254 (74)
Other Oceania	13	10 (77)	3	3 (100)	16	13 (81)
Asia	13	10 (77)	3	1 (33)	16	11 (69)
UK & Ireland	12	9 (75)	13	5 (38)	26	14 (54)
Other	15	10 (67)	5	3 (60)	20	13 (65)
p value		0.967		0.038		0.202
2016						
Australia	204	138 (68)	118	77 (65)	325	216 (66)
Other Oceania	5	5 (100)	1	1 (100)	7	7 (100)
Asia	6	5 (83)	1	0 (0)	7	5 (71)
UK & Ireland	10	5 (50)	3	1 (33)	13	6 (46)
Other	13	9 (69)	4	3 (75)	17	12 (71)
p value		0.391		0.498		0.179
2017						
Australia	196	133 (68)	107	79 (74)	306	212 (69)
Other Oceania	5	3 (60)	3	2 (67)	9	6 (67)
Asia	4	3 (75)	1	0 (0)	5	3 (60)
UK & Ireland	8	7 (88)	5	3 (60)	13	10 (77)
Other	17	14 (82)	1	0 (0)	19	14 (74)
p value		0.587		0.180		0.936
2018						
Australia	238	132 (55)	127	72 (57)	367	205 (56)
Other Oceania	9	4 (44)	3	1 (33)	12	5 (42)
Asia	6	5 (83)	0	0 (0)	6	5 (83)
UK & Ireland	8	3 (38)	12	6 (50)	20	9 (45)
Other	21	16 (76)	3	2 (67)	24	18 (75)
p value		0.140		0.826		0.121

HCV RNA prevalence

Table 8.4.1 HCV RNA prevalence by gender and survey year *

Victoria	Male		Female		Total	
Survey year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015	195	124 (64)	101	50 (50)	298	176 (59)
2016	203	102 (50)	115	41 (36)	321	143 (45)
2017	137	51 (37)	70	22 (31)	210	74 (35)
2018	199	46 (23)	99	20 (20)	299	66 (22)
X ² p trend		<0.001		0.002		<0.001

* Weighted for gender and HCV antibody status

Table 8.4.2 HCV RNA prevalence by sexual identity, gender and survey year *

Victoria	Male		Female		Total	
Sexual identity	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
Heterosexual	170	107 (63)	74	38 (51)	244	145 (59)
Bisexual	9	5 (56)	15	7 (47)	25	13 (52)
Homosexual	4	2 (50)	4	3 (75)	9	5 (56)
p value		0.798		0.592		0.801
2016						
Heterosexual	174	93 (53)	73	24 (33)	248	117 (47)
Bisexual	8	2 (25)	26	12 (46)	34	14 (41)
Homosexual	3	0 (0)	4	1 (25)	8	1 (13)
p value		0.059		0.340		0.107
2017						
Heterosexual	115	43 (37)	43	15 (35)	158	58 (37)
Bisexual	6	3 (50)	12	3 (25)	19	7 (37)
Homosexual	1	1 (100)	4	0 (0)	6	1 (17)
p value		0.313		0.366		0.627
2018						
Heterosexual	163	41 (25)	71	16 (23)	234	57 (24)
Bisexual	8	0 (0)	15	3 (20)	23	3 (13)
Homosexual	6	2 (33)	4	0 (0)	10	2 (20)
p value		0.222		0.548		0.325

Table 8.4.3 HCV RNA prevalence by age group, gender and survey year *

Victoria Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
<25 years	2	0 (0)	3	2 (67)	5	2 (40)
25-34 years	37	19 (51)	29	12 (41)	67	33 (49)
35-44 years	82	55 (67)	38	20 (53)	120	75 (63)
45+ years	73	50 (68)	31	16 (52)	105	66 (63)
p value		0.101		0.748		0.205
2016						
<25 years	2	1 (50)	6	3 (50)	9	4 (44)
25-34 years	32	14 (44)	26	9 (35)	59	23 (39)
35-44 years	93	51 (55)	48	21 (44)	142	72 (51)
45+ years	75	36 (48)	34	8 (24)	110	44 (40)
p value		0.735		0.150		0.224
2017						
<25 years	2	0 (0)	3	1 (33)	5	1 (20)
25-34 years	24	8 (33)	10	3 (30)	36	11 (31)
35-44 years	68	25 (37)	32	11 (34)	100	36 (36)
45+ years	43	18 (42)	25	7 (28)	68	25 (37)
p value		0.668		0.988		0.866
2018						
<25 years	2	0 (0)	5	3 (60)	8	3 (38)
25-34 years	23	5 (22)	23	5 (22)	47	10 (21)
35-44 years	86	25 (29)	34	7 (21)	121	32 (26)
45+ years	84	15 (18)	35	4 (11)	120	20 (17)
p value		0.295		0.077		0.131

Table 8.4.4 HCV RNA prevalence by years since first injection, gender and survey year *

Victoria Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
<3 years	9	3 (33)	4	2 (50)	13	5 (38)
3 to 10 years	25	13 (52)	17	8 (47)	44	22 (50)
11+ years	157	106 (68)	78	40 (51)	235	146 (62)
p value		0.051		0.941		0.127
2016						
<3 years	5	2 (40)	4	2 (50)	9	4 (44)
3 to 10 years	14	6 (43)	17	8 (47)	33	14 (42)
11+ years	175	90 (51)	90	31 (34)	266	121 (45)
p value		0.727		0.673		0.897
2017						
<3 years	2	0 (0)	2	0 (0)	5	0 (0)
3 to 10 years	15	3 (20)	9	3 (33)	24	6 (25)
11+ years	115	47 (41)	56	19 (34)	173	66 (38)
p value		0.167		0.622		0.139
2018						
<3 years	5	0 (0)	4	1 (25)	9	1 (11)
3 to 10 years	11	3 (27)	13	6 (46)	24	9 (38)
11+ years	170	39 (23)	77	12 (16)	248	51 (21)
p value		0.442		0.092		0.243

Table 8.4.5 HCV RNA prevalence by re-use of someone else's used needle and syringe last month, gender and survey year *

Victoria	Male		Female		Total	
Receptively shared syringe last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
No receptive sharing	138	83 (60)	73	35 (48)	214	120 (56)
Receptive sharing	39	32 (82)	17	11 (65)	56	43 (77)
p value		0.016		0.171		0.005
2016						
No receptive sharing	148	70 (47)	80	26 (33)	231	96 (42)
Receptive sharing	31	20 (65)	22	12 (55)	54	33 (61)
p value		0.092		0.046		0.012
2017						
No receptive sharing	99	36 (36)	58	19 (33)	160	55 (34)
Receptive sharing	32	14 (44)	5	1 (20)	37	15 (41)
p value		0.407		0.604		0.430
2018						
No receptive sharing	141	33 (23)	71	12 (17)	212	45 (21)
Receptive sharing	36	9 (25)	18	8 (44)	55	18 (33)
p value		0.761		0.005		0.065

Table 8.4.6 HCV RNA prevalence by last drug injected, gender and survey year *

Victoria	Male		Female		Total	
Last drug injected	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
Heroin	92	62 (67)	51	30 (59)	144	94 (65)
Methamphetamine	68	38 (56)	31	12 (39)	100	50 (50)
Other opioids	23	14 (61)	10	3 (30)	33	17 (52)
Other drugs	10	8 (80)	7	4 (57)	17	12 (71)
p value		0.275		0.154		0.061
2016						
Heroin	109	54 (50)	48	20 (42)	157	74 (47)
Methamphetamine	59	30 (51)	46	10 (22)	105	41 (39)
Other opioids	17	7 (41)	12	7 (58)	30	14 (47)
Other drugs	10	5 (50)	8	3 (38)	20	8 (40)
p value		0.923		0.086		0.568
2017						
Heroin	93	37 (40)	44	16 (36)	139	53 (38)
Methamphetamine	27	11 (41)	17	5 (29)	46	16 (35)
Other opioids	3	1 (33)	4	1 (25)	8	2 (25)
Other drugs	12	2 (17)	3	0 (0)	15	2 (13)
p value		0.606		0.615		0.369
2018						
Heroin	111	25 (23)	55	9 (16)	167	34 (20)
Methamphetamine	65	16 (25)	27	8 (30)	93	24 (26)
Other opioids	7	1 (14)	6	0 (0)	14	1 (7)
Other drugs	12	4 (33)	7	3 (43)	19	7 (37)
p value		0.800		0.187		0.199

Table 8.4.7 HCV RNA prevalence by frequency of drug injection last month, gender and survey year *

Victoria	Male		Female		Total	
Frequency of injection last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
Less than daily	83	54 (65)	46	22 (48)	131	76 (58)
Daily or more	95	61 (64)	44	25 (57)	141	87 (62)
Not last month	15	7 (47)	8	3 (38)	23	10 (43)
p value		0.389		0.544		0.240
2016						
Less than daily	69	32 (46)	51	18 (35)	122	50 (41)
Daily or more	111	60 (54)	51	20 (39)	163	80 (49)
Not last month	16	5 (31)	11	2 (18)	27	7 (26)
p value		0.202		0.407		0.067
2017						
Less than daily	47	16 (34)	29	8 (28)	77	24 (31)
Daily or more	84	34 (40)	36	13 (36)	121	47 (39)
Not last month	5	1 (20)	4	1 (25)	9	2 (22)
p value		0.596		0.856		0.475
2018						
Less than daily	70	14 (20)	33	6 (18)	104	20 (19)
Daily or more	107	28 (26)	57	14 (25)	164	42 (26)
Not last month	19	4 (21)	8	0 (0)	27	4 (15)
p value		0.538		0.219		0.186

Table 8.4.8 HCV RNA prevalence by imprisonment last year, gender and survey year *

Victoria	Male		Female		Total	
Imprisonment last year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
No imprisonment	150	94 (63)	88	45 (51)	240	140 (58)
Imprisonment	31	21 (68)	9	5 (56)	40	26 (65)
p value		0.589		0.826		0.430
2016						
No imprisonment	157	71 (45)	95	32 (34)	254	104 (41)
Imprisonment	26	20 (77)	13	7 (54)	40	27 (68)
p value		0.002		0.184		0.002
2017						
No imprisonment	109	39 (36)	57	17 (30)	168	56 (33)
Imprisonment	22	11 (50)	5	1 (20)	27	12 (44)
p value		0.203		0.687		0.239
2018						
No imprisonment	148	34 (23)	81	15 (19)	229	49 (21)
Imprisonment	33	8 (24)	13	4 (31)	46	12 (26)
p value		0.691		0.333		0.370

Table 8.4.9 HCV RNA prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year *

Victoria	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
Non Indigenous	167	104 (62)	89	47 (53)	258	153 (59)
Indigenous	25	18 (72)	12	3 (25)	37	21 (57)
p value		0.345		0.058		0.792
2016						
Non Indigenous	164	80 (49)	95	31 (33)	262	111 (42)
Indigenous	33	19 (58)	17	8 (47)	50	27 (54)
p value		0.370		0.305		0.149
2017						
Non Indigenous	114	42 (37)	55	14 (25)	171	56 (33)
Indigenous	22	8 (36)	14	7 (50)	37	15 (41)
p value		0.911		0.049		0.305
2018						
Non Indigenous	159	38 (24)	80	17 (21)	240	55 (23)
Indigenous	37	7 (19)	19	3 (16)	57	10 (18)
p value		0.417		0.840		0.411

Table 8.4.10 HCV RNA prevalence by main language spoken at home by parents, gender and survey year *

Victoria	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
English speaking	181	113 (62)	93	45 (48)	276	160 (58)
Non-English speaking	13	11 (85)	8	5 (63)	21	16 (76)
p value		0.110		0.493		0.100
2016						
English speaking	177	85 (48)	109	40 (37)	289	125 (43)
Non-English speaking	23	15 (65)	5	0 (0)	28	15 (54)
p value		0.125		0.091		0.289
2017						
English speaking	112	41 (37)	70	22 (31)	185	63 (34)
Non-English speaking	25	10 (40)	0	0 (0)	25	10 (40)
p value		0.715		--		0.537
2018						
English speaking	172	36 (21)	94	18 (19)	267	54 (20)
Non-English speaking	26	10 (38)	5	2 (40)	31	12 (39)
p value		0.061		0.097		0.013

Table 8.4.11 HCV RNA prevalence by region/country of birth, gender and survey year *

Victoria	Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
Australia	168	107 (64)	84	41 (49)	253	149 (59)
Other Oceania	6	4 (67)	2	2 (100)	8	6 (75)
Asia	4	3 (75)	2	1 (50)	6	4 (67)
UK & Ireland	9	4 (44)	9	4 (44)	20	9 (45)
Other	7	6 (86)	4	2 (50)	11	8 (73)
p value		0.535		0.721		0.610
2016						
Australia	173	90 (52)	102	38 (37)	276	128 (46)
Other Oceania	3	1 (33)	0	0 (0)	5	1 (20)
Asia	6	3 (50)	1	0 (0)	7	3 (43)
UK & Ireland	8	2 (25)	5	0 (0)	13	2 (15)
Other	8	3 (38)	6	2 (33)	14	5 (36)
p value		0.535		0.313		0.184
2017						
Australia	119	46 (39)	64	20 (31)	186	66 (35)
Other Oceania	3	1 (33)	2	1 (50)	5	2 (40)
Asia	2	1 (50)	0	0 (0)	2	1 (50)
UK & Ireland	4	1 (25)	3	1 (33)	7	2 (29)
Other	8	2 (25)	0	0 (0)	8	2 (25)
p value		0.947		0.757		0.921
2018						
Australia	168	34 (20)	84	14 (17)	254	48 (19)
Other Oceania	6	2 (33)	3	1 (33)	10	3 (30)
Asia	3	3 (100)	0	0 (0)	3	3 (100)
UK & Ireland	4	0 (0)	9	3 (33)	13	3 (23)
Other	15	7 (47)	3	2 (67)	18	9 (50)
p value		0.004		0.249		0.001

Western Australia

Table 9.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Western Australia	2014	2015	2016	2017	2018
Number of sites	3	2	4	4	4
N° surveyed	N=225	N=218	N=425	N=508	N=521
Response rate (%)	82%	70%	75%	72%	71%
Gender (%)					
Male	142 (63)	125 (57)	274 (64)	340 (67)	309 (59)
Female	81 (36)	89 (41)	148 (35)	166 (33)	211 (41)
Transgender	2 (1)	3 (1)	2 (<1)	1 (<1)	1 (<1)
Not reported	0 (0)	1 (<1)	1 (<1)	1 (<1)	0 (0)
Sexual identity (%)					
Heterosexual	184 (82)	173 (79)	336 (79)	421 (83)	408 (78)
Bisexual	25 (11)	16 (7)	33 (8)	32 (6)	48 (9)
Homosexual	6 (3)	8 (4)	14 (3)	9 (2)	16 (3)
Not reported	10 (4)	21 (10)	42 (10)	46 (9)	49 (9)
Aboriginal and Torres Strait Islander origin (%)					
No	200 (89)	184 (84)	326 (77)	397 (78)	367 (70)
Yes	19 (8)	23 (11)	76 (18)	106 (21)	139 (27)
Not reported	6 (3)	11 (5)	23 (5)	5 (1)	15 (3)
Region/country of birth (%)					
Australia	176 (78)	165 (76)	358 (84)	423 (83)	427 (82)
Other Oceania	10 (4)	11 (5)	17 (4)	9 (2)	21 (4)
Asia	2 (1)	4 (2)	4 (1)	7 (1)	11 (2)
UK & Ireland	18 (8)	18 (8)	19 (4)	45 (9)	33 (6)
Other	16 (7)	14 (6)	13 (3)	16 (3)	23 (4)
Not reported	3 (1)	6 (3)	14 (3)	8 (2)	6 (1)
Main language spoken at home by parents (%)					
English	211 (94)	201 (92)	388 (91)	484 (95)	489 (94)
Non-English	12 (5)	10 (5)	22 (5)	21 (4)	26 (5)
Not reported	2 (1)	7 (3)	15 (4)	3 (1)	6 (1)
Age and time since first injection (years)					
<i>Median age</i>	41	41	41	42	41
<i>Age range</i>	18-67	15-70	20-68	18-70	18-69
<i>Age group (%)</i>					
<25 years	6 (3)	18 (8)	14 (3)	19 (4)	30 (6)
25+ years	217 (96)	198 (91)	408 (96)	484 (95)	490 (94)
Not reported	2 (1)	2 (1)	3 (1)	5 (1)	1 (<1)
<i>Median age first injection</i>					
<i>Age range</i>	11-45	12-57	10-57	10-53	11-59
N° not reported	5	12	21	33	20
<i>Median yrs since first injection</i>					
<i>Range</i>	<1-49	2-50	<1-51	<1-54	<1-51
<i>Years since first injection</i>					
<3 years	9 (4)	6 (3)	25 (6)	31 (6)	35 (7)
3+ years	210 (93)	200 (92)	379 (89)	444 (87)	465 (89)
Not reported	6 (3)	12 (6)	21 (5)	33 (7)	21 (4)
Imprisonment last year (%)					
No	175 (78)	178 (82)	348 (82)	386 (76)	404 (78)
Yes	24 (11)	23 (11)	52 (12)	71 (14)	80 (15)
Not reported	26 (12)	17 (8)	25 (6)	51 (10)	37 (7)
N° in prison					
Injected in prison	11 (46)	8 (35)	13 (25)	20 (28)	25 (31)

Table 9.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year

Western Australia	2014	2015	2016	2017	2018
N° surveyed	N=225	N=218	N=425	N=508	N=521
Drug last injected (%)					
Cocaine	0 (0)	0 (0)	0 (0)	0 (0)	1 (<1)
Methamphetamine	78 (35)	98 (45)	256 (60)	275 (54)	357 (69)
Heroin	79 (35)	63 (29)	65 (15)	113 (22)	80 (15)
Pharm. opioids	20 (9)	17 (8)	30 (7)	24 (5)	18 (3)
Methadone	6 (3)	6 (3)	8 (2)	28 (6)	8 (2)
Buprenorphine	4 (2)	6 (3)	14 (3)	8 (2)	9 (2)
Buprenorphine/naloxone	7 (3)	4 (2)	8 (2)	9 (2)	6 (1)
PIEDs	6 (3)	1 (<1)	9 (2)	6 (1)	4 (1)
More than one	23 (10)	17 (8)	27 (6)	35 (7)	33 (6)
Other	1 (<1)	6 (3)	8 (2)	6 (1)	3 (1)
Not reported	1 (<1)	0 (0)	0 (0)	4 (1)	2 (<1)
Ever injected opioids					
No	-	-	128 (30)	142 (28)	187 (36)
Yes	-	-	297 (70)	363 (71)	330 (63)
Not reported	-	-	0 (0)	3 (1)	4 (1)
Frequency of injection last month (%)					
Not last month	16 (7)	12 (6)	27 (6)	40 (8)	28 (5)
Less than weekly	23 (10)	25 (11)	65 (15)	57 (11)	55 (11)
Weekly not daily	36 (16)	51 (23)	89 (21)	109 (21)	104 (20)
Daily or more	146 (65)	121 (56)	234 (55)	292 (57)	321 (62)
Not reported	4 (2)	9 (4)	10 (2)	10 (2)	13 (3)
Present when someone injected for the first time in the last 12 months (%)					
No	161 (72)	163 (75)	326 (77)	363 (71)	372 (71)
Yes	52 (23)	43 (20)	82 (19)	118 (23)	125 (24)
Not reported	12 (5)	12 (6)	17 (4)	27 (5)	24 (5)
Overdosed in last 12 months					
No	164 (73)	166 (76)	344 (81)	368 (72)	390 (75)
Yes	49 (22)	40 (18)	61 (14)	112 (22)	107 (21)
Not reported	12 (5)	12 (6)	20 (5)	28 (6)	24 (5)

Table 9.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year

Western Australia	2014	2015	2016	2017	2018
N° injected last month	N=205	N=197	N=388	N=458	N=480
Places injected last month (%)					
All private	112 (55)	109 (55)	179 (46)	207 (45)	193 (40)
Any public	89 (43)	88 (45)	209 (54)	247 (54)	286 (60)
Not reported	4 (2)	0 (0)	0 (0)	4 (1)	1 (<1)
Use of new and sterile needles and syringes last month (%)					
All injections	141 (69)	136 (69)	228 (59)	275 (60)	278 (58)
Most of the time	47 (23)	47 (24)	130 (34)	140 (31)	146 (30)
Half of the time	4 (2)	8 (4)	16 (4)	22 (5)	31 (6)
Some of the time	5 (2)	4 (2)	6 (2)	10 (2)	14 (3)
Not last month	2 (1)	1 (1)	4 (1)	4 (1)	5 (1)
Not reported	6 (3)	1 (1)	4 (1)	7 (2)	6 (1)
Re-used someone else's used needle & syringe last month (%)					
None	157 (77)	144 (73)	280 (72)	331 (72)	330 (69)
Once	15 (7)	15 (8)	23 (6)	33 (7)	56 (12)
Twice	7 (3)	12 (6)	33 (9)	28 (6)	27 (6)
3-5 times	11 (5)	17 (9)	25 (6)	33 (7)	32 (7)
>5 times	9 (4)	7 (4)	20 (5)	23 (5)	31 (6)
Not reported	6 (3)	2 (1)	7 (2)	10 (2)	4 (1)
Number of people needle & syringe was re-used after last month (%)					
None	157 (77)	144 (73)	280 (72)	331 (72)	330 (69)
One	16 (8)	24 (12)	41 (11)	51 (11)	62 (13)
Two	1 (<1)	8 (4)	10 (3)	14 (3)	14 (3)
Three to five	3 (1)	3 (2)	10 (3)	10 (2)	15 (3)
More than five	6 (3)	1 (1)	7 (2)	3 (1)	8 (2)
Don't know	6 (3)	7 (4)	22 (6)	25 (5)	18 (4)
Not reported	16 (8)	10 (5)	18 (5)	24 (5)	33 (7)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	15 (7)	13 (7)	41 (11)	41 (9)	58 (12)
Casual sex partner	2 (1)	1 (1)	3 (1)	4 (1)	7 (1)
Close friend	9 (4)	24 (12)	30 (8)	40 (9)	47 (10)
Acquaintance	3 (1)	4 (2)	17 (4)	16 (3)	17 (4)
Other	5 (2)	7 (4)	5 (1)	12 (3)	14 (3)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	44 (21)	53 (27)	74 (19)	107 (23)	91 (19)
Water	41 (20)	39 (20)	95 (24)	113 (25)	132 (28)
Filter	23 (11)	23 (12)	35 (9)	56 (12)	59 (12)
Drug mix	17 (8)	19 (10)	29 (7)	52 (11)	63 (13)
None	139 (68)	122 (62)	261 (67)	273 (60)	284 (59)
Injected by someone after that person injected themselves or others last month (%)					
No	157 (77)	159 (81)	302 (78)	345 (75)	361 (75)
Yes	36 (18)	36 (18)	83 (21)	104 (23)	110 (23)
Not reported	12 (6)	2 (1)	3 (1)	9 (2)	9 (2)
Source of needle acquisition					
Needle Syringe Program	167 (81)	161 (82)	312 (80)	363 (79)	374 (78)
Chemist/Pharmacy	53 (26)	58 (29)	138 (36)	157 (34)	185 (39)
Personal sources	26 (13)	26 (13)	65 (17)	60 (13)	72 (15)
Dispensing/Vending Machine	3 (1)	5 (3)	9 (2)	12 (3)	11 (2)
Other sources	5 (2)	5 (3)	11 (3)	24 (5)	21 (4)

Table 9.1.4 Number (percentage) of respondents by treatment for drug use and survey year

Western Australia	2014	2015	2016	2017	2018
N° surveyed	N=225	N=218	N=425	N=508	N=521
Ever any treatment/therapy for drug use (%)					
No	56 (25)	63 (29)	148 (35)	168 (33)	219 (42)
Yes	163 (72)	145 (67)	249 (59)	316 (62)	277 (53)
Not reported	6 (3)	10 (5)	28 (7)	24 (5)	25 (5)
History of methadone maintenance treatment (%)					
Currently	41 (18)	41 (19)	48 (11)	71 (14)	56 (11)
Previously	54 (24)	47 (22)	88 (21)	96 (19)	72 (14)
Never	124 (55)	119 (55)	255 (60)	324 (64)	373 (72)
Not reported	6 (3)	11 (5)	34 (8)	17 (3)	20 (4)
History of buprenorphine (Subutex®) treatment (%)					
Currently	16 (7)	15 (7)	14 (3)	35 (7)	28 (5)
Previously	59 (26)	53 (24)	63 (15)	83 (16)	88 (17)
Never	144 (64)	140 (64)	329 (77)	379 (75)	388 (74)
Not reported	6 (3)	10 (5)	19 (4)	11 (2)	17 (3)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	23 (10)	14 (6)	20 (5)	24 (5)	30 (6)
Previously	41 (18)	47 (22)	55 (13)	71 (14)	80 (15)
Never	156 (69)	146 (67)	328 (77)	397 (78)	393 (75)
Not reported	5 (2)	11 (5)	22 (5)	16 (3)	18 (3)

Table 9.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year

Western Australia	2014	2015	2016	2017	2018
N° surveyed	N=225	N=218	N=425	N=508	N=521
Previous HIV test (%)					
Yes, ever	173 (77)	172 (79)	327 (77)	384 (76)	389 (75)
Yes, last year	98 (44)	109 (50)	203 (48)	226 (44)	252 (48)
>1 year ago	75 (33)	63 (29)	124 (29)	158 (31)	137 (26)
Never tested	36 (16)	37 (17)	75 (18)	84 (17)	99 (19)
Not reported	16 (7)	9 (4)	23 (5)	40 (8)	33 (6)
Previous HCV test (%)					
Yes, ever	190 (84)	184 (84)	322 (75)	397 (78)	397 (76)
Yes, last year	113 (50)	115 (54)	210 (49)	252 (50)	273 (52)
>1 year ago	77 (34)	69 (32)	112 (26)	145 (29)	124 (24)
Never tested	14 (6)	20 (9)	53 (12)	51 (10)	64 (12)
Not reported	21 (9)	14 (6)	50 (12)	60 (12)	60 (12)
Lifetime treatment for HCV (%)#					
N° self-reported HCV diagnosis	N=61	N=54	N=92	N=97	N=99
Antiviral treatment	10 (16)	7 (13)	26 (28)	34 (35)	42 (42)
No antiviral treatment	48 (79)	42 (78)	65 (71)	62 (64)	55 (56)
Not reported	3 (5)	5 (9)	1 (1)	1 (1)	2 (2)
Treatment for HCV in past 12 months (%)#*					
N° self-reported HCV diagnosis	N=59	N=52	N=86	N=90	N=93
Antiviral treatment	0 (0)	1 (2)	14 (16)	20 (22)	28 (30)
No antiviral treatment	56 (95)	46 (88)	71 (83)	69 (77)	63 (68)
Not reported	3 (5)	5 (10)	1 (1)	1 (1)	2 (2)

among people who tested HCV antibody positive and did not report spontaneous clearance

* excludes people who reported treatment induced clearance more than 12 months previously

Table 9.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year

Western Australia	2014	2015	2016	2017	2018
N° surveyed	N=225	N=218	N=425	N=508	N=521
Sex with a regular partner last month (%)					
No	113 (50)	100 (46)	208 (49)	240 (47)	235 (45)
Yes	93 (41)	104 (48)	193 (45)	228 (45)	256 (49)
Not reported	19 (8)	14 (6)	24 (6)	40 (8)	30 (6)
Condom used with regular partner last month (%)					
N° surveyed	N=93	N=104	N=193	N=228	N=256
Never	73 (78)	76 (73)	132 (68)	157 (69)	195 (76)
Sometimes	8 (9)	9 (9)	35 (18)	35 (15)	37 (14)
Every time	7 (8)	13 (13)	18 (9)	25 (11)	15 (6)
Not reported	5 (5)	6 (6)	8 (4)	11 (5)	9 (4)
Sex with other partner(s) last month (%)					
No	169 (75)	169 (78)	324 (76)	385 (76)	390 (75)
Yes	34 (15)	34 (16)	72 (17)	78 (15)	99 (19)
Not reported	22 (10)	15 (7)	29 (7)	45 (9)	32 (6)
Condom used with other partner(s) last month (%)					
N° surveyed	N=34	N=34	N=72	N=78	N=99
Never	14 (41)	11 (32)	30 (42)	37 (47)	50 (51)
Sometimes	9 (26)	11 (32)	23 (32)	27 (35)	25 (25)
Every time	7 (21)	10 (30)	15 (21)	13 (17)	20 (20)
Not reported	4 (12)	2 (6)	4 (6)	1 (1)	4 (4)
Sex work last month (%)					
No	181 (80)	190 (87)	372 (88)	435 (86)	446 (86)
Yes	14 (6)	14 (6)	24 (6)	24 (5)	35 (7)
Not reported	30 (13)	14 (6)	29 (7)	49 (10)	40 (8)
Condom used at last sex work (%)					
Yes	6 (43)	10 (71)	18 (75)	15 (63)	23 (66)

HIV antibody prevalence

Table 9.2.1 HIV antibody prevalence by gender and survey year

Western Australia	Male		Female		Total	
Survey year	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014	131	1 (0.8)	75	0 (0.0)	208	1 (0.5)
2015	112	1 (0.9)	83	1 (1.2)	198	2 (1.0)
2016	270	2 (0.7)	146	2 (1.4)	419	5 (1.2)
2017	310	3 (1.0)	154	2 (1.3)	466	5 (1.1)
2018	299	6 (2.0)	207	4 (1.9)	507	10 (2.0)
X ² p trend		0.217		0.269		0.118

Table 9.2.2 HIV antibody prevalence by sexual identity, gender and survey year

Western Australia	Male		Female		Total	
Sexual identity	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
Heterosexual	118	0 (0.0)	52	0 (0.0)	170	0 (0.0)
Bisexual	6	1 (16.7)	15	0 (0.0)	23	1 (4.4)
Homosexual	3	0 (0.0)	3	0 (0.0)	6	0 (0.0)
p value		0.071		--		0.146
2015						
Heterosexual	99	0 (0.0)	57	1 (1.8)	158	1 (0.6)
Bisexual	1	0 (0.0)	15	0 (0.0)	16	0 (0.0)
Homosexual	2	1 (50.0)	3	0 (0.0)	5	1 (20.0)
p value		0.029		1.000		0.063
2016						
Heterosexual	228	1 (0.4)	103	2 (1.9)	331	3 (0.9)
Bisexual	7	1 (14.3)	24	0 (0.0)	33	2 (6.1)
Homosexual	9	0 (0.0)	5	0 (0.0)	14	0 (0.0)
p value		0.058		1.000		0.118
2017						
Heterosexual	265	2 (0.8)	116	2 (1.7)	382	4 (1.1)
Bisexual	10	1 (10.0)	22	0 (0.0)	32	1 (3.1)
Homosexual	6	0 (0.0)	3	0 (0.0)	9	0 (0.0)
p value		0.162		1.000		0.401
2018						
Heterosexual	249	4 (1.6)	148	2 (1.4)	397	6 (1.5)
Bisexual	16	1 (6.3)	31	2 (6.5)	47	3 (6.4)
Homosexual	10	1 (10.0)	5	0 (0.0)	16	1 (6.3)
p value		0.102		0.230		0.037

Table 9.2.3 HIV antibody prevalence by age group, gender and survey year

Western Australia Age group	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
<25 years	6	0 (0.0)	0	0 (0.0)	6	0 (0.0)
25-34 years	33	0 (0.0)	14	0 (0.0)	47	0 (0.0)
35-44 years	46	0 (0.0)	26	0 (0.0)	73	0 (0.0)
45+ years	45	1 (2.2)	35	0 (0.0)	81	1 (1.2)
p value		0.646		--		1.000
2015						
<25 years	6	0 (0.0)	6	0 (0.0)	14	0 (0.0)
25-34 years	21	0 (0.0)	14	0 (0.0)	35	0 (0.0)
35-44 years	40	0 (0.0)	34	0 (0.0)	74	0 (0.0)
45+ years	44	1 (2.3)	29	1 (3.5)	74	2 (2.7)
p value		1.000		0.590		0.716
2016						
<25 years	5	0 (0.0)	8	0 (0.0)	14	0 (0.0)
25-34 years	60	0 (0.0)	38	0 (0.0)	98	0 (0.0)
35-44 years	100	1 (1.0)	52	0 (0.0)	152	1 (0.7)
45+ years	103	1 (1.0)	47	2 (4.3)	152	4 (2.6)
p value		1.000		0.279		0.376
2017						
<25 years	14	0 (0.0)	5	0 (0.0)	19	0 (0.0)
25-34 years	53	0 (0.0)	38	0 (0.0)	92	0 (0.0)
35-44 years	114	0 (0.0)	59	0 (0.0)	174	0 (0.0)
45+ years	127	3 (2.4)	49	2 (4.1)	176	5 (2.8)
p value		0.323		0.231		0.064
2018						
<25 years	15	0 (0.0)	13	0 (0.0)	28	0 (0.0)
25-34 years	54	1 (1.9)	58	0 (0.0)	112	1 (0.9)
35-44 years	99	1 (1.0)	78	0 (0.0)	178	1 (0.6)
45+ years	131	4 (3.1)	57	4 (7.0)	188	8 (4.3)
p value		0.822		0.031		0.081

Table 9.2.4 HIV antibody prevalence by last drug injected, gender and survey year

Western Australia Last drug injected	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
Heroin	47	0 (0.0)	27	0 (0.0)	75	0 (0.0)
Methamphetamine	39	1 (2.6)	30	0 (0.0)	70	1 (1.4)
Other opioids	21	0 (0.0)	15	0 (0.0)	36	0 (0.0)
Other drugs	23	0 (0.0)	3	0 (0.0)	25	0 (0.0)
p value		0.638		--		0.638
2015						
Heroin	38	0 (0.0)	21	1 (4.8)	59	1 (1.7)
Methamphetamine	42	1 (2.4)	42	0 (0.0)	87	1 (1.2)
Other opioids	17	0 (0.0)	15	0 (0.0)	32	0 (0.0)
Other drugs	15	0 (0.0)	5	0 (0.0)	20	0 (0.0)
p value		1.000		0.494		1.000
2016						
Heroin	43	0 (0.0)	20	1 (5.0)	64	1 (1.6)
Methamphetamine	148	2 (1.4)	101	1 (1.0)	251	4 (1.6)
Other opioids	46	0 (0.0)	14	0 (0.0)	60	0 (0.0)
Other drugs	33	0 (0.0)	11	0 (0.0)	44	0 (0.0)
p value		1.000		0.523		1.000
2017						
Heroin	72	0 (0.0)	32	1 (3.1)	105	1 (1.0)
Methamphetamine	166	2 (1.2)	83	1 (1.2)	249	3 (1.2)
Other opioids	41	1 (2.4)	22	0 (0.0)	63	1 (1.6)
Other drugs	31	0 (0.0)	17	0 (0.0)	49	0 (0.0)
p value		0.647		0.711		1.000
2018						
Heroin	48	0 (0.0)	31	1 (3.2)	79	1 (1.3)
Methamphetamine	204	5 (2.5)	144	3 (2.1)	348	8 (2.3)
Other opioids	23	0 (0.0)	17	0 (0.0)	40	0 (0.0)
Other drugs	24	1 (4.2)	15	0 (0.0)	40	1 (2.5)
p value		0.508		0.769		1.000

Table 9.2.5 HIV antibody prevalence by years of injection, gender and survey year

Western Australia Years of injection	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
<3 years	8	0 (0.0)	1	0 (0.0)	9	0 (0.0)
3 to 10 years	9	0 (0.0)	9	0 (0.0)	18	0 (0.0)
11+ years	112	1 (0.9)	63	0 (0.0)	177	1 (0.6)
p value		1.000		--		1.000
2015						
<3 years	4	1 (25.0)	1	0 (0.0)	5	1 (20.0)
3 to 10 years	9	0 (0.0)	21	0 (0.0)	32	0 (0.0)
11+ years	93	0 (0.0)	57	1 (1.8)	151	1 (0.7)
p value		0.038		1.000		0.081
2016						
<3 years	14	0 (0.0)	11	0 (0.0)	25	0 (0.0)
3 to 10 years	31	1 (3.2)	24	0 (0.0)	56	1 (1.8)
11 + years	209	0 (0.0)	106	2 (1.9)	317	3 (1.0)
p value		0.177		1.000		0.599
2017						
<3 years	20	0 (0.0)	10	0 (0.0)	30	0 (0.0)
3 to 10 years	38	0 (0.0)	24	0 (0.0)	62	0 (0.0)
11 + years	252	3 (1.2)	120	2 (1.7)	374	5 (1.3)
p value		1.000		1.000		1.000
2018						
<3 years	15	1 (6.7)	17	0 (0.0)	32	1 (3.1)
3 to 10 years	46	0 (0.0)	46	0 (0.0)	92	0 (0.0)
11 + years	238	5 (2.1)	144	4 (2.8)	383	9 (2.4)
p value		0.309		0.698		0.259

Table 9.2.6 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

Western Australia Receptively shared syringe last month	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
No receptive sharing	90	1 (1.1)	56	0 (0.0)	147	1 (0.7)
Receptive sharing	25	0 (0.0)	11	0 (0.0)	36	0 (0.0)
p value		1.000		--		1.000
2015						
No receptive sharing	72	1 (1.4)	63	1 (1.6)	136	2 (1.5)
Receptive sharing	28	0 (0.0)	14	0 (0.0)	42	0 (0.0)
p value		1.000		1.000		1.000
2016						
No receptive sharing	176	2 (1.1)	98	1 (1.0)	276	4 (1.5)
Receptive sharing	68	0 (0.0)	31	0 (0.0)	100	0 (0.0)
p value		1.000		1.000		0.577
2017						
No receptive sharing	197	2 (1.0)	105	2 (1.9)	304	4 (1.3)
Receptive sharing	73	1 (1.4)	32	0 (0.0)	105	1 (1.0)
p value		1.000		1.000		1.000
2018						
No receptive sharing	193	4 (2.1)	130	3 (2.3)	323	7 (2.2)
Receptive sharing	85	0 (0.0)	58	0 (0.0)	143	0 (0.0)
p value		0.317		0.554		0.106

Table 9.2.7 HIV antibody prevalence by frequency of drug injection last month, gender and survey year

Western Australia	Male		Female		Total	
Frequency of injection	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
Less than daily	33	1 (3.0)	23	0 (0.0)	56	1 (1.8)
Daily or more	84	0 (0.0)	47	0 (0.0)	132	0 (0.0)
Not last month	10	0 (0.0)	5	0 (0.0)	16	0 (0.0)
p value		0.339		--		0.353
2015						
Less than daily	44	1 (2.3)	23	1 (4.4)	68	2 (2.9)
Daily or more	57	0 (0.0)	54	0 (0.0)	111	0 (0.0)
Not last month	4	0 (0.0)	4	0 (0.0)	10	0 (0.0)
p value		0.457		0.333		0.232
2016						
Less than daily	101	1 (1.0)	51	0 (0.0)	153	2 (1.3)
Daily or more	148	1 (0.7)	80	1 (1.3)	230	2 (0.9)
Not last month	16	0 (0.0)	10	1 (10.0)	26	1 (3.9)
p value		1.000		0.137		0.398
2017						
Less than daily	103	2 (1.9)	48	1 (2.1)	152	3 (2.0)
Daily or more	172	1 (0.6)	92	1 (1.1)	265	2 (0.8)
Not last month	26	0 (0.0)	13	0 (0.0)	39	0 (0.0)
p value		0.663		1.000		0.591
2018						
Less than daily	101	2 (2.0)	56	2 (3.6)	157	4 (2.6)
Daily or more	179	2 (1.1)	134	2 (1.5)	313	4 (1.3)
Not last month	12	2 (16.7)	15	0 (0.0)	27	2 (7.4)
p value		0.016		0.693		0.093

Table 9.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year

Western Australia	Male		Female		Total	
Imprisonment last year	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
No imprisonment	99	1 (1.0)	64	0 (0.0)	163	1 (0.6)
Imprisonment	17	0 (0.0)	3	0 (0.0)	21	0 (0.0)
p value		1.000		--		1.000
2015						
No imprisonment	91	1 (1.1)	72	0 (0.0)	165	1 (0.6)
Imprisonment	13	0 (0.0)	6	0 (0.0)	20	0 (0.0)
p value		1.000		--		1.000
2016						
No imprisonment	218	1 (0.5)	123	1 (0.8)	343	3 (0.9)
Imprisonment	38	1 (2.6)	13	0 (0.0)	51	1 (2.0)
p value		0.275		1.000		0.427
2017						
No imprisonment	232	2 (0.9)	123	2 (1.6)	356	4 (1.1)
Imprisonment	48	0 (0.0)	16	0 (0.0)	65	0 (0.0)
p value		1.000		1.000		1.000
2018						
No imprisonment	227	3 (1.3)	168	3 (1.8)	396	6 (1.5)
Imprisonment	51	3 (5.9)	28	0 (0.0)	79	3 (3.8)
p value		0.077		1.000		0.176

Table 9.2.9 HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year

Western Australia		Male		Female		Total	
Condom use at last sex	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2014							
No condom use	36	0 (0.0)	32	0 (0.0)	68	0 (0.0)	
Condom use	12	1 (8.3)	2	0 (0.0)	14	1 (7.1)	
p value		0.250		--		0.171	
2015							
No condom use	33	0 (0.0)	34	0 (0.0)	68	0 (0.0)	
Condom use	11	0 (0.0)	8	0 (0.0)	19	0 (0.0)	
p value		--		--		--	
2016							
No condom use	75	1 (1.3)	53	0 (0.0)	129	1 (0.8)	
Condom use	33	0 (0.0)	20	0 (0.0)	53	0 (0.0)	
p value		1.000		--		1.000	
2017							
No condom use	88	0 (0.0)	54	0 (0.0)	142	0 (0.0)	
Condom use	35	0 (0.0)	21	0 (0.0)	56	0 (0.0)	
p value		--		--		--	
2018							
No condom use	103	2 (1.9)	91	1 (1.1)	194	3 (1.6)	
Condom use	28	0 (0.0)	21	0 (0.0)	49	0 (0.0)	
p value		1.000		1.000		1.000	

Table 9.2.10 HIV antibody prevalence by sex work last month, gender and survey year

Western Australia		Male		Female		Total	
Sex work last month	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2014							
No sex work	100	1 (1.0)	66	0 (0.0)	167	1 (0.6)	
Sex work	10	0 (0.0)	3	0 (0.0)	13	0 (0.0)	
p value		1.000		--		1.000	
2015							
No sex work	99	1 (1.0)	72	1 (1.4)	174	2 (1.2)	
Sex work	6	0 (0.0)	7	0 (0.0)	13	0 (0.0)	
p value		1.000		1.000		1.000	
2016							
No sex work	239	2 (0.8)	125	2 (1.6)	366	5 (1.4)	
Sex work	11	0 (0.0)	12	0 (0.0)	24	0 (0.0)	
p value		1.000		1.000		1.000	
2017							
No sex work	265	3 (1.1)	131	2 (1.5)	398	5 (1.3)	
Sex work	13	0 (0.0)	8	0 (0.0)	21	0 (0.0)	
p value		1.000		1.000		1.000	
2018							
No sex work	262	5 (1.9)	174	2 (1.2)	436	7 (1.6)	
Sex work	15	0 (0.0)	18	0 (0.0)	33	0 (0.0)	
p value		1.000		1.000		1.000	

Table 9.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Western Australia Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
Non Indigenous	119	0 (0.0)	65	0 (0.0)	186	0 (0.0)
Indigenous	6	1 (16.7)	10	0 (0.0)	16	1 (6.3)
p value		0.048		--		0.079
2015						
Non Indigenous	99	1 (1.0)	69	1 (1.5)	171	2 (1.2)
Indigenous	10	0 (0.0)	10	0 (0.0)	20	0 (0.0)
p value		1.000		1.000		1.000
2016						
Non Indigenous	216	1 (0.5)	104	1 (1.0)	320	2 (0.6)
Indigenous	39	1 (2.6)	35	1 (2.9)	76	2 (2.6)
p value		0.283		0.442		0.168
2017						
Non Indigenous	248	0 (0.0)	116	1 (0.9)	364	1 (0.3)
Indigenous	59	3 (5.1)	36	1 (2.8)	97	4 (4.1)
p value		0.007		0.419		0.008
2018						
Non Indigenous	225	3 (1.3)	137	1 (0.7)	362	4 (1.1)
Indigenous	67	2 (3.0)	65	2 (3.1)	132	4 (3.0)
p value		0.324		0.243		0.219

Table 9.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and survey year

Western Australia Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2014						
English speaking	122	1 (0.8)	71	0 (0.0)	195	1 (0.5)
Non-English speaking	8	0 (0.0)	3	0 (0.0)	11	0 (0.0)
p value		1.000		--		1.000
2015						
English speaking	102	1 (1.0)	78	1 (1.3)	183	2 (1.1)
Non-English speaking	7	0 (0.0)	3	0 (0.0)	10	0 (0.0)
p value		1.000		1.000		1.000
2016						
English speaking	247	2 (0.8)	133	2 (1.5)	382	5 (1.3)
Non-English speaking	14	0 (0.0)	7	0 (0.0)	22	0 (0.0)
p value		1.000		1.000		1.000
2017						
English speaking	294	3 (1.0)	147	2 (1.4)	443	5 (1.1)
Non-English speaking	14	0 (0.0)	6	0 (0.0)	20	0 (0.0)
p value		1.000		1.000		1.000
2018						
English speaking	282	6 (2.1)	196	3 (1.5)	478	9 (1.9)
Non-English speaking	15	0 (0.0)	9	0 (0.0)	25	0 (0.0)
p value		1.000		1.000		1.000

Table 9.2.13 HIV antibody prevalence by region/country of birth, gender and survey year

Western Australia		Male		Female		Total	
Region/country of birth	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2014							
Australia	106	1 (0.9)	57	0 (0.0)	165	1 (0.6)	
Other Oceania	4	0 (0.0)	5	0 (0.0)	9	0 (0.0)	
Asia	1	0 (0.0)	1	0 (0.0)	2	0 (0.0)	
UK & Ireland	13	0 (0.0)	4	0 (0.0)	17	0 (0.0)	
Other	6	0 (0.0)	8	0 (0.0)	14	0 (0.0)	
p value		1.000		--		1.000	
2015							
Australia	82	1 (1.2)	66	1 (1.5)	150	2 (1.3)	
Other Oceania	8	0 (0.0)	2	0 (0.0)	10	0 (0.0)	
Asia	2	0 (0.0)	1	0 (0.0)	4	0 (0.0)	
UK & Ireland	10	0 (0.0)	7	0 (0.0)	17	0 (0.0)	
Other	7	0 (0.0)	5	0 (0.0)	12	0 (0.0)	
p value		1.000		1.000		1.000	
2016							
Australia	231	2 (0.9)	119	2 (1.7)	353	5 (1.4)	
Other Oceania	11	0 (0.0)	6	0 (0.0)	17	0 (0.0)	
Asia	4	0 (0.0)	0	0 (0.0)	4	0 (0.0)	
UK & Ireland	11	0 (0.0)	7	0 (0.0)	18	0 (0.0)	
Other	6	0 (0.0)	7	0 (0.0)	13	0 (0.0)	
p value		1.000		1.000		1.000	
2017							
Australia	251	3 (1.2)	135	2 (1.5)	388	5 (1.3)	
Other Oceania	5	0 (0.0)	3	0 (0.0)	8	0 (0.0)	
Asia	3	0 (0.0)	2	0 (0.0)	5	0 (0.0)	
UK & Ireland	33	0 (0.0)	10	0 (0.0)	43	0 (0.0)	
Other	13	0 (0.0)	1	0 (0.0)	14	0 (0.0)	
p value		1.000		1.000		1.000	
2018							
Australia	238	6 (2.5)	180	3 (1.7)	418	9 (2.2)	
Other Oceania	12	0 (0.0)	8	0 (0.0)	20	0 (0.0)	
Asia	7	0 (0.0)	4	0 (0.0)	11	0 (0.0)	
UK & Ireland	26	0 (0.0)	6	0 (0.0)	32	0 (0.0)	
Other	14	0 (0.0)	7	0 (0.0)	22	0 (0.0)	
p value		1.000		1.000		1.000	

HCV antibody prevalence

Table 9.3.1 HCV antibody prevalence by gender and survey year

Western Australia	Male		Female		Total	
Survey year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014	128	72 (56)	75	40 (53)	205	113 (55)
2015	107	58 (54)	82	39 (48)	192	98 (51)
2016	263	125 (48)	143	42 (29)	409	169 (41)
2017	296	140 (47)	153	57 (37)	451	198 (44)
2018	297	115 (39)	204	72 (35)	502	188 (37)
X ² p trend		0.029		0.090		0.006

Table 9.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Western Australia	Male		Female		Total	
Sexual identity	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
Heterosexual	116	64 (55)	52	30 (58)	168	94 (56)
Bisexual	6	4 (67)	15	8 (53)	23	13 (57)
Homosexual	3	1 (33)	3	0 (0)	6	1 (17)
p value		0.652		0.171		0.181
2015						
Heterosexual	94	51 (54)	57	25 (44)	153	77 (50)
Bisexual	1	0 (0)	14	9 (64)	15	9 (60)
Homosexual	2	0 (0)	3	1 (33)	5	1 (20)
p value		0.103		0.418		0.306
2016						
Heterosexual	221	105 (48)	100	26 (26)	321	131 (41)
Bisexual	7	4 (57)	24	12 (50)	33	17 (52)
Homosexual	9	3 (33)	5	0 (0)	14	3 (21)
p value		0.673		0.025		0.155
2017						
Heterosexual	252	117 (46)	116	41 (35)	369	158 (43)
Bisexual	10	6 (60)	21	9 (43)	31	15 (48)
Homosexual	6	0 (0)	3	0 (0)	9	0 (0)
p value		0.039		0.421		0.020
2018						
Heterosexual	249	94 (38)	147	57 (39)	396	151 (38)
Bisexual	16	8 (50)	30	5 (17)	46	13 (28)
Homosexual	10	3 (30)	5	3 (60)	16	7 (44)
p value		0.552		0.024		0.366

Table 9.3.3 HCV antibody prevalence by age group, gender and survey year

Western Australia Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
<25 years	6	1 (17)	0	0 (0)	6	1 (17)
25-34 years	32	13 (41)	14	9 (64)	46	22 (48)
35-44 years	45	26 (58)	26	10 (38)	72	36 (50)
45+ years	44	31 (70)	35	21 (60)	80	53 (67)
p value		0.013		0.174		0.023
2015						
<25 years	5	1 (20)	6	1 (17)	13	2 (15)
25-34 years	21	10 (48)	13	8 (62)	34	18 (53)
35-44 years	37	16 (43)	34	14 (41)	71	30 (42)
45+ years	43	30 (70)	29	16 (55)	73	47 (64)
p value		0.030		0.218		0.002
2016						
<25 years	5	0 (0)	7	1 (14)	13	2 (15)
25-34 years	59	16 (27)	38	8 (21)	97	24 (25)
35-44 years	98	53 (54)	51	12 (24)	149	65 (44)
45+ years	99	55 (56)	46	21 (46)	147	77 (52)
p value		<0.001		0.040		<0.001
2017						
<25 years	14	3 (21)	5	0 (0)	19	3 (16)
25-34 years	52	23 (44)	37	9 (24)	90	33 (37)
35-44 years	109	46 (42)	59	21 (36)	169	67 (40)
45+ years	119	66 (55)	49	25 (51)	168	91 (54)
p value		0.041		0.022		0.001
2018						
<25 years	14	5 (36)	13	4 (31)	27	9 (33)
25-34 years	53	19 (36)	57	16 (28)	110	35 (32)
35-44 years	99	30 (30)	77	26 (34)	177	57 (32)
45+ years	131	61 (47)	56	25 (45)	187	86 (46)
p value		0.086		0.311		0.022

Table 9.3.4 HCV antibody prevalence by years since first injection, gender and survey year

Western Australia Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
<3 years	8	0 (0)	1	0 (0)	9	0 (0)
3 to 10 years	9	4 (44)	9	4 (44)	18	8 (44)
11+ years	109	66 (61)	63	35 (56)	174	102 (59)
p value		0.002		0.596		0.001
2015						
<3 years	4	1 (25)	1	0 (0)	5	1 (20)
3 to 10 years	8	5 (63)	21	7 (33)	31	12 (39)
11+ years	89	51 (57)	56	31 (55)	146	83 (57)
p value		0.509		0.099		0.064
2016						
<3 years	14	1 (7)	11	1 (9)	25	2 (8)
3 to 10 years	31	8 (26)	23	3 (13)	55	12 (22)
11+ years	203	107 (53)	104	35 (34)	309	143 (46)
p value		<0.001		0.053		<0.001
2017						
<3 years	19	0 (0)	10	0 (0)	29	0 (0)
3 to 10 years	38	11 (29)	24	5 (21)	62	16 (26)
11+ years	225	119 (53)	104	44 (42)	330	163 (49)
p value		<0.001		0.005		<0.001
2018						
<3 years	15	2 (13)	17	1 (6)	32	3 (9)
3 to 10 years	45	11 (24)	45	15 (33)	90	26 (29)
11+ years	227	96 (42)	135	52 (39)	363	149 (41)
p value		0.009		0.019		<0.001

Table 9.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

Western Australia Receptively shared syringe last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
No receptive sharing	6	0 (0)	138	82 (59)	146	83 (57)
Receptive sharing	1	0 (0)	34	17 (50)	35	17 (49)
p value		--		0.320		0.376
2015						
No receptive sharing	2	0 (0)	131	71 (54)	134	71 (53)
Receptive sharing	1	0 (0)	38	22 (58)	41	24 (59)
p value		--		0.687		0.532
2016						
No receptive sharing	16	0 (0)	241	94 (39)	269	102 (38)
Receptive sharing	6	2 (33)	90	45 (50)	99	49 (49)
p value		0.065		0.071		0.045
2017						
No receptive sharing	25	0 (0)	251	110 (44)	292	123 (42)
Receptive sharing	2	0 (0)	92	54 (59)	102	59 (58)
p value		--		0.015		0.006
2018						
No receptive sharing	17	2 (12)	296	100 (34)	320	105 (33)
Receptive sharing	9	1 (11)	125	63 (50)	141	69 (49)
p value		1.000		0.001		0.001

Table 9.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year

Western Australia Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
Heroin	1	0 (0)	73	43 (59)	74	43 (58)
Methamphetamine	3	0 (0)	66	31 (47)	70	31 (44)
Other opioids	0	0 (0)	36	24 (67)	36	24 (67)
Other drugs	5	0 (0)	16	11 (69)	24	14 (58)
p value		--		0.165		0.132
2015						
Heroin	0	0 (0)	56	37 (66)	56	37 (66)
Methamphetamine	4	0 (0)	76	28 (37)	82	29 (35)
Other opioids	0	0 (0)	30	23 (77)	31	24 (77)
Other drugs	0	0 (0)	12	6 (50)	15	6 (40)
p value		--		<0.001		<0.001
2016						
Heroin	1	0 (0)	57	37 (65)	60	38 (63)
Methamphetamine	17	2 (12)	218	72 (33)	244	79 (32)
Other opioids	0	0 (0)	53	28 (53)	56	30 (54)
Other drugs	6	0 (0)	29	14 (48)	39	17 (44)
p value		0.638		<0.001		<0.001
2017						
Heroin	3	0 (0)	86	57 (66)	96	64 (67)
Methamphetamine	20	0 (0)	209	69 (33)	241	76 (32)
Other opioids	1	0 (0)	55	33 (60)	62	35 (56)
Other drugs	5	0 (0)	33	16 (48)	42	19 (45)
p value		<0.001		<0.001		<0.001
2018						
Heroin	0	0 (0)	76	40 (53)	78	41 (53)
Methamphetamine	29	3 (10)	294	93 (32)	337	105 (31)
Other opioids	0	0 (0)	40	20 (50)	40	20 (50)
Other drugs	3	0 (0)	33	17 (52)	37	17 (46)
p value		0.558		0.001		0.001

Table 9.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

Western Australia	<3 years		3+ years		Total	
Frequency of injection last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
Less than daily	5	0 (0)	49	31 (63)	56	32 (57)
Daily or more	2	0 (0)	128	70 (55)	130	70 (54)
Not last month	2	0 (0)	12	7 (58)	15	8 (53)
p value		--		0.585		0.912
2015						
Less than daily	1	0 (0)	65	36 (55)	68	37 (54)
Daily or more	2	0 (0)	105	57 (54)	108	58 (54)
Not last month	1	0 (0)	4	1 (25)	8	1 (13)
p value		--		0.560		0.082
2016						
Less than daily	14	1 (7)	134	60 (45)	152	63 (41)
Daily or more	8	1 (13)	204	84 (41)	223	93 (42)
Not last month	2	0 (0)	19	7 (37)	24	8 (33)
p value		1.000		0.714		0.726
2017						
Less than daily	10	0 (0)	130	56 (43)	148	62 (42)
Daily or more	18	0 (0)	219	111 (51)	254	123 (48)
Not last month	1	0 (0)	34	8 (24)	39	9 (23)
p value		--		0.010		0.010
2018						
Less than daily	11	2 (18)	143	53 (37)	157	57 (36)
Daily or more	16	1 (6)	280	112 (40)	308	120 (39)
Not last month	5	0 (0)	20	5 (25)	27	6 (22)
p value		0.734		0.381		0.217

Table 9.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

Western Australia	<3 years		3+ years		Total	
Imprisonment last year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
No imprisonment	9	0 (0)	148	85 (57)	160	87 (54)
Imprisonment	0	0 (0)	20	11 (55)	20	11 (55)
p value		--		0.837		0.958
2015						
No imprisonment	4	1 (25)	148	80 (54)	160	82 (51)
Imprisonment	1	0 (0)	16	7 (44)	19	8 (42)
p value		1.000		0.433		0.451
2016						
No imprisonment	19	1 (5)	298	119 (40)	333	129 (39)
Imprisonment	4	1 (25)	43	24 (56)	51	28 (55)
p value		0.324		0.049		0.029
2017						
No imprisonment	25	0 (0)	298	129 (43)	345	142 (41)
Imprisonment	1	0 (0)	56	30 (54)	62	35 (56)
p value		--		0.156		0.025
2018						
No imprisonment	26	3 (12)	357	137 (38)	392	146 (37)
Imprisonment	4	0 (0)	69	28 (41)	79	31 (39)
p value		1.000		0.731		0.738

Table 9.3.9 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Western Australia	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
Non Indigenous	117	64 (55)	65	36 (55)	184	101 (55)
Indigenous	6	4 (67)	10	4 (40)	16	8 (50)
p value		0.691		0.500		0.706
2015						
Non Indigenous	95	49 (52)	69	35 (51)	167	85 (51)
Indigenous	10	9 (90)	9	2 (22)	19	11 (58)
p value		0.020		0.159		0.563
2016						
Non Indigenous	209	103 (49)	102	31 (30)	311	134 (43)
Indigenous	39	16 (41)	34	8 (24)	75	26 (35)
p value		0.343		0.444		0.184
2017						
Non Indigenous	235	99 (42)	115	44 (38)	350	143 (41)
Indigenous	58	38 (66)	36	12 (33)	96	51 (53)
p value		0.001		0.593		0.032
2018						
Non Indigenous	224	76 (34)	136	42 (31)	360	118 (33)
Indigenous	66	36 (55)	64	28 (44)	130	64 (49)
p value		0.002		0.075		0.001

Table 9.3.10 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Western Australia	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2014						
English speaking	119	65 (55)	71	37 (52)	192	103 (54)
Non-English speaking	8	6 (75)	3	2 (67)	11	8 (73)
p value		0.261		1.000		0.216
2015						
English speaking	97	53 (55)	77	37 (48)	177	91 (51)
Non-English speaking	7	4 (57)	3	1 (33)	10	5 (50)
p value		1.000		1.000		1.000
2016						
English speaking	240	113 (47)	130	35 (27)	372	149 (40)
Non-English speaking	14	6 (43)	7	4 (57)	22	11 (50)
p value		0.758		0.101		0.356
2017						
English speaking	281	132 (47)	146	54 (37)	429	187 (44)
Non-English speaking	13	7 (54)	6	3 (50)	19	10 (53)
p value		0.628		0.672		0.437
2018						
English speaking	280	107 (38)	194	68 (35)	474	175 (37)
Non-English speaking	15	7 (47)	9	4 (44)	25	12 (48)
p value		0.512		0.723		0.265

Table 9.3.11 HCV antibody prevalence by region/country of birth, gender and survey year

Western Australia		Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2014							
Australia	103	57 (55)	56	27 (48)	161	85 (53)	
Other Oceania	4	1 (25)	5	3 (60)	9	4 (44)	
Asia	1	0 (0)	1	1 (100)	2	1 (50)	
UK & Ireland	13	11 (85)	5	4 (80)	18	15 (83)	
Other	6	2 (33)	8	5 (63)	14	7 (50)	
p value		0.044		0.590		0.097	
2015							
Australia	77	41 (53)	66	32 (48)	145	74 (51)	
Other Oceania	8	3 (38)	2	1 (50)	10	4 (40)	
Asia	2	1 (50)	4	0 (0)	4	1 (25)	
UK & Ireland	10	7 (70)	6	3 (50)	16	10 (63)	
Other	7	5 (71)	5	2 (40)	12	7 (58)	
p value		0.624		1.000		0.644	
2016							
Australia	224	106 (47)	116	31 (27)	343	139 (41)	
Other Oceania	11	7 (64)	6	2 (33)	17	9 (53)	
Asia	4	2 (50)	0	0 (0)	4	2 (50)	
UK & Ireland	11	5 (45)	7	2 (29)	18	7 (39)	
Other	6	1 (17)	7	4 (57)	13	5 (38)	
p value		0.506		0.382		0.856	
2017							
Australia	240	110 (46)	134	49 (37)	376	160 (43)	
Other Oceania	4	0 (0)	3	2 (67)	7	2 (29)	
Asia	3	2 (67)	2	2 (100)	5	4 (80)	
UK & Ireland	32	17 (53)	10	2 (20)	42	19 (45)	
Other	12	7 (58)	1	0 (0)	13	7 (54)	
p value		0.275		0.166		0.414	
2018							
Australia	236	84 (36)	178	64 (36)	414	148 (36)	
Other Oceania	12	5 (42)	8	0 (0)	20	5 (25)	
Asia	7	4 (57)	4	4 (100)	11	8 (73)	
UK & Ireland	26	12 (46)	6	1 (17)	32	13 (41)	
Other	14	9 (64)	7	3 (43)	22	13 (59)	
p value		0.158		0.008		0.018	

HCV RNA prevalence

Table 9.4.1 HCV RNA prevalence by gender and survey year *

Western Australia Survey year	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015	7	4 (57)	3	3 (100)	10	7 (70)
2016	16	4 (25)	8	1 (13)	24	5 (21)
2017	171	52 (30)	77	16 (21)	249	68 (27)
2018	67	17 (25)	48	10 (21)	115	27 (23)
X ² p trend		0.362		0.292		0.156

* Weighted for gender and HCV antibody status

Table 9.4.2 HCV RNA prevalence by sexual identity, gender and survey year *

Western Australia Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
Heterosexual	7	4 (57)	1	1 (100)	9	6 (67)
Bisexual	0	0 (0)	1	1 (100)	1	1 (100)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		0.514
2016						
Heterosexual	13	3 (23)	6	0 (0)	20	3 (15)
Bisexual	0	0 (0)	2	1 (50)	2	1 (0)
Homosexual	2	1 (50)	0	0 (0)	2	1 (0)
p value		0.748		0.105		0.475
2017						
Heterosexual	147	41 (28)	62	12 (19)	210	53 (25)
Bisexual	6	5 (83)	11	4 (36)	17	9 (53)
Homosexual	4	0 (0)	1	0 (0)	5	0 (0)
p value		0.010		0.535		0.039
2018						
Heterosexual	56	15 (27)	35	8 (23)	91	24 (26)
Bisexual	2	1 (50)	6	0 (0)	8	1 (13)
Homosexual	4	0 (0)	1	0 (0)	5	0 (0)
p value		0.311		0.355		0.362

Table 9.4.3 HCV RNA prevalence by age group, gender and survey year *

Western Australia Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	0	0 (0)	0	0 (0)	0	0 (0)
35-44 years	3	3 (100)	1	1 (100)	4	4 (100)
45+ years	4	1 (25)	1	1 (100)	6	3 (50)
p value	0.204		--		0.162	
2016						
<25 years	0	0 (0)	1	0 (0)	1	0 (0)
25-34 years	4	1 (25)	1	1 (100)	5	2 (40)
35-44 years	5	1 (20)	5	0 (0)	11	1 (9)
45+ years	6	1 (17)	1	0 (0)	7	1 (14)
p value	0.953		0.082		0.446	
2017						
<25 years	10	2 (20)	1	0 (0)	11	2 (18)
25-34 years	32	11 (34)	22	5 (23)	54	16 (30)
35-44 years	56	19 (34)	30	5 (17)	87	24 (28)
45+ years	71	19 (27)	24	6 (25)	95	26 (27)
p value	0.685		0.783		0.877	
2018						
<25 years	1	0 (0)	2	1 (50)	3	1 (33)
25-34 years	7	0 (0)	15	5 (33)	22	5 (23)
35-44 years	27	5 (19)	21	2 (10)	48	7 (15)
45+ years	32	12 (38)	10	2 (20)	42	14 (33)
p value	0.134		0.461		0.294	

Table 9.4.4 HCV RNA prevalence by years since first injection, gender and survey year *

Western Australia Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 10 years	0	0 (0)	0	0 (0)	0	0 (0)
11+ years	7	4 (57)	3	3 (100)	10	7 (70)
p value	--		--		--	
2016						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 10 years	2	0 (0)	0	0 (0)	2	0 (0)
11+ years	12	4 (33)	8	1 (13)	20	5 (25)
p value	0.361		--		0.464	
2017						
<3 years	11	0 (0)	6	0 (0)	17	0 (0)
3 to 10 years	23	6 (26)	12	5 (42)	35	11 (31)
11+ years	133	43 (32)	52	7 (13)	186	50 (27)
p value	0.067		0.072		0.040	
2018						
<3 years	2	0 (0)	4	2 (50)	6	2 (33)
3 to 10 years	9	1 (11)	10	3 (30)	19	4 (21)
11+ years	55	14 (25)	34	5 (15)	89	20 (22)
p value	0.519		0.291		0.795	

Table 9.4.5 HCV RNA prevalence by re-use of someone else's used needle and syringe last month, gender and survey year *

Western Australia Receptively shared syringe last month	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
No receptive sharing	4	4 (100)	1	1 (100)	6	6 (100)
Receptive sharing	3	0 (0)	1	1 (100)	4	1 (25)
p value		<0.001		--		0.088
2016						
No receptive sharing	12	3 (25)	3	0 (0)	15	3 (20)
Receptive sharing	2	1 (50)	2	1 (50)	4	2 (50)
p value		0.946		0.289		0.572
2017						
No receptive sharing	121	31 (26)	55	15 (27)	176	46 (26)
Receptive sharing	32	16 (50)	14	1 (7)	46	18 (39)
p value		0.008		0.221		0.109
2018						
No receptive sharing	44	7 (16)	36	7 (19)	80	14 (18)
Receptive sharing	17	8 (47)	4	2 (50)	21	10 (48)
p value		0.018		0.178		0.005

Table 9.4.6 HCV RNA prevalence by last drug injected, gender and survey year *

Western Australia Last drug injected	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
Heroin	4	3 (75)	3	3 (100)	7	6 (86)
Methamphetamine	0	0 (0)	0	0 (0)	0	0 (0)
Other opioids	1	1 (100)	0	0 (0)	1	1 (100)
Other drugs	2	0 (0)	0	0 (0)	2	0 (0)
p value		0.339		--		0.198
2016						
Heroin	4	1 (25)	2	0 (0)	6	1 (17)
Methamphetamine	11	3 (27)	6	1 (17)	17	4 (24)
Other opioids	0	0 (0)	0	0 (0)	0	0 (0)
Other drugs	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.474		0.672		0.413
2017						
Heroin	49	18 (37)	23	7 (30)	73	25 (34)
Methamphetamine	89	20 (22)	41	7 (17)	131	28 (21)
Other opioids	17	7 (41)	4	0 (0)	21	7 (33)
Other drugs	14	7 (50)	8	1 (13)	23	8 (35)
p value		0.122		0.371		0.176
2018						
Heroin	17	3 (18)	9	2 (22)	26	5 (19)
Methamphetamine	38	11 (29)	28	4 (14)	66	15 (23)
Other opioids	7	2 (29)	4	1 (25)	11	3 (27)
Other drugs	3	0 (0)	5	3 (60)	8	3 (38)
p value		0.657		0.251		0.849

Table 9.4.7 HCV RNA prevalence by frequency of drug injection last month, gender and survey year *

Western Australia	Male		Female		Total	
Frequency of injection last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
Less than daily	3	2 (67)	1	1 (100)	5	3 (60)
Daily or more	4	2 (50)	1	1 (100)	5	4 (80)
Not last month	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.756		--		0.801
2016						
Less than daily	7	2 (29)	5	0 (0)	12	2 (17)
Daily or more	7	2 (29)	2	1 (50)	9	3 (33)
Not last month	0	0 (0)	1	0 (0)	2	0 (0)
p value		0.844		0.351		0.511
2017						
Less than daily	62	15 (24)	21	6 (29)	83	22 (27)
Daily or more	93	34 (37)	49	10 (20)	143	44 (31)
Not last month	15	2 (13)	7	0 (0)	22	2 (9)
p value		0.092		0.269		0.105
2018						
Less than daily	15	5 (33)	16	4 (25)	31	9 (29)
Daily or more	46	11 (24)	24	3 (13)	70	14 (20)
Not last month	5	1 (20)	6	2 (33)	11	3 (27)
p value		0.820		0.554		0.579

Table 9.4.8 HCV RNA prevalence by imprisonment last year, gender and survey year *

Western Australia	Male		Female		Total	
Imprisonment last year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
No imprisonment	6	3 (50)	3	3 (100)	9	6 (67)
Imprisonment	1	1 (100)	0	0 (0)	1	1 (100)
p value		0.454		--		0.147
2016						
No imprisonment	13	3 (23)	6	0 (0)	19	3 (16)
Imprisonment	3	1 (33)	0	0 (0)	3	1 (33)
p value		0.277		--		0.140
2017						
No imprisonment	131	37 (28)	64	12 (19)	195	49 (25)
Imprisonment	27	11 (41)	8	2 (25)	35	13 (37)
p value		0.245		0.447		0.129
2018						
No imprisonment	52	13 (25)	41	8 (20)	93	21 (23)
Imprisonment	11	4 (36)	4	2 (50)	15	6 (40)
p value		0.696		0.181		0.289

Table 9.4.9 HCV RNA prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year *

Western Australia	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
Non Indigenous	6	4 (67)	3	3 (100)	9	7 (78)
Indigenous	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.315		--		0.165
2016						
Non Indigenous	14	3 (21)	5	1 (20)	19	4 (21)
Indigenous	2	1 (50)	0	0 (0)	2	1 (50)
p value		0.715		--		0.633
2017						
Non Indigenous	142	38 (27)	58	10 (17)	200	48 (24)
Indigenous	27	11 (41)	18	6 (33)	45	17 (38)
p value		0.104		0.163		0.049
2018						
Non Indigenous	53	11 (21)	30	6 (20)	83	17 (20)
Indigenous	13	6 (46)	16	3 (19)	29	9 (31)
p value		0.097		0.760		0.334

Table 9.4.10 HCV RNA prevalence by main language spoken at home by parents, gender and survey year *

Western Australia	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2015						
English speaking	6	4 (67)	3	3 (100)	9	7 (78)
Non-English speaking	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.315		--		0.165
2016						
English speaking	13	4 (31)	6	1 (17)	19	5 (26)
Non-English speaking	2	0 (0)	0	0 (0)	2	0 (0)
p value		0.335		--		0.405
2017						
English speaking	162	49 (30)	73	15 (21)	235	64 (27)
Non-English speaking	8	2 (25)	3	1 (33)	11	3 (27)
p value		0.770		0.474		0.896
2018						
English speaking	64	15 (23)	46	10 (22)	110	26 (24)
Non-English speaking	3	1 (33)	1	0 (0)	4	1 (25)
p value		0.567		0.597		0.798

Table 9.4.11 HCV RNA prevalence by region/country of birth, gender and survey year *

Western Australia		Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2015							
Australia	4	3 (75)	3	3 (100)	7	6 (86)	
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)	
Other	3	1 (33)	0	0 (0)	3	1 (33)	
p value		0.794		--		0.569	
2016							
Australia	11	3 (27)	5	1 (20)	16	4 (25)	
Other Oceania	1	1 (100)	1	0 (0)	2	1 (50)	
Asia	1	0 (0)	0	0 (0)	1	0 (0)	
UK & Ireland	1	0 (0)	0	0 (0)	2	0 (0)	
Other	0	0 (0)	0	0 (0)	0	0 (0)	
p value		0.640		0.754		0.773	
2017							
Australia	136	38 (28)	67	14 (21)	204	52 (25)	
Other Oceania	2	0 (0)	2	1 (50)	4	1 (25)	
Asia	3	2 (67)	1	0 (0)	4	2 (50)	
UK & Ireland	19	6 (32)	5	1 (20)	24	7 (29)	
Other	9	4 (44)	0	0 (0)	9	4 (44)	
p value		0.431		0.644		0.714	
2018							
Australia	54	12 (22)	41	9 (22)	95	21 (22)	
Other Oceania	1	0 (0)	2	0 (0)	3	0 (0)	
Asia	0	0 (0)	1	0 (0)	1	0 (0)	
UK & Ireland	9	2 (22)	1	1 (100)	10	3 (30)	
Other	3	2 (67)	2	0 (0)	5	2 (40)	
p value		0.227		0.306		0.565	

Appendix A: Participating NSP services

Year		'14	'15	'16	'17	'18
Number of NSP sites		50	47	50	52	53
Australian Capital Territory		1	1	1	1	1
Canberra	Directions ACT	✓	✓	✓	✓	✓
New South Wales		19	16	17	18	19
Albury	Albury Community Health Centre	✓				
Ballina	Harm Reduction Services	✓	✓	✓	✓	✓
Blacktown	HIV/Hepatitis C Prevention Service	✓	✓	✓	✓	✓
Byron/Tweed	Harm Reduction Services	✓	✓	✓	✓	✓
Coffs Harbour/Grafton	Harm Reduction Services	✓	✓	✓	✓	✓
Camperdown	Royal Prince Alfred Hospital			✓	✓	✓
Canterbury	Harm Minimisation Program		✓	✓	✓	✓
Central Coast	Gosford, Long Jetty and Woy Woy Harm Reduction	✓				
Liverpool	Health ConneXions					✓
Kings Cross	Clinic 180	✓	✓	✓	✓	✓
Kings Cross	Kirketon Road Centre	✓	✓	✓	✓	✓
Sutherland	KRC South	✓			✓	✓
Mt Druitt	Kelly Close Needle Syringe Program	✓	✓	✓	✓	✓
Kingswood	South Court Primary Care NSP	✓	✓	✓	✓	✓
Newcastle	Hunter Harm Reduction Services	✓	✓	✓	✓	✓
Newcastle	AIDS Council of NSW Hunter	✓	✓	✓	✓	✓
Nimbin/Lismore	Harm Reduction Services	✓	✓	✓	✓	✓
Parramatta	HIV/Hepatitis C Prevention Service	✓	✓	✓	✓	✓
Port Kembla	First Step Program	✓	✓	✓	✓	✓
Redfern	Harm Minimisation Program	✓	✓	✓	✓	✓
Surry Hills	NSW Users and AIDS Association	✓	✓	✓	✓	✓
Wagga Wagga	Wagga Wagga Community Health Centre	✓				
Northern Territory		3	3	3	3	3
Alice Springs	Northern Territory AIDS & Hepatitis Council	✓	✓	✓	✓	✓
Darwin	Northern Territory AIDS & Hepatitis Council	✓	✓	✓	✓	✓
Palmerston	Northern Territory AIDS & Hepatitis Council	✓	✓	✓	✓	✓
Queensland		7	8	8	9	9
Brisbane	Biala Community Alcohol and Drug Services	✓	✓	✓	✓	✓
Brisbane	Queensland Injectors Health Network	✓	✓	✓	✓	✓
Cairns	Cairns ATODS NSP	✓	✓	✓	✓	✓
Cairns	Youth Link				✓	✓
Gold Coast	Queensland Injectors Health Network	✓	✓	✓	✓	✓
Ipswich	West Moreton Sexual Health Service		✓	✓	✓	✓
Sunshine Coast	Queensland Injectors Health Network	✓	✓	✓	✓	✓
Toowoomba	Kobi House	✓	✓	✓	✓	✓
Townsville	Townsville ATODS NSP	✓	✓	✓	✓	✓

Year		'14	'15	'16	'17	'18
	Number of NSP sites	51	47	50	52	53
South Australia		7	7	7	7	7
Adelaide	Nunkuwarn Yunti Community Health Centre	✓	✓	✓	✓	✓
Adelaide	Streetlink Youth Services	✓	✓	✓	✓	✓
Angle Park	SAVIVE - Central Northern Adelaide Health Service	✓				
Hindmarsh	Hindmarsh Centre	✓	✓	✓	✓	
Noarlunga	Noarlunga Primary Health	✓	✓	✓	✓	✓
Port Adelaide	SAVIVE, Central Northern Adelaide Health Service	✓	✓	✓	✓	✓
Salisbury	Anglicare SA Salisbury	✓	✓	✓	✓	✓
Warradale	Drug Arm Australasia		✓	✓	✓	✓
Athol Park	CASSA – Community Access & Services SA					✓
Tasmania		4	4	4	4	4
Burnie	Burnie NSP Service			✓		
Clarence	Clarence Community Health Centre	✓	✓	✓	✓	✓
Glenorchy	Glenorchy NSP Service	✓	✓	✓	✓	✓
Hobart	Hobart NSP Service	✓	✓	✓	✓	✓
Launceston	Salvation Army Launceston	✓	✓		✓	✓
Victoria		6	6	6	6	6
Barwon	Barwon Health Drug and Alcohol Services	✓	✓	✓	✓	✓
Collingwood	Inner Space	✓	✓	✓	✓	✓
Footscray	Health Works	✓	✓	✓	✓	✓
Frankston	Southern Hepatitis/HIV/AIDS Resource & Prevention Service	✓	✓	✓	✓	✓
North Richmond	North Richmond NSP Services	✓	✓	✓	✓	✓
St Kilda	Health Information Exchange	✓	✓	✓	✓	✓
Western Australia		3	2	4	4	4
Bunbury	Peer Based Harm Reduction Western Australia (formerly WASUA)	✓		✓	✓	✓
Northbridge	HepatitisWA			✓	✓	✓
Perth	Peer Based Harm Reduction Western Australia (formerly WASUA)	✓	✓	✓	✓	✓
Perth	WA AIDS Council Mobile Exchange	✓	✓	✓	✓	✓

Appendix B: Methodological notes

Capillary blood was obtained by finger-prick using disposable lancets and cotton-fibre blotting paper. Dried blood samples were kept at room temperature at the survey sites and couriered to a central laboratory every second or third day. HIV antibody was detected using the Murex 1.2.0 ELISA (Diasorin). Repeatedly reactive specimens were subjected to Western blot confirmatory testing (Bio-Rad New LAV blot 1, France). A modified third generation enzyme immunoassay (Monolisa anti-HCV Plus Version 3 EIA, Biorad, France) was used to test for HCV antibody. A modified cut off value for optical density was calculated to capture greater than 95% of the seronegative population. Specimens were considered positive for HCV antibody if the optical density to cut off ratio was greater than or equal to one on initial and subsequent testing.

In 2015, HCV RNA was detected and quantified using a modified Abbott RealTime™ (Illinois, United States) HCV RNA assay. The Abbot RealTime HCV RNA assay involves specimen extraction automation using the Abbott M2000SP coupled with the M2000RT Realtime PCR instrument. A bias (+1.91 Log₁₀) applied post run gave a quantifiable DBS HCV viral load (VL) result with a lower limit of detection of 977IU/mL (plasma equivalency). A qualitative result of <12IU/mL detected (trace/equivocal) was applied to samples <977IU/mL (plasma equivalency).

In all subsequent years (2016-2018), HCV RNA was detected and quantified on the Hologic Panther™ using the Aptima™ HCV Quant Dx assay (Hologic, Inc. San Diego, Calif) which has a limit of quantitation (LOQ) 10 IU/mL and an upper limit of quantitation of 10⁸ IU/mL in plasma. An offboard DBS elution protocol was applied prior to sampling. To correct for haematocrit, all post run DBS VL results on the Aptima assay were multiplied by a plasma conversion factor of 36.36. This calculation was based on the following assumptions: 45% haematocrit average per DBS, 50uL DBS volume and 1000ul Aptima transport media volume. A qualitative result of <10IU/mL detected (trace/equivocal) was applied to samples <400IU/mL (plasma equivalency).

Data presented in this report were analysed using Stata, Version 14 (Stata Corporation, College Station TX). Temporal changes in HIV/HCV antibody and HCV RNA prevalence were assessed using the X^2 test for linear trend. Associations between demographic and behavioural variables and HIV/HCV antibody and HCV RNA prevalence were assessed using the X^2 test or Fisher's exact test where expected frequencies were less than five. It should be noted that only a sub-sample of respondents had sufficient DBS sample for HCV RNA testing. HCV RNA tables were weighted to account for sample bias with respect to HCV antibody status and gender. Weights were applied to national data and to each individual jurisdiction, such that jurisdictional HCV RNA results will not necessarily add to data presented at the national level. Further, results with small sample size, particularly at the jurisdictional level, should be interpreted with caution.

Percentage values in tables may not add to 100 due to rounding. Totals in HIV and HCV antibody prevalence tables stratified by gender include people whose gender was not reported or reported as transgender. Time since first injection was calculated by subtracting age at first injection from age at survey completion. Totals in HIV and HCV antibody prevalence tables stratified by time since first injection include people who did not report age at survey completion or age at first injection. Tables reporting HIV antibody prevalence stratified by demographic and drug use characteristics are not included in this report for states and territories or survey years where the number of HIV antibody positive participants was less than 5 in all years.

Where data were collected but no participants endorsed a particular response, results are presented as "0 (0)". The symbol "--" shown in some tables denotes missing data; and is used to identify circumstances where data were not collected in the reported format. The vast majority of survey questions were consistent over all survey years.

NSP staff recorded sex, age group and survey participation for all clients at the NSP during the survey period and this data was used to assess response rates. Some clients visited the site more than once during the survey week, and only one attendance per person was included in the response rate denominator. Ethical approvals for the study were obtained from Human Research Ethics Committees associated with the investigators and participating sites. Verbal rather than written informed consent was obtained to assure the anonymity of participants.

Appendix C: List of Tables

1. Demographic characteristics and drug use

Table 1.1.1	Number (percentage) of respondents by demographic characteristics and survey year
Table 1.1.2	Number (percentage) of respondents by last drug injected, frequency of injecting and survey year
Table 1.1.3	Number (percentage) of respondents by injecting behaviour in the last month and survey year
Table 1.1.4	Number (percentage) of respondents by treatment for drug use and survey year
Table 1.1.5	Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year
Table 1.1.6	Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year

2. HIV antibody prevalence

Table 1.2.1	HIV antibody prevalence by gender and survey year
Table 1.2.2	HIV antibody prevalence by sexual identity, gender and survey year
Table 1.2.3	HIV antibody prevalence by age group, gender and survey year
Table 1.2.4	HIV antibody prevalence by last drug injected, gender and survey year
Table 1.2.5	HIV antibody prevalence by years of injection, gender and survey year
Table 1.2.6	HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year
Table 1.2.7	HIV antibody prevalence by frequency of drug injection last month, gender and survey year
Table 1.2.8	HIV antibody prevalence by imprisonment last year, gender and survey year
Table 1.2.9	HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year
Table 1.2.10	HIV antibody prevalence by sex work last month, gender and survey year
Table 1.2.11	HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year
Table 1.2.12	HIV antibody prevalence by main language spoken at home by parents, gender and survey year
Table 1.2.13	HIV antibody prevalence by region/country of birth, gender and survey year

3. HCV antibody prevalence

Table 1.3.1	HCV antibody prevalence by gender and survey year
Table 1.3.2	HCV antibody prevalence by sexual identity, gender and survey year
Table 1.3.3	HCV antibody prevalence by age group, gender and survey year
Table 1.3.4	HCV antibody prevalence by years since first injection, gender and survey year
Table 1.3.5	HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year
Table 1.3.6	HCV antibody prevalence by last drug injected, years since first injection and survey year
Table 1.3.7	HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year
Table 1.3.8	HCV antibody prevalence by imprisonment last year, years since first injection and survey year
Table 1.3.9	HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year
Table 1.3.10	HCV antibody prevalence by main language spoken at home by parents, gender and survey year
Table 1.3.11	HCV antibody prevalence by region/country of birth, gender and survey year

4. HCV RNA prevalence

- Table 1.4.1 HCV RNA prevalence by gender and survey year
- Table 1.4.2 HCV RNA prevalence by sexual identity, gender and survey year
- Table 1.4.3 HCV RNA prevalence by age group, gender and survey year
- Table 1.4.4 HCV RNA prevalence by years since first injection, gender and survey year
- Table 1.4.5 HCV RNA prevalence by re-use of someone else's used needle and syringe last month, gender and survey year
- Table 1.4.6 HCV RNA prevalence by last drug injected, gender and survey year
- Table 1.4.7 HCV RNA prevalence by frequency of drug injection last month, gender and survey year
- Table 1.4.8 HCV RNA prevalence by imprisonment last year, gender and survey year
- Table 1.4.9 HCV RNA prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year
- Table 1.4.10 HCV RNA prevalence by main language spoken at home by parents, gender and survey year
- Table 1.4.11 HCV RNA prevalence by region/country of birth, gender and survey year

